<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for rosacea - van Zuuren, EJ - 2015 | Cochrane Library</title> <meta content="Interventions for rosacea - van Zuuren, EJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003262.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for rosacea - van Zuuren, EJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003262.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003262.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for rosacea" name="citation_title"/> <meta content="Esther J van Zuuren" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="E.J.van_Zuuren@lumc.nl" name="citation_author_email"/> <meta content="Zbys Fedorowicz" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Ben Carter" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Mireille MD van der Linden" name="citation_author"/> <meta content=" Institute of Psychiatry, Psychology &amp; Neuroscience" name="citation_author_institution"/> <meta content="Lyn Charland" name="citation_author"/> <meta content="Academic Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD003262.pub5" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/04/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003262.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003262.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003262.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Infective Agents [therapeutic use]; Brimonidine Tartrate; Cyclosporine [therapeutic use]; Dermatologic Agents [*therapeutic use]; Dicarboxylic Acids [therapeutic use]; Doxycycline [therapeutic use]; Ivermectin [therapeutic use]; Metronidazole [therapeutic use]; Ophthalmic Solutions [therapeutic use]; Quinoxalines [therapeutic use]; Randomized Controlled Trials as Topic; Rosacea [*drug therapy]; Tetracycline [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003262.pub5&amp;doi=10.1002/14651858.CD003262.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003262\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003262\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003262.pub5",title:"Interventions for rosacea",firstPublishedDate:"Apr 28, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003262.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003262.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003262.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003262.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003262.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003262.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003262.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003262.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003262.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003262.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12343 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003262.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0574"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-sec-0550"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/appendices#CD003262-sec-0579"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/table_n/CD003262StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/table_n/CD003262StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for rosacea</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#CD003262-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Esther J van Zuuren</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#CD003262-cr-0003">Zbys Fedorowicz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#CD003262-cr-0004">Ben Carter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#CD003262-cr-0005">Mireille MD van der Linden</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information#CD003262-cr-0006">Lyn Charland</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information/en#CD003262-sec-0590">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 April 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003262.pub5">https://doi.org/10.1002/14651858.CD003262.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003262-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003262-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003262-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003262-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003262-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003262-abs-0001" lang="en"> <section id="CD003262-sec-0001"> <h3 class="title" id="CD003262-sec-0001">Background</h3> <p>Rosacea is a common chronic skin condition affecting the face, characterised by flushing, redness, pimples, pustules and dilated blood vessels. The eyes are often involved and thickening of the skin with enlargement (phymas), especially of the nose, can occur in some people. A range of treatment options are available but it is unclear which are most effective. </p> </section> <section id="CD003262-sec-0002"> <h3 class="title" id="CD003262-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of treatments for rosacea.</p> </section> <section id="CD003262-sec-0003"> <h3 class="title" id="CD003262-sec-0003">Search methods</h3> <p>We updated our searches, to July 2014, of: the Cochrane Skin Group Specialised Register, CENTRAL in <i>The Cochrane Library</i> (2014, Issue 6), MEDLINE (from 1946), EMBASE (from 1974) and Science Citation Index (from 1988). We searched five trials registers and checked reference lists for further relevant studies. </p> </section> <section id="CD003262-sec-0004"> <h3 class="title" id="CD003262-sec-0004">Selection criteria</h3> <p>Randomised controlled trials in people with moderate to severe rosacea.</p> </section> <section id="CD003262-sec-0005"> <h3 class="title" id="CD003262-sec-0005">Data collection and analysis</h3> <p>Study selection, data extraction, risk of bias assessment and analyses were carried out independently by two authors. </p> </section> <section id="CD003262-sec-0006"> <h3 class="title" id="CD003262-sec-0006">Main results</h3> <p>We included 106 studies, comprising 13,631 participants. Sample sizes of 30‐100 and study duration of two to three months were most common. More women than men were included, mean age of 48.6 years, and the majority had papulopustular rosacea, followed by erythematotelangiectatic rosacea. </p> <p>A wide range of comparisons (67) were evaluated. Topical interventions: metronidazole, azelaic acid, ivermectin, brimonidine or other topical treatments. Systemic interventions: oral antibiotics, combinations with topical treatments or other systemic treatments, i.e. isotretinoin. Several studies evaluated laser or light‐based treatment. </p> <p>The majority of studies (57/106) were assessed as 'unclear risk of bias', 37 'high risk ' and 12 'low risk'. Twenty‐two studies provided no usable or retrievable data i.e. none of our outcomes were addressed, no separate data reported for rosacea or limited data in abstracts. </p> <p>Eleven studies assessed our primary outcome 'change in quality of life', 52 studies participant‐assessed changes in rosacea severity and almost all studies addressed adverse events, although often only limited data were provided. In most comparisons there were no statistically significant differences in number of adverse events, most were mild and transient. Physician assessments including investigators' global assessments, lesion counts and erythema were evaluated in three‐quarters of the studies, but time needed for improvement and duration of remission were incompletely or not reported. </p> <p>The quality of the body of evidence was rated moderate to high for most outcomes, but for some outcomes low to very low. </p> <p>Data for several outcomes could only be pooled for topical metronidazole and azelaic acid. Both were shown to be more effective than placebo in papulopustular rosacea (moderate quality evidence for metronidazole and high for azelaic acid). Pooled data from physician assessments in three trials demonstrated that metronidazole was more effective compared to placebo (risk ratio (RR) 1.98, 95% confidence interval (CI) 1.29 to 3.02). Four trials provided data on participants' assessments, illustrating that azelaic acid was more effective than placebo (RR 1.46, 95% CI 1.30 to 1.63). The results from three studies were contradictory on which of these two treatments was most effective. </p> <p>Two studies showed a statistically significant and clinically important improvement in favour of topical ivermectin when compared to placebo (high quality evidence). Participants' assessments in these studies showed a RR of 1.78 (95% CI 1.50 to 2.11) and RR of 1.92 (95% CI 1.59 to 2.32),which were supported by physicians' assessments. Topical ivermectin appeared to be slightly more effective than topical metronidazole for papulopustular rosacea, based on one study, for improving quality of life and participant and physician assessed outcomes (high quality evidence for these outcomes). </p> <p>Topical brimonidine in two studies was more effective than vehicle in reducing erythema in rosacea at all time points over 12 hours (high quality evidence). At three hours the participants' assessments had a RR of 2.21 (95% CI 1.52 to 3.22) and RR of 2.00 (95% CI 1.33 to 3.01) in favour of brimonidine. Physicians' assessments confirmed these data. There was no rebound or worsening of erythema after treatment cessation. </p> <p>Topical clindamycin phosphate combined with tretinoin was not considered to be effective compared to placebo (moderate quality evidence). </p> <p>Topical ciclosporin ophthalmic emulsion demonstrated effectiveness and improved quality of life for people with ocular rosacea (low quality evidence). </p> <p>Of the comparisons assessing oral treatments for papulopustular rosacea there was moderate quality evidence that tetracycline was effective but this was based on two old studies of short duration. Physician‐based assessments in two trials indicated that doxycycline appeared to be significantly more effective than placebo (RR 1.59, 95% CI 1.02 to 2.47 and RR 2.37, 95% CI 1.12 to 4.99) (high quality evidence). There was no statistically significant difference in effectiveness between 100 mg and 40 mg doxycycline, but there was evidence of fewer adverse effects with the lower dose (RR 0.25, 95% CI 0.11 to 0.54) (low quality evidence). There was very low quality evidence from one study (assessed at high risk of bias) that doxycycline 100 mg was as effective as azithromycin. Low dose minocycline (45 mg) was effective for papulopustular rosacea (low quality evidence). </p> <p>Oral tetracycline was compared with topical metronidazole in four studies and showed no statistically significant difference between the two treatments for any outcome (low to moderate quality evidence). </p> <p>Low dose isotretinoin was considered by both the participants (RR 1.23, 95% CI 1.05 to 1.43) and physicians (RR 1.18, 95% CI 1.03 to 1.36) to be slightly more effective than doxycycline 50‐100 mg (high quality evidence). </p> <p>Pulsed dye laser was more effective than yttrium‐aluminium‐garnet (Nd:YAG) laser based on one study, and it appeared to be as effective as intense pulsed light therapy (both low quality evidence). </p> </section> <section id="CD003262-sec-0007"> <h3 class="title" id="CD003262-sec-0007">Authors' conclusions</h3> <p>There was high quality evidence to support the effectiveness of topical azelaic acid, topical ivermectin, brimonidine, doxycycline and isotretinoin for rosacea. Moderate quality evidence was available for topical metronidazole and oral tetracycline. There was low quality evidence for low dose minocycline, laser and intense pulsed light therapy and ciclosporin ophthalmic emulsion for ocular rosacea. Time needed to response and response duration should be addressed more completely, with more rigorous reporting of adverse events. Further studies on treatment of ocular rosacea are warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003262-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003262-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003262-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003262-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003262-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003262-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003262-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003262-abs-0003" lang="en"> <h3>Treatments for rosacea</h3> <p><b>Review question</b> </p> <p>Which treatments are effective for rosacea?</p> <p><b>Background</b> </p> <p>Rosacea is a common skin condition causing flushing, redness, red pimples and pustules on the face, and should not be confused with acne. Dilated blood vessels may appear near the surface of the skin (telangiectasia). It can also cause inflammation of the eyes or eyelids, or both (ocular rosacea). Some people can develop a thickening of the skin, especially of the nose (rhinophyma). Although the cause of rosacea remains unclear, a wide variety of treatments are available for this persistent (chronic) and recurring and often distressing disease. These include medications applied directly to the skin (topical), oral medications and light‐based therapies. We wanted to discover how people assessed their treatments: if the treatments changed their quality of life, if they saw changes in their condition and if there were side effects. From the doctors, we wanted to discover whether treatments changed the severity of rosacea, as well as how long it took before symptoms reduced and reappeared. </p> <p><b>Study characteristics</b> </p> <p>We reviewed 106 studies (up to July 2014) which included 13,631 people with moderate to severe rosacea. Most were between 40 and 50 years old, with more than twice as many women as men. Most studies lasted between eight to 12 weeks, with the longest lasting 40 weeks. The majority of people in these studies suffered from two rosacea subtypes, the subtype with pimples and pustules, or the subtype that causes flushing and persistent redness. </p> <p>Of the 106 studies, 66 reported that they received funding, mainly by pharmaceutical companies. We were confident funding did not affect the results in 56 of these studies but had concerns about the remaining 10. </p> <p><b>Key results</b> </p> <p>Most of the treatments appeared to be effective in treating rosacea. Almost half of the studies reported how people assessed their treatments. Only 11 assessed changes to quality of life. Almost all studies reported side effects, although this information was often limited. Studies mostly evaluated changes in the number of pimples and pustules, and redness. Only five studies included ocular rosacea. None included the rare variant called 'granulomatous rosacea'. </p> <p><i>Topical treatments</i> </p> <p>Two separate treatments, metronidazole and azelaic acid, were effective and safe in reducing rosacea symptoms. Improvements tended to appear after three to six weeks. With metronidazole, very few people experienced mild itching, skin irritation and dry skin. For some, azelaic acid caused mild burning, stinging or irritation. More research is needed to conclude which of these two treatments is best. </p> <p>Ivermectin, a new treatment, was more effective than placebo and slightly more effective than metronidazole. Another newly registered treatment called brimonidine, especially for reducing redness, was shown to work up to 12 hours after being applied. </p> <p><i>Oral treatments</i> </p> <p>Antibiotics such as tetracycline, a low dose of doxycycline or a low dose of minocycline reduced the number of pimples and pustules. Low dose doxycycline (40 mg) was likely as effective as 100 mg, but with much fewer side effects of diarrhoea and nausea. Azithromycin may be as effective as 100 mg doxycycline, but only one study addressed this treatment and better quality studies are needed to confirm this. </p> <p>A low dose of isotretinoin (0.3 mg/kg), a vitamin A‐related drug, appeared to be slightly more effective than 50‐100 mg doxycycline for treating pimples and pustules. However, extra precautions need to be taken regarding contraception in women of childbearing age as this drug is known to cause malformations in the foetus. </p> <p><i>Light‐based therapies</i> </p> <p>Laser therapy and intense pulsed light therapy were both effective for the treatment of telangiectasia, but the studies examining these treatments only reported limited data. </p> <p><i>Rosacea of the eyes or eyelids, or both (ocular rosacea)</i> </p> <p>Better quality studies are required on ocular rosacea, though ciclosporin 0.05% ophthalmic emulsion appeared to be more effective than artificial tears. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence for several outcomes as very low to high. There was high quality evidence for azelaic acid, topical ivermectin, brimonidine, doxycycline and isotretinoin. The lower quality evidence for other treatments was mostly because there were few people in the studies, making the results less precise, and the lack of blinding (people knew which treatments they were receiving). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003262-sec-0574" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003262-sec-0574"></div> <h3 class="title" id="CD003262-sec-0575">Implications for practice</h3> <section id="CD003262-sec-0575"> <p>Based on only those studies which are most likely to have provided reliable results, that is those that are reproducible, repeatable and therefore valid, and selecting the most rigorously described and conducted studies, we have made several conclusions. Evidence of treatment effect could be demonstrated for several of the interventions studied. In daily practice often a combination of treatments should be chosen based on the activity of signs and symptoms of the specific subtype, or combination of subtypes. </p> <p> <ul id="CD003262-list-0277"> <li> <p>There is high quality evidence to support the effectiveness and safety of brimonidine topical gel for reducing erythema over 12 hours after application in the management of persistent erythema in rosacea. There was low to moderate quality evidence of the effectiveness of pulsed dye laser and intense pulsed light therapy for erythematotelangiectatic rosacea. </p> </li> </ul> <ul id="CD003262-list-0278"> <li> <p>For subtype 2, papulopustular rosacea, topical metronidazole, azelaic acid, topical ivermectin, anti‐inflammatory dose doxycycline (40 mg), tetracycline and isotretinoin 0.3 mg/kg appear to be effective and safe for short‐term use (moderate to high quality of evidence). It still needs to be established whether azelaic acid is more effective than topical metronidazole, but topical ivermectin appeared to be slightly more effective than topical metronidazole. There is evidence that 40 mg doxycycline is at least as effective as 100 mg, with evidence of fewer adverse effects (low quality of evidence). There is low quality evidence for the effectiveness and safety of low dose minocycline 45 mg and very low quality evidence of azithromycin for this subtype. There is no clear evidence that any one of these treatments, or any combination of treatments, has a particular advantage in terms of higher remission rates or fewer adverse effects. </p> </li> </ul> <ul id="CD003262-list-0279"> <li> <p>No studies could be included that addressed treatment of phymatous rosacea (subtype 3). </p> </li> </ul> <ul id="CD003262-list-0280"> <li> <p>For ocular rosacea (subtype 4), ciclosporin 0.05% ophthalmic emulsion was shown to be more beneficial than artificial tears (low quality evidence). </p> </li> </ul> </p> <p>Clinical decision making on the choice of intervention for rosacea should be based on high‐level evidence if it is available, but in the absence of such evidence for any specific intervention these decisions should continue to be guided by clinical experience and patients' individual characteristics and preferences until further evidence becomes available. </p> </section> <h3 class="title" id="CD003262-sec-0576">Implications for research</h3> <section id="CD003262-sec-0576"> <p>The impact of available treatment on ocular rosacea warrants further examination, and this might include the removal of Meibomian cysts. Less direct interventions, such as dietary adjustments, avoidance measures for trigger factors, the use of sunscreens and patient education, in addition to trials investigating which is the most effective treatment for phymatous rosacea and granulomatous rosacea, are further areas of much needed research. Conceivably some of the studies listed in the '<a href="./references#CD003262-sec-0599" title="">Characteristics of ongoing studies</a>' section of this review will be able to provide answers to these remaining questions. </p> <p>There was wide variability in not only the conduct but also the quality of reporting of many of the trials. A major area for improvement would be in the standardisation of outcome reporting in any future research, as suggested by the COMET (Core Outcome Measures in Effectiveness Trials) Initiative (http://www.comet‐initiative.org/). The use of proprietary severity scales and non‐standardised erythema scales significantly hampered our ability to combine study results for meta‐analysis. Outcomes collected in future trials should be primarily based on a standardised scale of the participant's assessment of the treatment efficacy, and also have a greater emphasis on changes in quality of life as a result of the interventions. Standardised and uniform scales should be developed and used for physicians' assessments, and these should reliably reflect global evaluation, lesion counts, and assessment of erythema and telangiectasia. </p> <p>Time needed for a response and response duration should be addressed more completely, and adverse events reported more rigorously. Furthermore, to ensure improved clinical decision making, future research should place a greater emphasis on the management and treatment of rosacea based on the staging pattern of the disease. </p> <p>Future randomised controlled trials must be well‐designed, well‐conducted, and adequately delivered with subsequent reporting, including high‐quality descriptions of all aspects of methodology. Rigorous reporting needs to conform to the Consolidated Standards of Reporting Trials (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>) statement, and this will enable appraisal and interpretation of results and accurate judgements to be made about the risk of bias and the quality of the evidence of the selected outcomes. Although it is uncertain whether the reported quality mirrors actual study conduct, it is noteworthy that studies with unclear methodology have been shown to produce biased estimates of treatment effects (<a href="./references#CD003262-bbs2-0283" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>). Adherence to guidelines, such as the CONSORT statement, would help ensure complete reporting. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003262-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003262-sec-0022"></div> <div class="table" id="CD003262-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metronidazole compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metronidazole compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Metronidazole<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Metronidazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> RR 1.68, 95% CI 1.25 to 2.28; P = 0.0007, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> RR 3.05, 95% CI 1.57 to 5.94; P = 0.001, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a> (within‐participant study) RR 7. These are clinically important improvements </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> <br/> (151 to 243) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.94 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1773<br/> (6 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most instances of these adverse events were mild and consisted of pruritus, skin irritation and dry skin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>570 per 1000</b> <br/> (371 to 869) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.98</b> <br/> (1.29 to 3.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/> (3 studies<sup>4</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are both statistically significant and clinically important</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602<br/> (7 studies<sup>6</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the separate studies (but not in <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>) there was a greater reduction of erythema in the groups treated with metronidazole, but data were inadequately reported. Except in <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a> data were adequately reported with a MD of ‐1.40 (95% CI ‐2.47 to ‐0.33; P = 0.01) in favour of metronidazole </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1964<br/> (8 studies<sup>8</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SDs reported, data were skewed but appeared to support data of physician‐assessed improvement </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514<br/> (5 studies<sup>9</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on interim data improvement started around four weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>205 per 1000</b> <br/> (102 to 405) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> <br/> (0.25 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study<sup>10</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/44 in metronidazole group relapsed, versus 18/44 in vehicle group during six months follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence intervals)<br/> <sup>3</sup><a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>, <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>4</sup><a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>5</sup> Although for two studies the sequence generation and allocation concealment was unclear (<a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> and <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>), the blinding was ensured for both <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a> and <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>, and stated as double‐blind for <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> and therefore we considered it unlikely that this would have an impact on this outcome assessment and decided only to downgrade for imprecision<br/> <sup>6</sup> Bitar 1990, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002,</a><a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>7</sup> Downgraded one level due to serious imprecision (small sample sizes in the individual studies, pooling not possible due to missing SDs)<br/> <sup>8</sup><a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>, <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>9</sup><a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>10</sup><a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a> </p> <p><sup>11</sup> Although we judged the domains for sequence generation, allocation concealment as unclear and the method of blinding of participants and physicians was not reported, there was no attrition bias nor selective reporting and therefore we concluded there was no serious risk of bias for this outcome assessment </p> <p>12 Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azelaic acid compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Azelaic acid<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Azelaic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Marked improvement to complete remission on Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>636 per 1000</b> <br/> (552 to 733) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/> (1.30 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1179<br/> (4 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a clinically important improvement in favour of azelaic acid</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/> (5 studies<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a> RR 1.00, 95% CI 0.62 to 1.62; P = 0.02, <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a> (within‐participant) 24/33 on the azelaic acid side and 19/33 on placebo side, <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> RR 2.39, 95% CI 1.12 to 5.09; P = 0.02, <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a> and <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> 18% and 8% respectively for azelaic acid treated groups and limited to no data for the placebo groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>497 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>655 per 1000</b> <br/> (586 to 730) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> <br/> (1.18 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1179<br/> (4 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for these assessments from four studies illustrated that azelaic acid was more effective than placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/> (5 studies<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decrease in erythema in groups treated with azelaic acid ranged from 44% to 47.9% and for placebo from 28% to 37.9%, telangiectasia minimal changes. SDs missing </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was <b>‐9.5 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was <b>3.90 lower</b> (5.87 to 1.93 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>401<br/> (1 study<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SDs were reported in (<a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>; <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>; <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>) and data were skewed in <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>. All four studies showed a greater reduction in lesions in azelaic acid treated groups (see <a href="./references#CD003262-fig-0009" title="">Analysis 2.3</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/> (5 studies<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome, but all studies showed clear improvement after three to six weeks </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>, <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>, <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>, <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> <br/> <sup>2</sup><a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>, <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>, <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>, <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>, <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> <br/> <sup>3</sup><a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> <br/> <sup>4</sup> Downgraded one level due to serious imprecision (wide confidence interval) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Topical ivermectin compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical ivermectin compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical ivermectin<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical ivermectin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> DLQI and RosaQoL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although data were statistically significant in favour of ivermectin, the clinical importance is unclear as MID in reduction of DLQI score was not reached and the MID is not yet established for RosaQoL<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Likert scale, good to excellent improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78, 95% CI 1.50 to 2.11 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), RR 1.92, 95% CI 1.59 to 2.32 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>). Both studies showed a statistically significant and clinically important improvement in favour of topical ivermectin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54, 95% CI 0.29 to 1.01 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), RR 1.00, 95% CI 0.55 to 1.82 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Investigator's Global Assessment of clear or almost clear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.30, 95% CI 2.27 to 4.79 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), RR 2.10, 95% CI 1.57 to 2.81 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>). The results of both studies are in concordance with the assessments of the participants </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐8.40, 95% CI ‐9.93 to ‐6.87 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), MD ‐8.90, 95% CI ‐10.45 to ‐7.35 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>). Both of these differences are statistically significant and clinically important </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in both studies was seen after four weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>, <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> <br/> <sup>2</sup> MID = minimal important difference </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topical brimonidine compared to vehicle for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical brimonidine compared to vehicle for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical brimonidine<br/> <b>Comparison:</b> Vehicle </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical brimonidine </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Patient Satisfaction Assessment ‐ grade 2 improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 3 hours RR 2.21, 95% CI 1.52 to 3.22 (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>) and RR 2.00, 95% CI 1.33 to 3.01 (<a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>). At each time point in both studies brimonidine was shown to be more effective than vehicle in an improvement which was statistically significant </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17, 95% CI 0.79 to 1.74 (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>), RR 1.40, 95% CI 0.97 to 2.02 (<a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>). Adverse events were mild and transient </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reporting of data other than "No aggravations in the severity of IGA were observed"</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Clinician Erythema Assessment ‐ grade 2 improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 3 hours RR 2.82, 95% CI 1.85 to 4.30 (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>), RR 1.78, 95% CI 1.25 to 2.55 (<a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reporting of data other than "No aggravations in the severity of lesion counts were observed" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement was seen within 30 min</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no rebound or worsening of erythema after treatment cessation in comparison to baseline assessments </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>, <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Topical azelaic acid compared to topical metronidazole for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical azelaic acid compared to topical metronidazole for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical azelaic acid<br/> <b>Comparison:</b> Topical metronidazole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical metronidazole</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical azelaic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.23, CI 95% 1.04 to 1.44; P = 0.01 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 1.00, 95% CI 0.83 to 1.21 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> (within‐participant) authors report P = 0.02 in favour of azelaic acid </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.64, 95% CI 1.81 to 7.31; P = 0.0003 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 0.74, 95% CI 0.52 to 1.07 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>). In <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> 1 participant reported stinging on azelaic acid treated site </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.26, 95% CI 1.03 to 1.53; P = 0.02 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 1.05, 95% CI 0.79 to 1.39 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> score 2.7 (SD 1.0) versus 3.1 (SD 1.0) (higher is worse) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.35, 95% CI 1.05 to 1.75; P = 0.02 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 0.99, 95% CI 0.69 to 1.42 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), in <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> the participants and physicians had contradictory judgements </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion counts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SDs were reported, all three studies demonstrated a clinically important reduction in lesion count in both treatment arms </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement for both arms was seen after four to six weeks in all three studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>, <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>, <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> <br/> <sup>2</sup> Downgraded one level due to serious risk of bias (all three studies stated to be double‐blind, but method of blinding was not described)<br/> <sup>3</sup> Downgraded one level due to serious inconsistency (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> no statistically significant difference (severe heterogeneity unexplained (I<sup>2</sup> &gt;60%), and the 95% CIs do overlap but lead to different interpretation of the effect estimate, but in <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> azelaic was more effective)<br/> <sup>4</sup> Downgraded one level due to serious inconsistency (statistically significant difference in participants reporting adverse events in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> (in favour of metronidazole), not confirmed in Wolf 2006 (severe heterogeneity unexplained (I<sup>2</sup>&gt;60% and the 95% CIs did not overlap))<br/> <sup>5</sup> Downgraded one level due to serious inconsistency (no statistically significant difference in <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>, but in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> azelaic acid is more effective, severe heterogeneity unexplained and the 95% CI do overlap but lead to different interpretation of the effect estimate)<br/> <sup>6</sup> Downgraded one level due to inconsistency (no statistically significant difference in <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>, but in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> azelaic acid is more effective according to physicians (but metronidazole is more effective according to participants in <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Topical ivermectin compared to topical metronidazole for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical ivermectin compared to topical metronidazole for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical ivermectin<br/> <b>Comparison:</b> Topical metronidazole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical metronidazole</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical ivermectin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> DLQI, proportion of participants that reported at end of study that rosacea had no impact on QoL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>640 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>711 per 1000</b> <br/> (647 to 775) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/> (1.01 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in DLQI was 5.18 in ivermectin group and 3.92 in metronidazole group (both meeting minimal important difference) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Likert scale ‐ good to excellent improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>748 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>853 per 1000</b> <br/> (800 to 912) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/> (1.07 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a statistically significant difference and in concordance with the results on number of participants that experienced no deleterious effect on their quality of life </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (6 to 61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.28</b> <br/> (0.71 to 7.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>754 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>852 per 1000</b> <br/> (799 to 905) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (1.06 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These assessments are consistent with the assessments of the participants</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control groups was<br/> <b>‐23.60 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention groups was<br/> <b>4.10 lower</b> <br/> (5.18 to 3.02 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both treatments showed clinically important reductions in lesion counts</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a predefined outcome, but clear improvement could be seen for both treatment arms around six weeks </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low occurrence of events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Ciclosporin ophthalmic emulsion 0.05% compared to artificial tears for ocular rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclosporin ophthalmic emulsion 0.05% compared to artificial tears for ocular rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with ocular rosacea<br/> <b>Intervention:</b> Ciclosporin ophthalmic emulsion 0.05%<br/> <b>Comparison:</b> Artificial tears </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Artificial tears</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclosporinophthalmic emulsion 0.05%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> Ocular Surface Disease Index (scale 0 to 100, 100 worst) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OSDI in the control group was<br/> <b>16.9</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OSDI in the intervention group was<br/> <b>8.6 lower</b> <br/> (15.42 to 1.78 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The difference between change scores at end of study equates to a moderate improvement in quality of life in favour of ciclosporin ophthalmic emulsion </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b> <br/> (0.10 to 53.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Schirmer score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the control group was<br/> <b>‐1.4</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the intervention group was<br/> <b>4.1 higher</b> <br/> (1.66 to 6.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a> <br/> <sup>2</sup> Downgraded two levels due to very serious imprecision (very wide confidence interval due to low sample size, optimal information size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Clindamycin phosphate 1.2% + tretinoin 0.025% gel compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clindamycin phosphate 1.2% + tretinoin 0.025% gel compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Clindamycin phosphate 1.2% + tretinoin 0.025% gel<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clindamycin phosphate 1.2% + tretinoin 0.025% gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> RosaQoL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No mean scores were provided, only percentages of participants that had improved per item on the 21 survey items, no statistically significant difference for any item </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>674 per 1000</b> <br/> (390 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.45</b> <br/> (1.42 to 4.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsening of rosacea, facial scaling, as well as dry skin were reported most often in the active treatment group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> PGA as defined by <a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the primary features of the PGA showed statistically significant differences between the treatment groups except for oedema in favour of placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> <br/> (105 to 627) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/> (0.70 to 4.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.71 (95% CI 0.70 to 4.18) refers to erythema. Telangiectasia RR 2.42, 95% CI 0.95 to 6.17 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐3.13 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>3.96 higher</b> <br/> (1.28 lower to 9.20 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no improvement</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Tetracycline compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tetracycline compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Tetracycline<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tetracycline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>701 per 1000</b> <br/> (403 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.48</b> <br/> (0.85 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (3 to 744) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/> (0.06 to 14.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only one adverse event was reported in each group, diarrhoea in the tetracycline group, maculopapular rash in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (2 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.04, 95% CI 1.66 to 9.83; P = 0.002 (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) and RR 1.72, 95% CI 1.18 to 2.50; P = 0.005 (<a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant changes in erythema (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>1.41 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>14.64 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crude MD ‐14.64 but skewed data (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>3</sup><a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> and <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a> <br/> <sup>4</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met)<br/> <sup>5</sup> Downgraded one level due to serious imprecision (skewed data and low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Doxycycline 40 mg compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxycycline 40 mg compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Doxycycline 40 mg<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14, 95% CI 0.85 to 1.53 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and RR 1.27, 95% CI 1.04 to 1.55 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Investigator's Global Assessment, two point improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.77, 95% CI 1.24 to 2.52; P = 0.002 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and RR 1.41, 95% CI 0.87 to 2.29 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) and IGA score of 0 or 1 RR 1.59, 95% CI 1.02 to 2.47; P = 0.04 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and RR 2.37, 95% CI 1.12 to 4.99; P = 0.02 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Clinician's Erythema Assessments scale 0 to 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in CEA ‐2.7 (doxycycline group) versus ‐1.8 (placebo group), investigators report P = 0.017 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>); and ‐1.4 and ‐1.2 respectively (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion counts</b> <br/> Scale from: ‐4.3 to ‐11.8 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5.90, 95% CI ‐9.37 to ‐2.43; P = 0.0009 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and MD ‐5.20, 95% CI ‐8.27 to ‐2.13; P = 0.0009 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The steepest changes in graph plots occurred within three weeks in the doxycycline group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a> and <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Azithromycin compared to doxycycline 100 mg for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azithromycin compared to doxycycline 100 mg for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Azithromycin<br/> <b>Comparison:</b> Doxycycline 100 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 100 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Azithromycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> <br/> (616 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.77 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no statistically significant difference between the groups, but in both treatment arms the majority of participants considered themselves improved </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> <br/> (21 to 551) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.62</b> <br/> (0.32 to 8.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion counts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesions count in the control group was<br/> <b>2.34 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesions count in the intervention group was<br/> <b>0 higher</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesion count decreased in azithromycin group from 19.24 (SD 9.67) to 1.90 (SD 3.28) at 3 months and for doxycycline from 18.86 (SD 8.95) to 2.34 (SD 3.47). Skewed data </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data on duration of remission, but both groups showed no statistically significant change between the third month of treatment and the second month post‐treatment in the mean inflammatory lesion counts </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a> <br/> <sup>2</sup> Downgraded two levels due to very serious risk of bias (allocation concealment was at high risk of bias, no blinding)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met, optimal sample size is not met)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>5</sup> Downgraded one level due to serious imprecision (large SDs and skewed data, low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Doxycycline 40 mg + metronidazole 1% gel compared to doxycycline 100 mg + metronidazole 1% gel for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxycycline 40 mg + metronidazole 1% gel compared to doxycycline 100 mg + metronidazole 1% gel for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Doxycycline 40 mg + metronidazole 1% gel<br/> <b>Comparison:</b> Doxycycline 100 mg + metronidazole 1% gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 100 mg + metronidazole 1% gel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg + metronidazole 1% gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>553 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (61 to 299) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.25</b> <br/> (0.11 to 0.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The majority of these adverse events were gastrointestinal complaints</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Reduction in Investigator's Global Assessment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the control group was<br/> <b>‐1.6</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the intervention group was<br/> <b>0.00 higher</b> <br/> (0.11 lower to 0.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Clinician's Erythema Assessment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the control group was<br/> <b>‐4.0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the intervention group was<br/> <b>0 higher</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in CEA 4.2 in doxycycline 40 mg and 4.0 in doxycycline 100 mg group, investigator's state P = 0.50 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐12.2 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>0.30 lower</b> <br/> (3.03 lower to 2.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clear improvement was seen from week four for both groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0024" title="DelRossoJQ , CaveneyS . Comparison of anti‐inflammatory dose doxycycline (30‐mg immediate‐release beads, 10 mg delayed‐release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery2012;31(1):A7‐8. [EMBASE: 70706922] DelRossoJQ , SchlessingerJ , WerschlerP . Comparison of anti‐inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology2008;7(6):573‐6. [PUBMED: 18561589] ">Del Rosso 2008</a> <br/> <sup>2</sup> Downgraded one level due to serious risk of selection bias and attrition bias (sequence generation and allocation concealment at unclear risk of bias, high drop‐out rate and although ITT analysis judged at unclear risk of bias)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Doxycycline 40 mg + azelaic acid gel compared to doxycycline 40 mg + metronidazole gel for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxycycline 40 mg + azelaic acid gel compared to doxycycline 40 mg + metronidazole gel for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Doxycycline 40 mg + azelaic acid gel<br/> <b>Comparison:</b> Doxycycline 40 mg + metronidazole gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg + metronidazole gel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg + azelaic acid gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Excellent improvement on a 4‐point Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>489 per 1000</b> <br/> (368 to 651) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> <br/> (0.79 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excellent improvement was reported in approximately half of each intervention group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (4 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.27</b> <br/> (0.06 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Investigator's Global Assessment of 0, 1 or 2 (clear to mild) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>723 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>781 per 1000</b> <br/> (672 to 918) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.93 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician's Erythema Assessment</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐9.4 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>1.10 lower</b> <br/> (4.91 lower to 2.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From four weeks on improvement could be seen for both treatment arms</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0014"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Minocycline 45 mg compared to minocycline 45 mg + azelaic acid gel for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Minocycline 45 mg compared to minocycline 45 mg + azelaic acid gel for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Minocycline 45 mg<br/> <b>Comparison:</b> Minocycline 45 mg + azelaic acid gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Minocycline 45 mg + azelaic acid gel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Minocycline 45 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>533 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> <br/> (208 to 651) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> <br/> (0.39 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Mean change in Investigator's Global Assessment (Likert scale 0 to 5). Scale from: 0 to 4. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the control groups was<br/> <b>‐2.0 on IGA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the intervention groups was<br/> <b>0.00 higher</b> <br/> (0.32 lower to 0.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Mean change in CEA scale (Likert scale 0 to 4). Scale from: 0 to 4. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the control group was<br/> <b>‐4 on CEA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the intervention group was<br/> <b>1.00 higher</b> <br/> (0.18 lower to 2.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐12 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>1.00 higher</b> <br/> (0.93 lower to 2.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In both groups there was a clinically important reduction in lesion counts of 11.00 (SD 4.49) in the minocycline group and 12.00 (SD 3.00) in the comparator group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement was seen in both arms at four weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a> <br/> <sup>2</sup> Downgraded one level due to serious risk of performance and detection bias (blinding was assessed as at unclear risk of bias)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0015"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Topical metronidazole compared to oral (oxy)tetracycline for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical metronidazole compared to oral (oxy)tetracycline for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical metronidazole<br/> <b>Comparison:</b> Oral (oxy)tetracycline </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral (oxy) tetracycline</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical metronidazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71, 95% CI 0.40 to 1.26 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), RR 0.96, 95% CI 0.80 to 1.17 (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>) and in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> no exact data were provided other than that "both groups considered their condition much improved" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (4 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse event (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>), RR 1.06, 95% CI 0.32 to 3.55 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), 12 adverse events reported in metronidazole group and 9 in tetracycline group (<a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>), RR 0.70, 95% CI 0.30 to 1.65 (<a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (2 studies<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80, 95% CI 0.47 to 1.35 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), RR 1.00, 95% 0.89 to 1.13 (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (4 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema score ‐1.4 versus ‐1.3 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), "the reduction of erythema was the same in both groups, and the number and extent of telangiectases were unchanged" (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>), in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> no differences in erythema nor telangiectasia were seen in either group. In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> the percentage of no improvement was 11.1 in the metronidazole group versus 12.5 in the tetracycline group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (4 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete clearance in 75% versus 66% of participants (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), "the reduction of papules and pustules was the same in both groups" (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>), decrease of 68% versus 77% in papule count and of 53% and 61% in pustule count (<a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>). In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> only medians were provided with 11.1 lesions in the metronidazole group and 0 in the tetracycline group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>, <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> (number of participants randomised in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> was unclear)<br/> <sup>2</sup> Downgraded one level due to serious imprecision (low sample sizes)<br/> <sup>3</sup><a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>, <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>, <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> (number of participants randomised in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> was unclear)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (wide confidence intervals due to low sample sizes)<br/> <sup>5</sup><a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> <br/> <sup>6</sup> Downgraded one level due to serious heterogeneity (in contrast to the other three studies, <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> did not show any improvement in erythema and telangiectasia </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0016"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Low dose isotretinoin 0.3 mg/kg compared to doxycycline 50‐100 mg for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Low dose isotretinoin 0.3 mg/kg compared to doxycycline 100 mg for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Low dose isotretinoin 0.3 mg/kg<br/> <b>Comparison:</b> Doxycycline 100 mg after 14 days tapered to 50 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 100 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Low dose isotretinoin 0.3 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b><sup>1</sup> <br/> Good to excellent improvement on 5‐point Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>644 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>792 per 1000</b> <br/> (676 to 921) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/> (1.05 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low dose isotretinoin is considered by the participants to be slightly more effective than doxycycline 100 mg </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (127 to 328) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.74 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b><sup>1</sup> <br/> Complete remission or marked improvement on a 6‐point Likert scale) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>689 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>813 per 1000</b> <br/> (710 to 938) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (1.03 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In agreement with the participant‐assessed changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Improved or healed </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>783 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>736 per 1000</b> <br/> (650 to 846) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/> (0.83 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia were improved or "healed" RR 1.03, 95% CI 0.77 to 1.37</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐13 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>3 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Per‐protocol analysis<br/> <sup>2</sup><a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0017"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Pulsed dye laser compared to Nd:YAG laser for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pulsed dye laser compared to Nd:YAG laser for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Pulsed dye laser<br/> <b>Comparison:</b> Nd:YAG laser </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Nd: YAG laser</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pulsed dye laser</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the control group was<br/> <b>34 percent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the intervention group was<br/> <b>16.33 higher</b> <br/> (1.94 to 34.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b><sup>1</sup> <br/> Pain as assessed by VAS (0 to 10; higher score is worse) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain was assessed on the PDL treated side 3.87 and 3.07 on the Nd:YAG side, the investigators state P = 0.0028 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b><sup>1</sup> <br/> Spectrophotometer to assess facial redness </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the control group was<br/> <b>‐2.5 percent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the intervention group was<br/> <b>6.4 lower</b> <br/> (11.6 to 1.2 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Within‐participant<br/> <sup>2</sup><a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a> <br/> <sup>3</sup> Downgraded two levels due to very serious imprecision (very wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>4</sup> Downgraded two levels due to very serious imprecision (very low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003262-tbl-0018"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Pulsed dye laser compared to intense pulsed light therapy for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pulsed dye laser compared to intense pulsed light therapy for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Pulsed dye laser (PDL)<br/> <b>Comparison:</b> Intense pulsed light therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intense Pulsed Light Therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pulsed Dye Laser</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b><sup>1</sup> <br/> VAS. Scale from: 0 to 10 (0 being a poor and 10 an excellent result) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the control group was<br/> <b>7</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the intervention group was<br/> <b>1 higher</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median was 8 (range 2 to 10) for PDL group and 7 (range 2 to 10) for IPL group (10% and 90% percentiles) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> <br/> Pain as assessed with a VAS scale. Scale from: 0 to 10 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Pain assessed on a VAS scale in the control group was<br/> <b>7</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Pain assessed on a VAS scale in the intervention group was<br/> <b>3 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median was 4 (range 2 to 6) for PDL group and 7 (range 2 to 10) for IPL group (10% and 90% percentiles) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> 5‐point Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>On the PDL treated side 18 had an excellent (75% to 100% vessel clearance) response and 12 a good response (50% to 74% clearance) and on the IPL treated sides 11 had an excellent response and 19 a good response </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Within‐participant design<br/> <sup>2</sup><a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a> <br/> <sup>3</sup> Downgraded one level due to serious performance and detection bias (investigators and participants were not blinded)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met)<br/> <sup>5</sup> "Clinical efficacy was evaluated by one blinded trained physician" </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003262-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003262-sec-0023"></div> <p>We have listed unfamiliar terms in the glossary of terms in <a href="#CD003262-tbl-0019">Table 1</a>. </p> <div class="table" id="CD003262-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Term</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A skin condition characterised by the inflammation or infection of sebaceous glands (usually attached to hair follicles) resulting in comedones (whiteheads and blackheads) and inflammatory lesions such as papules (pimples), pustules, and nodules) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Bacillus oleronius</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A bacteria found in Demodex mites</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance of a micro‐organism to an antimicrobial drug that was originally effective for treatment of infections caused by this micro‐organism </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body dysmorphic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anxiety disorder surrounding perceived flaws in one's own appearance</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cytokines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small protein released by cells, and having a specific effect on the behavior of other cells, or on the interactions or communications between cells </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Demodex folliculorum</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A species of face mite found in human hair follicles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Down‐regulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Process of reducing or suppressing a response to a stimulus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epidermal barrier</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The skin's front line of defence in the upper layer of the skin (the epidermis) against environmental factors such as UV light, chemicals, bacteria and other organisms and limits water loss from the body </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Innate immune response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The first line generic defence of the immune system against infection and other organisms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Keratinocytes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A predominant cell type in the outermost layer of skin (epidermis), and when found in the basal layer, are referred to as 'basal cells' or 'basal keratinocytes'. Their main function is the formation of a barrier against environmental damage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Matrix‐Metalloproteinases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc dependent enzymes that promote break down of proteins like collagen. They regulate various inflammatory and repair processes </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurovascular dysregulation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A failure of the vascular response, vasodilation, and neurosensory symptoms to regulate properly </p> <p>Dysfunction of both nerves and vascular elements, controlling the calibre of blood vessels </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nodule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Solid, raised area in or under the skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nodularities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An increased density of tissues</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pathophysiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The functional changes that accompany a particular syndrome or disease (combined terms of ‘patho’ (path, related to disease) and ‘physiology’ (a branch of biology that specialises in the study of the functions of living organisms and their parts) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phototype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A classification of skin type based on a person's sensitivity to sunlight</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pustule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small bump on the skin containing purulent material (pus) in the top layer (epidermis) or beneath it (dermis) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reactive oxygen species (ROS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemically reactive molecules containing oxygen, or oxygen‐derived radicals, having important roles in cell signalling (communication and interaction) and homeostasis (the maintenance of a steady state) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemical compounds related chemically to Vitamin A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stratum corneum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outermost layer of the epidermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A bacterial infection of a gland at the base of any eyelash, causing painful swelling on the inner or outer eyelid </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Toll‐like receptors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A class of proteins that play a key role in the innate immune system, activating immune cell responses </p> </td> </tr> </tbody> </table> </div> <section id="CD003262-sec-0024"> <h3 class="title" id="CD003262-sec-0024">Description of the condition</h3> <section id="CD003262-sec-0025"> <h4 class="title">Definition and clinical features</h4> <p>Rosacea is a chronic skin disease that can affect the cheeks, nose, eyes, chin and forehead. It is characterised by recurrent episodes of flushing, erythema (redness), papules (pimples), pustules and telangiectasia (permanent distended blood capillary vessels with a spidery appearance) (<a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0271" title="MarksR . The enigma of rosacea. Journal of Dermatological Treatment2007;18(6):326‐8. [PUBMED: 18058493] ">Marks 2007</a>; <a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>). Although there is no standard clinical definition of the condition, rosacea is generally classified into four subtypes and one variant (<a href="./references#CD003262-bbs2-0305" title="WilkinJ , DahlM , DetmarM , DrakeL , FeinsteinA , OdomR , et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Journal of the American Academy of Dermatology2002;46(4):584‐7. [MEDLINE: 11907512] ">Wilkin 2002</a>; <a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a>). </p> <p> <ul id="CD003262-list-0001"> <li> <p>Subtype 1: erythematotelangiectatic rosacea, where the clinical features include flushing and persistent central facial erythema (redness) with or without telangiectasia. </p> </li> <li> <p>Subtype 2: papulopustular rosacea, characterised by persistent central facial erythema with transient, central face papules or pustules, or both. </p> </li> <li> <p>Subtype 3: phymatous rosacea, where thickening of the skin is seen with irregular surface nodularities, and enlargement. This may occur on the nose (rhinophyma), chin, forehead, cheeks or ears. </p> </li> <li> <p>Subtype 4: ocular rosacea, characterised by ocular involvement, including inflammation of different parts of the eye and eyelid. It may be found in up to 58% of cases but it is frequently undiagnosed. </p> </li> <li> <p>Variant: granulomatous rosacea, which is non‐inflammatory and characterised by hard, brown, yellow or red cutaneous papules, or nodules of uniform size. </p> </li> </ul> </p> <p>Progression from one subtype to another is possible, patients may express signs and symptoms of more than one subtype, and each individual characteristic may change from absent to severe (<a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>; <a href="./references#CD003262-bbs2-0291" title="TanJ , Blume‐PeytaviU , OrtonneJP , WilhelmK , MarticouL , BaltasE , et al. An observational cross‐sectional survey of rosacea: clinical associations and progression between subtypes. British Journal of Dermatology2013;169(3):555‐62. [PUBMED: 23600367] ">Tan 2013</a>; <a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a>). </p> </section> <section id="CD003262-sec-0026"> <h4 class="title">Symptoms</h4> <p>Rosacea primarily affects the face and is accompanied by the physical discomfort of flushes, persistent erythema and the effects of eye lesions and inflammatory lesions, and it can also lead to psychological problems over and above these physical symptoms. </p> <p>The disease can cause embarrassment, anxiety, low self‐esteem and lack of confidence, and may even lead to depression, social anxiety disorder or body dysmorphic disorder (<a href="./references#CD003262-bbs2-0223" title="AbramK , SilmH , MaaroosHI , OonaM . Subjective disease perception and symptoms of depression in relation to healthcare‐seeking behaviour in patients with rosacea. Acta Dermato‐Venereologica2009;89(5):488‐91. [PUBMED: 19734974] ">Abram 2009</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>; <a href="./references#CD003262-bbs2-0267" title="LandowK . Rosacea: The battle goes on. Comprehensive Therapy2005;31(2):145‐58. [PUBMED: 15901945] ">Landow 2005</a>; <a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>). If there is eye involvement, it may result in varying and sometimes severe manifestations which may produce significant additional discomfort (<a href="./references#CD003262-bbs2-0269" title="LazaridouE , FotiadouC , ZiakasNG , GiannopoulouC , ApallaZ , IoannidesD . Clinical and laboratory study of ocular rosacea in northern Greece. Journal of the European Academy of Dermatology and Venereology2011;25(12):1428‐31. [PUBMED: 21366706] ">Lazaridou 2011</a>; <a href="./references#CD003262-bbs2-0278" title="OltzM , CheckJ . Rosacea and its ocular manifestations. Optometry2011;82(2):92‐103. [PUBMED: 21276570] ">Oltz 2011</a>; <a href="./references#CD003262-bbs2-0302" title="VieiraAC , MannisMJ . Ocular rosacea: common and commonly missed. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S36‐41. [PUBMED: 24229635] ">Vieira 2013</a>). </p> <p>There are no standard validated tools for assessing the severity of rosacea or its signs and symptoms (<a href="./references#CD003262-bbs2-0259" title="GessertCE , BamfordJT . Measuring the severity of rosacea: A review. International Journal of Dermatology2003;42(6):444‐8. [PUBMED: 12786870] ">Gessert 2003</a>). Thus clinicians tend to assess the severity of rosacea by focusing on the papules and pustules, whereas people with rosacea place greater emphasis on the erythema. There would appear to be poor consistency in assessments between individuals when detailed scoring scales are used (<a href="./references#CD003262-bbs2-0230" title="BamfordJTM , GessertCE , RenierCM . Measurement of the severity of rosacea. Journal of the American Academy of Dermatology2004;51(5):697‐703. [EMBASE: 2004494171] ">Bamford 2004</a>; <a href="./references#CD003262-bbs2-0259" title="GessertCE , BamfordJT . Measuring the severity of rosacea: A review. International Journal of Dermatology2003;42(6):444‐8. [PUBMED: 12786870] ">Gessert 2003</a>). Moreover, several studies have demonstrated that objective clinical parameters of skin disease are often poorly correlated with quality of life, and that physicians tend to underestimate the impact of skin disease on an individual (<a href="./references#CD003262-bbs2-0241" title="ChrenMM , LasekRJ , QuinnLM , MostowEN , ZyzanskiSJ . Skindex, a quality‐of‐life measure for patients with skin disease: reliability, validity, and responsiveness. Journal of Investigative Dermatology1996;107(5):707‐13. [PUBMED: 8875954] ">Chren 1996</a>; <a href="./references#CD003262-bbs2-0276" title="NicholsonK , AbramovaL , ChrenMM , YeungJ , ChonSY , ChenSC . A pilot quality‐of‐life instrument for acne rosacea. Journal of the American Academy of Dermatology2007;57(2):213‐21. [PUBMED: 17445948] ">Nicholson 2007</a>). Rosacea has a significant negative impact on quality of life (<a href="./references#CD003262-bbs2-0224" title="AksoyB , Altaykan‐HapaA , EgemenD , KaragözF , AtakanN . The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. British Journal of Dermatology2010;163(4):719‐25. [PUBMED: 20545683] ">Aksoy 2010</a>; <a href="./references#CD003262-bbs2-0244" title="CresceND , DavisSA , HuangWW , FeldmanSR . The quality of life impact of acne and rosacea compared to other major medical conditions. Journal of Drugs in Dermatology2014;13(6):692‐7. [PUBMED: 24918559] ">Cresce 2014</a>; <a href="./references#CD003262-bbs2-0273" title="MoustafaF , LewallenRS , FeldmanSR . The psychological impact of rosacea and the influence of current management options. Journal of the American Academy of Dermatology2014; Vol. 71, issue 5:973‐80. [PUBMED: 24993600] ">Moustafa 2014</a>; <a href="./references#CD003262-bbs2-0299" title="van derLindenMM , vanRappardDC , DaamsJG , SprangersMA , SpulsPI , deKorteJ . Health‐related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review. Acta Dermato‐Venereologica 2014 Oct 1 [Epub ahead of print]. [PUBMED: 25270577] ">van der Linden 2014</a>). A validated disease‐specific quality of life instrument (RosaQoL) has been developed, and RosaQoL scores have been used in several studies as one of the outcome parameters (<a href="./references#CD003262-bbs2-0229" title="BaldwinHE . A community‐based study of the effectiveness of doxycycline 40 mg (30‐mg immediate‐release and 10‐mg delayed‐release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis2010;86(5 Suppl):26‐36. [PUBMED: 21229828] ">Baldwin 2010</a>; <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>; <a href="./references#CD003262-bbs2-0127" title="FleischerA , SuephyC . The face and mind evaluation study: An examination of the efficacy of rosacea treatment using physician ratings and patients' self‐reported quality of life. Journal of Drugs in Dermatology2005;4(5):585‐90. [MEDLINE: 16167417] ">Fleischer 2005</a>; <a href="./references#CD003262-bbs2-0264" title="KiniSP , NicholsonK , DeLongLK , DannemannT , EstarisJ , FosterJ , et al. A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. Journal of the American Academy of Dermatology2010;62(6):1069‐71. [PUBMED: 20466185] ">Kini 2010</a>; <a href="./references#CD003262-bbs2-0276" title="NicholsonK , AbramovaL , ChrenMM , YeungJ , ChonSY , ChenSC . A pilot quality‐of‐life instrument for acne rosacea. Journal of the American Academy of Dermatology2007;57(2):213‐21. [PUBMED: 17445948] ">Nicholson 2007</a>). Much work remains to be done to improve the quality of reporting of patient reported outcomes (PRO) in studies on rosacea (<a href="./references#CD003262-bbs2-0301" title="vanZuurenEJ , FedorowiczZ . Lack of 'appropriately assessed' patient‐reported outcomes in randomized controlled trials assessing the effectiveness of interventions for rosacea. British Journal of Dermatology2013;168(2):442‐4. [PUBMED: 22803770] ">van Zuuren 2013</a>). </p> </section> <section id="CD003262-sec-0027"> <h4 class="title">Epidemiology and causes</h4> <p>Rosacea usually presents in the second or third decade of life, with up to 10% of the population affected (<a href="./references#CD003262-bbs2-0233" title="BergM , LidénS . An epidemiological study of rosacea. Acta Dermato‐Venereologica1989;69(5):419‐23. [PUBMED: 2572109] ">Berg 1989</a>). It is reportedly more common in fair‐skinned people of Celtic and northern European heritage (<a href="./references#CD003262-bbs2-0245" title="CulpB , ScheinfeldN . Rosacea: A Review. P &amp; T2009;34(1):38‐45. [PUBMED: 19562004] ">Culp 2009</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>) and women appear to be more often affected than men (<a href="./references#CD003262-bbs2-0245" title="CulpB , ScheinfeldN . Rosacea: A Review. P &amp; T2009;34(1):38‐45. [PUBMED: 19562004] ">Culp 2009</a>; <a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>). However, a proportionately larger number of men develop phymatous changes (thickening skin, irregular surface nodularities, and enlargement), sometimes as a result of progression from subtype 1 or subtype 2 to subtype 3 (<a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>; <a href="./references#CD003262-bbs2-0291" title="TanJ , Blume‐PeytaviU , OrtonneJP , WilhelmK , MarticouL , BaltasE , et al. An observational cross‐sectional survey of rosacea: clinical associations and progression between subtypes. British Journal of Dermatology2013;169(3):555‐62. [PUBMED: 23600367] ">Tan 2013</a>; <a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a>). The prevalence of rosacea varies from less than 1% to more than 20%, indicating a range which is most likely attributable to differences in the populations studied and the methodological approach used (<a href="./references#CD003262-bbs2-0292" title="TanJ , BergM . Rosacea: current state of epidemiology. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S27‐35. [PUBMED: 24229634] ">Tan 2013b</a>). Prevalence studies of rosacea in darker skin phototypes are sparse. </p> <p>The pathophysiology of rosacea is very complex and the exact cause remains unclear. A number of hypotheses have been proposed. Both genetic and mostly environmental stimuli and triggers, for example heat, sunlight, stress, certain foodstuffs and Demodex mites stimulate an augmented innate immune response and neurovascular dysregulation (<a href="./references#CD003262-bbs2-0246" title="DelRossoJQ . Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. Journal of Clinical and Aesthetic Dermatology2012;5(3):16‐25. [PUBMED: 22468176] ">Del Rosso 2012</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>; <a href="./references#CD003262-bbs2-0287" title="SteinhoffM , BuddenkotteJ , AubertJ , SulkM , NovakP , SchwabVD , et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. Journal of Investigative Dermatology2011;15(1):2‐11. [PUBMED: 22076321] ">Steinhoff 2011</a>; <a href="./references#CD003262-bbs2-0288" title="SteinhoffM , SchauberJ , LeydenJJ . New insights into rosacea pathophysiology: a review of recent findings. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S15‐26. [PUBMED: 24229632] ">Steinhoff 2013</a>). In rosacea affected skin, elevated abnormal cathelicidin (an antimicrobial peptide) and elevated serine protease (kallikrein‐5) induce increased LL‐37, which results in inflammation, neurovascular effects and vascular changes (<a href="./references#CD003262-bbs2-0246" title="DelRossoJQ . Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. Journal of Clinical and Aesthetic Dermatology2012;5(3):16‐25. [PUBMED: 22468176] ">Del Rosso 2012</a>; <a href="./references#CD003262-bbs2-0307" title="YamasakiK , DiNardoA , BardanA , MurakamiM , OhtakeT , CodaA , et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine2007;13(8):975‐80. [PUBMED: 17676051] ">Yamasaki 2007</a>;<a href="./references#CD003262-bbs2-0308" title="YamasakiK , GalloRL . Rosacea as a disease of cathelicidins and skin innate immunity. Journal of Investigative Dermatology. Symposium Proceedings / the Society for Investigative Dermatology, Inc. European Society for Dermatological Research2011;15(1):12‐5. [PUBMED: 22076322] ">Yamasaki 2011</a>). More recently mechanisms and components of rosacea pathophysiology have been categorised into (a) increase of Toll‐like receptors on keratinocytes, (b) augmented innate immunity, (c) neurovascular dysregulation (d) vascular changes, (e) reactive oxygen species (ROS), (f) stratum corneum permeability barrier dysfunction, (g) ultraviolet (UV) radiation and (h) microbes, e.g. Demodex,<i>Bacillus oleronius</i> (<a href="./references#CD003262-bbs2-0246" title="DelRossoJQ . Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. Journal of Clinical and Aesthetic Dermatology2012;5(3):16‐25. [PUBMED: 22468176] ">Del Rosso 2012</a>; <a href="./references#CD003262-bbs2-0247" title="DelRossoJQ , GalloRL , TanghettiE , WebsterG , ThiboutotD . An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis2013;91(3 Suppl):1‐8. [PUBMED: 23833998] ">Del Rosso 2013a</a>; <a href="./references#CD003262-bbs2-0287" title="SteinhoffM , BuddenkotteJ , AubertJ , SulkM , NovakP , SchwabVD , et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. Journal of Investigative Dermatology2011;15(1):2‐11. [PUBMED: 22076321] ">Steinhoff 2011</a>; <a href="./references#CD003262-bbs2-0296" title="TismaVS , Basta‐JuzbasicA , JaganjacM , BrcicL , DobricI , LipozencicJ , et al. Oxidative stress and ferritin expression in the skin of patients with rosacea. Journal of the American Academy of Dermatology2009;60(2):270‐6. [PUBMED: 19028405] ">Tisma 2009</a>). The current hypothesis is that rosacea is an inflammatory disorder that may develop in individuals with rosacea‐prone skin, initiated by several triggers (<a href="./references#CD003262-bbs2-0287" title="SteinhoffM , BuddenkotteJ , AubertJ , SulkM , NovakP , SchwabVD , et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. Journal of Investigative Dermatology2011;15(1):2‐11. [PUBMED: 22076321] ">Steinhoff 2011</a>). Possible triggers that have been investigated are gastrointestinal (digestive) tract diseases, infestation with <i>Demodex folliculorum</i> , <i>Bacillus oleronius</i>, epidermal barrier defect, and childhood stye (<a href="./references#CD003262-bbs2-0231" title="BamfordJT , GessertCE , RenierCM , JacksonMM , LaabsSB , DahlMV , et al. Childhood stye and adult rosacea. Journal of the American Academy of Dermatology2006;55(6):951‐5. [PUBMED: 17097390] ">Bamford 2006</a>; <a href="./references#CD003262-bbs2-0254" title="ElewskiBE . Results of a national rosacea patient survey: Common issues that concern rosacea sufferers. Journal of Drugs in Dermatology2009;8(2):120‐3. [PUBMED: 19213226] ">Elewski 2009</a>; <a href="./references#CD003262-bbs2-0257" title="FortonF . Standardized skin surface biopsy: method to estimate the Demodex folliculorum density, not to study the Demodex folliculorum prevalence. Journal of the European Academy of Dermatology and Venereology2007;21(9):1301‐2. [PUBMED: 17894752] ">Forton 2007</a>; <a href="./references#CD003262-bbs2-0258" title="FortonFM . Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. Journal of the European Academy of Dermatology and Venereology2012;26(1):19‐28. [PUBMED: 22017468] ">Forton 2012</a>; <a href="./references#CD003262-bbs2-0266" title="LaceyN , DelaneyS , KavanaghK , PowellFC . Mite‐related bacterial antigens stimulate inflammatory cells in rosacea. British Journal of Dermatology2007;157(3):474‐81. [PUBMED: 17596156] ">Lacey 2007</a>). </p> </section> </section> <section id="CD003262-sec-0028"> <h3 class="title" id="CD003262-sec-0028">Description of the intervention</h3> <p>As with most chronic skin diseases, rosacea requires long‐term treatment, therapies are numerous, and their use is frequently based on anecdotal evidence (<a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>; <a href="./references#CD003262-bbs2-0268" title="LaytonA , ThiboutotD . Emerging therapies in rosacea. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S57‐65. [PUBMED: 24229638] ">Layton 2013</a>; <a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>). Management strategies for people with rosacea can often be tailored to the specific subtype of rosacea (<a href="./references#CD003262-bbs2-0228" title="BaldwinHE . Oral therapy for rosacea. Journal of Drugs in Dermatology2006;5(1):16‐21. [PUBMED: 16468287] ">Baldwin 2006</a>; <a href="./references#CD003262-bbs2-0262" title="JansenT , PlewigG . Rosacea: Classification and treatment. Journal of the Royal Society of Medicine1997;90(3):144‐50. [PUBMED: 9135612] ">Jansen 1997</a>; <a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>) but, because rosacea can have a significant impact on quality of life, these strategies should also be directed towards achieving improvements in general well‐being (<a href="./references#CD003262-bbs2-0238" title="BikowskiJB , GoldmanMP . Rosacea: Where are we now?. Journal of Drugs in Dermatology2004;3(3):251‐61. [PUBMED: 15176158] ">Bikowski 2004</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>). In certain individuals successful management of rosacea is possible through avoidance of some of the triggers, in particular those which cause flushing, that is certain foods and beverages, sunlight and some types of cosmetics (<a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>). </p> <section id="CD003262-sec-0029"> <h4 class="title">Topical interventions</h4> <p>If a small number of papules and pustules are present, topical rather than systemic therapy is considered to be the first‐line of treatment (<a href="./references#CD003262-bbs2-0248" title="DelRossoJQ , ThiboutotD , GalloR , WebsterG , TanghettiE , EichenfieldL , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis2013;92(6):277‐84. [PUBMED: 24416742] ">Del Rosso 2013b</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>). This includes a range of formulations of metronidazole, azelaic acid, clindamycin lotion, permethrin 5% cream, tretinoin cream, 10% sulphacetamide with sulphur (5%) and benzoyl peroxide alone or in combination with erythromycin or clindamycin (<a href="./references#CD003262-bbs2-0245" title="CulpB , ScheinfeldN . Rosacea: A Review. P &amp; T2009;34(1):38‐45. [PUBMED: 19562004] ">Culp 2009</a>; <a href="./references#CD003262-bbs2-0248" title="DelRossoJQ , ThiboutotD , GalloR , WebsterG , TanghettiE , EichenfieldL , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis2013;92(6):277‐84. [PUBMED: 24416742] ">Del Rosso 2013b</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>). The Food and Drug Administration (FDA) approved topical ivermectin 1% for papulopustular rosacea and European Medicines Agency (EMA) approval is expected in the near future (<a href="./references#CD003262-bbs2-0268" title="LaytonA , ThiboutotD . Emerging therapies in rosacea. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S57‐65. [PUBMED: 24229638] ">Layton 2013</a>; <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>). Brimonidine tartrate gel 5%, a topical selective α‐adrenergic receptor agonist with vasoconstrictive activity, was recently approved for the treatment of persistent erythema in rosacea (<a href="./references#CD003262-bbs2-0249" title="DelRossoJQ . Management of facial erythema of rosacea: what is the role of topical α‐adrenergic receptor agonist therapy?. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S44‐56. [PUBMED: 24229637] ">Del Rosso 2013c</a>; <a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>). </p> </section> <section id="CD003262-sec-0030"> <h4 class="title">Systemic interventions</h4> <p>If the skin lesions are more extensive, oral antibiotics such as tetracyclines or azithromycin are usually recommended (<a href="./references#CD003262-bbs2-0225" title="AlikhanA , KurekL , FeldmanSR . The role of tetracyclines in rosacea. American Journal of Clinical Dermatology2010;11(2):79‐87. [PUBMED: 20141228] ">Alikhan 2010</a>; <a href="./references#CD003262-bbs2-0227" title="BakarO , DemircayZ , TokerE , CakirS . Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. Journal of the European Academy of Dermatology and Venereology2009;23(5):544‐9. [PUBMED: 19250326] ">Bakar 2009</a>; <a href="./references#CD003262-bbs2-0245" title="CulpB , ScheinfeldN . Rosacea: A Review. P &amp; T2009;34(1):38‐45. [PUBMED: 19562004] ">Culp 2009</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>). Second‐generation tetracyclines, for example doxycycline and minocycline, have been used more recently with reportedly fewer side effects (<a href="./references#CD003262-bbs2-0237" title="BikowskiJB . Subantimicrobial dose doxycycline for acne and rosacea. Skinmed2003;2(4):234‐45. [PUBMED: 14673277] ">Bikowski 2003</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0286" title="SloanB , ScheinfeldN . The use and safety of doxycycline hyclate and other second‐generation tetracyclines. Expert Opinion on Drug Safety2008;7(5):571‐7. [PUBMED: 18759709] ">Sloan 2008</a>). To reduce not only the side effects but also the risk of bacterial resistance, a novel approach has been advocated that involves the use of a subantimicrobial dosage of doxycycline, which separates the anti‐inflammatory effect of doxycycline from its antimicrobial properties by limiting the plasma concentration to a range below the minimum inhibitory concentrations for susceptible bacteria (<a href="./references#CD003262-bbs2-0229" title="BaldwinHE . A community‐based study of the effectiveness of doxycycline 40 mg (30‐mg immediate‐release and 10‐mg delayed‐release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis2010;86(5 Suppl):26‐36. [PUBMED: 21229828] ">Baldwin 2010</a>; <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>; <a href="./references#CD003262-bbs2-0282" title="SapadinAN , FleischmajerR . Tetracyclines: Nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology2006;54(2):258‐65. [PUBMED: 16443056] ">Sapadin 2006</a>; <a href="./references#CD003262-bbs2-0303" title="WalkerC , WebsterG . A multicenter, double‐blind, randomized trial to evaluate long‐term anti‐inflammatory dose doxycycline (40 mg) therapy: Results of the lack of effect on bacterial flora. Presented at: Fall Clinical Dermatology Conference. Las Vegas, NV, USA, 7‐11 October 2006. 2006. ">Walker 2006</a>). Not infrequently, oral treatment may be combined initially with topical treatment so that as the rosacea improves the systemic treatment can be discontinued and improvement can be maintained by continuation with the topical treatment alone (<a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>). </p> </section> <section id="CD003262-sec-0031"> <h4 class="title">Other interventions</h4> <p>The vascular manifestations of rosacea appear to respond fairly effectively to light‐based therapies such as pulsed dye laser or intense pulsed light (<a href="./references#CD003262-bbs2-0245" title="CulpB , ScheinfeldN . Rosacea: A Review. P &amp; T2009;34(1):38‐45. [PUBMED: 19562004] ">Culp 2009</a>; <a href="./references#CD003262-bbs2-0263" title="KawanaS , OchiaiH , TachiharaR . Objective evaluation of the effect of intense pulsed light on rosacea and solar lentigines by spectrophotometric analysis of skin color. Dermatologic Surgery2007;33(4):449‐54. [PUBMED: 17430379] ">Kawana 2007</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0294" title="TanghettiE , DelRossoJQ , ThiboutotD , GalloR , WebsterG , EichenfieldLF , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis2014;93(2):71‐6. [PUBMED: 24605343] ">Tanghetti 2014</a>). In the more severe or persistent cases of papulopustular and phymatous rosacea, oral 13‐cis‐retinoic acid (isotretinoin) therapy may be required. Isotretinoin has a well‐recognised safety profile but should only be given to women under close supervision and should include an appropriate contraception strategy (<a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0277" title="NickleSB , PetersonN , PetersonM . Updated Physician's Guide to the Off‐label Uses of Oral Isotretinoin. Journal of Clinical and Aesthetic Dermatology2014;7(4):22‐34. [PUBMED: 24765227] ">Nickle 2014</a>). </p> <p>Traditional therapies for ocular rosacea include oral tetracyclines, eyelid hygiene and warm compresses (<a href="./references#CD003262-bbs2-0289" title="StoneDU , ChodoshJ . Oral tetracyclines for ocular rosacea: An evidence‐based review of the literature. Cornea2004;23(1):106‐9. [PUBMED: 14701969] ">Stone 2004</a>; <a href="./references#CD003262-bbs2-0278" title="OltzM , CheckJ . Rosacea and its ocular manifestations. Optometry2011;82(2):92‐103. [PUBMED: 21276570] ">Oltz 2011</a>; <a href="./references#CD003262-bbs2-0302" title="VieiraAC , MannisMJ . Ocular rosacea: common and commonly missed. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S36‐41. [PUBMED: 24229635] ">Vieira 2013</a>). Topical metronidazole gel and fusidic acid gel are also reportedly successful (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>; <a href="./references#CD003262-bbs2-0155" title="SealDV , WrightP , FickerL , HaganK , TroskiM , MendayP . Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. British Journal of Ophthalmology1995;79(1):42‐5. [UI: 95186449; PUBMED: 7880791] ">Seal 1995</a>; <a href="./references#CD003262-bbs2-0302" title="VieiraAC , MannisMJ . Ocular rosacea: common and commonly missed. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S36‐41. [PUBMED: 24229635] ">Vieira 2013</a>). Rhinophyma may require surgical intervention, but low dose isotretinoin and laser therapy have also been used (<a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a>; <a href="./references#CD003262-bbs2-0290" title="TaghizadehR , MackaySP , GilbertPM . Treatment of rhinophyma with the Versajet Hydrosurgery System. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery2008;61(3):330‐3. [PUBMED: 18267312] ">Taghizadeh 2008</a>; <a href="./references#CD003262-bbs2-0294" title="TanghettiE , DelRossoJQ , ThiboutotD , GalloR , WebsterG , EichenfieldLF , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis2014;93(2):71‐6. [PUBMED: 24605343] ">Tanghetti 2014</a>). </p> </section> </section> <section id="CD003262-sec-0032"> <h3 class="title" id="CD003262-sec-0032">How the intervention might work</h3> <p>Although a lack of understanding of the pathophysiology of rosacea continues to hamper therapeutic efforts (<a href="./references#CD003262-bbs2-0228" title="BaldwinHE . Oral therapy for rosacea. Journal of Drugs in Dermatology2006;5(1):16‐21. [PUBMED: 16468287] ">Baldwin 2006</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>), metronidazole and azelaic acid are generally considered as the first‐line in topical medicaments. It is also now widely recognised that the therapeutic efficacy of both can be attributed to their anti‐inflammatory and antioxidant effects (<a href="./references#CD003262-bbs2-0236" title="BhatiaND , DelRossoJQ . Optimal management of papulopustular rosacea: rationale for combination therapy. Journal of Drugs in Dermatology2012;11(7):838‐44. [PUBMED: 22777226] ">Bhatia 2012</a>; <a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>; <a href="./references#CD003262-bbs2-0256" title="FeldmanSR , HuangWW , HuynhTT . Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease. Journal of Managed Care Pharmacy2014;20(6):623‐9. [PUBMED: 24856600] ">Feldman 2014</a>; <a href="./references#CD003262-bbs2-0275" title="NarayananS , HünerbeinA , GetieM , JäckelA , NeubertRH . Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. Journal of Pharmacy and Pharmacology2007;59(8):1125‐30. [PUBMED: 17725855] ">Naranayan 2007</a>). Ivermectin has demonstrated activity against Demodex in addition to possible inflammatory properties (<a href="./references#CD003262-bbs2-0268" title="LaytonA , ThiboutotD . Emerging therapies in rosacea. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S57‐65. [PUBMED: 24229638] ">Layton 2013</a>; <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>). Brimonidine targets the α‐adrenergic receptors in the smooth muscle sheath located around the vessel wall of the superficial blood vessels of the skin and coupled with its potent vasoconstrictive activity it can provide a reduction of facial erythema after application (<a href="./references#CD003262-bbs2-0249" title="DelRossoJQ . Management of facial erythema of rosacea: what is the role of topical α‐adrenergic receptor agonist therapy?. Journal of the American Academy of Dermatology2013;69(6 Suppl 1):S44‐56. [PUBMED: 24229637] ">Del Rosso 2013c</a>). </p> <p>Tetracyclines down‐regulate the production of inflammatory cytokines, inhibit matrix‐metalloproteinases (MMP), and down‐regulate the inflammatory response in papulopustular rosacea (<a href="./references#CD003262-bbs2-0228" title="BaldwinHE . Oral therapy for rosacea. Journal of Drugs in Dermatology2006;5(1):16‐21. [PUBMED: 16468287] ">Baldwin 2006</a>; <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>). Doxycycline has been shown to inhibit neutrophil activity and several pro‐inflammatory reactions including those associated with phospholipase A2, endogenous nitric oxide and interleukin‐6 (<a href="./references#CD003262-bbs2-0228" title="BaldwinHE . Oral therapy for rosacea. Journal of Drugs in Dermatology2006;5(1):16‐21. [PUBMED: 16468287] ">Baldwin 2006</a>; <a href="./references#CD003262-bbs2-0237" title="BikowskiJB . Subantimicrobial dose doxycycline for acne and rosacea. Skinmed2003;2(4):234‐45. [PUBMED: 14673277] ">Bikowski 2003</a>). Subantimicrobial doses of doxycycline can be important in minimising the development of microbial resistance (<a href="./references#CD003262-bbs2-0237" title="BikowskiJB . Subantimicrobial dose doxycycline for acne and rosacea. Skinmed2003;2(4):234‐45. [PUBMED: 14673277] ">Bikowski 2003</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0286" title="SloanB , ScheinfeldN . The use and safety of doxycycline hyclate and other second‐generation tetracyclines. Expert Opinion on Drug Safety2008;7(5):571‐7. [PUBMED: 18759709] ">Sloan 2008</a>). Isotretinoin has anti‐inflammatory properties, it diminishes sebaceous gland size and number and can help retard or halt development of rhinophyma (<a href="./references#CD003262-bbs2-0228" title="BaldwinHE . Oral therapy for rosacea. Journal of Drugs in Dermatology2006;5(1):16‐21. [PUBMED: 16468287] ">Baldwin 2006</a>; <a href="./references#CD003262-bbs2-0125" title="ErdoganFG , YurtseverP , AksoyD , EskiogluF . Efficacy of low‐dose isotretinoin in patients with treatment‐resistant rosacea. Archives of Dermatology1998;134(7):884‐5. [EMBASE: 1998253772] ">Erdogan 1998</a>; <a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a>; <a href="./references#CD003262-bbs2-0298" title="UsluM , ŞavkE , KaramanG , ŞendurN . Rosacea treatment with intermediate‐dose isotretinoin: follow‐up with erythema and sebum measurements. Acta Dermato‐Venereologica2012;92(1):73‐7. [PUBMED: 21952746] ">Uslu 2012</a>). </p> <p>Laser therapy is capable of reducing both erythema and telangiectasia (<a href="./references#CD003262-bbs2-0285" title="ShimTN , AbdullahA . The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. Journal of Clinical and Aesthetic Dermatology2013;6(4):30‐2. [PUBMED: 23630639] ">Shim 2013</a>). The pulsed dye laser (PDL) with the 595 nm wavelength targets haemoglobin and delivers all of the administered energy in a wavelength that is actively taken up by the haemoglobin in blood vessels causing vessel destruction (<a href="./references#CD003262-bbs2-0234" title="BernsteinEF , KligmanA . Rosacea treatment using the new‐generation, high‐energy, 595 nm, long pulse‐duration pulsed‐dye laser. Lasers in Surgery &amp; Medicine2008;40(4):233‐9. [PUBMED: 18412227] ">Bernstein 2008</a>; <a href="./references#CD003262-bbs2-0240" title="ButterwickKJ , ButterwickLS , HanA . Laser and light therapies for acne rosacea. Journal of Drugs in Dermatology2006;5(1):35‐9. [PUBMED: 16468290] ">Butterwick 2006</a>; <a href="./references#CD003262-bbs2-0050" title="KimTG , RohHJ , ChoSB , LeeJH , LeeSJ , OhSH . Enhancing effect of pretreatment with topical niacin in the treatment of rosacea‐associated erythema by 585‐nm pulsed dye laser in Koreans: A randomized, prospective, split‐face trial. British Journal of Dermatology2011; Vol. 38, issue 5:510‐3. [DOI: 10.1111/j.1365‐2133.2010.10174.x.; PUBMED: 21143465] ">Kim 2011</a>; <a href="./references#CD003262-bbs2-0285" title="ShimTN , AbdullahA . The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. Journal of Clinical and Aesthetic Dermatology2013;6(4):30‐2. [PUBMED: 23630639] ">Shim 2013</a>). The 532 nm frequency‐doubled, potassium‐titanyl‐phosphate (KTP) and the neodymium‐doped, yttrium‐aluminium‐garnet (Nd:YAG) laser can also deliver wavelengths which are readily absorbed by haemoglobin (<a href="./references#CD003262-bbs2-0234" title="BernsteinEF , KligmanA . Rosacea treatment using the new‐generation, high‐energy, 595 nm, long pulse‐duration pulsed‐dye laser. Lasers in Surgery &amp; Medicine2008;40(4):233‐9. [PUBMED: 18412227] ">Bernstein 2008</a>; <a href="./references#CD003262-bbs2-0240" title="ButterwickKJ , ButterwickLS , HanA . Laser and light therapies for acne rosacea. Journal of Drugs in Dermatology2006;5(1):35‐9. [PUBMED: 16468290] ">Butterwick 2006</a>; <a href="./references#CD003262-bbs2-0048" title="KarsaiS , RoosS , RaulinC . Treatment of facial telangiectasia using a dual‐wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery2008;34(5):702‐8. [PUBMED: 18318728] ">Karsai 2008</a>). Intense pulsed light with a wavelength between 550 nm and 670 nm is readily absorbed by both melanin and oxyhaemoglobin, and has also been used in the treatment of telangiectasia (<a href="./references#CD003262-bbs2-0240" title="ButterwickKJ , ButterwickLS , HanA . Laser and light therapies for acne rosacea. Journal of Drugs in Dermatology2006;5(1):35‐9. [PUBMED: 16468290] ">Butterwick 2006</a>; <a href="./references#CD003262-bbs2-0263" title="KawanaS , OchiaiH , TachiharaR . Objective evaluation of the effect of intense pulsed light on rosacea and solar lentigines by spectrophotometric analysis of skin color. Dermatologic Surgery2007;33(4):449‐54. [PUBMED: 17430379] ">Kawana 2007</a>; <a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a>). </p> </section> <section id="CD003262-sec-0033"> <h3 class="title" id="CD003262-sec-0033">Why it is important to do this review</h3> <p>Although rosacea is a common and distressing disorder, there is continuing debate over which therapy, or which combination of therapies, is most likely to offer benefits to patients. This systematic review was conducted to examine the different management options and to try and determine the most effective strategy in the treatment of rosacea. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003262-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003262-sec-0034"></div> <p>To assess the efficacy and safety of treatments for rosacea.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003262-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003262-sec-0035"></div> <section id="CD003262-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003262-sec-0037"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD003262-sec-0038"> <h4 class="title">Types of participants</h4> <p>People older than 19 years with moderate to severe rosacea (diagnosed clinically).</p> </section> <section id="CD003262-sec-0039"> <h4 class="title">Types of interventions</h4> <p>Any type of intervention used, either alone or in combination, to treat rosacea versus placebo, no treatment or active treatment. We also considered the effects of avoidance of some foodstuffs, for example spicy food, as well as the use of certain cosmetics and sunscreens. </p> </section> <section id="CD003262-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD003262-sec-0041"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD003262-list-0002"> <li> <p>Change in health‐related quality of life (HRQOL) at end of study</p> </li> <li> <p>Participant‐assessed changes in rosacea severity at end of study</p> </li> <li> <p>Proportion of participants who reported an adverse event throughout the study period</p> </li> </ol> </p> </section> <section id="CD003262-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003262-list-0003"> <li> <p>Physician‐assessed changes in rosacea severity. These included the following:</p> </li> </ol> <ul id="CD003262-list-0004"> <li> <p>physician's global assessment of rosacea severity at end of study;</p> </li> <li> <p>assessment of erythema or telangiectasia, or both, at end of study;</p> </li> <li> <p>reduction in lesion counts (treatment success defined as greater than 50% reduction in lesion counts); </p> </li> <li> <p>time needed until improvement of the skin lesions;</p> </li> <li> <p>duration of remission.</p> </li> </ul> </p> <p>We produced 'Summary of findings' tables of the following outcomes listed according to priority: </p> <p> <ol id="CD003262-list-0005"> <li> <p>change in HRQOL;</p> </li> <li> <p>participant‐reported improvement of rosacea;</p> </li> <li> <p>proportion of participants who reported an adverse event;</p> </li> <li> <p>physician's global assessment of improvement of rosacea;</p> </li> <li> <p>assessment of erythema or telangiectasia, or both;</p> </li> <li> <p>reduction in lesion counts;</p> </li> <li> <p>time needed until improvement of the skin lesions;</p> </li> <li> <p>duration of remission.</p> </li> </ol> </p> </section> </section> </section> <section id="CD003262-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press or in progress). </p> <section id="CD003262-sec-0044"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised the search strategies for all our databases (see the section on <a href="#CD003262-sec-0594">Differences between protocol and review</a> for details). We searched the following databases up to 1 July 2014: </p> <p> <ul id="CD003262-list-0006"> <li> <p>Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD003262-sec-0580">Appendix 1</a>; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 6) in <i>The Cochrane Library</i> using the strategy in <a href="./appendices#CD003262-sec-0581">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD003262-sec-0582">Appendix 3</a>; </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD003262-sec-0583">Appendix 4</a>; </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database) (from 1982) using the strategy in <a href="./appendices#CD003262-sec-0584">Appendix 5</a>; </p> </li> <li> <p>Science Citation Index (from 1988) (see <a href="./appendices#CD003262-sec-0585">Appendix 6</a>); and </p> </li> <li> <p>BIOSIS (previously searched from 1970 to March 2002) (see <a href="./appendices#CD003262-sec-0586">Appendix 7</a>). </p> </li> </ul> </p> <section id="CD003262-sec-0045"> <h5 class="title">Trials registers</h5> <p>We (EvZ and MvdL) searched the following trials registers on 20 July 2014 with the search terms 'rosacea' and 'rhinophyma': </p> <p> <ul id="CD003262-list-0007"> <li> <p>metaRegister of Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>Australian and New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>); </p> </li> <li> <p>the Ongoing Skin Trials Register (<a href="http://www.nottingham.ac.uk/ongoingskintrials" target="_blank">www.nottingham.ac.uk/ongoingskintrials</a>). </p> </li> </ul> </p> </section> </section> <section id="CD003262-sec-0046"> <h4 class="title">Searching other resources</h4> <section id="CD003262-sec-0047"> <h5 class="title">References from published studies</h5> <p>The reference lists of all identified RCTs and key review articles were checked for further references to relevant trials (EvZ and ZF). </p> </section> <section id="CD003262-sec-0048"> <h5 class="title">Unpublished literature</h5> <p>Attempts were made (EvZ and ZF) to locate unpublished and ongoing trials through correspondence with authors and pharmaceutical companies (see <a href="#CD003262-tbl-0020">Table 2</a> and <a href="#CD003262-tbl-0021">Table 3</a>). </p> <div class="table" id="CD003262-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Pharmaceutical companies contacted</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Additional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bayer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Added information on <a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> Christopher Billis &lt;<a class="__cf_email__" data-cfemail="016269736872756e716964732f63686d6d68724163607864732f626e6c" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt; and that ongoing studies were not yet published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roche</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASTA Medica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Merck</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dumex‐Alpharma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galderma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="93c3f2e7e1faf0faf2bdc5f2fddffae7fbd3f4f2fff7f6e1fef2bdf0fcfe" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a href="http://mailto:michael.graeber%40galderma.com?subject=NCT00989014, RD.06.SPR.18144, Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="0b666268636a6e67256c796a6e696e794b6c6a676f6e79666a25686466">[email protected]</span></a> </p> <p>August 2014 several times contact with Galderma NL, France and US, provided lots of extra information regarding brimonidine and ivermectin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHP Pharma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yamanouchi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dermik Laboratories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CollaGenex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taken over by Galderma</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003262-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Investigators contacted</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Additional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="4528222d2c24362c05362c2b246b313028366b24266b2c37" href="/cdn-cgi/l/email-protection">[email protected]</a>. (sequence generation and allocation concealment) "In efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomised open clinical trial" Patients were allocated to the trial using a randomised numbers table. Unfortunately this trial was not blinded" "The randomised number table generated by computer. The list was only in access of physician, and patients could not see that </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0109" title="AltinyazarHC , KocaR , TekinNS , EştürkE . Adalapene vs. metronidazole gel for the treatment of rosacea. International Journal of Dermatology2005;44(3):252‐5. [MEDLINE: 15807740] ">Altinyazar 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After email contact with the primary investigator and following on from discussion between the review authors, this was judged to be quasi‐randomised, i.e. a CCT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0006" title="BenkaliK , LeoniM , RonyF , BouerR , FernandoA , GraeberM , et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate‐to‐severe facial erythema associated with rosacea. British Journal of Dermatology2014;171(1):162‐9. [PUBMED: 24506775] ">Benkali 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="751b14011d14191c105b0214121b10073512141911100718145b161a18" href="/cdn-cgi/l/email-protection">[email protected]</a>, 1‐8‐2014 (sequence generation and allocation concealment)<br/> 1) Regarding the allocation sequence generated for the 4 subsequent groups consisting of different doses or regimen for topical applications, the randomisation list was created before the study started, with a 1:1:1:1 ratio and block size of 4. This randomisation list was generated by a designated biostatistician and was distributed to the clinical supply team in a sealed envelope (see the attached pdf file for the randomisation memo) </p> <p>2) As explained above, only the 4 arms treated with topical products were to be randomised. The block size of 4 was not known by the sites, so foreseeing the next allocation was possible but unlikely. Since the study had 2 treatment groups for QD regimen and 2 treatment groups for BID regimen, subjects and the personnel who distributed the medication necessarily knew this information </p> <p>Of note, the primary objective of this study was PK assessment (and not efficacy), an objective measure, and the primary comparison was topical versus eye drop which was in no way planned to be randomised or blinded </p> <p>3) This study was not posted on CT.gov since it was classified as a phase 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0114" title="BerardescaE , CameliN , CavallottiC , LevyJL , PiérardGE , dePaoli AmbrosiG . Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. Journal of Cosmetic Dermatology2008;7(1):8‐14. [MEDLINE: 18254805] ">Berardesca 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="094b6c7b687b6d6c7a6a68496b6c7b687b6d6c7a6a6827607d" href="/cdn-cgi/l/email-protection">[email protected]</a>. After email communication with the investigators to clarify aspects of trial conduct, the criterion for sequence generation was changed from UNCLEAR to High risk, i.e. the study was not a RCT and participants appear to have been allocated to the intervention by alternation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0007" title="BerardescaE , IorizzoM , AbrilE , GuglielminiG , CaseriniM , PalmieriR , et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology2012;11(1):37‐41. [PUBMED: 22360333] ">Berardesca 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐8‐2014 <a class="__cf_email__" data-cfemail="365b5743445f4c5f591855574553445f585f7646595a5f555e535b1855595b" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation and allocation concealment and blinding) </p> <p>29‐9‐2013 replies </p> <p>1. This was a randomised, double‐blind, parallel‐group, placebo‐controlled study</p> <p>Patients, having signed their informed consent and who satisfied all inclusion and exclusion criteria at inclusion visit were randomly assigned to one of two treatment groups (P‐3075 cream, placebo), according to a computer‐generated randomisation list </p> <p>Patients were sequentially assigned to the next available randomisation number, starting from the lowest number provided to each investigational site </p> <p>Furthermore, for ethical reason, in order to minimise the exposure to placebo, randomisation was unbalanced between the P‐3075 and placebo groups with a 2:1 ratio using blocks of 3 treatments </p> <p>2/3. The double blind study design was guaranteed by the use of placebo cream units, which were identical to the active product in terms of size, shape, volume, colour. The tubes (P‐3075 and placebo) were identically labelled for clinical use as it is in a double‐blind procedure </p> <p>4. Thank you for this observation (you are the first). We confirm that the correct value is ‐167.00 and not 167.00, as reported in our database. It was a typing error that was not detected when the manuscript was transformed in draft paper by the editor </p> <p>5. As described in the paper, a 4‐point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) was used by the investigators at each visit for the clinical evaluation of erythema </p> <p>The results at Day 28 (end of treatment) showed that, in the P‐3075 group, erythema was absent in 27 patients (96.4%) and mild in 1 (3.6%), while in the placebo group, erythema was absent in 9 patients (64.3%) and mild in 5 (35.7%). There were no cases of moderate or severe intensity at Day 28 in both groups. The statistically significance values were reported in the paper as you underlined. For completeness the baseline clinical assessment for erythema was as follows: for P‐3075 absent in 7 patients, mild in 14, moderate in 6 and severe in 1 and for placebo absent in 3 patients, mild in 6 and moderate in 5 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="d0bbb2b5a5a4beb5a290b1beb1b3bfa2feb3bfbd" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="94f6f7f5f8e2f5e6f1e7f1d4f0fbe3e4fcf5e6f9e7f7fdbaf7fbf9" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="2b676a464f4a43476b4f445c5b434a594658484205484446" href="/cdn-cgi/l/email-protection">[email protected]</a>. Useful additional information provided by primary investigator, on randomisation, allocation concealment and characteristics of patients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'<a class="__cf_email__" data-cfemail="a3d1cac7cbc28dc1d1cac1c6c0cbe3c4cec2cacf8dc0ccce" href="/cdn-cgi/l/email-protection">[email protected]</a>' 30‐8‐2014<br/> Dear professor Bribeche (allocation concealment and blinding)<br/> reply 7‐9‐2014: 1‐ During enrolment we used an allocation randomiser programme: http://www.randomizer.org/<br/> 2‐ Only the participants were blinded to treatment, praziquantel ointment and the placebo had the same colour (white), and ointment were given to participants in identical boxes for both groups (white box with a blue cover)<br/> Next mail 7‐9‐2014: The reply to our first question is more on sequence generation, and not concealment of the allocation. Who was responsible for using that programme and who had access to the generated list? </p> <p>Reply 10‐9‐2014: Me and professor Fedotov VP, were responsible for using this programme, both of us had access to the generated list and a doctor from our department (Dr Makurina); who was fully unaware of the aims of the study and overseen the enrolment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] ">Buendia‐Bordera 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Can't find mail address, sent invite on LinkedIn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chosidow 2014</p> <p><a href="./references#CD003262-bbs2-0173" title="NCT00882531 . Evaluation of the efficacy of isotretinoin versus placebo in terms of response rate among patients presenting papular‐pustular rosacea resistant to standard therapy. clinicaltrials.gov/ct2/show/NCT00882531 (accessed 18 July 2014). ">NCT00882531</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="e6898a8f908f8394c8858e89958f828991a68e8b88c887968e96c88094" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="d0b5bdb9bcb9b5fea3b2b9b4b9b1be90b8bdbefeb1a0b8a0feb6a2" href="/cdn-cgi/l/email-protection">[email protected]</a>,18‐7‐2014<br/> Is the NCT00882531 published and if so give us a pdf of the publication? </p> <p>Reply 18‐7‐2014 "Hi Esther, we are still in processing the manuscript and hope submitting the paper before the end of 2014" and "We could send your our submitted manuscript?" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0121" title="CunliffeWJ , DodmanB , BinnerJG . Clonidine and facial flushing in rosacea. British Medical Journal1977;1(6053):105. [EMBASE: 0978017820] ">Cunliffe 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0021" title="DahlMV , JarrattMJ , KaplanD , TuleyMR , BakerMD . Once‐daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. Journal of the American Academy of Dermatology2001;45(5):723‐30. [PUBMED: 11606923] ">Dahl 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="9adefbf2f6b4d7fbe8f1ccdaf7fbe3f5b4fffeef" href="/cdn-cgi/l/email-protection">[email protected]</a>."Subjects will be randomised to 1 of the 2 treatment groups at a ratio of 1:1. The randomisation process will be done in blocks of 4, stratified by investigators. The randomisation will be carried out using SAS PROC PLAN" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="8ee4ffeaebe2fce1fdfde1cef7efe6e1e1a0ede1e3" href="/cdn-cgi/l/email-protection">[email protected]</a>, 1‐8‐2014 ‎(sequence generation, allocation concealment)</p> <p>Chris Billis ‎[<a class="__cf_email__" data-cfemail="2e6d465c475d5a415e464b5c004c474242475d6e4c4f574b5c004d4143" href="/cdn-cgi/l/email-protection">[email protected]</a>]‎‎; Keith Flanders ‎[<a class="__cf_email__" data-cfemail="5338363a273b7d353f323d373621201331322a36217d303c3e" href="/cdn-cgi/l/email-protection">[email protected]</a>]‎<br/> 15‐8‐2014 Randomisation was done centrally by the generation of a randomisation list using the randomisation program RANCODE (version 3.6). Randomisation used blocks. Whole randomisation blocks were allocated to each site. In each study site, each newly enrolled patient was allocated to study medication with the lowest randomisation number available in that particular site at the subjects baseline visit. The patient randomisation number was entered into the CRF immediately after allocation. Each patient retained the randomisation number originally allocated at Baseline for the duration of the study<br/> <br/> Six drug tubes (tubes with a blinded label to cover the trademarks) and 3 bottles were packaged by a CMO in individual numbered kit boxes. Each patient was issued an individual numbered kit box containing 6 tubes and 3 bottles of study materials. The study drug was not to be dispensed by the investigator, but was dispensed by and returned to qualified study personnel (e.g., practice or clinic nurses) not involved with the selection and the assessment of the patients. At the control visits after Weeks 4, 8 and 12, patients returned empty, partially used, and unused containers to qualified study personnel before being examined by the investigator. Study drug compliance was assessed by the qualified study personnel. The patient was advised not to discuss the treatment schedule with the investigator<br/> 19‐8‐2014 sent additional mail regarding SD of lesions<br/> 3‐9‐2014, resent, received 4‐9‐2014 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0031" title="DrenoB , DubertretL , NaeyaertJM , de laBrassineM , MarksR , PowellF , et al. Comparison of the clinical efficacy and safety of metronidazole 0.75% cream with metronidazole 0.75% gel in the treatment of rosacea. Journal of the European Academy of Dermatology &amp; Venereology1998;11(2 Suppl):S272‐3. ">Dreno 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Old study, no further data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0026" title="DraelosZD , FullerBB . Efficacy of 1% 4‐ethoxybenzaldehyde in reducing facial erythema. Dermatologic Surgery2005;31(7 Pt 2):881‐5. [PUBMED: 16029682] ">Draelos 2005b</a>; <a href="./references#CD003262-bbs2-0027" title="DraelosZD , GreenBA , EdisonBL . An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. Journal of Cosmetic Dermatology2006;5(1):23‐9. [PUBMED: 17173568] ">Draelos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="a7ddc3d5c6c2cbc8d4e7c9c8d5d3cfd4d3c6d3c289c9c2d3" href="/cdn-cgi/l/email-protection">[email protected]</a>. On 2006. Sequence generation? "Subjects were randomised based on the order in which they presented to the office". Allocation concealment? "The research coordinator maintained the blind which was not shared with anyone, including the investigator."<br/> 5 dropouts but in which group? The dropouts were for personal reasons, not related to product. They were random between the groups<br/> On 2005 Sequence generation? "Subjects were randomised based on severity of disease and the order in which they presented to the office". Allocation concealment? 'The research coordinator maintained the double blind." Dropouts? "The drop outs were one in each group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0028" title="DraelosZ , ErthelK , SchnickerM , BaconR , VickeryS . Facial foundation with niacinamide and N‐acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB82. [EMBASE: 70142048] ">Draelos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="c8b2acbaa9ada4a7bb88a6a7babca0bbbca9bcade6a6adbc" href="/cdn-cgi/l/email-protection">[email protected]</a>, 2‐8‐2014 (sequence generation and allocation concealment and blinding, how many randomised to each group, separate data for participants with rosacea? losses to follow‐up?) </p> <p>9‐8‐2014 sent again. No reaction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="49332d3b282c25263a0927263b3d213a3d283d2c67272c3d" href="/cdn-cgi/l/email-protection">[email protected]</a>, 2‐8‐2014 (blinding and details on RosaQoL data)</p> <p>Reply 2‐8‐2014 This was the pivotal trial for FDA approval. The blind was maintained by dispensing the vehicle and the vehicle plus the active in identical containers. I do not have more detail on the QOL scores </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0030" title="DraelosZ , HornbyS , WaltersRM , AppaY . Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers. Journal of Cosmetic Dermatology2013;12(4):314‐21. [PUBMED: 24305430] HornbyS , FowlerJ , WaltersRM , AppaY , DraelosZ . Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB66. [EMBASE: 70997350] ">Draelos 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="http://mailto:zdraelos@northstate.net" target="_blank"><span class="__cf_email__" data-cfemail="0a706e786b6f6665794a6465787e62797e6b7e6f24646f7e">[email protected]</span></a> (sequence generation, stratification and allocation concealment and blinding) </p> <p>Reply 2‐8‐2014 <br/> I will answer your questions below:<br/> 1. the method used to generate the allocation sequence as “were divided equally into two groups” does not seem at random. Subjects were randomised in two balanced populations based on a computer generated randomisation sequence<br/> 2. How was stratification done during the sequence generation? That is, can you describe the method used to generate the allocation sequence in sufficient detail to allow us an assessment of whether it should produce comparable groups stratified for demographics and presence and severity of acne, eczema, rosacea and atopic dermatitis?<br/> The data for each person was entered into a database and then the computer randomisation balanced the two groups for all of the characteristics you have mentioned<br/> 3. the method used to conceal the allocation sequence to ensure that intervention allocations could not have been foreseen in advance of, or during, enrolment i.e. participants and investigators enrolling participants could not foresee the upcoming assignment (this is not the same as blinding!!).<br/> I realize that randomisation and blinding are not the same. The products were identically packaged<br/> 4. How were the investigators and participants blinded to the treatment the participants received?<br/> Yes, both the investigator and the participant did not know the product identity which was concealed through identically appearing products packaged identically<br/> 5. Are there separate data for women on rosacea? No, the data was not analysed in this fashion. </p> <p>follow‐up mail that allocation concealment is not yet satisfactorily answered<br/> 9‐8: sent again, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0033" title="ErtlGA , LevineN , KligmanAM . A comparison of the efficacy of topical tretinoin and low‐dose oral isotretinoin in rosacea. Archives of Dermatology1994;130(3):319‐24. [UI: 94175557; PUBMED: 8129410] ">Ertl 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dr Levine, study 17 years old, no further data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] ">Fabi 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="http://mailto:sfabi@gbkderm.com" target="_blank"><span class="__cf_email__" data-cfemail="0d7e6b6c6f644d6a6f6669687f60236e6260">[email protected]</span></a> 2‐8‐2014 (sequence generation and allocation concealment and dropouts?) </p> <p>Follow‐up mail 11‐8‐2014 and 17‐8‐2014, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="c8aea7bfa4adbaa2a7ad88a5bba6e6aba7a5" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="ee8d869c879d9a878f80c082818b9d8d868bae898f828a8b9c838fc08d8183" href="/cdn-cgi/l/email-protection">[email protected]</a>. "Randomisation was done by using a computer generated table provided by the sponsor. Neither subjects nor investigators and study staff had any control over this" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>; <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>; <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="d0b6bfa7bcb5a2babfb590bda3befeb3bfbd" href="/cdn-cgi/l/email-protection">[email protected]</a> and Jean Jacovella (<a class="__cf_email__" data-cfemail="09436c68672743484a465f4c454548496e68656d6c7b6468276a6664" href="/cdn-cgi/l/email-protection">[email protected]</a>) 22‐8‐2014, 27‐8</p> <p>Asked for separate exact data of PSA and CEA at different time points, wash‐out period and details on AE </p> <p>Received replies 25‐9‐2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20‐7‐2014 asked Galderma if it is published (Patricia van Lith) is this Fowler 2013? 28‐7‐2014 confirmed (NCT01355471 and NCT01789775 are the same studies) </p> <p>Received replies 25‐9‐2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0128" title="FreemanSA , MoonSD , SpencerJM . Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo‐controlled, double‐blind trial. Journal of Drugs in Dermatology2012;11(12):1410‐4. [PUBMED: 23377509] ">Freeman 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'<a class="__cf_email__" data-cfemail="384b4d55555d4a165557575678555d5c16545d5b5755165d5c4d" href="/cdn-cgi/l/email-protection">[email protected]</a>' 3‐8‐2014 (sequence generation and allocation concealment and blinding)<br/> Follow‐up mail 11‐8‐2014 <br/> reply 12‐8‐2014 1) Random selection by study coordinator<br/> 2) Medication and placebo allocation was the responsibility of the study coordinator who randomly selected which product to provide each subject (2:1 ratio). The investigators were unaware of the selection process and the study coordinator was not privy, prior to selection of product, of the type or severity of disease of any subject </p> <p>3) Investigators were not privy to the medication/placebo selection process. No medication tubes were shown to the investigators. No questions were asked about the topical product (i.e. Odor, color or feel). There was no communication between the study coordinator and the investigators regarding the medication/placebo selection </p> <p>follow‐up mail 12‐8‐2014 <br/> Regarding 1) this answer still does not inform us the method, so what method did the study coordinator used?<br/> Regarding 2) You describe that the investigators were unaware of selection process, but if the study coordinator was aware who received what, then the allocation was NOT concealed, even if he was not privy<br/> Regarding 3) if the patients knew what they received they could tell the investigators, as slip of the tongue. So it might be that study coordinator did not say anything, the patients could say something to the investigator. So was there any possibility that patients knew what they received? And if not why not? Why did they not know what they received (as stated as double‐blinded)<br/> Response: 12‐8‐2014: Randomisation: every third patient was given placebo to create a 2:1 ratio<br/> Follow‐up mail: then it is not truly randomised but quasi‐randomised as you know every third patient gets placebo it is no longer at random and we have to exclude the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0130" title="Frucht‐PeryJ , SagiE , HemoI , Ever‐HadaniP . Efficacy of doxycycline and tetracycline in ocular rosacea. American Journal of Ophthalmology1993;116(1):88‐92. [UI: 93318953; PUBMED: 8328549] ">Frucht‐Pery 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐8‐2014 <a class="__cf_email__" data-cfemail="41292033202d256f262e2d2d2f28222a012c24256f2e3726346f2524" href="/cdn-cgi/l/email-protection">[email protected]</a> <a class="__cf_email__" data-cfemail="67040f150e141308170f49100e0b0b02151427060b0a0e15060b0b4904080a" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation and allocation concealment clarification of N)<br/> 5‐9‐2014 follow‐up, and received replies with clear information </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0044" title="HuangYE , LiXL , LiTJ . Clinical research of topical tacrolimus ointment combined with 585 nm pulsed dye laser in the treatment of rosacea [Chinese]. Journal of Clinical Dermatology2012;41(5):308‐9. [EMBASE: 2012449799] ">Huang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 <a class="__cf_email__" data-cfemail="f8949f94828b92b8c9cecbd69b9795" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation and allocation concealment)</p> <p>9‐8‐2014 follow‐up mail and 17‐8‐2014, no reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0137" title="JacksonM . Combined effect of anti‐inflammatory dose doxycycline and azelaic acid gel 15% in the treatment of rosacea. Journal of the American Academy of Dermatology2007;56(2 Suppl 2):AB19. ">Jackson 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f59f94969e869a9b9f9894879eb59298949c99db969a98" href="/cdn-cgi/l/email-protection">[email protected]</a> 9‐8‐2014<br/> 1. The dropouts are noted below: 5 total<br/> Two adverse events were classified as possibly related to the study medication – an upset stomach and generalized urticaria in separate patients both receiving ER minocycline + azelaic acid 15%. Four adverse events in three patients (all receiving ER minocycline + azelaic acid 15%) were severe but not suspected to be related to the study medication (bilateral oophorectomy with dermoid cyst removal, gastric erosion after lap band surgery, a severe respiratory infection, and cholecystitis)<br/> <br/> 2. The CEA was a scale of 0 to 4 so there was a typo on 295. The IGA went from 0 to 5. As for the total CEA it was a combined number of the CEA for each location of the face as per the table below<br/> APPENDIX B<br/> Clinician’s Erythema Assessment Scale<br/> ERYTHEMA Definition<br/> 0 None No redness present 1 Mild Slight pinkness 2 Moderate Definite redness 3 Significant Marked erythema 4 Severe Fiery redness<br/> ERYTHEMA Score<br/> • Check one box for each area of the face based upon the definitions given above • Enter the Erythema Score for each area of the face • Sum all of the individual Erythema Scores to obtain the Total Erythema Score<br/> Erythema Score Forehead Chin Nose Right Cheek Left Cheek none (0) none (0) none (0) none (0) none (0) mild (1) mild (1) mild (1) mild (1) mild (1) moderate (2) moderate (2) moderate (2) moderate (2) moderate (2) significant (3) significant (3) significant (3) significant (3) significant (3) severe (4) severe (4) severe (4) severe (4) severe (4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0262" title="JansenT , PlewigG . Rosacea: Classification and treatment. Journal of the Royal Society of Medicine1997;90(3):144‐50. [PUBMED: 9135612] ">Jansen 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0047" title="JorizzoJL , LebwohlM , TobeyRE . The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double blind clinical trial. Journal of the American Academy of Dermatology1998;39(3):502‐4. [UI: 98409174; PUBMED: 9738794] ">Jorizzo 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0138" title="KarabulutAA , Izol SerelB , EksiogluHM . A randomized, single‐blind, placebo‐controlled, split‐face study with pimecrolimus cream 1% for papulopustular rosacea. Journal of the European Academy of Dermatology and Venereology2008;22(6):729‐34. [PUBMED: 18328059] ">Karabulut 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="8de9ffa3ececa3e6ecffeceff8e1f8f9cdeae0ece4e1a3eee2e0" href="/cdn-cgi/l/email-protection">[email protected]</a>. After email contact with the primary investigator this study was excluded </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0048" title="KarsaiS , RoosS , RaulinC . Treatment of facial telangiectasia using a dual‐wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery2008;34(5):702‐8. [PUBMED: 18318728] ">Karsai 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="http://mailto:james.kendall@galderma.com" target="_blank"><span class="__cf_email__" data-cfemail="3f555e525a4c11545a515b5e53537f585e535b5a4d525e115c5052">[email protected]</span></a> 6‐8‐2014 (sequence generation and allocation concealment and blinding and dropouts) </p> <p>9‐9‐2014 reply: </p> <p>I did not receive your previous e‐mails as my address is <a class="__cf_email__" data-cfemail="5933303477323c373d383535193e38353d3c2b3438773a3634" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>70 patients were enrolled in the study. Two subjects withdrew from the study and they were both in the brimonidine tartrate gel 0.5% treatment group in phase 1 and did not enter phase 2. One for an adverse event and one for a protocol deviation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0053" title="KochR , WilbrandG . Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea [P‐011]. Journal of the European Academy of Dermatology and Venerology1999;12(32 Suppl):S143‐4. ">Koch 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appeared to be wrong R Koch</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0139" title="Koçak‐AltintasAG , Koçak‐MidilliogluI , GulU , BilezickciB , IsiksacanO , DumanS . Effects of topical metranidazole in ocular rosacea. Annals of Ophthalmology2005;37(2):77‐84. [EMBASE: 2005358977] ">Koçak‐Altintas 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After extensive email contact, clarified as a CCT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0140" title="LaquiezeS , CzernielewskiJ , BaltasE . Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. Journal of Dermatological Treatment2007;18(3):158‐62. [PUBMED: 17538804] ">Laquieze 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Old study, no further data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f09a9a9c958994959eb09d999e94838082999e97de939f9d" href="/cdn-cgi/l/email-protection">[email protected]</a> 7‐8‐2014 (sequence generation and allocation concealment)<br/> Reply 12‐8‐2014: I am now Emeritus and mostly out of the loop and my clinical research nurse has retired. Nobody in the clinical trials unit was there when that study was done and I can't get the details you are asking for Sorry! Jim Leyden </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, <a href="http://mailto:info@sol-gel.com" target="_blank">info@sol‐gel.com</a> Ofer.Toledano@sol‐gel.com </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT00940992 “A Study of DER 45‐EV Gel to Treat Rosacea (SGTDER45EV)”. Can you tell us if the NCT00940992 is published and if so give us a pdf of the publication? </p> <p>Reply 19‐7‐2014 Ofer.Toledano@sol‐gel.com, Gaby.Peleg@sol‐gel.com . The study results were published by James Leyden in the JDD (journal of drugs in dermatology) in June 2014, volume 13, issue 6, p.685 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mderma@uni‐muenster.de (allocation concealment and blinding)</p> <p>Reply 18‐8‐2014 <br/> The generation of the random code list was performed in a validated environment by an independent CRO not involved in study conduct and monitoring using the software RANCODE Version 3.6. Central randomisation was performed by this CRO. For eligible subjects, investigators called the randomisation centre and provided the patient’s identification number and gender. Patients were subsequently randomised and the study centre was notified of the treatment number of the patient via telefax by the randomisation centre. Treatment allocation provided by the central randomisation service was documented in the CRF and monitored.<br/> ad 2) The investigational product and its matching vehicle had a similar appearance and all subject kits were packaged in the same way. The randomisation list was kept strictly confidential. It was accessible only to authorized persons who were not involved in the conduct, monitoring and analysis of the study, until time of unblinding. Based on the randomisation list, sets of sealed individual code envelopes were prepared for emergency procedures. No emergency unblinding occurred during the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0058" title="LupinM . Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB43. [EMBASE: 71390263] ">Lupin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulthera, Inc. Mark Lupin, M.D 23‐7‐2014 info @cosmedica.ca <a class="__cf_email__" data-cfemail="a9c6cfcfc0cacce9cac6dac4cccdc0cac887cac6c4" href="/cdn-cgi/l/email-protection">[email protected]</a>, sent several mails no reply (sequence generation and allocation concealment, dropouts) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0063" title="MostafaFF , ElHarrasMA , GomaaSM , Al MokademS , NassarAA , Abdel GawadEH . Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(1):22‐8. [PUBMED: 18705632] ">Mostafa 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S Mokadem no response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Rosacea Society</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0068" title="NeuhausIM , ZaneLT , TopeWD . Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery2009;35(6):920‐8. [PUBMED: 19397667] ">Neuhaus 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G Plewig</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A Rebora</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0074" title="RigopoulosD , KalogeromitrosD , GregoriouS , PacouretJM , KochC , FisherN , et al. Randomized placebo‐controlled trial of a flavonoid‐rich plant extract‐based cream in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2005;19(5):564‐8. [PUBMED: 16164709] ">Rigopoulos 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0154" title="SainthillierJ‐M , Mac‐MaryS , CreidiP , MsikaP , ChadoutaudB , HumbertP . Comparative evaluation by colorimetry and videocapillaroscopy of the efficacy of a cream composed of peptide of lupin and soya isoflavones on erythrocouperose [Évaluation comparative par colorimétrie et vidéocapillaroscopie de l'efficacité d'une crème composée de peptide de lupin et d'isoflavones de soja sur l'érythrocouperose]. Nouvelles Dermatologiques2005;24(2):99‐104. [EMBASE: 2005110281] ">Sainthillier 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="7f1b0d201b101e1e0c1e131a123f061e171010511c1012" href="/cdn-cgi/l/email-protection">[email protected]</a> 10‐08‐2014 Resent 17‐8‐2014 and 3‐9‐2014 (sequence generation and allocation concealment and blinding), no replies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0082" title="SeitéS , BenechF , BerdahS , BayerM , VeyratS , SegotE , et al. Management of rosacea‐prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche‐Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology2013;12(8):920‐4. [EMBASE: 2013521246] ">Seité 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="166579667e7f733865737f6273567a796473777a3875797b" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014 (sequence generation and allocation concealment and blinding, dropouts)<br/> Reply 12‐8‐2014: </p> <p>1. The allocation sequence was generated by a statistician using a specific software</p> <p>2. As soon as they have been recruited (because they answered to the inclusion criteria) by the investigating dermatologist (only one = Dr Zelenkova) a number given chronologically, as indicated in the allocation sequence purchase to the investigator, was attributed to the patient (the first was the N°1, the 2<sup>nd</sup> the N° 2…) </p> <p>3. After enrolment and at the end of the 1<sup>st</sup> visit, a nurse (in the absence of the investigating dermatologist) give the products allocated to the patient’s number. Both products was in the same packaging (blind white packaging) without any indication about formula reference (only reference of study and number of patient) and some information about use (topical use only…) </p> <p>4. None dropped out between the stop of metronidazole treatment (Week 8) and the end of the study (week 16). 67 patients were included before metronidazole treatment, 1 dropped out due to irritative dermatitis at day 53 (before the end of the 8‐week Metronidazole treatment); So 66 patients remained after 8 weeks, 32 received the test formula and 34 the vehicle </p> <p>5. More detail about the 66 patients included in this study are available (see below (printscreens))<br/> 25‐8‐2014, received additional info on Investigator's assessments </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 asked Galderma if NCT01493687 it is published and looks the same as NCT01494467 (Patricia van Lith), confirmed 28‐7 are the same and are Stein Gold<br/> <a class="__cf_email__" data-cfemail="b2fffee1e6f7fbfc83f2dad4dac19cddc0d5" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="38725d59561672797b776e7d747479785f59545c5d4a5559165b5755" href="/cdn-cgi/l/email-protection">[email protected]</a> on details DLQI and SDs </p> <p>3‐9‐2014, received data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 asked Galderma if NCT01493947 is published (Patricia van Lith), confirmation 28‐7‐2014, EADV abstract 2014 </p> <p>alain.taieb@chu‐bordeaux.fr (sequence generation and allocation concealment and blinding, dropouts)<br/> Response 19‐8‐2014 </p> <p>The study was a parallel group study of 960 subjects; however 1800 kit numbers are randomised in blocks of 6. The RANUNI routine of the SAS system was used to randomly assign, in balanced blocks, kit to a treatment (Ivermectin 1% cream, Metronidazole 0.75% cream). Prior to the start of the study, a randomisation list was generated by the statistician and was secured with restricted access. Treatment assignment was balanced into consecutive blocks in a 1:1 ratio and kit numbers were assigned sequentially in chronological order. The study design was investigator‐blinded. The integrity of the blinding was ensured by packaging the products in identical tubes, not allowing the investigator and subject to discuss study treatments, and requiring a third party other than the investigator to dispense the medication. </p> <p>Study population and causes for withdrawal are summarised in the figure below</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>; <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>; <a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>; <a href="./references#CD003262-bbs2-0093" title="ThiboutotDM , FleischerAB , DelRossoJQ , RichPH . A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. Journal of Drugs in Dermatology2009;8(7):639‐48. [PUBMED: 19588640] ">Thiboutot 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="3b5d525c5e554f5249555a504852417b5c565a525715585456" href="/cdn-cgi/l/email-protection">[email protected]</a> 17‐8‐2014 ((sequence generation and allocation concealment)<br/> resent 3‐9‐2014 no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="bcd4d9d0d9d2d1c8d3ced3d7fcddd3d092dfd3d1" href="/cdn-cgi/l/email-protection">[email protected]</a>. "The patients were not cognizant nor were they aware of the different formulations Nor their unique characteristics so they were easily utilized and dispensed in unmarked tubes". "Central randomisation that was computer generated" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="a4d6c3c5c8c8cbe4d1c7d7c08ac1c0d1" href="/cdn-cgi/l/email-protection">[email protected]</a> 17‐8‐2014 (sequence generation and allocation concealment and blinding)<br/> resent 3‐9‐2014, received reply 4‐9‐2014 </p> <p>1. The allocation sequence was generated by an unblinded member of the study team who worked off‐site in a separate laboratory to group in a 2‐to‐1 fashion, so that 8 of those numbers were assigned to the treatment group, and 4 to the control group. As subjects were enrolled in the study, they were sequentially assigned a unique study identification number from 1‐12 by the blinded study coordinator, with the first subject to enrol in the study being assigned the study identification number of 1. The list matching study identification numbers to their corresponding treatment group was only accessible by this unblinded member of the study team </p> <p>2. The allocation sequence was created prior to enrolling any subjects in the study, therefore ensuring that intervention allocations could not be foreseen in advance of, or during, enrolment </p> <p>3. This study was conducted in a double‐blind fashion so that both participants and investigators were blinded as to which intervention group participants were assigned. As stated previously, randomisation was completed by an unblinded member of the study team who worked off‐site and had no contact with enrolled subjects. The list of treatment group assignments was stored on a password‐protected computer accessible only to this unblinded study team member. This same unblinded member of the study team was also responsible for preparing all study medication. Once prepared, the study medication was placed into a bottle labelled with the participant’s unique study identification number that was assigned to the participant at the time of enrolment in the trial. The unblinded study team member dispensed the bottles of prepared medication to the study’s clinical coordinator, who was also blinded, for distribution to subjects. Both the treatment and the control creams were identical in appearance and viscosity so that the two drugs could not be distinguished by look or feel<br/> Resent regarding exact data IGE and CEA 12‐9‐2013<br/> Received 12‐9‐2013 exact data + SD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0102" title="WilkinJK . Effect of nadolol on flushing reactions in rosacea. Journal of the American Academy of Dermatology1989;20(2 Pt 1):202‐5. [PUBMED: 2521641] ">Wilkin 1989</a>; <a href="./references#CD003262-bbs2-0103" title="DeWittS , WilkinJK . Double blind, parallel study of efficacy and safety of clindamycin lotion in the treatment of rosacea. Clinical Pharmacology and Therapeutics1987;41(2):176. WilkinJK , DeWittS . Treatment of rosacea: topical clindamycin versus oral tetracycline. International Journal of Dermatology1993;32(1):65‐7. [UI: 93146772; PUBMED: 8425809] ">Wilkin 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Additional information could not be used</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. ">Yoo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="e6838a8a8388c88b87948b9394a68b89938892958f88878fc8899481" href="/cdn-cgi/l/email-protection">[email protected]</a> 18‐8‐2014 (sequence generation and allocation concealment and blinding) </p> <p>Resent 3‐9 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0169" title="ACTRN12614000004662 . A single‐blind randomised controlled trial of topical Kanuka honey for the treatment of rosacea. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365179 (accessed 21 July 2014). ">ACTRN12614000004662</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medical Research Institute of New Zealand, Anna Hunt <a class="__cf_email__" data-cfemail="9afbf4f4fbb4f2eff4eedaf7e8f3f4e0b4fbf9b4f4e0" href="/cdn-cgi/l/email-protection">[email protected]</a>. sent 23‐7‐2014</p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> ACTRN12614000004662 “A single‐blind randomised controlled trial of topical Kanuka honey for the treatment of rosacea”. Can you tell us if ACTRN12614000004662 is published and if so give us a pdf of the publication? </p> <p>email reply 29‐7‐2014 </p> <p>Dear Dr van Zuuren,</p> <p>Thank you for your email and interest in our study. We are currently analysing this 138 participant Phase 3 study. It is not yet published, but we would be happy to send you the publication when that time comes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0181" title="EUCTR2006‐001999‐20‐HU . Assessment of the efficacy and safety of three concentration:1%, 0.3%, 0.1% of CD5024 cream once daily and CD5024 1% cream twice daily, versus its vehicle and versus metronidazole cream (Rozex®) in patients with papulopustular rosacea over 12 weeks. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2006‐001999‐20‐HU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0182" title="EUCTR2006‐003707‐40‐DE . Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato‐telangiectatic rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2006‐003707‐40‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0185" title="EUCTR2009‐013111‐35‐DE . Effect of CD08514 versus placebo, in patients presenting with type 1 rosacea, over an 8‐week treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2009‐013111‐35‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0186" title="EUCTR2010‐018319‐13‐DE . A double‐blind, vehicle controlled, parallel group study assessing the activity of CD5024 1% cream in subjects with papulopustular rosacea over 12 weeks treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2010‐018319‐13‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0187" title="EUCTR2010‐021150‐19‐NL . Doxycycline versus minocycline in the treatment of rosacea: a randomised controlled trial. ‐ DoMino‐study. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2010‐021150‐19‐NL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study of Mireille, is still ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0188" title="EUCTR2010‐023566‐43‐DE . No English title [Multizentrische, randomisierte, doppelblinde, kontrollierte Phase III‐Studie zur Behandlung der papulopustulären Rosazea mit Permethrin Creme 5 % (InfectoScab®) versus Permethrin Creme 2,5 % versus Metronidazol Creme 0,75 % (Rozex®) ‐ Papulopustuläre Rosazea‐Behandlung mit Permethrin Creme versus Metronidazol Creme]. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2010‐023566‐43‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014 Dr. Bertil Wachall, <a class="__cf_email__" data-cfemail="e09394958489858ea0898e868583948f908881928dce838f8d" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>2‐10‐2014 Thank you for your request concerning our permethrin rosacea trial (permethrin 5% and 2.5% vs metronidazole cream). Unfortunately, the data are not published or submitted up to now. We hope this will be done in the next months, but the principal investigator who is responsible for the publication seems to be very busy. </p> <p>In addition, please be informed that we are currently conducting another permethrin trial (permethrin 5% vs placebo cream) in PPR‐patients. We expect the results of this trial in spring 2015 (we discussed with PI, study does NOT appear in EUCTR (EUDRACT‐Nr. 2013‐000979‐32) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0189" title="EUCTR2011‐002057‐65‐DE . Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2011‐002057‐65‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0190" title="EUCTR2011‐002058‐30‐DE . Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6‐week treatment period. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2011‐002058‐30‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0191" title="EUCTR2011‐004791‐11‐CZ . Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36‐week extension period. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2011‐004791‐11‐CZ</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0192" title="EUCTR2012‐001044‐22‐SE . A multicenter, randomized, double‐blind, vehicle‐controlled, parallel group study to demonstrate the efficacy and assess the safety of CD07805/47 gel 0.5%applied topically once daily in subjects with moderate to severe facial erythema of rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2012‐001044‐22‐SE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0193" title="EUCTR2013‐005083‐26‐DE . Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea ‐ Effect of CD07805/47 gel in rosacea flushing. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2013‐005083‐26‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0194" title="IRCT2014010516079N1 . Comparison of dapsone 5% topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">IRCT2014010516079N1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014 <a class="__cf_email__" data-cfemail="df9880b9beb8b7b6b7b69fb2babbf1b2aab6f1bebcf1b6ad" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="1666497d7e796564776077787f566473657f72737862387b637f387775387f64" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already completed or submitted for publication.<br/> IRCT2014010516079N1 “Comparison of dapsone 5% Topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea”. Can you tell us if IRCT2014010516079N1 is already completed? Or submitted for publication? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0194" title="IRCT2014010516079N1 . Comparison of dapsone 5% topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">IRCT2014010516079N1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014 <a class="__cf_email__" data-cfemail="7c17130f1d0e1d13131a153c051d141313521f1311" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="9ff4f0ecfeedfef0f0f9f6dff8f2fef6f3b1fcf0f2" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="4c21292428253e260c2d2320622f23623927" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already submitted for publication.<br/> IRCT2014030416837N1 “Effects of permethrin 5% topical gel in comparison with placebo on Demodex density in rosacea patients: a double‐blind, randomised clinical trial”. Can you tell us if IRCT2014030416837N1 is already submitted for publication? </p> <p>Reply: 23‐9‐2014</p> <p>Dear Dr Zuuren</p> <p>Many thanks for your query,</p> <p>We are in the process of completing and submitting the article.</p> <p>Regards,</p> <p>Mehdi</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0195" title="JPRN‐UMIN000008315 . Clinical trial for development of topical rapamycin treatment for rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">JPRN‐UMIN000008315</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mari Wataya‐Kaneda <a class="__cf_email__" data-cfemail="325f59535c575653725657405f531c5f57561c5d41535953" href="/cdn-cgi/l/email-protection">[email protected]</a>‐u.ac.jp not sent mail as they are still recruiting </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0196" title="NCT00041977 . A multicenter, randomized, double‐blind, placebo‐controlled, clinical trial to determine the effects of doxycycline hyclate 20 mg tablets [Periostat(R)] administered twice daily for the treatment of acne rosacea. clinicaltrials.gov/ct2/show/NCT00041977 (accessed 21 July 2014). ">NCT00041977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="95dcfbf3fad5e5f4e7fce6f0e7f1f0e7f8bbf6faf8" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014<br/> My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion (NCT00041977 “A Multicentre, randomised, Double‐Blind, Placebo‐Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea”)<br/> <br/> Has this study ever been published as I could not find it? If not, do you have a contact at CollaGenex Pharmaceuticals, as on the web site of clinicaltrials.gov this is not provided, but we found your name on it, also asked Galderma (Patricia van Lith) </p> <p>Follow up mail to Dr Pariser 11‐8‐2014 <br/> Reply 13‐8: They sent me a study, but is not correct one, but on acne, so sent again request </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0064" title="NCT00249782 . A phase II, randomized, partial‐blind, parallel‐group, active‐ and vehicle‐controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). ">NCT00249782</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan, results published on the Internet, as word doc and pdf we made several, but unsuccessful, attempts to contact Allergan </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00348335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="2a40585d435e5e5a4f44446a4b454604494547" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="1379647a676763767d7d537c707f7a3d7d7667" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014</p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion (NCT00348335 “Efficacy of topical cyclosporin 0.05% for the treatment of ocular rosacea”)<br/> Has this study ever been published as I could not find it? (I do have the 2005 one) </p> <p>Follow‐up mail 11‐8‐2014 <br/> Reply: 12‐8‐2014 The study was discontinued when early results showed that we did not have a reproducible method of quantifying injection. It was far too variable and did not appear to correspond at all to patients reporting symptomatic improvement. </p> <p>John Wittpenn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00417937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 Alan Fleischer &lt;<a class="__cf_email__" data-cfemail="dabbbcb6bfb3a9b9b29aadbbb1bfb2bfbbb6aeb2f4bfbeaf" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;My colleagues and I are updating our Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already included in our review?<br/> NCT00417937 “A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily”. Is this the same study as published in Thiboutot DM, Fleisher AB, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology 2008;7(6):541‐6.? Or is it another one? </p> <p>Reply 19‐7‐2014: I do believe that this is the exact same study. Sorry that my name appears in lots of clinical trials settings (<a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0197" title="NCT00436527 . MetroGel 1% hydration study: a kinetic regression study. clinicaltrials.gov/show/NCT00436527 (accessed 19 July 2014). ">NCT00436527</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, asked Galderma if it is published (Patricia van Lith), several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="f892978b9dd68a8d9d9c99b89f99949c9d8a9599d69b9795" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00483145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="6f02070e0a0b0a1d1c0b0e032f0b0e0b03010a1b410b04" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014<br/> My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion (NCT00483145 Laser‐mediated photodynamic therapy of acne vulgaris and rosacea). It has been completed in 2007.<br/> Has this study ever been published as I could not find it? </p> <p>Reply 16‐7‐2014: We were unsuccessful in recruiting rosacea patients and as thus, published a case report, which is attached. Results from treating acne patients were published as a RCT, we have removed this one from ongoing studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0198" title="NCT00495313 . Determine the effects of COL‐101 administered once daily with metronidazole topical gel, 1% versus doxycycline hyclate 100 mg administered once daily with metronidazole topical gel, 1% in patients with moderate to severe rosacea. clinicaltrials.gov/ct2/show/NCT00495313 (accessed 16 July 2014). ">NCT00495313</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sent 16‐7‐2014 message via LinkedIn, and Galderma (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="c5afaab6a0ebb7b0a0a1a485a2a4a9a1a0b7a8a4eba6aaa8" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0171" title="NCT00560703 . Efficacy and safety of COL‐101 for the treatment of blepharitis in patients with facial rosacea. clinicaltrials.gov/ct2/show/NCT00560703 (accessed 16 July 2014). ">NCT00560703</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16‐7‐2014, asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="98f2f7ebfdb6eaedfdfcf9d8fff9f4fcfdeaf5f9b6fbf7f5" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0172" title="NCT00617903 . A 12‐week exploratory, multicenter, double‐blind, vehicle‐controlled study to investigate the efficacy and safety of topical azelaic acid 15% foam twice daily in patients with papulopustular rosacea. clinicaltrials.gov/ct2/show/NCT00617903 (accessed 18 July 2014). ">NCT00617903</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 clinical‐trials‐<a class="__cf_email__" data-cfemail="4a2925243e2b293e0a282b332f38222f2b263e22292b382f64292527" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT00617903 “Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea”. I found a study of Draelos published in 2013 in CUTIS, but that one included far more participants than the 84 mentioned in the NCT00617903 study.<br/> Can you tell us if the NCT00617903 is published and if so give us a pdf of the publication?<br/> 11‐8‐2014 follow‐up mail<br/> 15‐8‐2014: Christopher Billis &lt;<a class="__cf_email__" data-cfemail="6a09021803191e051a020f18440803060603192a080b130f1844090507" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;, resent<br/> 15‐8‐2014, not published and no additional info </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0199" title="NCT00621218 . A pilot study to compare tretinoin gel, 0.05% to tretinoin gel vehicle when dosed once or twice daily in female subjects with classical rosacea. clinicaltrials.gov/ct2/show/NCT00621218 (accessed 18 July 2014). ">NCT00621218</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 via website Valeant Pharmaceuticals who took over Coria Laboratories, asked if it is published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0200" title="NCT00667173 . A phase 2, multi‐center, evaluator‐blind, randomized, vehicle‐controlled clinical study to assess the safety and efficacy of IDP‐115 in the treatment of rosacea. clinicaltrials.gov/ct2/show/NCT00667173 (accessed 18 July 2014). ">NCT00667173</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 via website Valeant Pharmaceuticals who took over Dow Pharmaceutical Sciences, Inc, asked if it is published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0201" title="NCT00697541 . A phase II, single‐center, two‐way crossover relative systemic bioavailability study of Col‐118 administered topically as a 0.18 % facial gel and brimonidine ophthalmic solution 0.2% administered to the eye in subjects with moderate to severe erythematous rosacea. clinicaltrials.gov/ct2/show/NCT00697541 (accessed 18 July 2014). ">NCT00697541</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="e983869a8cc79b9c8c8d88a98e88858d8c9b8488c78a8684" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0202" title="NCT01016782 . Multi‐center, double‐blind, randomized, vehicle‐controlled, parallel group study of 0444 gel. clinicaltrials.gov/ct2/show/NCT01016782 (accessed 19 July 2014). ">NCT01016782</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, mail though website Sandoz. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT01016782 “Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea)”. Can you tell us if the NCT01016782 is published and if so give us a pdf of the publication? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0174" title="NCT01125930 . Investigation of the topical retinoid, Atralin gel 0.05% for the treatment of erythematotelangiectatic rosacea. clinicaltrials.gov/ct2/show/NCT01125930 (accessed 19 July 2014). ">NCT01125930</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, <a href="http://mailto:maierl%40med.umich.edu?subject=NCT01125930, Derm 616, Atralin Gel for the Treatment of Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="d3beb2bab6a1bf93beb6b7fda6bebab0bbfdb6b7a6">[email protected]</span></a>. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT01125930 “Atralin Gel for the Treatment of Rosacea”. Can you tell us if NCT01125930 is published and if so give us a pdf of the publication?<br/> Reply 29‐7‐2014: </p> <p>Dear Dr. van Zuuren, The study has not yet been published yet. When it has been accepted for publication, I can notify you. Thank you, Lisa Maier </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0203" title="NCT01134991 . Pilot, randomized, double blind, placebo controlled, parallel group, dose range finding study, to evaluate the tolerability and safety of FXFM244 antibiotic foam and to monitor its clinical effect in moderate to severe rosacea patients. clinicaltrials.gov/ct2/show/NCT01134991 (accessed 19 July 2014). ">NCT01134991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 <a class="__cf_email__" data-cfemail="14707b6254727b75797d6c3a777b3a7d78" href="/cdn-cgi/l/email-protection">[email protected]</a>. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? NCT01134991 “Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients”. Can you tell us if NCT01134991 is published and if so give us a pdf of the publication? </p> <p>Reply 21‐7 Dov Tamarkin, Ph.D. <a class="__cf_email__" data-cfemail="b9ddd6cf97cdd8d4d8cbd2d0d7f9dfd6d8d4d0c1c9d1d8cbd4d897dad6d4" href="/cdn-cgi/l/email-protection">[email protected]</a>, study is still ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0204" title="NCT01186068 . A randomized, double‐blind, vehicle‐controlled, parallel‐group study of the dose‐response profile of V‐101 cream in subjects with erythematous rosacea. clinicaltrials.gov/ct2/show/NCT01186068 (accessed 19 July 2014). ">NCT01186068</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 <a class="__cf_email__" data-cfemail="fc9a938b90998e969399bc918f92d29f9391" href="/cdn-cgi/l/email-protection">[email protected]</a> My colleagues and I are updating our Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT01186068 “A randomised, double‐blind, vehicle‐controlled, parallel‐group study of the dose‐response profile of V‐101 cream in subjects with erythematous rosacea”<br/> Can you tell us if the NCT01186068 is published and if so give us a pdf of the publication? (By the way we will include your dose‐finding studies and phase III studies on brimonidine, and might need to contact you later about these. </p> <p>Follow‐up 11‐8‐2014 <a class="__cf_email__" data-cfemail="4321263a26310330222e21312c342d6d202c2e" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> Reply 12‐8‐2014 Dr Fowler: not published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0205" title="NCT01257919 . Investigator‐blinded, randomized, cross‐over, multiple dose phase I study on safety and pharmacokinetics of topically applied azelaic acid foam, 15% compared to azelaic acid gel, 15% in subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01257919 (accessed 19 July 2014). ">NCT01257919</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014. Bayer sent though website, Novum, <a class="__cf_email__" data-cfemail="1c75727a735c72736a69716c6e6f327f7371" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? </p> <p>The study was supported by Bayer and Novum are listed as "locations" on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> </p> <p>NCT01257919 “ Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea </p> <p>Can you tell us if the study has been published if so could I request a pdf of the publication? </p> <p>If not could we please access the data?<br/> 15‐8‐2014: Christopher Billis &lt;<a class="__cf_email__" data-cfemail="98fbf0eaf1ebecf7e8f0fdeab6faf1f4f4f1ebd8faf9e1fdeab6fbf7f5" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;, resent<br/> 15‐8‐2014, not published and no additional info </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0206" title="NCT01308619 . A multicenter, randomized, double‐blind, placebo‐controlled evaluation of rosacea‐related inflammatory biochemical markers in the skin of adults with papulopustular rosacea treated with daily doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) capsules. clinicaltrials.gov/show/NCT01308619 (accessed 19 July 2014). ">NCT01308619</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="442e2b37216a36312120250423252820213629256a272b29" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT01398280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014 Tissa Hata, MD, University of California, San Diego, <a class="__cf_email__" data-cfemail="ccb8a4adb8ad8cb9afbfa8e2a9a8b9" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? </p> <p>NCT01398280 Effects of Aminocaproic Acid (ACA) on Rosacea‐specific Inflammation</p> <p>If this has been published could I kindly ask for the citation and/or if you have a pdf available? </p> <p>If it has not been published are the data available?<br/> Follow‐up 11‐8‐2014 and 17‐8‐2014 </p> <p>17‐8‐2014: EvZ: This is <b>Two 2014</b>!!! </p> <p>Reply: 18‐8‐2014: Thank you for your interest in our research. Attached is the paper which was published in the JID. Thanks! Tissa </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="9bf1f4e8feb5e9eefefffadbfcfaf7fffee9f6fab5f8f4f6" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 August with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> <p>5‐9‐2014: <a class="__cf_email__" data-cfemail="8cdbedfefee9e2a2dbc5c2c7c9c0c1cdc2ccebede0e8e9fee1eda2efe3e1" href="/cdn-cgi/l/email-protection">[email protected]</a>. ‎ 22‐9‐2014, received all we needed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Novartis Pharmaceuticals, no contact details, sent mail through Dutch website<br/> 12‐8‐2014 reply <a href="http://mailto:pieter.ekkel@novartis.com_" target="_blank"><span class="__cf_email__" data-cfemail="215148445544530f444a4a444d614f4e5740535548520f424e4c">[email protected]</span></a> </p> <p>U vraagt om informatie over de studie NCT01449591 (CBFH772A2203) met als compound BFH772. </p> <p>De enige informatie die we nu kunnen delen over deze studie zijn gepubliceerd op ‘Novartis clinical trial database’, onder ‘Novartis Institute for Biomedical Research’, Dermatology/Skin, CBFH772 <a href="http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public" target="_blank">http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public</a> <br/> 22‐8‐2014: What was the rationale behind study, are they going to proceed with further studies? will it be published? </p> <p>Reply 9‐9‐2014: BFH772 is currently under investigation and has not been approved for use other than for use as part of a clinical trial.<br/> Therefore, at this present time, no further information can be provided other than what is publicly available at the previously indicated location (http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public )<br/> Whether or not results of trial NCT01449591 "Safety, Tolerability and Efficacy of BFH77s in Rosacea Patients" will be published in medical journals in the future cannot be anticipated at this stage.<br/> Please do not hesitate to reach out to us again in six months' time to inquire about potential updates, if of interest.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0175" title="NCT01451619 . A randomized, double‐blind, placebo‐controlled, multi‐center, parallel group study to assess the pharmacodynamics of MK‐0524 in subjects with moderate to severe erythematotelangiectatic rosacea. (protocol No. 155). clinicaltrials.gov/show/NCT01451619 (accessed 19 July 2014). ">NCT01451619</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014. Merck Sharp &amp; Dohme Corp, <a class="__cf_email__" data-cfemail="2053544556454e0e435241474c45604d4552434b0e434f4d" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="48202d293c202d3a663b3c2925293c292b273b08252d3a2b23662b2725" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="e58e808989809ccb818a90828d8097919ca5888097868ecb868a88" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> Reply 23‐7‐2014<a href="http://mailto:pamela_eisele@merck.com" target="_blank"><span class="__cf_email__" data-cfemail="7b0b1a161e171a241e12081e171e3b161e09181055181416">[email protected]</span></a> I checked with our researchers and have been told that the study results have been submitted for publication and are currently under review for consideration by the <i>Journal of Clinical Pharmacology</i>. It is unclear at this point when the data may be available, as they are being considered by the publication </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0207" title="NCT01513863 . A randomized, double‐blind, placebo controlled, parallel design, multi‐site clinical study to compare the bioequivalence of two metronidazole 1% topical gel formulations in patients with moderate to severe rosacea. clinicaltrials.gov/show/NCT01513863 (accessed 19 July 2014). ">NCT01513863</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 <a class="__cf_email__" data-cfemail="490e0d0e26272e283a0927263f3c24393b3a672a2624" href="/cdn-cgi/l/email-protection">[email protected]</a>. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? NCT01513863 “A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea (MTZG)”. Can you tell us if NCT01513863 is published and if so give us a pdf of the publication? </p> <p>21‐7‐2014 reply Aimee Brown, <a class="__cf_email__" data-cfemail="69282b1b061e072907061f1c04191b1a470a0604" href="/cdn-cgi/l/email-protection">[email protected]</a>. "Thank you Dr. Zuuren for your inquiry, however this study has not yet been published." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0208" title="NCT01555463 . A randomized, double‐blind, vehicle‐controlled, multicenter, parallel‐group clinical trial to assess the safety and efficacy of azelaic acid foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01555463 (accessed 20 Juy 2014). ">NCT01555463</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bayer, mailed via website 22‐7‐2014<br/> 15‐8‐2014: Christopher Billis &lt;<a class="__cf_email__" data-cfemail="b6d5dec4dfc5c2d9c6ded3c498d4dfdadadfc5f6d4d7cfd3c498d5d9db" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;, resent<br/> 15‐8‐2014, not published and no additional info </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0176" title="NCT01579084 . Safety and tolerability of AGN‐199201 in patients with erythema associated with rosacea. clinicaltrials.gov/show/NCT01579084 (accessed 21 July 2014). ">NCT01579084</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan, sent mail 22‐07‐2014 through website no response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0177" title="NCT01614743 . A double‐blinded, randomized placebo controlled pilot study comparing the efficacy and safety of Incobotulinumtoxin A versus saline injections to the cheek region in patients with rosacea. clinicaltrials.gov/show/NCT01614743 (accessed 19 July 2014). ">NCT01614743</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014 Steven H. Dayan, Medical Director, DeNova Research, <a href="http://mailto:MyClinicalTeam@drdayan.com" target="_blank"><span class="__cf_email__" data-cfemail="04497d47686d6a6d6765685061656944607660657d656a2a676b69">[email protected]</span></a> </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, could you kindly confirm the status? </p> <p>It is reported on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> as <b>This study is ongoing, but not recruiting participants</b> </p> <p>When do you expect to complete it or if it is completed ... publish the data?</p> <p>Reply 22‐7‐2014. We appreciate your inquiry, and look forward to speaking with you. We are currently forwarding your message to Annie, our patient coordinator, and she will respond soon. </p> <p>emailed again 29‐7 2014. reply 29‐7‐2014 of <a href="http://mailto:Selika@denovaresearch.com" target="_blank"><span class="__cf_email__" data-cfemail="a9faccc5c0c2c8e9cdccc7c6dfc8dbccdaccc8dbcac187cac6c4">[email protected]</span></a> I appreciate you reaching out to us. This study is in the process of being written up, unfortunately due to a signed confidentiality agreement, we cannot provide you with any of the data at this time </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0178" title="NCT01631656 . Combination Finacea gel and vascular Nd:Yag laser therapy for mild to moderate rosacea. clinicaltrials.gov/show/NCT01631656 (accessed 20 July 2014). ">NCT01631656</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amy McMichael, Wake Forest School of Medicine</p> <p>23‐7‐2014</p> <p><a class="__cf_email__" data-cfemail="81e0ece2ece8e2e9e0c1f6e0eae4e9e4e0edf5e9afe4e5f4" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="54353937393d373c35142332213639377a313021" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation, allocation concealment), several e‐mail exchanges, no replies to this </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0209" title="NCT01659853 . A multicenter, randomized, controlled, double‐masked, crossover design study to compare efficacy and assess safety of CD07805/47 gel 0.5% applied once daily vs azelaic acid gel 15% applied twice daily in subjects with erythema of rosacea. clinicaltrials.gov/show/NCT01659853 (accessed 20 July 2014). ">NCT01659853</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20‐7‐2014 asked Galderma if it is published (Patricia van Lith), 28‐7‐2014, not yet published, but I thought already submitted so sent another mail. several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="96fcf9e5f3b8e4e3f3f2f7d6f1f7faf2f3e4fbf7b8f5f9fb" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 August with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0179" title="NCT01735201 . AGN‐199201 for the treatment of erythema with rosacea. clinicaltrials.gov/show/NCT01735201 (accessed 21 July 2014). ">NCT01735201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan, results posted on clinicaltrials.gov <a href="http://mailto:clinicaltrials%40allergan.com?subject=NCT01735201, 199201-002, AGN-199201 for the Treatment of Erythema With Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="77141b1e191e14161b03051e161b0437161b1b12051016195914181a">[email protected]</span></a>, 23‐7‐2014 </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published, we saw results published on clinicaltrials.gov? NCT01735201 “AGN‐199201 for the Treatment of Erythema With Rosacea”. Can you tell us if NCT01735201 is published and if so give us a pdf of the publication? </p> <p>Follow‐up 11‐8‐2014 and 17‐8‐2014 no replies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0180" title="NCT01740934 . An eight‐week, multi‐site, double‐blind, randomized, vehicle‐controlled, parallel‐group trial to evaluate the safety, tolerability, and effects of Anatabloc® crème in subjects with rosacea followed by an open‐label extension. clinicaltrials.gov/show/NCT01740934 (accessed 20 July 2014). ">NCT01740934</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rock Creek Pharmaceuticals, Inc. M Varga, 23‐7‐2014 <a class="__cf_email__" data-cfemail="c3aba6a2afb7ab83b1aca0a8a0b1a6a6a8b3aba2b1aea2eda0acae" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> response 1‐8‐2014: Thanks very much for your interest in our just concluded clinical trial, we are in the process of writing the clinical study report. We will make it available to you. If you have additional question, please do not hesitate to contact me.Dr Ernest Okorie,MD <a href="http://mailto:gddssconsultant@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="8becefeff8f8e8e4e5f8fee7ffeae5ffcbece6eae2e7a5e8e4e6">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0210" title="NCT01784133 . A phase 2, randomized, vehicle‐controlled, double‐blind, multicenter study to evaluate the safety and efficacy of three once‐daily CLS001 topical gels versus vehicle administered for 12 weeks to subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01784133 (accessed 20 July 2014). ">NCT01784133</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutanea Life Sciences, Inc</p> <p>23‐7‐2014, <a class="__cf_email__" data-cfemail="6801060e07280b1d1c09060d0904010e0d460b0705" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>This study has been completed. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) this study has been identified as potentially eligible for inclusion. Can you please indicate if the study has been published and if so could I request a pdf or the citation? If not are the data available? </p> <p>10‐8‐2014 Resent e‐mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0211" title="NCT01828177 . A multicenter randomized evaluator‐blinded vehicle‐controlled parallel group evaluation of twice daily PDI‐320 in comparison to its monads in adults with rosacea. clinicaltrials.gov/show/NCT01828177 (accessed 20 July 2014). ">NCT01828177</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PreCision Dermatology, Inc.Syd Dromgoole, as study is still ongoing not sent mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="563c3925337824233332371631373a3233243b377835393b" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> <p>19‐8‐2014 received poster abstracts Layton 2014 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0212" title="NCT01917539 . Efficacy of Pulsed Light Therapy for Meibomian gland dysfunction and dry eye syndrome. clinicaltrials.gov/show/NCT01917539 (accessed 21 July 2014). ">NCT01917539</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angela Chang, University of Miami <a href="http://mailto:AChang2%40med.miami.edu?subject=NCT01917539, 20120140, Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome" target="_blank"><span class="__cf_email__" data-cfemail="acedefc4cdc2cb9eecc1c9c882c1c5cdc1c582c9c8d9">[email protected]</span></a> or Bradford Lee <a href="http://mailto:blee%40post.harvard.edu?subject=NCT01917539, 20120140, Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome" target="_blank"><span class="__cf_email__" data-cfemail="63010f060623130c10174d0b0211150211074d060716">[email protected]</span></a> </p> <p>Still recruiting patients at the moment, not sent mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0213" title="NCT01933464 . An analysis of the effect of topical cromolyn sodium on rosacea‐associated erythema. clinicaltrials.gov/show/NCT01933464 (accessed 20 July 2014). ">NCT01933464</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anna Di Nardo, MD, PhD, University of California, San Diego. As study is still recruiting not sent mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0214" title="NCT01993446 . A randomized, double‐blind, vehicle controlled study of the safety and efficacy of topical DRM02 in subjects with rosacea. clinicaltrials.gov/show/NCT01993446 (accessed 20 July 2014). ">NCT01993446</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dermira, Inc. Beth Zib, <a href="http://mailto:info@dermira.com" target="_blank"><span class="__cf_email__" data-cfemail="1d74737b725d79786f70746f7c337e7270">[email protected]</span></a> 23‐7‐2014 </p> <p>Follow‐up 11‐8‐2014 no replies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0215" title="NCT02036229 . A randomised, double blind, placebo controlled, half‐face study to evaluate the effect of topical ivermectin cream 0.5% on demodicidosis. clinicaltrials.gov/ct2/show/NCT02036229 (accessed 20 July 2014). ">NCT02036229</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rina Segal, Rabin Medical Center, <a href="http://mailto:rinas3%40clalit.org.il?subject=NCT02036229, topical ivermectin, demodex, Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis" target="_blank"><span class="__cf_email__" data-cfemail="54263d3a35276714373835383d207a3b26337a3d38">[email protected]</span></a> not sent mail as not yet open to recruitment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0216" title="NCT02052999 . An open label pilot study to evaluate the efficacy of PAC‐14028 in the treatment of erythematotelangiectatic rosacea and papulopustular rosacea. clinicaltrials.gov/show/NCT02052999 (accessed 20 July 2014). ">NCT02052999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amorepacific Corporation BeomJoon Kim, Professor Department of Dermatology, Chungang University Hospital, sent mail through website 23‐7‐2014 </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT02052999 “Study to evaluate the efficacy and safety of PAC‐14028 cream in rosacea patients”. Can you tell us if NCT02052999 is published and if so give us a pdf of the publication? Study is performed by BeomJoon Kim </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0217" title="NCT02075671 . Photodynamic therapy for papulopustular rosacea. clinicaltrials.gov/show/NCT02075671 (accessed 20 July 2014). ">NCT02075671</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>George Washington University, Jack Short, <a href="http://mailto:jshort%40mfa.gwu.edu?subject=NCT02075671, 031416, Photodynamic Therapy for Papulopustular Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="a9c3dac1c6dbdde9c4cfc887cededc87cccddc">[email protected]</span></a> as they are still recruiting, not sent mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0218" title="NCT02120924 . A multicenter, double‐blind, randomized, parallel‐group, vehicle‐controlled study to evaluate the safety and clinical equivalence of a generic azelaic acid gel, 15% and the reference listed Finacea® (azelaic acid) gel, 15% in patients with moderate facial rosacea. clinicaltrials.gov/show/NCT02120924 (accessed 20 July 2014). ">NCT02120924</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Actavis Inc. John Capicchioni Akesis, LLC As they are still recruiting, not sent mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0219" title="NCT02132117 . Safety and efficacy of AGN‐199201 in patients with persistent erythema associated with rosacea. clinicaltrials.gov/show/NCT02132117 (website accessed 20 July 2014). ">NCT02132117</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan <a href="http://mailto:clinicaltrials%40allergan.com?subject=NCT02132117, 199201-005, Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="1477787d7a7d77757860667d75786754757878716673757a3a777b79">[email protected]</span></a> seems the same as NCT02131636 which I did NOT add? </p> <p><b>NCT02131636</b> Efficacy and Safety of AGN‐199201 in Patients With Persistent Erythema Associated With Rosacea </p> <p><b>NCT02132117</b> Safety and Efficacy of AGN‐199201 in Patients With Persistent Erythema Associated With Rosacea </p> <p>Also <b>NCT02095158</b> Longterm and efficacy and safety<br/> <a href="http://mailto:clinicaltrials%40allergan.com?subject=NCT02132117, 199201-005, Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="284b444146414b49445c5a4149445b684944444d5a4f4946064b4745">[email protected]</span></a> sent several mails, to ask if these are same studies, no replies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0220" title="NCT02144181 . Evaluation of the safety and efficacy of the Ulthera® System for the treatment of signs and symptoms of erythematotelangiectatic rosacea. clinicaltrials.gov/show/NCT02144181 (accessed 20 July 2014). ">NCT02144181</a> </p> <p>Evaluation of the Safety and Efficacy of the Ulthera® System for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulthera, Inc. Mark Lupin, MD is LUPIN 2014 part of this? As they are still recruiting, not sent mail </p> <p>e‐mail sent 29‐7‐2014 to confirm, <a class="__cf_email__" data-cfemail="39565f5f505a5c795a564a545c5d505a58175a5654" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>Dear Colleagues</p> <p>I have received no further response could you please confirm with Dr Lupin?There appears to be a poster in JAAD 2014 vol17 Iss 5 referring to this trial? <b>NCT01756027</b> </p> <p>Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea Mark Lupin, MD, The Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada<br/> I also have this trial <a href="http://nct02144181/" target="_blank">NCT02144181</a> which appears to be still recruiting and the contact person is Dr Mark Lupin<br/> Resent 22‐8‐2014 no replies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0221" title="NCT02147691 . Finacea 15% and brimonidine 0.33% gel in the treatment of rosacea ‐ a pilot study. clinicaltrials.gov/show/NCT02147691 (accessed 20 July 2014). ">NCT02147691</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leon Kircik, M.D., Derm Research, PLLC <a href="http://mailto:wedoderm%40yahoo.com?subject=NCT02147691, FIN1302, Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study" target="_blank"><span class="__cf_email__" data-cfemail="87f0e2e3e8e3e2f5eac7fee6efe8e8a9e4e8ea">[email protected]</span></a> As they are still recruiting, not sent mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0222" title="NCT02204254 . Prospective, open label, randomized study comparing bipolar radiofrequency potentiated by infrared light to doxycycline in patient with papulopustular rosacea. clinicaltrials.gov/show/NCT02204254 (accessed 23 September 2014). ">NCT02204254</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Florence Le Duff, leduff.f2@chu‐nice.fr, not sent e‐mail as they are still recruiting</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCT = randomised controlled trial<br/> CCT = controlled clinical trial (quasi‐randomised) </p> </div> </div> </section> <section id="CD003262-sec-0049"> <h5 class="title">Translation</h5> <p>We did not apply any language restrictions and several studies published in the French, Spanish, Italian, Norwegian and Danish languages were translated by one author (EvZ). One article in the Chinese language was translated by Ching‐Chi Chi (see <a href="#CD003262-sec-0577">Acknowledgements</a>). </p> </section> </section> </section> <section id="CD003262-sec-0050"> <h3 class="title" id="CD003262-sec-0050">Data collection and analysis</h3> <p>We followed the previously published protocol (<a href="./references#CD003262-bbs2-0309" title="vanZuurenEJ , PowellFC , GraberM . Interventions for rosacea. Cochrane Database of Systematic Reviews2000, Issue 12. [DOI: 10.1002/14651858.CD003262] ">van Zuuren 2000</a>) for this review. As this is the third update of the original publication (<a href="./references#CD003262-bbs2-0310" title="vanZuurenEJ , GraberMA , HollisS , ChaudhryM , GuptaAK . Interventions for rosacea. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003262.pub2; PUBMED: 14974010] ">van Zuuren 2004</a>), changes have been made over time in accordance with the current requirements of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). These changes are clarified in '<a href="#CD003262-sec-0594">Differences between protocol and review</a>'. Some parts of the methods section of this review use text that was originally published in other Cochrane reviews co‐authored by EVZ, ZF and BC (predominantly <a href="./references#CD003262-bbs2-0253" title="El‐GoharyM , vanZuurenEJ , FedorowiczZ , BurgessH , DoneyL , StuartB , et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD009992.pub2] ">El‐Gohary 2014</a> and <a href="./references#CD003262-bbs2-0300" title="vanZuurenEJ , FedorowiczZ , CarterB , AndrioloRB , SchoonesJ . Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD007628.pub3] ">van Zuuren 2012</a>). </p> <section id="CD003262-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EvZ and ZF) independently assessed the abstracts of studies identified from the searches. We obtained full‐text copies of all relevant and potentially relevant studies, those appearing to meet the inclusion criteria, and those for which there were insufficient data in the title and abstract to make a clear decision. The two authors then independently assessed the full‐text papers and resolved any disagreement on the eligibility of included studies through discussion and consensus, or through a third party (MvdL). All irrelevant studies were excluded and their details and reasons for exclusion were noted in the '<a href="./references#CD003262-sec-0597" title="">Characteristics of excluded studies</a>' table in RevMan (<a href="./references#CD003262-bbs2-0281" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Revman 2014</a>). </p> </section> <section id="CD003262-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>Details of eligible trials were extracted and summarised using structured data extraction forms (EvZ, ZF). Disagreements were resolved by discussion. Study details were entered into the '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>' table in RevMan (<a href="./references#CD003262-bbs2-0281" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Revman 2014</a>) by two authors (EvZ, ZF). The review authors only included data if there was an independently reached consensus, and any disagreements were resolved by discussion between the authors. </p> <p>The following details were extracted:</p> <p> <ol id="CD003262-list-0008"> <li> <p>trial methods, method of allocation, masking of participants and outcomes assessors, and date and setting of study; </p> </li> <li> <p>participants, sample size, age, sex, inclusion and exclusion criteria, if there was ocular involvement, exclusion of participants after randomisation, and proportion of losses at follow up; </p> </li> <li> <p>intervention and comparison, length of study, type and dosage;</p> </li> <li> <p>outcomes, primary and secondary outcomes reported in the study;</p> </li> <li> <p>sources of funding and support if reported.</p> </li> </ol> </p> </section> <section id="CD003262-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (EvZ and ZF) independently assessed risk of bias using the Cochrane Collaboration tool for assessing risk of bias as described in Chapter 8, section 8.5 in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>The following domains were rated for each of the included studies as 'low risk of bias', 'high risk of bias', and 'unclear risk of bias' if the risk of bias was uncertain or unknown: </p> <p>(a) the allocation sequence was adequately generated ('sequence generation');<br/> (b) the allocation was adequately concealed ('allocation concealment');<br/> (c) knowledge of the allocated interventions was adequately prevented during the study ('blinding');<br/> (d) incomplete outcome data were adequately addressed;<br/> (e) reports of the study were free of suggestion of selective outcome reporting; and<br/> (f) the study was apparently free of other sources of bias that could put it at high risk of bias. This would include adequate study duration, i.e. a minimum of four weeks, and that previous oral and topical rosacea therapy was discontinued for a minimum of four weeks prior to the initial assessment. If the investigators declared any support or funding of the study by the pharmaceutical industry this was noted and assessed to determine if it represented a potential risk of bias in the conduct or reporting of the study (<a href="./references#CD003262-bbs2-0235" title="BeroL . Why the Cochrane risk of bias tool should include funding source as a standard item 2013. www.thecochranelibrary.com/details/editorial/5655431/Why‐the‐Cochrane‐risk‐of‐bias‐tool‐should‐include‐funding‐source‐as‐a‐standard‐item.html (accessed 14 January 2015). ">Bero 2013</a>). </p> <p>These assessments were reported in the 'Risk of bias' table for each individual study. See '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>'. </p> <p>We also categorised and reported the overall risk of bias of each of the included studies according to the following: </p> <p> <ul id="CD003262-list-0009"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria were met; </p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria were assessed as unclear; or </p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria were not met. </p> </li> </ul> </p> </section> <section id="CD003262-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003262-sec-0055"> <h5 class="title">Two treatment comparisons</h5> <p>We presented continuous outcomes, where possible, on the original scale as reported in each individual study with a mean change from baseline with its associated standard deviation in parentheses. Risk ratios (RR) were calculated for dichotomous outcomes and if statistically significant were presented with either: the number needed to treat for one additional beneficial outcome (NNTB); or number needed to treat for one additional harmful outcome (NNTH). </p> <p>Any outcome data which reported physician‐assessments of the time needed until improvement of the skin lesions were presented as a descriptive narrative of the general trend within the groups at the first time point where an improvement was seen. In future updates, and if studies report adequate time‐to‐event outcomes data, we will follow the recommendations for analysing this type of outcome as described in Chapter 9, section 9.2.6 in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>All outcome data were reported with their associated 95% confidence interval (CI).</p> </section> <section id="CD003262-sec-0056"> <h5 class="title">Skewed data</h5> <p>Outcome data reported for asymmetrical distributions as counts, for example papules or pustules, were often skewed and frequently inappropriately analysed. We did not enter these types of outcome data into a meta‐analysis but reported them separately for individual comparisons, where this was possible (section 9.4.5.3) (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> </section> <section id="CD003262-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <section id="CD003262-sec-0058"> <h5 class="title">Cross‐over studies</h5> <p>Unit of analysis issues can arise in studies where participants have been randomised to multiple treatments in multiple periods, or where there has been an inadequate wash‐out period. In general, for cross‐over studies we only used data from the first treatment period, unless otherwise stated. </p> </section> <section id="CD003262-sec-0059"> <h5 class="title">Within‐patient studies</h5> <p>In studies that reported paired data but where these were not adjusted for the within‐participant variability, a McNemar's test was applied and presented with the corresponding P value. If only the crude RR or raw data were presented and we were not able to adjust for the within‐participant variability, the RR was reported without a P value or 95% CI. In future updates, paired data from studies with no suspicion of contamination across intervention sites will be analysed separately using the generic inverse‐variance method in RevMan after accounting for the within‐participant variability (see Chapter 16, section 16.4.4: Methods of analysis for cross‐over trials) (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If this is not possible but adequate data are available, the McNemar's test will be applied. For future updates and in those instances where data from within‐participant studies may be pooled together with data from between‐participant studies, the RR from the between‐participant studies will be calculated and combined in a meta‐analysis using the generic inverse‐variance method. </p> <p><b>More than two treatment comparisons</b> </p> <p>Multi‐arm trials were included in the review if at least one arm constituted a relevant intervention for rosacea, and separate data extraction was carried out for each pair‐wise comparison. These studies were included as pair‐wise comparisons. For future updates, to prevent double‐counts of participants if treatment arms from multi‐arm studies are to be pooled more than once, these will be partitioned according to the number of comparisons carried out and the analysis will follow the recommendations in Chapter 16, section 16.5.4 in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> </section> <section id="CD003262-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>If data were missing from trials which were less than 10 years old, reasonable attempts were made to contact the investigators or sponsors of these studies (see <a href="#CD003262-tbl-0020">Table 2</a>; <a href="#CD003262-tbl-0021">Table 3</a>). We re‐analysed data according to the intention‐to‐treat (ITT) principle whenever possible. For dichotomous outcomes, if authors had conducted a per‐protocol analysis we carried out an ITT analysis with imputation setting the missing data to their baseline values, after checking the degree of imbalance in the dropouts between the arms to determine the potential impact of bias (section 16.2.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)). For continuous outcomes a per‐protocol analysis was carried out in place of an ITT analysis. </p> </section> <section id="CD003262-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical heterogeneity was assessed by examining the characteristics of the studies, the similarity between the types of participants, the interventions, the comparisons and the outcomes as were specified in the criteria for included studies. Although there is inevitably a degree of heterogeneity between the studies included in a review, if this could be explained by clinical reasoning and a coherent argument could be made for combining the studies, these were entered into a meta‐analysis. </p> <p>The clinical diversity between many of the studies in this review as well as the limited number of studies that could be combined for each intervention only allowed us to make assessments of heterogeneity between the studies in just two of the comparisons. We assessed heterogeneity based on thresholds for the interpretation of I² where &lt; 40% might not be important, 30% to 60% represents moderate and 50% to 90% substantial heterogeneity (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If the I² statistic was more than 60% (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and could not be explained by clinical reasoning we did not enter these data into a meta‐analysis. </p> </section> <section id="CD003262-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>The low number of studies evaluating similar interventions and comparisons did not permit an assessment of publication bias. In future updates, if a sufficient number of trials assessing similar effects are identified for inclusion in this review, publication bias will be assessed according to the recommendations on testing for funnel plot asymmetry (<a href="./references#CD003262-bbs2-0252" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563 ] ">Egger 1997</a>) as described in section 10.4.3.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If asymmetry is identified we will try to assess other possible causes and these will be explored in the discussion if appropriate. </p> </section> <section id="CD003262-sec-0063"> <h4 class="title">Data synthesis</h4> <p>Two review authors (EvZ, ZF) analysed the data in RevMan (<a href="./references#CD003262-bbs2-0281" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Revman 2014</a>) and reported them as specified in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Data synthesis was only carried out if we were able to identify a sufficient number of studies (n ≥ 3) investigating similar treatments and which reported data that could be pooled (<a href="./references#CD003262-bbs2-0297" title="Treadwell , JT , TregearSJ , RestonJT , TurkelsonCM . A system for rating the stability and strength of medical evidence. BMC Medical Research Methodology2006;6:52. ">Treadwell 2006</a>). We used a random‐effects model to combine the results of individual studies in this review. For comparisons where data synthesis was not feasible, the data has been reported separately in tables as 'Incomplete data on which further analysis is not possible' and presented in the review as a narrative summary, where appropriate. If applicable in future updates, synthesis of data and reporting of analyses from multiple studies evaluating similar interventions will take into consideration individual studies categorised with a summary high or variable risk of bias. If a sufficient number of such studies are identified, we will present analyses stratified according to overall risk or alternatively restrict the analyses to studies at low risk of bias and this will be reported accordingly.<br/> <br/> The GRADE approach was applied to interpret the results for the main comparisons, and GRADE profiler (GRADEpro) was used to create 'Summary of findings' tables (<a href="./references#CD003262-bbs2-0284" title="SchünemannH , BrożekJ , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. www.cc‐ims.net/gradepro. Version 3.2 [updated March 2009] 2009. ">Schünemann 2009</a>). Outcome‐specific information concerning the quality of evidence from studies per comparison was addressed and the magnitude of effect of the interventions was examined and presented. </p> </section> <section id="CD003262-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In view of the paucity of included studies covering any one specific intervention, we did not carry out any subgroup analyses. In future updates, we plan to carry out subgroup analyses if we identify at least moderate to substantial heterogeneity (as defined above) and if we are able to include at least 10 studies. The subgroups we will consider include: differences in treatment effect by differing baseline risk, and possible differences in effect caused by the range of modes of administration of the interventions used, that is topical, systemic and different dosing regimens. </p> </section> <section id="CD003262-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We did not conduct any sensitivity analyses in this review. If a sufficient number of studies (n = 10) investigating similar interventions had been included, we planned to conduct sensitivity analyses to assess the robustness of our review results. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003262-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003262-sec-0066"></div> <section id="CD003262-sec-0067"> <h3 class="title">Description of studies</h3> <p>See '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>' and '<a href="./references#CD003262-sec-0597" title="">Characteristics of excluded studies</a>'. </p> <section id="CD003262-sec-0068"> <h4 class="title">Results of the search</h4> <p>The updated searches for this review identified an additional 823 citations of potentially eligible studies. Searching the trial registers identified 54 ongoing studies, and three additional references were found through other resources giving a total of 880 references. There were 23 duplicates, and a further 751 references were excluded from further evaluation after examination of the titles and abstracts. The remaining 106 studies were further assessed for eligibility. Of these, 40 studies (reported in 37 references as three references reported on two studies) were included. Twelve studies appeared to be duplicate publications and are listed under the primary references, three were excluded with reasons (see '<a href="./references#CD003262-sec-0597" title="">Characteristics of excluded studies</a>'), 12 studies are awaiting further assessment (see '<a href="./references#CD003262-sec-0598" title="">Characteristics of studies awaiting classification</a>'), and 42 are ongoing trials (see '<a href="./references#CD003262-sec-0599" title="">Characteristics of ongoing studies</a>' section) (see <a href="#CD003262-fig-0001">Figure 1</a>). We also undertook a re‐assessment of the studies which had been excluded in the earlier version of this review, and eight of these are now included in this update (see also '<a href="#CD003262-sec-0594">Differences between protocol and review</a>') (see <a href="#CD003262-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003262-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003262-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003262-sec-0069"> <h4 class="title">Included studies</h4> <p>The current version of this review has 106 included studies. In addition to the 58 trials already in this review there are 40 newly included studies. There are also eight studies which had been excluded in earlier versions of this review but have been re‐evaluated for eligibility and included (see <a href="#CD003262-tbl-0022">Table 4</a>). A total of 13,631 participants were studied (see '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>'). </p> <div class="table" id="CD003262-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Newly included studies for this update</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Newly included studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0006" title="BenkaliK , LeoniM , RonyF , BouerR , FernandoA , GraeberM , et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate‐to‐severe facial erythema associated with rosacea. British Journal of Dermatology2014;171(1):162‐9. [PUBMED: 24506775] ">Benkali 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0007" title="BerardescaE , IorizzoM , AbrilE , GuglielminiG , CaseriniM , PalmieriR , et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology2012;11(1):37‐41. [PUBMED: 22360333] ">Berardesca 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] ">Buendia‐Bordera 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0028" title="DraelosZ , ErthelK , SchnickerM , BaconR , VickeryS . Facial foundation with niacinamide and N‐acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB82. [EMBASE: 70142048] ">Draelos 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0030" title="DraelosZ , HornbyS , WaltersRM , AppaY . Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers. Journal of Cosmetic Dermatology2013;12(4):314‐21. [PUBMED: 24305430] HornbyS , FowlerJ , WaltersRM , AppaY , DraelosZ . Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB66. [EMBASE: 70997350] ">Draelos 2013b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] ">Fabi 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0044" title="HuangYE , LiXL , LiTJ . Clinical research of topical tacrolimus ointment combined with 585 nm pulsed dye laser in the treatment of rosacea [Chinese]. Journal of Clinical Dermatology2012;41(5):308‐9. [EMBASE: 2012449799] ">Huang 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0045" title="HuangE , DiNardoA , GalloR , CaveneyS , GottschalkRW . Surface cathelicidin expression is a predictor of treatment success in papulopustular rosacea. 2013 International Investigative Dermatology Meeting Edinburgh United Kingdom. Conference Start: 20130508 Conference End: 20130511. Journal of Investigative Dermatology2013;133 Suppl 1:S181. [EMBASE: 71083535] HuangEY , DiNardoA , PresonNJ , GalloRL , GottschalkRW . Multicenter, randomized, double‐blind, placebo‐controlled evaluation of rosacea related inflammatory biomarkers in papulopustular rosacea adults treated with doxycycline 40 mg modified release. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [EMBASE: 71390129] ">Huang 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0050" title="KimTG , RohHJ , ChoSB , LeeJH , LeeSJ , OhSH . Enhancing effect of pretreatment with topical niacin in the treatment of rosacea‐associated erythema by 585‐nm pulsed dye laser in Koreans: A randomized, prospective, split‐face trial. British Journal of Dermatology2011; Vol. 38, issue 5:510‐3. [DOI: 10.1111/j.1365‐2133.2010.10174.x.; PUBMED: 21143465] ">Kim 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0058" title="LupinM . Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB43. [EMBASE: 71390263] ">Lupin 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0064" title="NCT00249782 . A phase II, randomized, partial‐blind, parallel‐group, active‐ and vehicle‐controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). ">NCT00249782</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0075" title="Rodríguez AcarM , Medina HernándezE . A comparative, double‐blind study about efficacy and safety of crotamiton vs benzyl benzoate in the treatment of rosacea with demodecidosis [Estudio doble ciego, comparativo, sobre la eficacia y seguridad del crotamitón versus benzoato de bencilo en el tratamiento de la rosácea con demodecidosis]. Dermatología Revista Mexicana2003;47(3):126‐30. [EMBASE: 2007502703] ">Rodríguez 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0082" title="SeitéS , BenechF , BerdahS , BayerM , VeyratS , SegotE , et al. Management of rosacea‐prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche‐Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology2013;12(8):920‐4. [EMBASE: 2013521246] ">Seité 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. ">Yoo 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Formerly excluded studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0013" title="BlomI , HornmarkAM . Topical treatment with sulfur 10 per cent for rosacea. Acta Dermato‐Venereologica1984;64(4):358‐9. [EMBASE: 1984179892] ">Blom 1984</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0033" title="ErtlGA , LevineN , KligmanAM . A comparison of the efficacy of topical tretinoin and low‐dose oral isotretinoin in rosacea. Archives of Dermatology1994;130(3):319‐24. [UI: 94175557; PUBMED: 8129410] ">Ertl 1994</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0034" title="EspagneE , GuillaumeJC , ArchimbaudA , BaspeyrasM , BoitierF , BussièreM , et al. Double‐blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea [Étude en double insu contre excipient du métronidazole gel a 0,75 p.100 dans le traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1993;120(2):129‐33. [UI: 93370955; PUBMED: 8240534] ">Espagne 1993</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0073" title="RehmusW , KimJ . A double‐blind, placebo‐controlled study of a natural anti‐inflammatory for treatment of rosacea. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB64. ">Rehmus 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0091" title="ThiboutotD . Efficacy and safety of subantimicrobial‐dose doxycycline for the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl 1):17. ">Thiboutot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0097" title="UtaşS , ÜnverÜ . Treatment of rosacea with ketoconazole. Journal of the European Academy of Dermatology and Venereology1997;8(1):69‐70. [EMBASE: 1997013740] ">Utaş 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0098" title="VanLanduytH , Joubert‐LequainI , HumbertP , LucasA , DrobacheffC , MercierM , et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results) [Traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1997;124(10):729. [PUBMED: 9740876] ">Van Landuyt 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a> </p> </td> </tr> </tbody> </table> </div> <section id="CD003262-sec-0070"> <h5 class="title">Characteristics of the participants</h5> <p>Most of the participants in the included studies had papulopustular rosacea, however in 16 of the studies most or all of the participants had erythematotelangiectatic rosacea. The participants were between 40 and 50 years of age, with a mean of 48.6 years; there were more women (8332) than men (3718) and the gender was unreported for 1581 participants. Thirty‐five of the studies were carried out before the year 2000, the remainder (71) were conducted after 2000. The number of participants in the individual studies varied widely from 6 to 1299 and sample sizes of between 30 and 100 participants were the most common. </p> <p>It was agreed between the review authors that two studies, <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a> and <a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>, should be included but that these were considered as maintenance studies. In <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>, 130 participants took part in the second phase of the study and were randomised to doxycycline 40 mg or placebo after having obtained an Investigator's Global Assessment (IGA) of clear or near clear during the open‐label first phase of treatment with doxycycline 40 mg combined with metronidazole gel, both once daily. In <a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>, the investigators enrolled 172 participants in the pilot phase of the study out of which only 136 continued into the second phase (maintenance phase), but these constituted the participants who had already achieved an improvement of &gt; 75% reduction in inflammatory lesions. </p> </section> <section id="CD003262-sec-0071"> <h5 class="title">Characteristics of the interventions</h5> <p>The trials were grouped into 11 categories of interventions: topical metronidazole (15); topical azelaic acid (7); topical brimonidine (6); topical ivermectin (2); topical metronidazole, azelaic acid or other topical treatments, or both (35); oral antibiotics (10); oral antibiotics combined with topical treatments (6); oral antibiotics compared with topical antibiotics (5); other systemic treatments (10); laser and light‐based therapies (7); and other treatments or combined treatments (3). </p> <p>In 13 of the studies the individuals served as their own controls, with active treatment and placebo assigned to either the left or right side of the face (<a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a>; <a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>; <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] ">Buendia‐Bordera 2013</a>; <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>; <a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] ">Fabi 2011</a>; <a href="./references#CD003262-bbs2-0048" title="KarsaiS , RoosS , RaulinC . Treatment of facial telangiectasia using a dual‐wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery2008;34(5):702‐8. [PUBMED: 18318728] ">Karsai 2008</a>; <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>; <a href="./references#CD003262-bbs2-0063" title="MostafaFF , ElHarrasMA , GomaaSM , Al MokademS , NassarAA , Abdel GawadEH . Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(1):22‐8. [PUBMED: 18705632] ">Mostafa 2009</a>; <a href="./references#CD003262-bbs2-0068" title="NeuhausIM , ZaneLT , TopeWD . Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery2009;35(6):920‐8. [PUBMED: 19397667] ">Neuhaus 2009</a>; <a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a>; <a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a>; <a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. ">Yoo 2011</a>). The duration of treatment ranged between two and three months with a mean of 9.7 weeks, and only five studies addressed interventions for ocular rosacea (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>; <a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a>; <a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a>; <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a>; <a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a>). </p> <p>Heterogeneity in study design, skewed data, missing standard deviations, and a mix of different comparators and dosing regimens did not, in general, permit pooling of the data or allow the authors to make accurate and direct comparisons of a substantial number of the interventions. </p> </section> <section id="CD003262-sec-0072"> <h5 class="title">Characteristics of the outcomes</h5> <p>Only 11 out of the 106 included studies (<a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>; <a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a>; <a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a>; <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>; <a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a>; <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>; <a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a>; <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>; <a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>; <a href="./references#CD003262-bbs2-0101" title="WeissenbacherS , MerklJ , HildebrandtB , WollenbergA , BraeutigamM , RingJ , et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle‐controlled double‐blind trial. British Journal of Dermatology2007;156(4):728‐32. [PUBMED: 17493072] ">Weissenbacher 2007</a>) reported assessments of change in 'quality of life' as a result of the interventions. However, this number has risen by nine compared to the former update, which would appear to illustrate the steadily increasing recognition of quality of life as a key outcome by investigators in rosacea studies. Nearly half (52) of the remaining studies evaluated participant‐assessed changes in rosacea severity. The patient‐reported outcomes (PROs) which were reported in the 52 studies included not only assessments of changes in severity but also, in most instances, patient satisfaction associated with these changes. </p> <p>We evaluated these PROs against the checklist for describing and assessing patient‐reported outcomes in clinical trials (see <a href="#CD003262-tbl-0023">Table 5</a>), which is described in Chapter 17.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003262-bbs2-0261" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We found that hardly any of them matched the recommended criteria. In the vast majority of studies the self‐assessments were made by way of questionnaires and instruments which evaluated the resolution of symptoms either jointly or separately with patient satisfaction related to the treatment. While most of these instruments were based on Likert‐type scales, a very small number of the studies utilised visual analogue scales (VAS) in their assessments (<a href="./references#CD003262-bbs2-0068" title="NeuhausIM , ZaneLT , TopeWD . Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery2009;35(6):920‐8. [PUBMED: 19397667] ">Neuhaus 2009</a>; <a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a>; <a href="./references#CD003262-bbs2-0101" title="WeissenbacherS , MerklJ , HildebrandtB , WollenbergA , BraeutigamM , RingJ , et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle‐controlled double‐blind trial. British Journal of Dermatology2007;156(4):728‐32. [PUBMED: 17493072] ">Weissenbacher 2007</a>). </p> <div class="table" id="CD003262-tbl-0023"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Checklist for describing and assessing patient‐reported outcomes (PROs) in clinical trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. What were PROs measuring?<br/> a. What concepts were the PROs used in the study measuring?<br/> b. What rationale (if any) for selection of concepts or constructs did the authors provide?<br/> c. Were patients involved in the selection of outcomes measured by the PROs? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Omissions<br/> a. Were there any important aspects of health (e.g. symptoms, function, perceptions) or quality of life (e.g. overall evaluation, satisfaction with life) that were omitted in this study from the perspectives of the patient, clinician, significant others, payers, or other administrators and decision‐makers? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. If randomised trials and other studies measured PROs, what were the instruments' measurement strategies?<br/> a. Did investigators use instruments that yield a single indicator or index number, a profile, or a battery of instruments?<br/> b. If investigators measure PROs, did they use specific or generic measures, or both? </p> <p>c. Who exactly completed the instruments?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Did the instruments work in the way they were supposed to work ‐ validity?<br/> a. Had the instruments used been validated previously (provide reference)? Was evidence of prior validation for use in this population presented?<br/> b. Were the instruments re‐validated in this study? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Did the instruments work in the way they were supposed to work ‐ ability to measure change?<br/> a. Are the PROs able to detect change in patient status, even if those changes are small? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Can you make the magnitude of effect (if any) understandable to readers?<br/> a. Can you provide an estimate of the difference in patients achieving a threshold of function or improvement, and the associated number needed to treat (NNT)? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Table 17.6.a </p> <p>Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient‐reported outcomes. In: Higgins JPT, Green S (editors), <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. </p> </td> </tr> </tbody> </table> </div> <p>There was wide diversity in the format of the questionnaires; many appeared to be unvalidated, used a range of scaling which offered a choice of from three to seven points on a Likert scale covering similar outcomes across the different questionnaires, and in several of them the physician and participant assessments were combined and expressed as composite scores. In the majority of the questionnaires it was not clear how the ratings correlated with the scaling of the items nor how reliable the interval‐level measurements were between the individual items (see also <a href="./references#CD003262-bbs2-0301" title="vanZuurenEJ , FedorowiczZ . Lack of 'appropriately assessed' patient‐reported outcomes in randomized controlled trials assessing the effectiveness of interventions for rosacea. British Journal of Dermatology2013;168(2):442‐4. [PUBMED: 22803770] ">van Zuuren 2013</a>). Additionally, in a number of the patient satisfaction questionnaires the judgements appeared to have been framed in such a way that only positive responses were possible, which would most likely lead to biased assessments being made (<a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a>; <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>; <a href="./references#CD003262-bbs2-0079" title="SauderDN , MillerR , GrattonD , DanbyW , GriffithsC , PhilipsSB . The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double‐blind study. Journal of Dermatological Treatment1997;8(2):79‐85. [EMBASE: 1997242784] ">Sauder 1997</a>). </p> <p>The quality of life assessment tools which were utilised in nine of the studies had been validated and were internationally recognised. Three studies used more than one instrument (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>; <a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>). The disease‐specific RosaQoL was used in eight studies (<a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>; <a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a>; <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>; <a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a>; <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>; <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>; <a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>). Another disease‐specific instrument, the Ocular Surface Disease Index (OSDI), was used in <a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a> and the dermatology‐specific instrument Dermatology Life Quality Index (DLQI) in the other studies (<a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a>; <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>; <a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>; <a href="./references#CD003262-bbs2-0101" title="WeissenbacherS , MerklJ , HildebrandtB , WollenbergA , BraeutigamM , RingJ , et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle‐controlled double‐blind trial. British Journal of Dermatology2007;156(4):728‐32. [PUBMED: 17493072] ">Weissenbacher 2007</a>). In all of these studies the investigators provided citations to reports indicating that the tools had been previously validated, as was specified in the PRO checklist (<a href="#CD003262-tbl-0023">Table 5</a>). </p> <p>Adverse events were addressed in the majority of the included studies, although often limited data were provided. </p> <p>Most of the studies (81) assessed erythema or telangiectasia, or both, although the presence of erythema or telangiectasia was an inclusion criterion in just 63 of the 106 studies (16 of these were conducted in participants with subtype 1 rosacea). In this update there were clearly more studies focusing on erythema, which was assessed utilising mostly four to five‐point Likert scales. The Clinician's Erythema Assessment with a grading scale from 0 (clear skin, no signs of erythema) to 4 (severe erythema, fiery redness) was used in 16 of the studies (<a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a>; <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>; <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>; <a href="./references#CD003262-bbs2-0024" title="DelRossoJQ , CaveneyS . Comparison of anti‐inflammatory dose doxycycline (30‐mg immediate‐release beads, 10 mg delayed‐release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery2012;31(1):A7‐8. [EMBASE: 70706922] DelRossoJQ , SchlessingerJ , WerschlerP . Comparison of anti‐inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology2008;7(6):573‐6. [PUBMED: 18561589] ">Del Rosso 2008</a>; <a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a>; <a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>; <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>; <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>; <a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a>; <a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a>; <a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a>; <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>; <a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a>; <a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a>; <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>). The inter‐rater and intra‐rater reliability of this scale have recently been evaluated, and were demonstrated to be reliable when used by trained investigators (<a href="./references#CD003262-bbs2-0293" title="TanJ , LiuH , LeydenJJ , LeoniMJ . Reliability of Clinician Erythema Assessment grading scale. Journal of the American Academy of Dermatology2014; Vol. 71, issue 4:760‐3. [PUBMED: 24999270] ">Tan 2014</a>). In 68 studies clinician‐assessed numbers of papules or pustules were used as an outcome in preference to a more patient‐relevant measure such as participant assessment of appearance. </p> <p>Outcomes assessments of ocular disease were only carried out in five of the included studies (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>; <a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a>; <a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a>; <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a>; <a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a>). </p> </section> <section id="CD003262-sec-0073"> <h5 class="title">Funding</h5> <p>In 66 of the 106 included studies the investigators reported they had received funding, mostly from pharmaceutical companies, and declarations of competing interest were provided by the investigators in 46 of the total number. In 10 instances we were not reassured that the funding support, or employment, of any of the investigators by the pharmaceutical company would not represent a potential source of bias. However, in most cases when studies were double or even triple‐blinded and there was no evidence of selective reporting we did not consider funding an additional source of bias. </p> </section> </section> <section id="CD003262-sec-0074"> <h4 class="title">Excluded studies</h4> <p>Sixty‐two studies, three of which were newly identified, were excluded from this review. Thirty‐nine out of the total number of studies were excluded only after evaluation of their full‐text copies and this was largely on the basis that they were non‐randomised trials. Eleven studies were designated controlled clinical trials after contact with the investigators or following examination of the full‐text of the reports, and the remaining 12 studies were excluded for other reasons (see '<a href="./references#CD003262-sec-0597" title="">Characteristics of excluded studies</a>' and <a href="#CD003262-fig-0001">Figure 1</a>). </p> </section> </section> <section id="CD003262-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>Only 12 of the studies (<a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a>; <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>; <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>; <a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>; <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>; <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>; <a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a>; <a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a>; <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>) met all of the criteria across all of the domains in the Cochrane Collaboration's tool for assessing the risk of bias, and therefore these studies were considered to be at 'low risk of bias' (plausible bias unlikely to seriously alter the results). Almost half of the studies (57) were categorised as 'unclear risk of bias' (plausible bias that raised some doubt about the results) because one or more criteria were assessed as unclear, and the remaining 37 studies were assessed as 'high risk of bias' (plausible bias that seriously weakened confidence in the results) because one or more of the criteria were not met. Further details of these assessments are available in the 'Risk of bias' table corresponding to each study in the '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>', and are also presented in the 'Risk of Bias' graph in <a href="#CD003262-fig-0002">Figure 2</a> and the 'Risk of Bias' summary in <a href="#CD003262-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003262-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003262-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003262-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003262-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Some of these assessments were to a certain extent based on the inadequate reporting of the criteria that are a prerequisite in the evaluation of methodological rigour in terms of trial design and conduct. Concealment of the allocation sequence and blinding are key domains in the assessment of risk of bias and most of the studies in this review provided insufficient detail to enable accurate judgements to be made. Protocol deviations, losses to follow‐up with incomplete data, and subsequent per‐protocol analyses, were other important sources of potential bias in a number of the included studies (see 'Risk of bias' table in '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>'). </p> <section id="CD003262-sec-0076"> <h4 class="title">Allocation</h4> <p>The methods used to generate the allocation sequence and how the sequence was concealed, such that participants and investigators enrolling participants could not foresee the upcoming assignment, are the most important and sensitive indicators that bias has been minimised in a clinical trial (<a href="./references#CD003262-bbs2-0283" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>). </p> <section id="CD003262-sec-0077"> <h5 class="title">Sequence generation</h5> <p>In 59 out of the 106 trials in this review the method of sequence generation was not described at all, or was at best unclear. In one study (<a href="./references#CD003262-bbs2-0034" title="EspagneE , GuillaumeJC , ArchimbaudA , BaspeyrasM , BoitierF , BussièreM , et al. Double‐blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea [Étude en double insu contre excipient du métronidazole gel a 0,75 p.100 dans le traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1993;120(2):129‐33. [UI: 93370955; PUBMED: 8240534] ">Espagne 1993</a>) allocation to the intervention was based on up to four participants in each of 18 clinics, but not all clinics enrolled four participants. The report did not provide any reassurance that the allocation sequence was adequately generated and there was lack of evidence that any form of central randomisation had been employed for the 18 clinics involved in this study, and therefore we judged this domain as high risk of bias. In the remaining studies (46) the method used to generate the allocation sequence was described in sufficient detail; therefore this domain was judged as low risk of bias for these studies. </p> </section> <section id="CD003262-sec-0078"> <h5 class="title">Allocation concealment</h5> <p>Concealment of the allocation sequence was reported adequately in only 33 of the trials and involved either a form of central allocation, was pharmacy‐controlled or was through the use of serially numbered opaque envelopes (see 'Risk of bias' tables in '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>'). The majority of studies received a judgement of unclear risk of bias for this domain and the investigators in three studies (<a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a>; <a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a>; <a href="./references#CD003262-bbs2-0050" title="KimTG , RohHJ , ChoSB , LeeJH , LeeSJ , OhSH . Enhancing effect of pretreatment with topical niacin in the treatment of rosacea‐associated erythema by 585‐nm pulsed dye laser in Koreans: A randomized, prospective, split‐face trial. British Journal of Dermatology2011; Vol. 38, issue 5:510‐3. [DOI: 10.1111/j.1365‐2133.2010.10174.x.; PUBMED: 21143465] ">Kim 2011</a>) informed us that the providers of care had access to the computer‐generated list, which we judged as high risk of bias. </p> </section> </section> <section id="CD003262-sec-0079"> <h4 class="title">Blinding</h4> <p>Effective blinding was achieved in half of the studies by the use of unmarked or identically appearing tubes, capsules or tablets. Some of the interventions were coded left or right for the within‐patient studies. Blinding of outcome assessment was reported clearly in only 50 of the 106 included studies. </p> </section> <section id="CD003262-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>In slightly more than half of the studies (64/106) incomplete outcome data appeared to have been adequately addressed and any missing outcome data were reasonably well‐balanced across intervention groups with similar reasons for missing data across the groups. However, in 42 of the 106 studies the reporting of missing outcome data was largely inadequate. Attrition was one of the main causes of incomplete outcome data. The reasons for attrition varied and these were often dependent on the assignment of the participant to one or other particular group; thus, for example, more dropouts tended to occur in groups receiving the active intervention secondary to any side effects, as opposed to dropouts due to lack of efficacy in the corresponding placebo group. In 30 studies we judged this domain as at unclear risk of bias. When there were more than 20% of dropouts and no ITT analysis was applied, or when dropouts in one arm exceeded 20%, we judged this domain as at high risk of bias (12 studies). </p> </section> <section id="CD003262-sec-0081"> <h4 class="title">Selective reporting</h4> <p>The reporting quality in most of the older studies was consistent with the editorial style and standards existing at the time of publication. Although the protocols for most of the included studies were not available, based on the information in the methods section of the reports 73 out of the 106 studies appeared to have reported all pre‐specified outcomes and were therefore judged to be free of selective reporting. In the remaining studies, rarely was more than one outcome inadequately addressed, but in some instances these outcomes were reported only as a graph plot without any clearly discernible data. For 21 studies this domain was therefore judged as at unclear risk of bias. In those instances where one or more pre‐specified primary or secondary outcomes were not addressed, or if the data analysis appeared to be flawed after it was re‐analysed, we judged this domain as at a high risk of bias (12 studies). </p> </section> <section id="CD003262-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>Fifty‐eight of the studies appeared to be free of other forms of bias, whereas in 41 studies this domain was judged to be unclear. This judgement was based in part on an assessment of the extent to which funding by the sponsors may have had an impact on the results of a study. When there was no evidence of selection bias, nor performance or detection bias as double‐blinding was ensured, we did not consider sponsoring or financial compensation a threat for other bias. However, if we were uncertain about selection bias and if the method of blinding was not described in sufficient detail, we concluded that there was insufficient information to permit a clear judgement. Further reasons for possible other bias were: if groups were treated unequally or, in some of the older studies, if there was an inadequate wash‐out period before the start of the study. Seven of the included studies were largely not free of other forms of bias. In most of these studies there was baseline imbalance between the groups, but in one study participants switched to the other treatment arm if they failed to respond to the allocated treatment, and one study was designed as a superiority trial but reported as a non‐inferiority trial. </p> </section> </section> <section id="CD003262-sec-0083"> <h3 class="title" id="CD003262-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD003262-tbl-0001"><b>Summary of findings for the main comparison</b> Metronidazole compared to placebo for rosacea</a>; <a href="./full#CD003262-tbl-0002"><b>Summary of findings 2</b> Azelaic acid compared to placebo for rosacea</a>; <a href="./full#CD003262-tbl-0003"><b>Summary of findings 3</b> Topical ivermectin compared to placebo for rosacea</a>; <a href="./full#CD003262-tbl-0004"><b>Summary of findings 4</b> Topical brimonidine compared to vehicle for rosacea</a>; <a href="./full#CD003262-tbl-0005"><b>Summary of findings 5</b> Topical azelaic acid compared to topical metronidazole for rosacea</a>; <a href="./full#CD003262-tbl-0006"><b>Summary of findings 6</b> Topical ivermectin compared to topical metronidazole for rosacea</a>; <a href="./full#CD003262-tbl-0007"><b>Summary of findings 7</b> Ciclosporin ophthalmic emulsion 0.05% compared to artificial tears for ocular rosacea</a>; <a href="./full#CD003262-tbl-0008"><b>Summary of findings 8</b> Clindamycin phosphate 1.2% + tretinoin 0.025% gel compared to placebo for rosacea</a>; <a href="./full#CD003262-tbl-0009"><b>Summary of findings 9</b> Tetracycline compared to placebo for rosacea</a>; <a href="./full#CD003262-tbl-0010"><b>Summary of findings 10</b> Doxycycline 40 mg compared to placebo for rosacea</a>; <a href="./full#CD003262-tbl-0011"><b>Summary of findings 11</b> Azithromycin compared to doxycycline 100 mg for rosacea</a>; <a href="./full#CD003262-tbl-0012"><b>Summary of findings 12</b> Doxycycline 40 mg + metronidazole 1% gel compared to doxycycline 100 mg + metronidazole 1% gel for rosacea</a>; <a href="./full#CD003262-tbl-0013"><b>Summary of findings 13</b> Doxycycline 40 mg + azelaic acid gel compared to doxycycline 40 mg + metronidazole gel for rosacea</a>; <a href="./full#CD003262-tbl-0014"><b>Summary of findings 14</b> Minocycline 45 mg compared to minocycline 45 mg + azelaic acid gel for rosacea</a>; <a href="./full#CD003262-tbl-0015"><b>Summary of findings 15</b> Topical metronidazole compared to oral (oxy)tetracycline for rosacea</a>; <a href="./full#CD003262-tbl-0016"><b>Summary of findings 16</b> Low dose isotretinoin 0.3 mg/kg compared to doxycycline 50‐100 mg for rosacea</a>; <a href="./full#CD003262-tbl-0017"><b>Summary of findings 17</b> Pulsed dye laser compared to Nd:YAG laser for rosacea</a>; <a href="./full#CD003262-tbl-0018"><b>Summary of findings 18</b> Pulsed dye laser compared to intense pulsed light therapy for rosacea</a> </p> <p>Twenty‐two studies provided no usable or retrievable data and did not contribute further to the results of this review (see <a href="#CD003262-tbl-0024">Table 6</a>). The main reasons why data could not be used were: none of our outcomes were addressed, no separate data were reported for participants with rosacea, very limited data were available in abstracts to conference proceedings, and it was unclear how many participants were randomised to each treatment arm. Pooling of outcome data across studies to provide a summary estimate of effect was only possible for two interventions and comparisons; these investigated the effects of topical metronidazole and topical azelaic acid against placebo. </p> <div class="table" id="CD003262-tbl-0024"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Included studies with no usable or irretrievable data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions and comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0006" title="BenkaliK , LeoniM , RonyF , BouerR , FernandoA , GraeberM , et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate‐to‐severe facial erythema associated with rosacea. British Journal of Dermatology2014;171(1):162‐9. [PUBMED: 24506775] "><b>Benkali 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four different concentrations brimonidine tartrate gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of our outcomes were addressed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0013" title="BlomI , HornmarkAM . Topical treatment with sulfur 10 per cent for rosacea. Acta Dermato‐Venereologica1984;64(4):358‐9. [EMBASE: 1984179892] "><b>Blom 1984</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulphur 10% cream versus lymecycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many were randomised to each group, minimal reporting of outcomes. Participants who failed to respond or got worse were switched to the alternative treatment, unclear who and how many </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] "><b>Buendia‐Bordera 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL + post‐laser serum versus PDL + placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, very limited data reported, not able to contact PI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0027" title="DraelosZD , GreenBA , EdisonBL . An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. Journal of Cosmetic Dermatology2006;5(1):23‐9. [PUBMED: 17173568] "><b>Draelos 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azelaic acid 15% gel + habitual self‐selected skin cleanser and moisturizer versus</p> <p>azelaic acid 15% gel + standardised PHA (polyhydroxy acid) containing cleanser, and anti‐aging moisturizer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of our primary outcomes were addressed combined with that it was unclear how many participants were randomised to each intervention. Because very limited outcomes data were reported no reliable conclusions could be drawn </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0028" title="DraelosZ , ErthelK , SchnickerM , BaconR , VickeryS . Facial foundation with niacinamide and N‐acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB82. [EMBASE: 70142048] "><b>Draelos 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Facial foundation with niacinamide and N‐acetylglucosamine, cleanser and moisturizer versus marketed foundation + cleanser and moisturizer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, lot of data missing, PI did not reply to e‐mail. Also included patients with sensitive skin, no separate data reported for participants with rosacea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0030" title="DraelosZ , HornbyS , WaltersRM , AppaY . Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers. Journal of Cosmetic Dermatology2013;12(4):314‐21. [PUBMED: 24305430] HornbyS , FowlerJ , WaltersRM , AppaY , DraelosZ . Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB66. [EMBASE: 70997350] "><b>Draelos 2013b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gentle foaming cleanser containing hydrophobically modified polymers versus commercial gentle liquid non‐foaming facial cleanser </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants with other skin diseases (atopic dermatitis, eczema, acne) were included and no separate data reported for participants with rosacea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0033" title="ErtlGA , LevineN , KligmanAM . A comparison of the efficacy of topical tretinoin and low‐dose oral isotretinoin in rosacea. Archives of Dermatology1994;130(3):319‐24. [UI: 94175557; PUBMED: 8129410] "><b>Ertl 1994</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isotretinoin + topical tretinoin versus topical tretinoin versus isotretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data unreliable, its re‐analysis using the individual participant data confirmed its flawed analysis by the investigators </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0034" title="EspagneE , GuillaumeJC , ArchimbaudA , BaspeyrasM , BoitierF , BussièreM , et al. Double‐blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea [Étude en double insu contre excipient du métronidazole gel a 0,75 p.100 dans le traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1993;120(2):129‐33. [UI: 93370955; PUBMED: 8240534] "><b>Espagne 1993</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole gel versus placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to intervention was based on up to four participants in each of 18 clinics but not all clinics enrolled four participants. The report did not provide any reassurance that the allocation sequence was adequately generated and no evidence that any form of central randomisation had been employed for the 18 clinics involved in this study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] "><b>Fabi 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPL + azelaic acid versus IPL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, very limited data reported, PI failed to respond to several e‐mails</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0043" title="GuilletB , RostainE , PowellF , Gimenez CamarasaC , DahanE , Piérard , et al. Metronidazole 0.75% gel and lotion are both effective in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology1999;12(2 Suppl):S145. "><b>Guillet 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole 75% gel versus metronidazole 0.75% lotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, very limited data reported, old study, not able to contact PI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0045" title="HuangE , DiNardoA , GalloR , CaveneyS , GottschalkRW . Surface cathelicidin expression is a predictor of treatment success in papulopustular rosacea. 2013 International Investigative Dermatology Meeting Edinburgh United Kingdom. Conference Start: 20130508 Conference End: 20130511. Journal of Investigative Dermatology2013;133 Suppl 1:S181. [EMBASE: 71083535] HuangEY , DiNardoA , PresonNJ , GalloRL , GottschalkRW . Multicenter, randomized, double‐blind, placebo‐controlled evaluation of rosacea related inflammatory biomarkers in papulopustular rosacea adults treated with doxycycline 40 mg modified release. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [EMBASE: 71390129] "><b>Huang 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxycycline 40 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster abstract, limited data, unclear how many were randomised to each group, PI failed to respond to several e‐mails </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0047" title="JorizzoJL , LebwohlM , TobeyRE . The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double blind clinical trial. Journal of the American Academy of Dermatology1998;39(3):502‐4. [UI: 98409174; PUBMED: 9738794] "><b>Jorizzo 1998</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many participants were initially recruited. Unclear how many participants started in each group, no SDs, dropout rate unclear. Data seem very skewed </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0058" title="LupinM . Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB43. [EMBASE: 71390263] "><b>Lupin 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MFU‐V one treatment versus MFU‐V two treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster abstract, limited data, unclear how many were randomised to each group, PI failed to respond to several e‐mails </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0064" title="NCT00249782 . A phase II, randomized, partial‐blind, parallel‐group, active‐ and vehicle‐controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). "><b>NCT00249782</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dapsone 5% gel QD vs dapsone 5% BID, versus metronidazole gel versus dapsone + metronidazole gel versus vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many were randomised to each group, Allergan failed to respond to several e‐mails requesting further data </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0073" title="RehmusW , KimJ . A double‐blind, placebo‐controlled study of a natural anti‐inflammatory for treatment of rosacea. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB64. "><b>Rehmus 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antiinflammatory cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, no results provided, very limited data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0091" title="ThiboutotD . Efficacy and safety of subantimicrobial‐dose doxycycline for the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl 1):17. "><b>Thiboutot 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxycycline versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, lot of data are missing, PI did not reply to e‐mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0097" title="UtaşS , ÜnverÜ . Treatment of rosacea with ketoconazole. Journal of the European Academy of Dermatology and Venereology1997;8(1):69‐70. [EMBASE: 1997013740] "><b>Utaş 1997</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketoconazole oral versus ketoconazole cream versus ketoconazole oral + cream versus placebo cream versus placebo pills </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Letter, limited and no exact data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0098" title="VanLanduytH , Joubert‐LequainI , HumbertP , LucasA , DrobacheffC , MercierM , et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results) [Traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1997;124(10):729. [PUBMED: 9740876] "><b>Van Landuyt 1997</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clonidine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim report only on first 30 participants, incomplete and very limited data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0102" title="WilkinJK . Effect of nadolol on flushing reactions in rosacea. Journal of the American Academy of Dermatology1989;20(2 Pt 1):202‐5. [PUBMED: 2521641] "><b>Wilkin 1989</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nadolol versus placebo, four arms, crossover, 3 periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small groups, unclear what dropout rate was. No separate data for period A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0103" title="DeWittS , WilkinJK . Double blind, parallel study of efficacy and safety of clindamycin lotion in the treatment of rosacea. Clinical Pharmacology and Therapeutics1987;41(2):176. WilkinJK , DeWittS . Treatment of rosacea: topical clindamycin versus oral tetracycline. International Journal of Dermatology1993;32(1):65‐7. [UI: 93146772; PUBMED: 8425809] "><b>Wilkin 1993</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical clindamycin versus tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many participants were assigned to each group, dropouts not mentioned, no exact data provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. "><b>Wittpenn 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical ciclosporin A versus artificial tears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many randomised to each group, poster with very limited data see also <a href="#CD003262-tbl-0021">Table 3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. "><b>Yoo 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL + calcium dobesilate versus PDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, with incomplete and missing data</p> </td> </tr> </tbody> </table> </div> <p>A substantial number of the studies included in this review were categorised as 'unclear' or 'high' risk of bias (see <a href="#CD003262-fig-0002">Figure 2</a> and <a href="#CD003262-fig-0003">Figure 3</a>) and therefore caution is advised in the interpretation of their results and in the extrapolation of the effects of the interventions. </p> <p>We have addressed our pre‐specified outcomes under the following intervention headings.</p> <p> <ul id="CD003262-list-0010"> <li> <p>Topical interventions: studies with only topical metronidazole (comparisons 1 to 5).</p> </li> <li> <p>Topical interventions: studies with only topical azelaic acid (comparisons 6 to 8).</p> </li> <li> <p>Topical interventions: studies with only topical ivermectin (comparison 9).</p> </li> <li> <p>Topical interventions: studies with only topical brimonidine (comparisons 10 to 13).</p> </li> <li> <p>Topical interventions: studies with topical metronidazole, azelaic acid, and/or other topical treatments (comparisons 14 to 41). </p> </li> <li> <p>Systemic interventions: studies with oral antibiotics (comparisons 42 to 49).</p> </li> <li> <p>Systemic interventions: studies with oral antibiotics combined with topical treatments (comparisons 50 to 55). </p> </li> <li> <p>Systemic interventions: studies with oral antibiotics compared with topical antibiotics (comparison 56). </p> </li> <li> <p>Studies with other systemic treatments (comparisons 57 to 61).</p> </li> <li> <p>Other interventions: studies with laser‐/light‐based treatment (comparisons 62 to 67). </p> </li> </ul> </p> <section id="CD003262-sec-0084"> <h4 class="title">Topical interventions: studies with only topical metronidazole</h4> <section id="CD003262-sec-0085"> <h5 class="title">(1) Topical metronidazole versus placebo</h5> <p>Nine trials at low to unclear risk of bias provided data for this comparison (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>; <a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>; <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>; <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>; <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>; <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>), see also <a href="./full#CD003262-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD003262-sec-0086"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0087"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0088"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Only three studies reported relevant data and although these could not be pooled for this outcome they provided some evidence that metronidazole was more effective than placebo. </p> <p>In <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> 43 out of 50 participants in the metronidazole group considered themselves improved compared with 24 out of 47 in the placebo group (RR 1.68, 95% CI 1.25 to 2.28; P = 0.0007; NNTB = 3, 95% CI 2 to 6); and similarly in <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> 25 out of 41 (metronidazole group) versus 8 out of 40 (placebo) (RR 3.05, 95% CI 1.57 to 5.94; P = 0.001; NNTB = 3, 95% CI 2 to 5). These were clinically important improvements. A within‐participant design was used in <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, which did not report the analysis adjusted appropriately for this design, therefore pooling of data with the other two studies was not possible. In this study the majority (28/37) of participants reported a greater improvement on the metronidazole treated side than on the placebo side (4/37), RR of 7. </p> </section> <section id="CD003262-sec-0089"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Six of the studies (<a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>; <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>; <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>; <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>) provided adequate data for this outcome. In the three‐armed study of <a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a> the proportion of participants reporting adverse events in the two active treatment arms were similar (32% to 33%) and, therefore, following statistical advice these totals were combined and entered into the analysis. The number of participants in the metronidazole group compared to the placebo group who experienced adverse events (RR 1.19, 95% CI 0.94 to 1.51; I² = 0%) was not significantly different across the six studies and in most instances these adverse events were mild and consisted of pruritus, skin irritation and dry skin. See <a href="./references#CD003262-fig-0004" title="">Analysis 1.1</a>. </p> </section> </section> <section id="CD003262-sec-0090"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0091"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The pooled data from three studies (<a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>) for this outcome pointed to an improvement in rosacea severity in the active intervention group, which was largely in agreement with the participant‐assessed outcomes for this comparison. Topical metronidazole was more effective than placebo and the results were both statistically significant and clinically important (RR 1.98, 95% CI 1.29 to 3.02; P = 0.002; NNTB 4, 95% CI 3 to 10). Heterogeneity between the studies was assessed with I² = 44%. See <a href="./references#CD003262-fig-0005" title="">Analysis 1.2</a>. </p> <p>Although a different rating scale (1 to 7, worst = 7) was used in <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, the results were not dissimilar to those in the other three studies. In this study the mean rating in severity in the metronidazole group (n = 50) was 2.80 (SD 1.41) and 3.30 (SD 1.41) in the placebo group (n = 50) with a mean difference (MD) of ‐0.50 (95% CI ‐1.05 to 0.05; P = 0.08).<br/> In the split‐face study (<a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>) 29/37 participants were assessed as improved on the metronidazole treated side compared with 1/37 on the placebo side (RR = 29). </p> <p>Only one study assessed ocular rosacea (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>) but the data as reported were unusable and not amenable to re‐analysis. See <a href="./references#CD003262-fig-0006" title="">Analysis 1.3</a>. </p> <p> <ul id="CD003262-list-0011"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Erythema was assessed in seven studies (<a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>; <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>; <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>; <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>). However, in all of these studies this outcome was inadequately reported that is standard deviations were missing or data were given without baseline values except for the three‐armed study of <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>. In this study the mean change from baseline in erythema score (0 to 3) was ‐1.45 (SD 2.00) in the metronidazole group compared to ‐0.05 (SD 1.39) in the placebo group with a MD of ‐1.40 (95% CI ‐2.47 to ‐0.33; P = 0.01). <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a> and <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> also showed a greater reduction of erythema with metronidazole treatment (see <a href="./references#CD003262-fig-0006" title="">Analysis 1.3</a>). </p> <p> <ul id="CD003262-list-0012"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>In eight of the studies these outcomes were reported as continuous data but without the corresponding SDs and the data were skewed, that is not normally distributed. Although the data analysis in these studies was potentially flawed, it did nevertheless provide some supporting evidence of a positive treatment effect of metronidazole over placebo (see <a href="./references#CD003262-fig-0006" title="">Analysis 1.3</a>). </p> <p> <ul id="CD003262-list-0013"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>This was not a pre‐specified outcome for any of the studies but based on interim data from five of the studies (<a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>; <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>) a noticeable improvement was seen at around four weeks. </p> <p> <ul id="CD003262-list-0014"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Only one trial (<a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>) addressed this outcome and demonstrated that continued treatment with metronidazole gel alone could maintain remission (initiated by tetracycline and topical metronidazole) of moderate to severe rosacea. </p> </section> </section> </section> <section id="CD003262-sec-0092"> <h5 class="title">(2) Metronidazole and sunscreen sun protection factor (SPF) 15 versus placebo</h5> <p>Only one study at high risk of bias with a 26% dropout rate and skewed data provided data for this comparison (<a href="./references#CD003262-bbs2-0088" title="TanJKL , GirardC , KrolA , MurrayHE , PappKA , PoulinY , et al. Randomized placebo‐controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. Journal of Cutaneous Medicine and Surgery2002;6(6):529‐34. [PUBMED: 12001006] ">Tan 2002</a>). </p> <section id="CD003262-sec-0093"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0094"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0095"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Although the data for this outcome were presented as graph plots and were largely indiscernible, the investigators reported that there was a more noticeable improvement in rosacea severity in the metronidazole combined with sunscreen SPF 15 group than in the placebo group (P = 0.0002). </p> </section> <section id="CD003262-sec-0096"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>A small number of participants reported adverse events and these were similar in both groups: 1/61 in the metronidazole group and 3/59 in the placebo (RR 0.32, 95% CI 0.03 to 3.01). There was no statistically significant difference in local tolerance of the intervention between the two groups. </p> </section> </section> <section id="CD003262-sec-0097"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0098"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>In the metronidazole group 17/61 had clearing or marked improvement compared to 2/59 in the placebo group (RR 8.22, 95% CI 1.99 to 34.04; P = 0.004; NNTB = 5, 95% CI 3 to 9). </p> <p> <ul id="CD003262-list-0015"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean reduction in erythema at the end of the study, measured on a 4‐point scale (4 = severe) was 0.89 (SD 0.6) in the treatment group and 0.58 (SD 0.13) in the placebo group (P = 0.001), however these data were skewed. Telangiectasia (on a 4‐point scale) were reduced by 0.3 (SD 0.53) in the metronidazole + sunscreen SPF 15 group compared to 0.07 (SD 0.47) in the placebo group (P = 0.03). </p> <p> <ul id="CD003262-list-0016"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>There was a reduction in the mean number of lesions, 13.6 (SD 17.25) in the active intervention group compared with placebo, 4.6 (SD 12.28) (MD ‐9.00, 95% CI ‐15.23 to ‐2.77). However the data were incomplete and skewed. </p> <p> <ul id="CD003262-list-0017"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0018"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0099"> <h5 class="title">(3) Metronidazole 0.75% cream versus metronidazole 1% cream</h5> <p>Only one study assessed as at high risk of bias compared these interventions and provided relevant outcome data (<a href="./references#CD003262-bbs2-0021" title="DahlMV , JarrattMJ , KaplanD , TuleyMR , BakerMD . Once‐daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. Journal of the American Academy of Dermatology2001;45(5):723‐30. [PUBMED: 11606923] ">Dahl 2001</a>). </p> <section id="CD003262-sec-0100"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0101"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0102"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0103"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Adverse events were mild and comparable in both groups, 14/36 compared to 15/36 (RR 0.93, 95% CI 0.53 to 1.64). </p> </section> </section> <section id="CD003262-sec-0104"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0105"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>There was no statistically significant difference in assessments between the two groups at the end of the study. Twenty of the 36 participants using the 0.75% metronidazole cream were clear or nearly clear at the end of the study compared with 13 out of 36 in the 1% cream group (RR 1.54, 95% CI 0.91 to 2.60). </p> <p> <ul id="CD003262-list-0019"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The percentage change in the total erythema severity score from baseline to endpoint was comparable (range 25% to 30%) with a difference that was not statistically significant between the two groups. </p> <p> <ul id="CD003262-list-0020"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The overall reductions in lesion counts were similar in both groups at the end of the study (62% versus 60%). </p> <p> <ul id="CD003262-list-0021"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>After six weeks both groups showed a reduction in inflammatory lesion counts of around 50%. </p> <p> <ul id="CD003262-list-0022"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0106"> <h5 class="title">(4) Metronidazole 0.75% cream versus 0.75% gel</h5> <p>The investigators in a single study assessed as at a high risk of bias compared these two interventions and were unable to provide any additional data over and above what had been reported in the poster (<a href="./references#CD003262-bbs2-0031" title="DrenoB , DubertretL , NaeyaertJM , de laBrassineM , MarksR , PowellF , et al. Comparison of the clinical efficacy and safety of metronidazole 0.75% cream with metronidazole 0.75% gel in the treatment of rosacea. Journal of the European Academy of Dermatology &amp; Venereology1998;11(2 Suppl):S272‐3. ">Dreno 1998</a>). </p> <section id="CD003262-sec-0107"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0108"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0109"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0110"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>No serious adverse events were reported, with no details about the number of participants reporting side effects. </p> </section> </section> <section id="CD003262-sec-0111"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0112"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Although this was a pre‐specified outcome it was not addressed (see 'Risk of Bias' under <a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a> for this study). </p> <p> <ul id="CD003262-list-0023"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The investigators reported "both erythema and telangiectasia scores were not significantly different at evaluation time". </p> <p> <ul id="CD003262-list-0024"> <li> <p>Lesion count</p> </li> </ul> </p> <p>The reduction in lesion count was similar in both the cream and gel groups (61.3% in the cream group versus 63.5% in the gel group). </p> <p> <ul id="CD003262-list-0025"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0026"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0113"> <h5 class="title">(5) Metronidazole 0.75% in microemulsion versus metronidazole 0.75% in commercial gel </h5> <p>One within‐participant study assessed as at unclear risk of bias, evaluated this comparison (<a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a>). </p> <section id="CD003262-sec-0114"> <h6 class="title">Change in HRQOL at end of study</h6> </section> <section id="CD003262-sec-0115"> <h6 class="title">Participant‐assessed changes in rosacea severity at end of study</h6> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0116"> <h6 class="title">Proportion of participants who reported an adverse event throughout the study period</h6> <p>There were no side effects on either treated side of the face.</p> </section> <section id="CD003262-sec-0117"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0118"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0027"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean change from baseline in erythema (0 to 3, with 3 being worse) was ‐1.75 (SD 0.49) for the microemulsion group compared to ‐0.91 (SD 0.60) in the commercial gel group with a MD of ‐0.84, however no 95% CI or P value could be calculated as we were not able to adjust for within‐participant variability. Telangiectasia were also scored on a scale from 0 to 3 and the mean change from baseline was ‐1.28 (SD 0.37) for the microemulsion group versus ‐0.41 (SD 0.65) in the commercial gel group, with a MD of ‐0.87; like in the assessment of erythema no 95% CI nor P value could be calculated. </p> <p> <ul id="CD003262-list-0028"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean change from baseline in lesion counts was ‐2.18 (SD 2.02) in the microemulsion group compared to ‐1.18 (SD 1.24) in the commercial gel group, with a MD of ‐1.0, but we were not able to adjust for within‐participant variability and therefore no 95% CI and P value could be calculated. </p> <p> <ul id="CD003262-list-0029"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0030"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0119"> <h4 class="title">Topical interventions: studies with only topical azelaic acid</h4> <section id="CD003262-sec-0120"> <h5 class="title">(6) Azelaic acid versus placebo</h5> <p>This comparison was evaluated by five trials assessed as at unclear risk of bias (<a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>; <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>; <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>; <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>; <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>), see also <a href="./full#CD003262-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD003262-sec-0121"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0122"> <p><b>Change in HRQOL at end of study</b></p> <p>This outcome was addressed in <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>, but only limited data were provided; the investigators reported "there were no statistically significant differences between the two groups in end‐of‐treatment or end‐of‐study erythema, telangiectasia, or QOL scores". E‐mail correspondence with the trialists provided no additional details. </p> </section> <section id="CD003262-sec-0123"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Four studies reported data for this outcome. Pooled outcome data from these studies indicated an improvement in rosacea severity and that the rates of complete remission or marked improvement, as assessed by the participants, were 60% to 80% in the azelaic acid group as compared with 45% to 55% in the placebo group (RR 1.46, 95% CI 1.30 to 1.63; P &lt; 0.00001; NNTB = 5, 95% CI 4 to 8). This was a clinically important improvement in favour of azelaic acid. Heterogeneity between the studies was assessed with I² = 0%. See <a href="./references#CD003262-fig-0007" title="">Analysis 2.1</a>. </p> </section> <section id="CD003262-sec-0124"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>There was no statistically significant difference in the number of adverse events reported by the participants in <a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>: in the azelaic acid group 30/76 compared with 15/38 in the placebo group (RR 1.00, 95% CI 0.62 to 1.62). In the <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a> study, 24/33 participants reported adverse events on the side treated with azelaic acid and 19/33 on the side treated with placebo. In <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> 21 adverse events were reported in 198 participants in the azelaic acid foam group and nine adverse events in the vehicle foam group (203 participants) (RR 2.39, 95% CI 1.12 to 5.09; P = 0.02; NNTH = 17; 95% CI 10 to 100). These were considered to be transient and of mild to moderate intensity, with burning, stinging or irritation being the most commonly reported. </p> <p>The data for adverse events in <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a> and <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> were combined and inadequately reported with minimal data available for the adverse events in the placebo group. Adverse events related to azelaic acid were reported in 18% of the participants in <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a> and in 8.4% in <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>. Burning, stinging and itching were more frequent in the azelaic acid treated group. </p> </section> </section> <section id="CD003262-sec-0125"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0126"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Data for these assessments from four studies illustrated that azelaic acid was more effective than placebo. The rates of treatment success in <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> were 69.2% in the azelaic acid group and 57.6% in the vehicle group. In both the <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a> and <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> studies the percentages were 61% and 62% in the azelaic acid groups and 40% and 48% in the placebo groups, and correspondingly 80% and 60% in <a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a> (RR 1.32, 95% CI 1.18 to 1.47; P &lt; 0.00001; NNTB = 7, 95% CI 5 to 10). There was low heterogeneity between the studies, which was unlikely to be important as I² = 16%. See <a href="./references#CD003262-fig-0008" title="">Analysis 2.2</a>. </p> <p>In the single within‐patient study (<a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>), 16/33 of the participants showed an improvement, based on a Likert scale rating, on the azelaic acid treated side compared with 1/33 on the placebo treated side, and there was no visible improvement in the remaining 16 participants (P &lt; 0.001, McNemar's test). There was an overall improvement with complete remission or marked improvement in 30/33 sides treated with azelaic acid compared to 11/33 of the sides treated with placebo; crude RR of 2.72. The report did not provide SDs for any of the outcomes data and it was not possible to calculate the RR, therefore the data were not pooled with the other studies evaluating this comparison. </p> <p> <ul id="CD003262-list-0031"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>There was minimal to no effect in improvement of erythema and telangiectasia in all five of the studies (see <a href="./references#CD003262-fig-0009" title="">Analysis 2.3</a>). </p> <p> <ul id="CD003262-list-0032"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean number of lesions in <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> reduced by 13.4 (SD 10.4) in the azelaic acid group compared to 9.5 (SD 9.73) in the vehicle foam group (MD ‐3.90, 95% CI ‐5.87 to ‐1.93; P = 0.0001). No SDs were reported for these outcomes in <a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>; <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a> and <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>, and in <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a> the data were skewed. See <a href="./references#CD003262-fig-0009" title="">Analysis 2.3</a>. </p> <p> <ul id="CD003262-list-0033"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>This was not a pre‐specified outcome in any of the studies but all studies showed clear improvement after three to six weeks. </p> <p> <ul id="CD003262-list-0034"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0127"> <h5 class="title">(7) Azelaic acid 15% gel once daily versus azelaic acid 15% gel twice daily</h5> <p>A single study at high risk of bias compared the safety and effectiveness of azelaic acid 15% gel applied once daily versus twice daily (<a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>). No statistically significant differences were reported in any of the efficacy endpoints between the two regimens. </p> <section id="CD003262-sec-0128"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0129"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0130"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>At the end of the study 29/45 participants on the once daily regimen considered themselves improved, which they rated as marked to excellent, compared to 27/47 on the twice daily regimen (RR 1.12, 95% CI 0.81 to 1.56). </p> <p><i>Proportion of participants who reported an adverse event throughout the study period</i> </p> <p>The number of participants experiencing adverse events was comparable in both groups, that is 18 out of 45 participants in the once daily group versus 17 out of 47 in the twice daily group (RR 1.11, 95% CI 0.66 to 1.86), with pain, pruritus and burning sensations being the most frequently reported. </p> </section> </section> <section id="CD003262-sec-0131"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0132"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>There was no statistically significant difference between the two treatment regimens: 20 of the 45 participants in the single daily application improved versus 22 of 47 in the twice daily group (RR 0.95, 95% CI 0.61 to 1.48). Treatment success, defined as clear or minimal lesions, was achieved in 13 of 45 in the once daily group versus 15 of 47 in the twice daily group (RR 0.91, 95% CI 0.49 to 1.68). </p> <p> <ul id="CD003262-list-0035"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>No exact data were provided but the investigators stated that "treatment with AzA 15% gel led to a decrease in the intensity of erythema over the course of the study with no statistically significant difference between the QD group and BID group", where QD is treatment once daily and BID twice daily. Six participants in both groups showed an improvement in telangiectasia (RR 1.04, 95% CI 0.36 to 3.00). </p> <p> <ul id="CD003262-list-0036"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean change from baseline in the once daily group in lesion counts was ‐11.60 (SD 4.98) compared to ‐13.80 (SD 4.65) for the twice daily group (MD 2.20, 95% CI 0.23 to 4.17; P = 0.03). This difference was statistically significant but not clinically important. </p> <p> <ul id="CD003262-list-0037"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Improvement was seen from week four in both groups.</p> <p> <ul id="CD003262-list-0038"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0133"> <h5 class="title">(8) Azelaic acid 15% gel twice daily as maintenance therapy versus vehicle twice daily</h5> <p><a href="./references#CD003262-bbs2-0093" title="ThiboutotDM , FleischerAB , DelRossoJQ , RichPH . A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. Journal of Drugs in Dermatology2009;8(7):639‐48. [PUBMED: 19588640] ">Thiboutot 2009</a> was a two‐phase study in which participants, demonstrating a level of treatment effectiveness at week 12, were randomised to receive either azelaic acid gel or its vehicle twice daily as maintenance therapy. We have only included data from the maintenance phase (second phase) of this study. The study was assessed at high risk of bias due to selective reporting. </p> <section id="CD003262-sec-0134"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0135"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0136"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>This was a predefined outcome but was not addressed and we therefore judged the domain for selective reporting as at a high risk of bias (see 'Risk of Bias' under <a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a> for this study). </p> </section> <section id="CD003262-sec-0137"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Adverse events were reported in 22 of the 67 participants using azelaic acid and in 20 of 69 in the vehicle‐only group (RR 1.13, 95% CI 0.68 to 1.87). </p> </section> </section> <section id="CD003262-sec-0138"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0139"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Success, as determined by an IGA and defined as clear, minimal or mild, was reported for 39 out of 67 participants in the azelaic acid group and for 31 out of 69 in the vehicle‐only group (RR 1.30, 95% CI 0.93 to 1.80). There was no statistically significant difference between the groups for this outcome. </p> <p> <ul id="CD003262-list-0039"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>No exact data were provided, but the investigators stated that no change in erythema or in telangiectasia was observed in either group. </p> <p> <ul id="CD003262-list-0040"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The increase in mean inflammatory lesion count in the maintenance phase was 5.5 in the azelaic acid group and 7.5 (data estimated from figure) in the vehicle group, investigators stated that P = 0.03. However, this difference of two lesions between groups was not considered to be clinically important. </p> <p> <ul id="CD003262-list-0041"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not applicable.</p> <p> <ul id="CD003262-list-0042"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Seventeen out of the 67 participants in the azelaic acid group relapsed compared with 24 of 69 in the vehicle‐only group (RR 0.73, 95% CI 0.43 to 1.23) with no statistically significant difference between the two groups. </p> </section> </section> </section> </section> <section id="CD003262-sec-0140"> <h4 class="title">Topical interventions: studies with only topical ivermectin</h4> <section id="CD003262-sec-0141"> <h5 class="title">(9) Topical ivermectin versus placebo</h5> <p>Two studies at low risk of bias addressed this comparison (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>), see also <a href="./full#CD003262-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD003262-sec-0142"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0143"> <p><b>Change in HRQOL at end of study</b></p> <p>More participants in the ivermectin group experienced improvements in HRQOL at the end of the study than in the control groups. Based on the DLQI at the end of the <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a> study, 231/451 participants in the ivermectin group compared to 77/232 in the vehicle group considered that the disease had "no effect on their overall quality of life" (RR 1.54, 95% CI 1.26 to 1.89; P &lt; 0.0001; NNTB = 6, 95% CI 4 to 10). In <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> these were 236/459 in the ivermectin group versus 76/229 in the vehicle group (RR 1.55, 95% CI 1.26 to 1.90; P &lt; 0.0001; NNTB = 6, 95% CI 4 to 10). </p> <p>Scores in the DLQI range from 0 to 30: a DLQI score of 0 to 1 is considered to have almost no impact on HRQOL, whereas 2 to 5 is considered to have a small effect, 6 to 10 a moderate effect, 11 to 20 a very large effect and 21 to 30 an extremely large effect on HRQOL. Therefore a reduction in score can be seen as an improvement in HRQOL. The mean change from baseline in DLQI for the ivermectin group (n = 436, per‐protocol population as provided for this outcome) in <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a> was ‐3.50 (SD 2.77) compared to ‐2.30 (SD 2.71) in the vehicle group (n = 221) with a MD of ‐1.20 (95% CI ‐1.64 to ‐0.76; P &lt; 0.00001). In <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> the reductions in DLQI were similar: ‐3.20 (SD 2.54) in the ivermectin group (n = 445, per‐protocol population as provided for this outcome) versus ‐2.10 (SD 2.48) in the vehicle group (n = 218) with a MD of ‐1.10 (95% CI ‐1.51 to ‐0.69; P &lt; 0.00001). Although the minimal important difference (MID) for the DLQI is yet to be established for the different skin diseases there is general acceptance that this ranges between 2.5 and 5, and therefore the impact of both treatments provided a small improvement in HRQOL but the difference, although statistically significant, was not clinically important (<a href="./references#CD003262-bbs2-0232" title="BasraMK , FenechR , GattRM , SalekMS , FinlayAY . The Dermatology Life Quality Index 1994‐2007: a comprehensive review of validation data and clinical results. British Journal of Dermatology2008;159(5):997‐1035. [PUBMED: 18795920] ">Basra 2008</a>). </p> <p>In re‐analysing the data for this outcome we used the identical N per protocol populations for the groups as for the DLQI outcome. The disease‐specific RosaQoL (range 1 to 5) assessments in <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a> showed reductions of 0.64 (SD 0.7) in the ivermectin group and 0.35 (SD 0.5) in the vehicle group (MD ‐0.29, 95% CI ‐0.38 to ‐0.20; P &lt; 0.00001). In <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> the reductions were 0.60 (SD 0.6) in the ivermectin group versus a reduction of 0.35 (SD 0.5) in the vehicle group (MD ‐0.25, 95% CI ‐0.34 to ‐0.16; P &lt; 0.00001). Although the differences were statistically significant, the clinical importance was unclear as the MID for RosaQoL still needs to be established. </p> </section> <section id="CD003262-sec-0144"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Data for this outcome were reported in an ITT analysis (last observation carried forward (LOCF)). Participants' assessments at the end of the study (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>) showed that there was a good to excellent improvement in 311/451 in the ivermectin group compared to 90/232 in the vehicle group (RR 1.78, 95% CI 1.50 to 2.11; P &lt; 0.00001; NNTB = 4, 95% CI 3 to 5). In <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> these numbers were 304/459 in the ivermectin group versus 79/229 in the vehicle group (RR 1.92, 95% CI 1.59 to 2.32; P &lt; 0.00001; NNTB = 4, 95% CI 3 to 5). Both studies showed a statistically significant and clinically important improvement in favour of topical ivermectin. </p> <p><i>Proportion of participants who reported an adverse event throughout the study period</i> </p> <p>In <a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a> 19/451 reported side effects in the ivermectin group compared to 18/232 in the vehicle group (RR 0.54, 95% CI 0.29 to 1.01), skin burning was reported in eight and six cases respectively. In <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> 30/459 participants reported an adverse event in the ivermectin group compared to 15/229 in the vehicle group (RR 1.00, 95% CI 0.55 to 1.82). </p> </section> </section> <section id="CD003262-sec-0145"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0146"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>An Investigator's Global Assessment of clear or almost clear (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>) was attained by 173/451 in the ivermectin group and 27/232 in the vehicle group (RR 3.30, 95% CI 2.27 to 4.79; P &lt; 0.00001; NNTB = 4, 95% CI 4 to 5). In <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> similar global assessments were reported in 181/459 of the ivermectin group and 43/229 of the vehicle group (RR 2.10, 95% CI 1.57 to 2.81; P &lt; 0.00001; NNTB = 5, 95% CI 4 to 8). The results of both studies were in concordance with the assessments of the participants. </p> <p> <ul id="CD003262-list-0043"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0044"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>A mean change from baseline of ‐20.40 (SD 8.72) was seen in the ivermectin group (n = 451) at the end of the study compared to ‐12.00 (SD 10.10) in the vehicle group (n = 232) with a MD of ‐8.40 (95% CI ‐9.93 to ‐6.87; P &lt; 0.00001) (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>). The reductions in lesion counts in <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> were ‐22.3 (SD 8.21) in the ivermectin group (n = 459) and ‐13.40 (SD 10.50) in the vehicle group (n = 229) with a MD of ‐8.90 (95% CI ‐10.45 to ‐7.35; P &lt; 0.00001). Both of these differences were statistically significant and clinically important. </p> <p> <ul id="CD003262-list-0045"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>This was not a predefined outcome, but improvement in both studies was seen after four weeks. </p> <p> <ul id="CD003262-list-0046"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0147"> <h4 class="title">Topical interventions: studies with topical brimonidine</h4> <section id="CD003262-sec-0148"> <h5 class="title">(10) Various concentrations of topical brimonidine gel once daily versus vehicle once daily after a single application </h5> <p>In a single study assessed at low risk of bias various concentrations of brimonidine gel (0.07%, 0.18% and 0.5%) were compared versus vehicle to determine which concentration was most effective for reducing erythema in rosacea after a single application (<a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>). </p> <section id="CD003262-sec-0149"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0150"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0151"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>This outcome was evaluated with the Patient's Self Assessment (PSA) tool with scores from 0 to 4 (clear to severe). A cumulative grade 1 improvement was experienced over 12 hours by 25/28 (89.3%) participants in the 0.07% group, 27/31 (87.1%) in the 0.18% group, 28/31 (90.3%) in the 0.5% group, and in 18/32 (56.3%) in the vehicle group. The highest concentration (0.5%) of brimonidine was more effective than vehicle in reducing erythema based on participants' assessments (RR 1.61, 95% CI 1.16 to 2.23; P = 0.004; NNTB = 3, 95% CI 3 to 8). </p> <p>A cumulative grade 2 improvement over 12 hours was noticed in 12/28 (42.9%) participants in the 0.07% group, 14/31 (45.9%) in the 0.18% group, 19/31 (61.3%) in the 0.5% group, and 7/32 in the vehicle group. The 0.5% brimonidine gel was more effective than vehicle (RR 2.80, 95% CI 1.37 to 5.71; P = 0.005; NNTB = 3, 95% CI 2 to 6). </p> </section> <section id="CD003262-sec-0152"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>The majority of the adverse events were transient and mild in intensity and consisted of skin irritation, erythema, skin burning and dry skin. In the 0.07% group 5/28 participants reported an adverse event, 4/31 in the 0.18% group, 6/31 in the 0.5% group, and 6/32 in the vehicle group. Comparing the highest brimonidine concentration with vehicle there was no statistically significant difference in participants experiencing an adverse event between the two groups (RR 1.03, 95% 0.37 to 2.86). </p> </section> </section> <section id="CD003262-sec-0153"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0154"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0047"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Physicians used the Clinician's Erythema Assessment (CEA) scale (0 to 4, clear to severe) to assess this outcome. The cumulative grade 1 improvement over 12 hours was reached in 24/28 participants in the group treated with 0.07%, in 28/31 in the group treated with 0.18%, in 30/31 treated with 0.5%, and in 21/32 of the participants treated with vehicle. The physician‐assessed changes in the comparison of the highest concentration (0.5%) with vehicle showed that brimonidine 0.5% was more effective (RR 1.47, 95% CI 1.14 to 1.91; P = 0.003; NNTB = 4, 95% CI 3 to 8). </p> <p>A cumulative grade 2 improvement was seen in 14/28 of the participants in the 0.07% gel group, in 24/31 in the 0.18% gel group, in 24/31 in the 0.5% gel group, and in 9/32 in the vehicle gel group. Brimonidine 0.5% demonstrated greater efficacy than vehicle, represented by an effect which was statistically significant (RR 2.75, 95% CI 1.53 to 4.94; P = 0.0007; NNTB = 3, 95% CI 2 to 4). These physician‐assessed changes were in concordance with the assessments made by the participants. </p> <p>Erythema was also assessed with a Chroma Meter, and the investigators reported that the values for brimonidine 0.5% were lower (investigators report P &lt; 0.001) and that the onset of effect was within 30 minutes, reaching a maximum effect with a duration of between four to six hours, followed by a reappearance of the redness after eight hours. </p> <p> <ul id="CD003262-list-0048"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>No data were provided but investigators reported that "no aggravations in the severity of inflammatory lesions were observed". </p> <p> <ul id="CD003262-list-0049"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0050"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0155"> <h5 class="title">(11) Various concentrations of topical brimonidine gel versus vehicle, with different dosing regimens over four weeks </h5> <p>A dose‐ranging study assessed as at low risk of bias to evaluate optimal concentration and dose regimen of brimonidine tartrate (BT) (0.18% once a day (QD), 0.18% twice a day (BID), 0.5% QD versus vehicle (QD and BID) (<a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>). We have only reported end‐of‐study data, that is at day 29. </p> <section id="CD003262-sec-0156"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0157"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0158"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>A grade 2 improvement on the Patient's Self Assessment (PSA) scale was assessed every three hours up to 12 hours for participants treated with brimonidine 0.18% once daily, 0.18% twice daily, 0.5% once daily and vehicle once or twice daily. Of note, the participants in the vehicle twice daily group scored themselves better on the PSA scale than in the vehicle once daily group. </p> <p> <div class="table" id="CD003262-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA grade 2 improvement</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.18% QD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.18% BID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5% QD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle QD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle BID</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/53</p> </td> </tr> </tbody> </table> </div> </p> <p>At three hours after application brimonidine 0.5% was shown to be more effective than once daily vehicle (RR 3.71, 95% CI 1.75 to 7.83; P = 0.0006; NNTB = 4, 95% CI 2 to 6) and also when compared to vehicle twice daily (RR 2.27, 95% CI 1.25 to 4.13; P = 0.007; NNTB = 4, 95% CI 3 to 10). Brimonidine 0.5% was more effective than vehicle once or twice daily at every time point, even at 12 hours, compared to vehicle twice daily (RR 2.00, 95% 1.04 to 3.86; P = 0.04; NNTB = 6, 95% CI 3 to 50). </p> </section> <section id="CD003262-sec-0159"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>The adverse events were mild and transient, with fewer participants reporting adverse events in the vehicle twice daily group. There were no meaningful changes in intraocular pressure, blood pressure or heart rate in any of the treatments. In the 0.18% once daily group 22/54 participants reported an adverse event, in the 0.18% twice daily group 25/54, in the 0.5% once daily group 24/53, in the vehicle once daily group 25/55, and in the vehicle twice daily group 17/53. There was no statistically significant difference in the proportion of participants that experienced an adverse event in the 0.5% brimonidine group versus vehicle twice daily group (RR 1.41, 95% CI 0.86 to 2.31). </p> </section> </section> <section id="CD003262-sec-0160"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0161"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0051"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>This outcome was assessed with the CEA scale, and a grade 2 improvement at the different time points was compared. </p> <p> <div class="table" id="CD003262-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CEA grade 2 improvement</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.18% QD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.18% BID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5% QD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle QD</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle BID</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/53</p> </td> </tr> </tbody> </table> </div> </p> <p>Three hours after application the number of participants in the brimonidine 0.5% group achieving a grade 2 improvement on the CEA scale was statistically significant higher than in the vehicle twice daily group (RR 3.00, 95% CI 1.56 to 5.75; P = 0.0009; NNTB = 3, 95% CI 2 to 6). Participants in the brimonidine 0.5% group showed greater improvement than those in the vehicle twice daily group at all time points with the exception of 12 hours after application (RR 1.25, 95% CI 0.73 to 2.14). </p> <p> <ul id="CD003262-list-0052"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>No data were provided but investigators reported that "no aggravations in the severity of inflammatory lesions were observed". </p> <p> <ul id="CD003262-list-0053"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0054"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>In the four week follow‐up no important aggravation in facial erythema was seen in any of the groups. However, isolated cases that had a worsening in PSA or CEA were seen but were not tied to a specific treatment group. </p> </section> </section> </section> <section id="CD003262-sec-0162"> <h5 class="title">(12) Topical brimonidine 0.5% versus vehicle over 4 weeks</h5> <p>Two studies with similar study design assessed as at low risk of bias addressed this comparison (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>; <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>) (see <a href="./full#CD003262-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD003262-sec-0163"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0164"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0165"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Assessments with the PSA scale were performed at day 1, 15 and 29, but we have chosen to report only the day 29 data. </p> <p> <div class="table" id="CD003262-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA grade 1 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013a</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA grade 2 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013a</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/131</p> </td> </tr> </tbody> </table> </div> </p> <p> <div class="table" id="CD003262-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA grade 1 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013b</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA grade 2 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013b</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/145</p> </td> </tr> </tbody> </table> </div> </p> <p>After 30 minutes a grade 1 improvement on the PSA scale (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>) was seen in 92/129 participants in the brimonidine group compared to 65/131 in the vehicle group (RR 1.44, 95% CI 1.17 to 1.76; P = 0.0005; NNTB = 5, 95% CI 3 to 10). In <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> similar results were seen in 93/148 in the brimonidine group versus 73/145 in the vehicle group (RR 1.25, 95% CI 1.02 to 1.53; P = 0.03; NNTB = 9, 95% CI 5 to 100). A grade 2 improvement on the PSA scale was observed in <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> in 39/129 participants treated with brimonidine 0.5% and 19/131 in the vehicle group (RR 2.08, 95% CI 1.28 to 3.41; P = 0.003; NNTB = 7, 95% CI 4 to 17), which was statistically significant in favour of brimonidine, but was not confirmed in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 1.41, 95% CI 0.89 to 2.23). </p> <p>We have chosen to not report RR at every time point, and have only reported the data three hours after application as it is fairly clear that the effect of brimonidine diminishes progressively over the 12 hour period. Three hours after application in the <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> study a grade 1 improvement on the PSA scale was reported in 99/129 treated with brimonidine and in 61/131 treated with vehicle (RR 1.65, 95% CI 1.34 to 2.03; P &lt; 0.00001; NNTB = 4, 95% CI 3 to 6). This was confirmed in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 1.43, 95% CI 1.19 to 1.70; P &lt; 0.00001; NNTB = 5, 95% CI 4 to 9). Brimonidine was more effective than vehicle at each time point in both studies except at 12 hours in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>. </p> <p>In <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> a statistically significant 2 grade improvement in PSA was noticed in the brimonidine group three hours after application (RR 2.21, 95% CI 1.52 to 3.22; P &lt; 0.0001; NNTB = 4, 95% CI 3 to 7) and in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 2.00, 95% CI 1.33 to 3.01; P = 0.0009; NNTB = 6, 95% CI 4 to 13). At each time point in both studies brimonidine was shown to be more effective than vehicle with an improvement which was statistically significant. </p> </section> <section id="CD003262-sec-0166"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>In the brimonidine group in <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> 38/129 participants reported an adverse event compared to 33/131 in the vehicle group (RR 1.17, 95% CI 0.79 to 1.74), and in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> 50/148 in the brimonidine group versus 35/145 in the vehicle group (RR 1.40, 95% CI 0.97 to 2.02). In both studies (<a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>) adverse events were mild and transient, and the most frequently reported were worsening of erythema, flushing, pruritus and skin irritation. </p> </section> </section> <section id="CD003262-sec-0167"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0168"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>No data were reported for both studies other than "no aggravations in the severity of telangiectasia, IGA or inflammatory lesion counts were observed during either the treatment or follow‐up phase of either study". </p> <p> <ul id="CD003262-list-0055"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>As with the participants' assessments we chose to report the end of study (day 29) data. </p> <p> <div class="table" id="CD003262-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CEA grade 1 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013a</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CEA grade 2 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013a</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/131</p> </td> </tr> </tbody> </table> </div> </p> <p> <div class="table" id="CD003262-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CEA grade 1 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013b</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CEA grade 2 improvement</b> </p> <p><a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] "><b>Fowler 2013b</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BT 0.5%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vehicle</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 minutes after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours after application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/145</p> </td> </tr> </tbody> </table> </div> </p> <p>In (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>) physicians' assessments at 30 minutes after application recorded a grade 1 improvement in the CEA scale in 87/129 participants in the brimonidine group versus 57/131 in the vehicle group, which was statistically significant in favour of brimonidine, and in concordance with the assessments made by the participants (RR 1.55, 95% CI 1.23 to 1.95; P = 0.0002; NNTB = 5, 95% CI 3 to 9); and further confirmed in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 1.34, 95% CI 1.09 to 1.65; P = 0.005; NNTB = 6, 95% CI 4 to 20). In <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> a grade 2 improvement 30 minutes after application was seen in 31/129 participants treated with brimonidine versus 11/131 treated with vehicle (RR 2.86, 95% CI 1.50 to 5.45; P = 0.001; NNTB = 7, 95% CI 5 to 15). This was not confirmed in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 1.41, 95% CI 0.89 to 2.23), but both the participants and the physicians were in agreement in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> about the grade 2 improvements in erythema. </p> <p>In <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> at three hours after application a grade 1 improvement in CEA was seen in 105/129 in the brimonidine group versus 64/131 in the vehicle group (RR 1.67, 95% CI 1.37 to 2.02; P &lt; 0.00001; NNTB = 4, 95% CI 3 to 5). Similar results were seen in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 1.49, 95% CI 1.26 to 1.77; P &lt; 0.00001; NNTB = 4, 95% CI 3 to 7). At all time points in both studies brimonidine was more effective than vehicle in reaching a grade 1 improvement on the CEA scale. </p> <p>In <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> at three hours after application, a grade 2 improvement in CEA was observed in 61/129 in the brimonidine group versus 22/131 in the vehicle group (RR 2.82, 95% CI 1.85 to 4.30; P &lt; 0.00001; NNTB = 4, 95% CI 3 to 5), which was statistically significant in favour of brimonidine; and in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> (RR 1.78, 95% CI 1.25 to 2.55; P = 0.002; NNTB = 6, 95% CI 4 to 15). In both studies there was a statistically significant difference favouring brimonidine at all time points except at 30 minutes, 9 and 12 hours in <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>, </p> <p> <ul id="CD003262-list-0056"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>See above, no aggravations.</p> <p> <ul id="CD003262-list-0057"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Improvement was seen within 30 minutes.</p> <p> <ul id="CD003262-list-0058"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>There was no rebound or worsening of erythema after treatment cessation in comparison to baseline assessments. </p> </section> </section> </section> <section id="CD003262-sec-0169"> <h5 class="title">(13) Brimonidine 0.33% versus vehicle</h5> <p>One study assessed as at unclear risk of bias examined the effect of brimonidine 0.33% gel versus vehicle on erythema and considered only patient‐reported outcomes (<a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a>). </p> <section id="CD003262-sec-0170"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0171"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0172"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Patient‐reported outcomes were assessed using the following instruments: a 'facial redness questionnaire' that addressed satisfaction, embarrassment and self‐consciousness; a 'subject satisfaction questionnaire' which addressed satisfaction with overall treatment, improvement of facial redness and time it took to work; and a 'Subject Diary' (treatment compliance and redness control). PSA was also addressed, but no exact data were provided and it was reported that the mean scores were statistically significantly lower in the brimonidine group. </p> <p>The results of the facial redness questionnaire at baseline showed that a small number of participants, 2/48 in the brimonidine group and 0/44 in the vehicle group, were satisfied to very satisfied with their appearance. At day 8 (end of study) 17/48 (36.9%) in the brimonidine group were satisfied or very satisfied compared to 9/44 (21.5%) in the vehicle group (RR 1.73, 95% CI 0.86 to 3.48; P = 0.12, however the investigators reported P &lt; 0.05). Participant assessments included perceptions of embarrassment, such that at baseline 44/48 (91.7%) in the brimonidine group felt embarrassed and in the vehicle group 42/44 (95.5%). At day 8 the figures were 34/48 (71.7%) compared to 40/44 (90.4%) respectively (RR 0.78, 95% CI 0.64 to 0.96; P = 0.02; NNTB = 5, 95% CI 3 to 20). Feeling self conscious was also evaluated by the participants, and at baseline 40/48 (83.3%) in the brimonidine group felt self conscious and 41/44 (93.1%) in the vehicle group. At day 8 35/48 (73.4%) in the brimonidine group and 39/44 (88%) in the vehicle group felt self conscious (RR 0.82, 95% CI 0.67 to 1.01; P = 0.06). </p> <p>The results of the Subject Satisfaction Questionnaire (SSQ) (feedback on treatment regimen) revealed that 25/48 (52.2%) in the brimonidine group were either satisfied or very satisfied with the overall treatment compared to 14/44 (30.9%) in the vehicle group (RR 1.64, 95% CI 0.98 to 2.73; P = 0.06). Improvement in facial redness was scored satisfied or very satisfied in 21/48 (43.5%) in the active treatment group versus 8/44 (19%) in the vehicle group (RR 2.41, 95% CI 1.19 to 4.87; P = 0.01; NNTB = 4, 95% CI 3 to 15). The time taken to reach an effect was assessed by the participants and 22/48 (45.6%) in the brimonidine group were satisfied to very satisfied compared to 9/44 (21.4%) in the vehicle group (RR 2.24, 95% CI 1.16 to 4.33; P = 0.02; NNTB = 4, 95% CI 3 to 15). </p> <p>The participant diaries revealed that 39/48 (81.1%) of the participants in the brimonidine group were able to control their facial redness that day compared to 18/44 (40.6%) participants in the control group (RR 1.99, 95% CI 1.36 to 2.90; P = 0.0004; NNTB = 3, 95% CI 2 to 5). </p> </section> <section id="CD003262-sec-0173"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>The adverse events that were reported were mild and transient worsening of erythema or worsening of rosacea, more of which were reported in the brimonidine group, with 14/48 participants in the brimonidine group reporting an adverse event versus 7/44 in the vehicle group (RR 1.83, 95% CI 0.82 to 4.12). </p> </section> </section> <section id="CD003262-sec-0174"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0175"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0059"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>No data were provided, but investigators reported that mean scores in CEA were statistically significantly lower in the brimonidine groups at all time points (P &lt; 0.001). </p> <p> <ul id="CD003262-list-0060"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0061"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0062"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0176"> <h4 class="title">Topical interventions: studies with topical metronidazole, azelaic acid, and/or other topical treatments </h4> <section id="CD003262-sec-0177"> <h5 class="title">(14) Topical azelaic acid versus topical metronidazole</h5> <p>Three studies assessed as at unclear risk of bias provided data for this comparison (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>; <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>; <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), which had a within‐participant study design but the trialists did not account for this within their analyses, therefore only summary statistics are presented. See also <a href="./full#CD003262-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD003262-sec-0178"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0179"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0180"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>In <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> 97/124 participants in the azelaic acid gel group considered themselves to have a good to excellent improvement versus 81/127 in the metronidazole gel group (RR 1.23, CI 95% 1.04 to 1.44; P = 0.01; NNTB = 8, 95% CI 4 to 34), and in <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> 57 out of 78 versus 60 of 82, respectively (RR 1.00, 95% CI 0.83 to 1.21). </p> <p>In the <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> study participants considered the 20% azelaic acid cream more effective than the metronidazole 0.75% cream. Severity was rated on a 5‐point scale (0 to 4, higher = worse), the mean score on the azelaic acid treated side was 1.87 (SD 0.76) compared with 2.33 (SD 0.95) on the metronidazole treated side (investigators reported P = 0.02). </p> </section> <section id="CD003262-sec-0181"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>The number of participants in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> experiencing adverse events was higher and statistically significant in the azelaic acid group with 32 of 124 as compared to 9 of 127 in the metronidazole group (RR 3.64, 95% CI 1.81 to 7.31; P = 0.0003; NNTH = 6, 95% CI 4 to 10). There was no statistically significant difference in adverse events between the groups in <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>: 29 of 78 versus 41 of 82 (RR 0.74, 95% CI 0.52 to 1.07). The adverse events reported in both <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> were mild to moderate and mostly transient, with skin dryness, scaling, stinging and burning being the most frequent. In <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> only one participant reported an adverse event, that is stinging, on the side of the face which had been treated with azelaic acid cream. </p> </section> </section> <section id="CD003262-sec-0182"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0183"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>In agreement with the participants' assessments, the physicians in the <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> study considered the azelaic acid group significantly more improved than the metronidazole group. In the azelaic acid group 86/124 participants were considered to have an IGA score of clear, minimal or mild versus 70/127 in the placebo group (RR 1.26, 95% CI 1.03 to 1.53; P = 0.02; NNTB = 8, 95% CI 4 to 50). In <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> 44 out of the 78 participants in the azelaic acid group were considered to be cleared or nearly cleared versus 44 of the 82 in the metronidazole group, with no statistically significant difference between the groups (RR 1.05, 95% CI 0.79 to 1.39). </p> <p>The investigators in the <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> study evaluated 'Global Improvement in severity of rosacea' (1 = complete clearance to 6 = exacerbation). At 15 weeks the score for the azelaic acid treated side was 2.7 (SD 1.0) compared with 3.1 (SD 1.0) on the metronidazole treated side; the investigators suggested limited superiority of azelaic acid over metronidazole but they failed to adjust for the within‐participant design of their study. </p> <p> <ul id="CD003262-list-0063"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>In <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> 70/124 showed improvement in erythema in the azelaic acid group compared to 53/127 in the metronidazole group (RR 1.35, 95% CI 1.05 to 1.75; P = 0.02; NNTB = 7, 95% CI 4 to 50). A decrease of one point on the four‐point Likert scale (none to severe) was considered to be an improvement. In <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> 33/78 participants in the azelaic acid group attained an erythema score of 0 or 1 (same scale) compared to 35/82 in the metronidazole gel group (RR 0.99, 95% CI 0.69 to 1.42). In <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> both participants and investigators assessed erythema. The investigators scored a reduction of 0.83 on the azelaic acid treated side compared to a reduction of 0.51 on the metronidazole side, whilst the participants scored a greater reduction on the metronidazole side (reduction of 0.23 (SD 0.58) on the azelaic acid side and a reduction of 0.74 (SD 0.57) on the metronidazole treated side). </p> <p> <ul id="CD003262-list-0064"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The decrease in inflammatory lesion counts reported in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> was 12.9 in the azelaic acid group versus 10.7 in the metronidazole group. No SDs were provided, but the investigators reported a P value of 0.003 and although this was a statistically significant difference it was not clinically important. In <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> the decrease in lesion count was expressed as a percentage, 78.5% in the azelaic acid group versus 69.4% in the metronidazole group. In <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> this was reported as median change reductions of 80% and 77% respectively. </p> <p> <ul id="CD003262-list-0065"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>An improvement for both arms was seen after four to six weeks in all three studies.</p> <p> <ul id="CD003262-list-0066"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0184"> <h5 class="title">(15) Azelaic acid 20% versus metronidazole 0.75% versus permethrin 5%</h5> <p>Only one study at high risk of bias with a within‐participant design compared these interventions (<a href="./references#CD003262-bbs2-0063" title="MostafaFF , ElHarrasMA , GomaaSM , Al MokademS , NassarAA , Abdel GawadEH . Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(1):22‐8. [PUBMED: 18705632] ">Mostafa 2009</a>). Investigators' conclusions were based on the analysis of skewed and unreliable data analysis. </p> <section id="CD003262-sec-0185"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0186"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0187"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0188"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>Side effects included itching, burning sensation, oedema and scales, and were mostly transient. The investigators reported that "there were no statistically significant differences among the three groups and almost decreased at the end visit". </p> </section> </section> <section id="CD003262-sec-0189"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0190"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0067"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The reductions in mean erythema scores (scale unclear) was 0.60 (SD 0.66) for the 16 sites treated with azelaic acid, 0.30 (SD 0.48) for the 16 sites treated with metronidazole, and 0.25 (SD 0.51) for the sites treated with permethrin. The investigators stated that the changes from baseline were statistically significant (P &lt; 0.05), but that there was no statistically significant difference between the three treatments. </p> <p> <ul id="CD003262-list-0068"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Although the analysis was based on skewed data and unreliable data analysis, all three treatments reduced the mean number of lesion counts, with 3.60 (SD 2.33) for azelaic acid, 3.70 (SD 2.92) for metronidazole and 2.60 (SD 3.24) for permethrin cream. </p> <p> <ul id="CD003262-list-0069"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0070"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Lesion counts and erythema assessments were provided six months after the end of treatment, but the report provided no indication of how long the participants were in remission before they relapsed. </p> </section> </section> </section> <section id="CD003262-sec-0191"> <h5 class="title">(16) Topical permethrin versus topical metronidazole</h5> <p>One three‐armed study (<a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>) assessed as at unclear risk of bias reported data for this comparison. Most of the data that were reported were skewed. The authors, however, concluded that permethrin 5% cream showed comparable effectiveness to metronidazole on both erythema and papules, but indicated that this did not apply to pustules. </p> <section id="CD003262-sec-0192"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0193"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0194"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0195"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>No adverse events were reported in either intervention group.</p> </section> </section> <section id="CD003262-sec-0196"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0197"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0071"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean change in erythema score (scale 0 to 3, 3 = severe) from baseline to day 60 was ‐1.26 (SD 2.09) in the permethrin group versus 1.45 (SD 2.00) in the metronidazole 0.75% group. Data were skewed. Neither treatment was shown to be more effective than the other for rhinophyma or telangiectasia. </p> <p> <ul id="CD003262-list-0072"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The MD in number of papules was ‐4.33 (SD 28.72) in the permethrin group versus ‐5.10 (SD 23.36) in the metronidazole group. The MD in pustules was ‐1.74 (SD 13.52) for the permethrin group and ‐2.5 (SD 13.65) in the metronidazole group. Data were skewed, but not for pustules. </p> <p>Most of the data that were reported were skewed but the authors concluded that permethrin 5% cream showed comparable effectiveness to metronidazole on both erythema and papules, but indicated this did not apply to pustules. </p> <p> <ul id="CD003262-list-0073"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0074"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0198"> <h5 class="title">(17) Topical permethrin versus placebo</h5> <p>This was the last comparison of this three‐armed study (<a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>). Most data were skewed. </p> <section id="CD003262-sec-0199"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0200"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0201"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0202"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>No adverse events were reported in either intervention group.</p> </section> </section> <section id="CD003262-sec-0203"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0204"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0075"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean change in erythema score (scale 0 to 3, 3 = severe) from baseline to day 60 was ‐1.26 (SD 2.09) in the permethrin group versus ‐0.05 (SD 1.39) in the placebo group. Data were skewed. Neither treatment was shown to be more effective than the other for rhinophyma or telangiectasia. </p> <p> <ul id="CD003262-list-0076"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The MD in number of papules was ‐4.33 (SD 28.72) in the permethrin group versus +0.25 (SD 11.25) in the placebo group. The MD in pustules was ‐1.74 (SD 13.52) for the permethrin group and ‐0.20 (SD 9.20) in the placebo group. Data were skewed, but not for pustules. </p> <p>Most of the data that were reported were skewed, but the authors concluded that permethrin 5% cream was more effective than placebo. </p> <p> <ul id="CD003262-list-0077"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0078"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0205"> <h5 class="title">(18) Benzoyl peroxide acetone versus vehicle</h5> <p>Two studies provided data for this comparison. <a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> was a three‐armed study comparing benzoyl peroxide 1% and 5% against vehicle and was assessed as at unclear risk of bias. Only data for our secondary outcomes were provided. <a href="./references#CD003262-bbs2-0062" title="MontesLF , CorderoAA , KrinerJ , LoderJ , FlanaganAD . Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis1983;32(2):185‐90. [PUBMED: 6225627] ">Montes 1983</a> was assessed as at high risk of bias and complete data were only reported for the first four weeks. The lack of baseline values hampered our ability to interpret the data. </p> <section id="CD003262-sec-0206"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0207"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0208"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0209"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>There was no statistically significant difference between the two groups in the number of participants reporting adverse events (<a href="./references#CD003262-bbs2-0062" title="MontesLF , CorderoAA , KrinerJ , LoderJ , FlanaganAD . Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis1983;32(2):185‐90. [PUBMED: 6225627] ">Montes 1983</a>): 26/33 in the benzoyl peroxide group versus 18/31 in the vehicle group (RR 1.36, 95% CI 0.96 to 1.92). Irritation and burning were the most frequently reported side effects in both groups. The rate of adverse events was high in both groups, which the authors indicated could be attributed to the vehicle in that the benzoyl peroxide gel may have a greater dehydrating effect than the newer aqueous gels. This outcome was not assessed in <a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a>. </p> </section> </section> <section id="CD003262-sec-0210"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0211"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>In the study of <a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> the physicians rated 12/32 participants as a treatment success in the benzoyl peroxide 1% group compared to 6/30 in the vehicle group, which was not statistically significant (RR 1.88, 95% CI 0.81 to 4.36). However, the higher concentration did show a statistically significant difference as 16/30 in the benzoyl peroxide 5% group were considered to have a treatment success (RR 2.67, 95% CI 1.21 to 5.88; P = 0.01). There was no statistically significant difference between the 5% and the 1% group (RR 0.70, 95% CI 0.40 to 1.23). In <a href="./references#CD003262-bbs2-0062" title="MontesLF , CorderoAA , KrinerJ , LoderJ , FlanaganAD . Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis1983;32(2):185‐90. [PUBMED: 6225627] ">Montes 1983</a> the overall response score, rated on a scale of 0 to 4 (4 = worst), at the end of four weeks was 2.69 (benzoyl peroxide) versus 3.71 (vehicle). However, no baseline values were reported. </p> <p> <ul id="CD003262-list-0079"> <li> <p>Assessment of erythema or telangiectasia or both at end of study</p> </li> </ul> </p> <p>In the study of <a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> the investigators reported there were no changes in persistent erythema or telangiectasia in any of the groups. In <a href="./references#CD003262-bbs2-0062" title="MontesLF , CorderoAA , KrinerJ , LoderJ , FlanaganAD . Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis1983;32(2):185‐90. [PUBMED: 6225627] ">Montes 1983</a> the investigators also reported that there were no statistically significant differences seen in the severity of erythema and telangiectasia. </p> <p> <ul id="CD003262-list-0080"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>In <a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> lesion counts reduced by 21.6 (SD 23.31) in the benzoyl 1% group versus 7.4 (SD 17.24) in the vehicle group (MD ‐14.20, 95% CI ‐24.36 to ‐4.04; P = 0.006), which was a statistically significant difference in favour of benzoyl peroxide 1%. The reduction in the 5% group was smaller (14.1 (SD 8.78)) and compared to the vehicle the MD was ‐6.70 (95% CI ‐13.62 to 0.22; P = 0.06). There was no statistically significant difference between the 1% and 5% group (MD ‐7.50, 95% CI ‐16.17 to 1.17). These were rated on a scale of 0 to 3 (3 = worst) in <a href="./references#CD003262-bbs2-0062" title="MontesLF , CorderoAA , KrinerJ , LoderJ , FlanaganAD . Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis1983;32(2):185‐90. [PUBMED: 6225627] ">Montes 1983</a> and the improvement in scores appeared to favour benzoyl peroxide. The papule scores at four weeks were 0.89 (benzoyl peroxide) compared with 1.91 (vehicle), and pustules scores 0.46 (benzoyl peroxide) versus 1.31 in the placebo group (investigators reported P &lt; 0.05). No baseline values were reported. </p> <p> <ul id="CD003262-list-0081"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0082"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0212"> <h5 class="title">(19) Benzoyl peroxide 5% with clindamycin 1% gel versus placebo</h5> <p>There were two individual reports at unclear risk of bias (<a href="./references#CD003262-bbs2-0015" title="BrenemanD , SavinR , VandePolC , VamvakiasG , LevyS , LeydenJ . Double‐blind, randomized, vehicle‐controlled clinical trial of once‐daily benzoyl peroxide/clindamycin topical gel in the treatment of moderate to severe rosacea. International Journal of Dermatology2004;43(5):381‐7. [PUBMED: 15117375] LeydenLL , ThiboutotD , ShalitaA . Photographic review of results from a clinical study comparing benzoyl peroxide 5%/Clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis2004;73(6 Suppl):11‐7. [PUBMED: 15228129] ">Breneman 2004</a>; <a href="./references#CD003262-bbs2-0270" title="LeydenJJ , ThiboutotD , ShalitaA . Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis2004;73(6 Suppl):11‐7. [PUBMED: 15228129] ">Leyden 2004</a>) involving the same study participants but focusing on different outcomes measures. Some SDs were lacking, and most data were skewed. </p> <section id="CD003262-sec-0213"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0214"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0215"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>The mean scores, rated as 0 to 4 (4 = worst), at the end of the study were 1.54 (much to slightly better) in the benzoyl peroxide with clindamycin group versus 2.50 (slightly better) in the placebo group (investigators reported P = 0.0002). This outcome was only assessed at 12 weeks. </p> </section> <section id="CD003262-sec-0216"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>There was no statistically significant difference in the number of participants between the groups reporting adverse events. There were 7 out of 27 participants in the benzoyl peroxide with clindamycin group who reported adverse events versus 4/26 in the placebo group (RR 1.69, 95% CI 0.56 to 5.08). Treatment‐related adverse events included localised burning and itching, which are both well‐known side effects of benzoyl peroxide. </p> </section> </section> <section id="CD003262-sec-0217"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0218"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The mean scores, rated 0 to 5 (5 = worst), at the end of the study were 1.85 (which was equivalent to a marked improvement) in the active treatment group versus 2.96, indicating minimal improvement in the placebo group. In the benzoyl peroxide with clindamycin group 11 of the 27 participants compared with 4/26 in the placebo group were considered to have a marked improvement or complete clearance (RR 2.65, 95% CI 0.96 to 7.25). The mean percentage change from baseline in overall rosacea severity assessment was ‐29.3% for benzoyl peroxide with clindamycin and ‐10.6 for the vehicle group (investigators reported P = 0.01). </p> <p>Global photographic improvement was assessed on a 7‐point scale (−2 to +4, 4 = best) in <a href="./references#CD003262-bbs2-0270" title="LeydenJJ , ThiboutotD , ShalitaA . Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis2004;73(6 Suppl):11‐7. [PUBMED: 15228129] ">Leyden 2004</a>. The investigators reported a mean Global photographic comparison rating of 1.6 in the active intervention group versus 0.7 in the placebo group (P &lt; 0.001, investigator reported). </p> <p> <ul id="CD003262-list-0083"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Mean erythema score decreased, 0.63 in the benzoyl peroxide with clindamycin group and 0.33 in the vehicle group (investigators reported P = 0.07). There were also no statistically significant differences between the two groups in telangiectasia. </p> <p> <ul id="CD003262-list-0084"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The reduction in mean lesion counts in the treatment group was 71.3% (SD 25.3) versus 19.3% (SD 89.6) in the placebo group (<a href="./references#CD003262-bbs2-0015" title="BrenemanD , SavinR , VandePolC , VamvakiasG , LevyS , LeydenJ . Double‐blind, randomized, vehicle‐controlled clinical trial of once‐daily benzoyl peroxide/clindamycin topical gel in the treatment of moderate to severe rosacea. International Journal of Dermatology2004;43(5):381‐7. [PUBMED: 15117375] LeydenLL , ThiboutotD , ShalitaA . Photographic review of results from a clinical study comparing benzoyl peroxide 5%/Clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis2004;73(6 Suppl):11‐7. [PUBMED: 15228129] ">Breneman 2004</a>). Mean papule counts decreased from 15.6 (SD 7.8) to 3.9 (SD 3.6) in the benzoyl peroxide with clindamycin group versus a decrease from 16.8 (SD 10) to 13.4 (SD 14.6) in the placebo group, and the pustule counts decreased from 2.5 (SD 3.8) to 0.8 (SD 2.4) versus from 2.5 (SD 4.0) to 2.0 (SD 4.5) respectively. The investigators in this study also concluded that a treatment effect, that is a reduction in the number of lesions, was demonstrated in the benzoyl peroxide and clindamycin group, which we were unable to confirm because the data as reported were skewed. </p> <p> <ul id="CD003262-list-0085"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0086"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0219"> <h5 class="title">(20) Sodium sulphacetamide 10% and sulphur 5% versus placebo</h5> <p>Only one study evaluated these interventions but the overall reporting quality was inadequate: the number of participants in each treatment arm was not reported, improvement as an outcome was ill‐defined, and the data reported as continuous outcomes were skewed and largely unusable (<a href="./references#CD003262-bbs2-0079" title="SauderDN , MillerR , GrattonD , DanbyW , GriffithsC , PhilipsSB . The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double‐blind study. Journal of Dermatological Treatment1997;8(2):79‐85. [EMBASE: 1997242784] ">Sauder 1997</a>). This study was categorised as at unclear risk of bias. For further details see the 'Risk of bias' tables in '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>'. </p> <section id="CD003262-sec-0220"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0221"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0222"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>A larger percentage of participants (90%) in the active treatment group considered themselves improved as compared with the placebo group (58%) (investigators reported P &lt; 0.001). </p> <p><i>Proportion of participants who reported an adverse event throughout the study period</i> </p> <p>Adverse events were reported as 38% in the active group versus 29% in the placebo group. Application site reactions such as dryness, erythema and pruritus were the most commonly reported adverse events. </p> </section> </section> <section id="CD003262-sec-0223"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0224"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Based on these assessments, 98% in the active treatment group versus 68% of the participants in the placebo group demonstrated an improvement (investigators reported P &lt; 0.001). </p> <p> <ul id="CD003262-list-0087"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Improvement in erythema was seen in 83% of the active treatment group compared to 31% in the vehicle group (investigators reported P &lt; 0.001). </p> <p> <ul id="CD003262-list-0088"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean lesion count reductions were reported as 78% versus 36% for the active treatment group and vehicle group respectively, with a corresponding reduction of 30.5 lesions and 9.4 lesions (investigators reported P &lt; 0.001). </p> <p> <ul id="CD003262-list-0089"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0090"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0225"> <h5 class="title">(21) Sodium sulphacetamide 10% and sulphur 5% versus metronidazole 0.75%</h5> <p>Two studies which we assessed as unclear to high risk of bias reported data for this comparison (<a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a>; <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a>). </p> <section id="CD003262-sec-0226"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0227"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0228"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>No exact data were provided in <a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a>, but the investigators reported there were no statistically significant treatment differences in any of the participant assessments. Although this was a pre‐specified outcome in <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a>, this was not addressed (see 'Risk of bias' under <a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a> for this study). </p> </section> <section id="CD003262-sec-0229"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>Fewer participants experienced adverse events in the metronidazole group but the difference between groups was not statistically significant. In <a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a> 5/31 versus 3/32 (RR 1.72, 95% CI 0.45 to 6.59) and in <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a> 48/75 versus 41/77 (RR 1.20, 95% CI 0.92 to 1.57) reported adverse events. Most adverse events were mild and transient and consisted of dryness, pruritus, burning and stinging. </p> </section> </section> <section id="CD003262-sec-0230"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0231"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>These assessments indicated that there was some evidence that sodium sulphacetamide 10% with sulphur 5% was more effective than metronidazole 0.75% gel. Although no SDs were provided in <a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a> the overall severity reduced from 2.2 to 1.1 on a scale of 0 to 3 (none to severe) in the sodium sulphacetamide 10% with sulphur 5% (investigators reported P &lt; 0.01) and from 2.1 to 0.6 in the metronidazole group (investigators reported P &lt; 0.01). The difference was, according to the investigators, statistically significant (P = 0.002). No baseline values were reported on Physician's Global Assessment but the investigators concluded that "treatment mean contrasts show statistically significant differences favouring sodium sulphacetamide/sulphur at all times points (week eight P = 0.001)". </p> <p>In <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a> 51 of the 75 participants were considered to have been cleared, or to have shown good to excellent improvement, in the sulphacetamide plus sulphur group versus 43 of the 77 in the metronidazole gel group (RR 1.22, 95% CI 0.95 to 1.57). </p> <p> <ul id="CD003262-list-0091"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>In <a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a> the mean erythema scores decreased from 2.3 to 1.2 after eight weeks (SDs were missing, investigators reported P &lt; 0.05) in the sulphacetamide plus sulphur group and from 2.2 to 0.7 in the metronidazole group (investigators reported P &lt; 0.05). The difference was reported to be statistically significant in favour the sulphacetamide plus sulphur group (P = 0.017). This difference was not confirmed in <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a> where 45/75 treated with sulphacetamide plus sulphur showed at least one grade improvement on a scale from 0 to 3 compared to 43/77 on metronidazole (RR 1.07, 95% CI 0.82 to 1.41). </p> <p> <ul id="CD003262-list-0092"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>No SDs were provided for baseline values. There was no statistically significant difference in decrease of the papule count for these interventions in <a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a> as reported by the authors. However, there was a statistically significant difference in decrease in the pustule count in favour of sodium sulphacetamide plus sulphur (investigators reported P = 0.006). For <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a> the mean reductions in lesion counts were 80% in the sulphacetamide plus sulphur group and 72% in the metronidazole group. </p> <p> <ul id="CD003262-list-0093"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>This was not a predefined outcome but improvement was noted after four to six weeks in both studies. </p> <p> <ul id="CD003262-list-0094"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0232"> <h5 class="title">(22) Pimecrolimus 1% versus placebo</h5> <p>Twice daily applications of pimecrolimus 1% were compared with placebo (vehicle) in <a href="./references#CD003262-bbs2-0101" title="WeissenbacherS , MerklJ , HildebrandtB , WollenbergA , BraeutigamM , RingJ , et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle‐controlled double‐blind trial. British Journal of Dermatology2007;156(4):728‐32. [PUBMED: 17493072] ">Weissenbacher 2007</a>. The study was assessed as at unclear risk of bias. </p> <section id="CD003262-sec-0233"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0234"> <p><b>Change in HRQOL at end of study</b></p> <p>The 'quality of life impairment' (Dermatology Life Quality Index, score 0 to 30, higher score = more impairment) showed a reduction of the mean absolute value from 5.50 to 3.10 in the pimecrolimus group versus 6.70 to 3.70 in the vehicle group, which were both small reductions (investigators reported P = 0.75). </p> </section> <section id="CD003262-sec-0235"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>The subjective severity score (VAS 0 to 100 mm, higher = worse) indicated an improvement of the mean absolute value from 53.45 to 48.95 in the pimecrolimus group and from 64.75 to 43.35 in the vehicle group (investigator reported P = 0.48). </p> </section> <section id="CD003262-sec-0236"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>Two adverse events were reported, but it was unclear in which group.</p> </section> </section> <section id="CD003262-sec-0237"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0238"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Mean absolute values for the total rosacea severity score reduced from 6.88 to 4.68 in four weeks in the pimecrolimus group versus 7.00 to 4.33 in the vehicle group. The difference was not statistically significant (investigators stated P = 0.59). </p> <p> <ul id="CD003262-list-0095"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0096"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0097"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0098"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0239"> <h5 class="title">(23) Metronidazole 1% cream versus pimecrolimus cream</h5> <p>One study at high risk of bias compared these interventions (<a href="./references#CD003262-bbs2-0051" title="KocaR , AltinyazarHC , AnkaraliH , MuhtarS , TekinNS , CinarS . A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open‐label clinical trial. Clinical and Experimental Dermatology2010;35(3):251‐6. [PUBMED: 19594764] ">Koca 2010</a>) but there was an appreciable baseline imbalance at enrolment, that is an increased duration and severity of disease in the pimecrolimus arm as compared with the metronidazole arm. The conclusions reached by the investigators did not appear to plausibly reflect the data that were reported as the data were massively skewed. </p> <section id="CD003262-sec-0240"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0241"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0242"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> <p><i>Proportion of participants who reported an adverse event throughout the study period</i> </p> <p>Four of the 24 participants in the metronidazole group reported adverse events (burning and stinging) compared to 2/25 in the pimecrolimus group (itching) (RR 2.08, 95% CI 0.42 to 10.34). </p> </section> </section> <section id="CD003262-sec-0243"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0244"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>There was no statistically significant difference in global improvement between the two groups. In the metronidazole group all (24/24) of the participants showed a measure of improvement as compared with 22 out of 25 participants in the pimecrolimus group (RR 1.13, 95% CI 0.96 to 1.33). </p> <p> <ul id="CD003262-list-0099"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>On a scale from 0 to 3 (higher = worse), erythema scores reduced by 0.92 (SD 0.24) in the metronidazole group and 0.92 (SD 0.35) in the pimecrolimus group (MD 0.0, 95% CI 0.17 to 0.17). Both treatments failed to show any improvement in telangiectasia. </p> <p> <ul id="CD003262-list-0100"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean changes in number of lesion counts were from 16.0 (SD 4.6) to 0.6 (SD 1.5) in the metronidazole group and from 26 (SD 14.4) to 3.7 (SD 6.8) in the pimecrolimus group. These data were skewed, and there was a clinically important baseline imbalance in the number of lesions. </p> <p> <ul id="CD003262-list-0101"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0102"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0245"> <h5 class="title">(24) Brimonidine 0.05% gel versus azelaic acid 15% gel</h5> <p>Limited data from a poster abstract were reported in the single study at unclear risk of bias comparing these interventions in 70 participants (<a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a>). </p> <section id="CD003262-sec-0246"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0247"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0248"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>After 2 weeks 9/35 of the participants reported a two grade improvement on the PSA on a scale from 0 to 4 (higher indicating worse) in the brimonidine group compared to 7/35 in the azelaic acid group (RR 1.29, 95% CI 0.54 to 3.07). </p> </section> <section id="CD003262-sec-0249"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>Not assessed.</p> </section> </section> <section id="CD003262-sec-0250"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0251"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>No global assessments were assessed.</p> <p> <ul id="CD003262-list-0103"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The judgements of the investigators were not in concordance with the judgements of the participants. A two grade improvement on the CEA (scale 0 to 4, higher indicating worse) was seen in 12/35 of the participants in the brimonidine group versus 4/35 in the azelaic acid group (RR 3.00, 95% CI 1.07 to 8.40; P = 0.04), which was a statistically significant difference in favour of brimonidine. Chroma Meter readings decreased by 9.64% and 2.35% respectively. </p> <p> <ul id="CD003262-list-0104"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0105"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0106"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0252"> <h5 class="title">(25) Ivermectin 1% cream versus metronidazole 0.75% cream</h5> <p>This comparison was evaluated in a single study at low risk of bias (<a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>), see <a href="./full#CD003262-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD003262-sec-0253"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0254"> <p><b>Change in HRQOL at end of study</b></p> <p>The DLQI score at baseline was 6.93 in the ivermectin group and 6.05 in the metronidazole group. A reduction of 5.18 on the DLQI was seen in the ivermectin group compared to a reduction of 3.92 in the metronidazole group but no SDs were provided. A DLQI score of 0 to 1 equates to no effect on HRQOL, a score of 2 to 5 a small effect, and a score of 6 to 10 represents a moderate effect. Although the minimal important difference (MID) for the DLQI is yet to be established for the different skin diseases there is general acceptance that this ranges between 2.5 and 5, and therefore the impact of both these treatments was a small improvement in HRQOL but the difference between the groups in terms of reduction of the DLQI scores was not clinically important (<a href="./references#CD003262-bbs2-0232" title="BasraMK , FenechR , GattRM , SalekMS , FinlayAY . The Dermatology Life Quality Index 1994‐2007: a comprehensive review of validation data and clinical results. British Journal of Dermatology2008;159(5):997‐1035. [PUBMED: 18795920] ">Basra 2008</a>). At the end of the 16 weeks 339/478 in the ivermectin group compared to 310/484 in the metronidazole group reported that the disease had no deleterious effect on their quality of life (RR 1.11, 95% CI 1.01 to 1.21; P = 0.02; NNTB = 15, 95% CI 8 to 100), which was statistically significant in favour of ivermectin. </p> </section> <section id="CD003262-sec-0255"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>In the ivermectin group 409/478 participants rated their improvement as good or excellent compared to 362/484 in the metronidazole group (RR 1.14, 95% CI 1.07 to 1.22; P &lt; 0.0001; NNTB = 10, 95% CI 7 to 17), which was a statistically significant difference and in concordance with the results on the number of participants that experienced no deleterious effect on their quality of life. </p> <p><i>Proportion of participants who reported an adverse event throughout the study period</i> </p> <p>In the ivermectin group 9/478 participants experienced an adverse event compared to 4/484 in the metronidazole group (RR 2.28, 95% CI 0.71 to 7.35). The reactions were mild and consisted of skin irritation, dryness and hypersensitivity. </p> </section> </section> <section id="CD003262-sec-0256"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0257"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Based on an IGA scale 406/478 were clear or almost clear in the ivermectin group compared to 365/484 in the metronidazole group (RR 1.13, 95% CI 1.06 to 1.20; P = 0.0002; NNTB = 10, 95% CI 7 to 20), which was consistent with the assessments of the participants. </p> <p> <ul id="CD003262-list-0107"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0108"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean change from baseline in lesion count was ‐27.70 (SD 8.85) in the ivermectin group compared to ‐23.60 (SD 8.23), which were both clinically important reductions (MD ‐4.10, 95% CI ‐5.18 to ‐3.02; P &lt; 0.00001). </p> <p> <ul id="CD003262-list-0109"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>This was not a predefined outcome but clear improvement could be seen for both treatment arms around six weeks. </p> <p> <ul id="CD003262-list-0110"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0258"> <h5 class="title">(26) Erythromycin 2% gel versus metronidazole 0.75% gel</h5> <p>Only one study with a small sample size compared these two interventions (<a href="./references#CD003262-bbs2-0100" title="Verea HernandoM , Margusino FramiñánL , Seco VilariñoC , Feal CortizasB , Cuña EstévezB . Comparative study of topical erythromycin and topical metronidazole in the treatment of rosacea [Estudio comparativo entre eritromicina tópica y metronidazol tópico en el tratamiento de la rosácea]. Farmacia Clinica1992;9(6):472‐9. [EMBASE: 1992280716] ">Verea Hernando 1992</a>). A baseline imbalance in severity of the disease at enrolment placed the study at a serious risk of bias. </p> <section id="CD003262-sec-0259"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0260"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0261"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>There was no statistically significant difference between the two groups for this outcome: 16 of the 22 participants considered themselves improved with erythromycin gel versus 17 of 18 in the metronidazole gel group (RR 0.77, 95% CI 0.58 to 1.02). </p> <p><i>Proportion of participants who reported an adverse event throughout the study period</i> </p> <p>These were inadequately reported in the study and therefore we have not included any of the data in this review. </p> </section> </section> <section id="CD003262-sec-0262"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0263"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Although this was a pre‐specified outcome it was not addressed (see 'Risk of bias' under <a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a> for this study). </p> <p> <ul id="CD003262-list-0111"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Only one participant in the erythromycin group had an improvement in erythema compared with two in the metronidazole group. </p> <p> <ul id="CD003262-list-0112"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Baseline imbalance between the groups with respect to the number of papules and pustules was quite marked and placed the study at a serious risk of bias. The total number of papules in the erythromycin group was 571 at baseline, which reduced to 250 after three months, while the number at baseline in the metronidazole group was 476, which reduced to 317. The baseline number of pustules was 160 for the erythromycin group and reduced to 126 after three months, and for the metronidazole group the baseline number of pustules was 63 and the number at the end of the study was 33. </p> <p> <ul id="CD003262-list-0113"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0114"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0264"> <h5 class="title">(27) Topical ciclosporin ophthalmic emulsion 0.05% versus artificial tears for the treatment of ocular rosacea </h5> <p>One study at unclear risk of bias examined this comparison (<a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a>), see <a href="./full#CD003262-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD003262-sec-0265"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0266"> <p><b>Change in HRQOL at end of study</b></p> <p>Assessment of changes in quality of life were carried out with the Ocular Surface Disease Index (OSDI) (scale 0 to 100, 100 = worst). Baseline scores were 19.1 (SD 13.9) in the topical ciclosporin group and 16.9 (SD 15.8) in the artificial tears group. The difference between the change scores at completion of the study was ‐8.6 in favour of topical ciclosporin (95% CI ‐15.42 to ‐1.78; P = 0.01), which equated to a moderate improvement in quality of life. </p> </section> <section id="CD003262-sec-0267"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0268"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>Only one participant in the topical ciclosporin group (n = 21) reported an adverse event and 0/16 in the artificial tears group, which consisted of stinging (RR 2.32, 95% CI 0.10 to 53.42). </p> </section> </section> <section id="CD003262-sec-0269"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0270"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The data from these assessments provided evidence for the effectiveness of topical ciclosporin in the treatment of ocular rosacea. The Schirmer's test determines whether the eye produces enough tears to keep it moist. Paper strips are inserted into the eye for several minutes to measure the production of tears, and then the paper is removed and the amount of moisture measured. At baseline the mean Schirmer scores were 9.7 mm (SD 5.1) in the ciclosporin group compared with 10.2 mm (SD 5.8) in the artificial tears group. The difference in change scores between the groups at the end of the study was 4.1 (95% CI 1.66 to 6.54; P = 0.001), which points to a significant improvement in the ciclosporin group. Furthermore, the change score of 3.6 in the tear break‐up time (95% CI 2.59 to 4.61; P &lt; 0.00001) provided an indication of the role played by topical ciclosporin in increasing tear production. </p> <p> <ul id="CD003262-list-0115"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0116"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0117"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0118"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0271"> <h5 class="title">(28) Clindamycin phosphate 1.2% + tretinoin 0.025% gel versus placebo</h5> <p>The efficacy of this topical treatment was examined in one study at low risk of bias (<a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a>), see <a href="./full#CD003262-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD003262-sec-0272"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0273"> <p><b>Change in HRQOL at end of study</b></p> <p>Quality of life was assessed with the disease‐specific RosaQoL. However, no means of scores were provided, only percentages of participants that had improved per item on the 21 survey items, making these data less usable. The investigators reported that there were no statistically significant differences for any item. </p> </section> <section id="CD003262-sec-0274"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0275"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>Twenty‐nine adverse events were reported in 43 participants on the combination treatment of clindamycin and tretinoin, compared to 11 adverse events in 40 participants in the placebo group (RR 2.45, 95% CI 1.42 to 4.23; P = 0.001, NNTH = 3, 95% CI 2 to 5). Worsening of rosacea, facial scaling as well as dry skin were reported most often in the active treatment group. </p> </section> </section> <section id="CD003262-sec-0276"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0277"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>None of the primary features of the Physician's Global Assessment as defined by <a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a> showed statistically significant differences between the treatment groups except for oedema in favour of placebo. </p> <p> <ul id="CD003262-list-0119"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Regarding improvement of subtype only the erythematotelangiectatic subtype showed a statistically significant difference in favour of the combination treatment of clindamycin and tretinoin as 12/43 were improved compared to 4/40 in the placebo group (RR 2.79, 95% CI 0.98 to 7.95; P = 0.05; NNTB = 6, 95% CI 3 to 50). Erythema improved in 11/43 on the active treatment versus 6/40 on placebo (RR 1.71, 95% CI 0.70 to 4.18), and telangiectasia in 13/43 compared to 5/40 (RR 2.42, 95% CI 0.95 to 6.17). </p> <p> <ul id="CD003262-list-0120"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Both treatments had no or minimal effect on inflammatory lesions. The mean change from baseline in lesion count was 0.83 (SD 10.84) in the group treated with clindamycin and tretinoin and ‐3.13 (SD 13.28) in the group treated with placebo, with a MD of 3.96 (95% CI ‐1.28 to 9.20). </p> <p> <ul id="CD003262-list-0121"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0122"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0278"> <h5 class="title">(29) Rosacea treatment system (RTS) (gentle cleanser, metronidazole 0.75% gel, hydrating complexion corrector and skin balancing sunscreen SPF 30) versus RTS without metronidazole </h5> <p>One three‐armed study with a small sample size (30 participants) assessed as at unclear risk of bias addressed this comparison (<a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a>). </p> <section id="CD003262-sec-0279"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0280"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0281"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Participant assessments were made with a 5‐point Likert scale (0 = none, 4 = severe). No SDs were provided and the investigator was unable to provide these. The mean score in the RTS + metronidazole group went from 2.6 to 2.0, whilst the group on RTS without metronidazole had a smaller reduction from 2.5 to 2.2. </p> <p>In the RTS + metronidazole group 50% were very satisfied and 20% satisfied compared to 30% very satisfied and 40% satisfied in the comparator group. </p> </section> <section id="CD003262-sec-0282"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>No adverse events were reported in either group.</p> </section> </section> <section id="CD003262-sec-0283"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0284"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>None had more than moderate improvement on a 7‐point Likert scale. In the RTS + metronidazole group 4/10 achieved moderate improvement versus 1/10 in the comparator group (RR 4.00, 95% CI 0.54 to 29.80). </p> <p> <ul id="CD003262-list-0123"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Erythema decreased on a 5‐point Likert scale from 2.8 to 2.4 in the RTS + metronidazole group and from 2.5 to 2.3 in the RTS without metronidazole group. No SDs were provided. </p> <p> <ul id="CD003262-list-0124"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0125"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0126"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0285"> <h5 class="title">(30) Rosacea treatment system (RTS) (gentle cleanser, metronidazole 0.75% gel, hydrating complexion corrector and skin balancing sunscreen SPF 30) versus metronidazole 0.75% and standard skin care regimen </h5> <p>This was the second comparison from the three‐armed study of <a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a>. </p> <section id="CD003262-sec-0286"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0287"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0288"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Assessments were made on a 5‐point Likert scale. In the RTS + metronidazole group the scores went from 2.6 to 2.0, and in the metronidazole group + standard skin care regimen the score remained unchanged at 2.0. </p> <p>Percentages regarding satisfaction were for the RTS + metronidazole group 50% very satisfied and 20% satisfied, and for the metronidazole group + standard skin care regimen 78% was satisfied. </p> </section> <section id="CD003262-sec-0289"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>No adverse events were reported in the group on RTS + metronidazole (n = 10), and two participants reported adverse events in the group treated with metronidazole + standard skin care regimen (n = 10) (RR 0.20, 95% CI 0.01 to 3.70). </p> </section> </section> <section id="CD003262-sec-0290"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0291"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>In the RTS + metronidazole group 4/10 showed moderate improvement versus 1/10 in the metronidazole + standard skin care regimen group (RR 4.00, 95% CI 0.54 to 29.80). </p> <p> <ul id="CD003262-list-0127"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>There was a decrease in erythema from 2.8 to 2.4 in the RTS + metronidazole group, it remained at 2.3 in the metronidazole + standard care regimen group. </p> <p> <ul id="CD003262-list-0128"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0129"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0130"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0292"> <h5 class="title">(31) Rosacea treatment system (RTS) without metronidazole versus metronidazole 0.75% and standard skin care regimen </h5> <p>This was the third comparison in <a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a>. </p> <section id="CD003262-sec-0293"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0294"> <p><b>Change in health‐related quality of life (HRQOL) at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0295"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>In the RTS group without metronidazole the score went from 2.5 to 2.2, and in the metronidazole group + standard skin care regimen it remained at 2.0. </p> <p>In the RTS group without metronidazole 30% were very satisfied and 40% satisfied, whilst in the group on the metronidazole and standard skin care regimen 78% were satisfied. </p> </section> <section id="CD003262-sec-0296"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>No adverse events were reported in the RTS without metronidazole group (n = 10), and two participants reported adverse events in the group treated with the metronidazole + standard skin care regimen (n = 10) (RR 0.20, 95% CI 0.01 to 3.70). </p> </section> </section> <section id="CD003262-sec-0297"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0298"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Only 1/10 showed moderate improvement in both groups (RR 1.00, 95% CI 0.07 to 13.87).</p> <p> <ul id="CD003262-list-0131"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>There was a slight reduction from 2.5 to 2.3 in the RTS without metronidazole group and it remained at 2.3 in the metronidazole + standard skin care regimen group. </p> <p> <ul id="CD003262-list-0132"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0133"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0134"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0299"> <h5 class="title">(32) 4‐Ethoxybenzaldehyde 1% versus placebo</h5> <p>The anti‐inflammatory effect of this intervention in reducing facial erythema was evaluated in only one study (<a href="./references#CD003262-bbs2-0026" title="DraelosZD , FullerBB . Efficacy of 1% 4‐ethoxybenzaldehyde in reducing facial erythema. Dermatologic Surgery2005;31(7 Pt 2):881‐5. [PUBMED: 16029682] ">Draelos 2005b</a>), assessed as at high risk of bias. No SDs were reported. </p> <section id="CD003262-sec-0300"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0301"> <p><b>Change in health‐related quality of life (HRQOL) at end of study</b></p> </section> <section id="CD003262-sec-0302"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0303"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>There were no adverse events reported in either group.</p> </section> </section> <section id="CD003262-sec-0304"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0305"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Ten out of 20 participants in the active group had a marked improvement from baseline compared to 0/10 in the vehicle group (RR 11.00, 95% CI 0.71 to 170.64), which was not statistically significant. </p> <p> <ul id="CD003262-list-0135"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>In the active treatment group an improvement in erythema was seen in 43.7% in the active treatment group, and a 16.7% improvement in the vehicle group. No exact baseline values or study endpoint values were reported. </p> <p> <ul id="CD003262-list-0136"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0137"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0138"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0306"> <h5 class="title">(33) Cream containing 1% extract of a flavonoid‐rich plant <i>Chrysanthellum indicum</i> versus placebo </h5> <p>One trial (<a href="./references#CD003262-bbs2-0074" title="RigopoulosD , KalogeromitrosD , GregoriouS , PacouretJM , KochC , FisherN , et al. Randomized placebo‐controlled trial of a flavonoid‐rich plant extract‐based cream in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2005;19(5):564‐8. [PUBMED: 16164709] ">Rigopoulos 2005</a>) assessed as at high risk of bias reported data for this comparison. </p> <section id="CD003262-sec-0307"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0308"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0309"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>A larger number of participants in the active intervention than in the placebo cream group reported improvement in rosacea severity, 60 of 125 participants with the flavonoid cream and 36 of 121 in the placebo arm (RR 1.61, 95% CI 1.16 to 2.24; P = 0.004; NNTB = 6, 95% CI 4 to 17). </p> </section> <section id="CD003262-sec-0310"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>There was no statistically significant difference in the number of participants experiencing adverse events: 13 of the 125 in the flavonoid cream group experienced adverse events and eight out of 121 in the placebo group (RR 1.57, 95% CI 0.68 to 3.66). </p> </section> </section> <section id="CD003262-sec-0311"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0312"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Based on the final investigators' assessment 64 of 125 participants in the active treatment group showed improvement versus 52 out of 121 in the placebo group (RR 1.19, 95% CI 0.91 to 1.56). Clearing or marked improvement on the rosacea overall assessment (seven grade scale) was scored as 78/125 in the active treatment group compared to 61/121 on placebo (RR 1.24, 95% CI 0.99 to 1.55). </p> <p> <ul id="CD003262-list-0139"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Reduction in erythema was 53.65% in the flavonoid rich cream group versus 44.23% for the placebo group. </p> <p> <ul id="CD003262-list-0140"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0141"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0142"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0313"> <h5 class="title">(34) Praziquantel 3% ointment versus vehicle ointment</h5> <p>This comparison was evaluated in a single study at high risk of bias (<a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a>). </p> <section id="CD003262-sec-0314"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0315"> <p><b>Change in HRQOL at end of study</b></p> <p>The DLQI decreased in the praziquantel group from 15.8 (very large effect on quality of life) to 4.6 (small effect on quality of life), which was a clinically important reduction. The reduction in the placebo group was smaller, from 14.6 to 7.9 (moderate effect on quality of life). </p> </section> <section id="CD003262-sec-0316"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0317"> <p><b><i>Proportion of participants who reported an adverse event throughout the study period</i> </b></p> <p>In the praziquantel group 1/43 reported an adverse event versus 2/22 in the vehicle group (RR 0.26, 95% CI 0.02 to 2.67). Dryness was mild in intensity and resolved after using a moisturizer. </p> </section> </section> <section id="CD003262-sec-0318"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0319"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Based on the IGA (5‐point Likert scale) at baseline 39/43 had a score of mild to moderate in the praziquantel group and at the end of study 35/43 had a score of minimal or clear. For the vehicle group at baseline 21/22 scored mild to moderate and after 16 weeks 5/22 scored minimal or clear. </p> <p> <ul id="CD003262-list-0143"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>At the start of the study 38/43 had a score of moderate to significant erythema on the 5‐point CEA scale, and at the end of the study 38/43 had no or mild erythema. In the vehicle group 19/22 had moderate to significant erythema at the start of study and after 16 weeks 9/22 had no or mild erythema. </p> <p> <ul id="CD003262-list-0144"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0145"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0146"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0320"> <h5 class="title">(35) BFH772 1% (betamethasone, calcipotriol) ointment versus metronidazole 1% cream</h5> <p>One small sample size (N = 36) three‐armed study of participants with erythema consistent with erythematotelangiectatic rosacea reported data for this comparison (<a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a>). This study was assessed as at unclear risk of bias. </p> <section id="CD003262-sec-0321"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0322"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0323"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>The mean participant's assessment of flushing frequency was ‐0.2 in the BFH772 1% group compared to ‐0.3 in the metronidazole group. </p> <p>The mean change in self assessments of erythema, after 12 weeks, in the BFH772 1% group showed no change: 0 (SD 0.7) compared to ‐0.5 (SD 0.8) in the metronidazole group with a MD of 0.5 (95% CI ‐0.10 to 1.10). </p> </section> <section id="CD003262-sec-0324"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Six out of the 12 participants in the BFH722 1% group reported adverse events compared to 4/12 in the metronidazole group (RR 1.50, 95% CI 0.56 to 4.00). Most adverse events were not drug related (gastrointestinal disorders, psychiatric disorders etc). </p> </section> </section> <section id="CD003262-sec-0325"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0326"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The mean change in IGA of rosacea was ‐0.4 (SD 0.5) in the BFH722 1% group versus ‐0.5 (SD 0.5) in the metronidazole group (MD 0.10, 95% CI ‐0.30 to ‐0.50). </p> <p> <ul id="CD003262-list-0147"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>IGA of telangiectasia showed a change from baseline of ‐0.2 (SD 0.4) in the BFH722 1% group compared to 0.4 (SD 1.2) in the metronidazole group with a MD of ‐0.60 (95% CI ‐1.32 to 0.12). </p> <p> <ul id="CD003262-list-0148"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>There was a small increase in mean number of lesion counts of 0.5 (SD 0.1) in the BFH722 1% group compared to a small decrease of 0.5 (SD 1.4) in the metronidazole group (MD 1.00, 95% CI 0.21 to 1.79; P = 0.01). </p> <p> <ul id="CD003262-list-0149"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0150"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0327"> <h5 class="title">(36) BFH772 1% (betamethasone, calcipotriol) ointment versus vehicle ointment</h5> <p>This comparison was evaluated in <a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a>. None of the data showed that BFH772 1% was any better than vehicle ointment. </p> <section id="CD003262-sec-0328"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0329"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0330"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>In the group treated with BFH722 1% ointment the mean participant‐assessed change in flushing frequency was ‐0.2 compared to ‐0.7 in the vehicle ointment group. </p> <p>The change in facial redness was 0 (SD 0.7) for the BFH772 group compared to ‐0.5 (SD 0.9) in the vehicle ointment group (MD 0.50, 95% CI ‐0.15 to 1.15). </p> </section> <section id="CD003262-sec-0331"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>In the BFH722 1% group 6/12 reported an adverse event compared to 4/12 in the vehicle group (RR 1.50, 95% CI 0.56 to 4.00). </p> </section> </section> <section id="CD003262-sec-0332"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0333"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The reductions on the IGA scale were 0.4 (SD 0.5) for the BFH772 1% group and 0.5 (SD 0.7) for the vehicle ointment group (MD 0.10, 95% CI ‐0.39 to 0.59). </p> <p> <ul id="CD003262-list-0151"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>IGA of telangiectasia showed a change from baseline of ‐0.2 (SD 0.4) in the BFH722 1% group compared to 0.1 (SD 0.6) in the vehicle ointment group with a MD of ‐0.30 (95% CI ‐0.71 to 0.11). </p> <p> <ul id="CD003262-list-0152"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>There were minimal changes in lesion counts: 0.5 (SD 1.0) in the BFH772 1% group and 0.1 (SD 0.4) in the vehicle ointment group (MD 0.40, 95% CI ‐0.21 to 1.01). </p> <p> <ul id="CD003262-list-0153"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0154"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0334"> <h5 class="title">(37) TDT 068 gel versus vehicle gel</h5> <p>TDT 068, a topical drug‐free gel containing ultra‐deformable Sequessome<sup>TM</sup> vesicles, was evaluated in a single study (<a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a>) assessed as at low risk of bias. None of the outcomes suggested that TDT 068 gel was more effective than vehicle gel. </p> <section id="CD003262-sec-0335"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0336"> <p><b>Change in HRQOL at end of study</b></p> <p>The RosaQoL (range 1 to 5) reduced by 0.08 (SD 0.38) in the TDT 068 gel group and by 0.08 (SD 0.37) in the vehicle group (MD 0.00, 95% CI ‐0.20 to 0.20). </p> </section> <section id="CD003262-sec-0337"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0338"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Adverse events were reported in 5/40 in the TDT 068 gel group versus 4/21 in the vehicle group and consisted mostly of skin irritation and pruritus (RR 0.66, 95% CI 0.20 to 2.19). </p> </section> </section> <section id="CD003262-sec-0339"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0340"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>This outcome was assessed with the Rosacea Standard Grading System (RSGS) (<a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a>). Investigators stated that there was no statistically significant difference in reduction in the total score at the end of the four week study (investigators reported a difference at 4 weeks of 0.94 (SD 2.03), 95% CI –0.20 to 2.08; P value of 0.11). </p> <p> <ul id="CD003262-list-0155"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Non‐transient erythema decreased from baseline by 0.34 (SD 0.63) in the TDT 068 gel group (n = 38) and 0.05 (SD 0.51) in the vehicle group (n = 20) (MD ‐0.29, 95% CI ‐0.59 to 0.01). Transient erythema reduced from baseline by 0.55 (SD 0.66) and 0.35 (SD 0.50) respectively (MD ‐0.20, 95% CI ‐0.50 to 0.10). Telangiectasia reduced by 0.26 (SD 0.55) and 0.15 (SD 0.50) respectively (MD ‐0.11, 95% CI ‐0.39 to 0.17). All of these differences were not statistically significant. </p> <p> <ul id="CD003262-list-0156"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>No exact data were provided other than as a graphical representation, which suggested no change. </p> <p> <ul id="CD003262-list-0157"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0158"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0341"> <h5 class="title">(38) Crotamiton versus benzyl benzoate</h5> <p>This comparison was examined in a single study that only addressed one of our outcomes, that is adverse events (<a href="./references#CD003262-bbs2-0075" title="Rodríguez AcarM , Medina HernándezE . A comparative, double‐blind study about efficacy and safety of crotamiton vs benzyl benzoate in the treatment of rosacea with demodecidosis [Estudio doble ciego, comparativo, sobre la eficacia y seguridad del crotamitón versus benzoato de bencilo en el tratamiento de la rosácea con demodecidosis]. Dermatología Revista Mexicana2003;47(3):126‐30. [EMBASE: 2007502703] ">Rodríguez 2003</a>). The study was assessed as at unclear risk of bias. </p> <section id="CD003262-sec-0342"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0343"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0344"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0345"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>There were no adverse events in either group.</p> </section> </section> <section id="CD003262-sec-0346"> <h6 class="title">Secondary outcomes</h6> <p>None of our secondary outcomes were assessed.</p> </section> </section> <section id="CD003262-sec-0347"> <h5 class="title">(39) Skin care product containing ambophenol, neurosensine and La Roche‐Posay thermal spring water versus vehicle </h5> <p>This cosmetic was evaluated in one study that provided limited data (<a href="./references#CD003262-bbs2-0082" title="SeitéS , BenechF , BerdahS , BayerM , VeyratS , SegotE , et al. Management of rosacea‐prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche‐Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology2013;12(8):920‐4. [EMBASE: 2013521246] ">Seité 2013</a>). The study was assessed as at unclear risk of bias. </p> <section id="CD003262-sec-0348"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0349"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0350"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Global efficacy of rosacea was assessed by the participants to be good or excellent in 10/32 in the test formula group compared to 5/34 in the vehicle group (RR 2.13, 95% CI 0.81 to 5.54). </p> </section> <section id="CD003262-sec-0351"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Not assessed.</p> </section> </section> <section id="CD003262-sec-0352"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0353"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Rosacea improved or was cured in 20/32 in the test formula group compared to 11/34 in the vehicle group (RR 1.93, 95% CI 1.11 to 3.37; P = 0.02). A rating of global efficacy of good to excellent was seen in 10/32 in the test formula group compared to 1/34 in the vehicle group (RR 10.63, 95% CI 1.44 to 78.36; P = 0.02). Both these assessments were not in concordance with the participants' judgements, where no statistically significant difference was seen. </p> <p> <ul id="CD003262-list-0159"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0160"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0161"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0162"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0354"> <h5 class="title">(40) SEI003 cream versus vehicle</h5> <p>One study with a small sample size (<a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a>), assessed as at high risk of bias, evaluated the efficacy of this topical serine protease inhibitor. </p> <section id="CD003262-sec-0355"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0356"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0357"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0358"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>No adverse events were reported in either group.</p> </section> </section> <section id="CD003262-sec-0359"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0360"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The IGA decreased by 1.00 (SD 0.57) in the SEI003 group (n = 11) and 0.7 (SD 0.5) in the vehicle group (n = 4), MD of 0.30, however these data were skewed, analysed inappropriately and have not been summarised or reported here. </p> <p> <ul id="CD003262-list-0163"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The CEA reduced by 4.10 (SD 1.62) in the SEI003 group and by 3.5 (SD 1.43) in the vehicle group (MD ‐0.60). However, as with the IGA outcome, these data were skewed. </p> <p> <ul id="CD003262-list-0164"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0165"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> <ul id="CD003262-list-0166"> <li> <p>Not assessed.</p> </li> </ul> <ul id="CD003262-list-0167"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0361"> <h5 class="title">(41) P‐3075 cream (based on hydroxypropyl chitosan and potassium azeloyl diglycinate) versus placebo cream </h5> <p>This comparison was evaluated in a single study at unclear risk of bias (<a href="./references#CD003262-bbs2-0007" title="BerardescaE , IorizzoM , AbrilE , GuglielminiG , CaseriniM , PalmieriR , et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology2012;11(1):37‐41. [PUBMED: 22360333] ">Berardesca 2012</a>) and which provided limited data, mainly on erythema. </p> <section id="CD003262-sec-0362"> <h6 class="title">Primary outcomes</h6> <p>None of our primary outcomes were assessed.</p> </section> <section id="CD003262-sec-0363"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0364"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>No global efficacy assessment was done.</p> <p> <ul id="CD003262-list-0168"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>No exact data per group were provided on the data assessed with the Mexameter, but the authors stated that at the end of treatment "the composite erythema index representing the sum of the 4 site‐specific erythema indices showed a statistically significant decrease at day 28 of 167.00; P &lt; 0.001)", in favour of P‐3075. </p> <p>Based on a 4‐point Likert scale (0 = none, 3 = severe) the investigators concluded "that at day 28 in the P‐3075 group, the clinical assessment of erythema showed a statistically significant decrease (P = 0.005 in the chi‐square test and P = 0.011 in the Fisher exact test)". At day 28, 27/28 of the participants treated with P‐3075 had no erythema, 1/28 had mild erythema, and in the placebo group 9/14 had no erythema and 5 had mild erythema. </p> <p> <ul id="CD003262-list-0169"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0170"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0171"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0365"> <h4 class="title">Systemic interventions: studies with oral antibiotics</h4> <section id="CD003262-sec-0366"> <h5 class="title">(42) Tetracycline versus placebo</h5> <p>Two trials at unclear risk of bias were included (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>; <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a>), see <a href="./full#CD003262-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD003262-sec-0367"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0368"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0369"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Only one of the studies provided data for this outcome (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>). Based on these participant‐assessed outcomes there was insufficient evidence to demonstrate that tetracycline was more effective than placebo. In the tetracycline group 14/20 participants considered they were better to much better versus 9/19 in the placebo group (RR 1.48, 95% CI 0.85 to 2.57). </p> </section> <section id="CD003262-sec-0370"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>In <a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> only one adverse event was reported in each group, diarrhoea in the tetracycline group and maculopapular erythema in the placebo group (RR 0.95, 95% CI 0.06 to 14.13). This outcome was not assessed in <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a>. </p> </section> </section> <section id="CD003262-sec-0371"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0372"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>In contrast with the participant‐assessed changes these assessments indicated that tetracyclines appeared to be significantly more effective than placebo in the treatment of rosacea. In the <a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> study 17 out of 20 participants in the tetracycline group were considered to be improved versus 4 of 19 in the placebo group (RR 4.04, 95% CI 1.66 to 9.83; P = 0.002; NNTB = 2, 95% CI 2 to 3). In <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a> 28 of 36 participants in the tetracycline group improved versus 19 of 42 in placebo (RR 1.72, 95% CI 1.18 to 2.50; P = 0.005; NNTB = 4, 95% CI 2 to 9). </p> <p> <ul id="CD003262-list-0172"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>This outcome was not assessed in <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a>, and there were no significant changes in erythema in <a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>. </p> <p> <ul id="CD003262-list-0173"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean reduction in number of lesions in <a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> was 16.05 (SD 13.45) in the tetracycline group (n = 17) compared to 1.41 (SD 9.52) in the placebo group (n = 17) but these data were skewed (MD ‐14.64). </p> <p> <ul id="CD003262-list-0174"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0175"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0373"> <h5 class="title">(43) Anti‐inflammatory dose doxycycline 40 mg versus placebo</h5> <p>Two studies assessed as at low risk of bias evaluated this comparison. Study duration in <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a> and <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> was 16 weeks, but in <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> the participants were re‐evaluated at 20 weeks, and therefore only the data from the 16 week assessment was analysed for this review. See <a href="./full#CD003262-tbl-0010">summary of findings Table 10</a>. </p> <section id="CD003262-sec-0374"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0375"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0376"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0377"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>The number of participants reporting adverse events was 56/127 in the doxycycline group versus 48/124 in the placebo group (RR 1.14, 95% CI 0.85 to 1.53) in <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>, and 93/142 versus 74/144 respectively in <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> (RR 1.27, 95% CI 1.04 to 1.55; P = 0.02; NNTH = 8, 95% CI 4 to 34). The majority of these adverse events were considered to be mild or moderate in severity. </p> </section> </section> <section id="CD003262-sec-0378"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0379"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The data from the IGA in <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a> indicated that doxycycline 40 mg was more effective than placebo. Fifty‐eight participants out of the 127 in the doxycycline 40 mg group achieved a 2‐point or greater improvement in IGA score compared with 32 out of 124 in the placebo group (RR 1.77, 95% CI 1.24 to 2.52; P = 0.002; NNTB = 5, 95% CI 4 to 13). Thirty‐nine participants in the doxycycline group achieved an IGA score of 0 (clear) or 1 (near clear) versus 24 in the placebo group (RR 1.59, 95% CI 1.02 to 2.47; P = 0.04; NNTB = 10, 95% CI 5 to 100). </p> <p>In <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> there was no statistically significant difference in IGA: 32 participants of the 142 in the doxycycline 40 mg group had achieved a 2‐point or greater improvement in IGA score compared with 23 of 144 in the placebo group (RR 1.41, 95% CI 0.87 to 2.29). However, more than twice as many participants achieved an IGA score of 0 (clear) or 1 (near clear) in the doxycycline group: 21 participants in the doxycycline group achieved an IGA score of 0 or 1 versus 9 in the placebo group (RR 2.37, 95% CI 1.12 to 4.99; P = 0.02; NNTB = 12, 95% CI 7 to 100). </p> <p> <ul id="CD003262-list-0176"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>In <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a> the mean change in CEA scale (range 0 to 4, 0 = none and 4 is severe redness) was ‐2.7 in the doxycycline group versus ‐1.8 in the placebo group (investigators stated P = 0.017). In <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> there was no statistically significant difference between the groups with a reduction of 1.4 in the doxycycline group and 1.2 in the placebo group. </p> <p> <ul id="CD003262-list-0177"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean reduction in lesion count in <a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a> was 11.8 (SD 14.04) in the doxycycline group and 5.9 (SD 14.04) in the placebo group (MD ‐5.90, 95% CI ‐9.37 to ‐2.43; P = 0.0009). In <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> these reductions were 9.50 (SD 13.23) and 4.3 (SD 13.23) for the doxycycline group and placebo group respectively (MD ‐5.20, 95% CI ‐8.27 to ‐2.13; P = 0.0009). </p> <p> <ul id="CD003262-list-0178"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>The data were presented in the reports as graph plots, which did not permit accurate data to be extracted. However, the steepest changes in the graph plots occurred within the first three weeks in the doxycycline group, which provided an indication of the time needed for improvement of inflammatory lesions relative to placebo. </p> <p> <ul id="CD003262-list-0179"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0380"> <h5 class="title">(44) Anti‐inflammatory dose doxycycline 40 mg versus placebo as maintenance therapy during 40 weeks </h5> <p>This study at high risk of bias evaluated the efficacy in preventing relapse and safety of long‐term treatment with doxycycline after a 12 week treatment with doxycycline 40 mg and topical metronidazole. Only participants that achieved an IGA of clear or near clear entered the second, randomised phase (<a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>). </p> <section id="CD003262-sec-0381"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0382"> <p><b>Change in HRQOL at end of study</b></p> <p>The RosaQoL scores (1 to 5) were 3.3 for both groups at the end of the first open phase of the study and decreased to 2.8 in the participants that continued with doxycycline (n = 65), while the participants that switched to placebo (n = 65) had a smaller reduction to 3.1. </p> </section> <section id="CD003262-sec-0383"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>This outcome was assessed with a satisfaction questionnaire which reported the percentages of participants that were not bothered by or did not experience symptoms. The percentages for tightness of the skin were 64.6% for the doxycycline group and 60% for the placebo group, sensitivity of the skin 64.6% versus 55.4%, stinging and burning 66.1% versus 47.7%, roughness 55.4% versus 49.3%, and itchy skin sensation 58.4% versus 52.3%, indicating that higher percentages not experiencing symptoms were in the doxycycline group. </p> </section> <section id="CD003262-sec-0384"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Adverse events were reported in 8/65 of the participants in the doxycycline group and 9/65 in the placebo group (RR 0.89, 95% CI 0.37 to 2.16). </p> </section> </section> <section id="CD003262-sec-0385"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0386"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>At the start of the randomised second phase all 65 participants in both groups had an IGA of clear or near clear. At the end of 40 weeks 41/65 were still clear to near clear in the doxycycline group, while in the placebo group this number had dropped to 33/65. </p> <p> <ul id="CD003262-list-0180"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean score change in CEA score was ‐0.50 (SD 2.14) for the doxycycline group and 0.40 (SD 2.36) for the placebo group (MD ‐0.90, 95% CI ‐1.67 to ‐0.13; P = 0.02), which was a statistically significant difference in favour of doxycycline. </p> <p> <ul id="CD003262-list-0181"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean number of lesion counts increased by 0.90 (SD 1.61) in the doxycycline group and 0.30 (SD 1.20) in the placebo group (MD 0.60, 95% CI 0.11 to 1.09; P = 0.02), which was a statistically significant difference in favour of placebo; but such a small difference in lesion count was unlikely to be clinically important. However, it suggested that when treatment success had been achieved with doxycycline there was a prolonged, sustained and relevant effect which was shown to continue up to 40 weeks in the placebo group. </p> <p> <ul id="CD003262-list-0182"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0183"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> <p>During the 40 weeks, 9/65 relapsed in the doxycycline group compared to 18/65 in the placebo group (RR 0.50, 95% CI 0.24 to 1.03). </p> </section> </section> </section> <section id="CD003262-sec-0387"> <h5 class="title">(45) Azithromycin versus doxycycline</h5> <p>Only one study assessed as at high risk of bias addressed this comparison (<a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a>). See <a href="./full#CD003262-tbl-0011">summary of findings Table 11</a>. </p> <section id="CD003262-sec-0388"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0389"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0390"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Although there was no measurable difference in change in severity between the two treatment groups, 29 out of 37 participants in the azithromycin group considered themselves improved versus 24 of 30 in the doxycycline group (RR 0.98, 95% CI 0.77 to 1.25). </p> </section> <section id="CD003262-sec-0391"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Diarrhoea was reported in four of the 37 participants in the azithromycin group, and two out of 30 in the doxycycline group experienced epigastric burning (RR 1.62, 95% CI 0.32 to 8.26). </p> </section> </section> <section id="CD003262-sec-0392"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0393"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0184"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0185"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>At baseline these were 19.24 (SD 9.67) in the azithromycin group and 1.90 (SD 3.28) at 3 months, and similarly in the doxycycline group 18.86 (8.95) and 2.34 (3.47) at three months. However, in addition to having large SDs these data were skewed. </p> <p> <ul id="CD003262-list-0186"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0187"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>No data were available for the duration of remission, but both groups showed no statistically significant change between the third month of treatment and the second month post‐treatment in the mean inflammatory lesion counts. </p> </section> </section> </section> <section id="CD003262-sec-0394"> <h5 class="title">(46) Ampicillin versus placebo</h5> <p>One study at unclear risk of bias provided data for this comparison (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>). The dosage of ampicillin was not reported. </p> <section id="CD003262-sec-0395"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0396"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0397"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>These assessments demonstrated significant improvements, which were in favour of ampicillin over placebo, such that 14 out of 17 participants treated with ampicillin versus 9/19 in the placebo group (RR 1.74, 95% CI 1.03 to 2.93; P = 0.04; NNTB = 3, 95% CI 2 to 17) considered themselves improved. </p> </section> <section id="CD003262-sec-0398"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Three of the 17 participants treated with ampicillin reported adverse events versus 1/19 in the placebo group (RR 3.35, 95% CI 0.38 to 29.26). The adverse events were mild and transient, and one participant in the ampicillin group experienced diarrhoea. </p> </section> </section> <section id="CD003262-sec-0399"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0400"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>These were generally in line with the participant‐assessed changes but there was no statistically significant difference between the groups. Nine of 17 participants treated with ampicillin reported improvement compared with 4/19 in the placebo group (RR 2.51, 95% CI 0.94 to 6.70). </p> <p> <ul id="CD003262-list-0188"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>There were no significant changes in erythema.</p> <p> <ul id="CD003262-list-0189"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean change from baseline was ‐11.2 (SD 19.23) in the ampicillin group (n = 15) and 1.41 (SD 9.52) in the placebo group, but these had large SDs and skewed data (MD ‐9.79, SD 14.86; P = 0823). </p> <p> <ul id="CD003262-list-0190"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0191"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0401"> <h5 class="title">(47) Oral tetracycline versus ampicillin</h5> <p>Only one study at unclear risk of bias provided data for this comparison (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>). </p> <section id="CD003262-sec-0402"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0403"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0404"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>These assessments did not indicate any difference in efficacy between the two interventions: 14 of 20 participants treated with tetracycline considered themselves improved versus 14 of 17 in the ampicillin group (RR 0.85, 95% CI 0.59 to 1.22). </p> </section> <section id="CD003262-sec-0405"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Most side effects were mild and transient, 3/17 participants in the ampicillin group reported adverse events compared with 1/20 in the tetracycline group (RR 0.28, 95% CI 0.03 to 2.48). </p> </section> </section> <section id="CD003262-sec-0406"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0407"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>These were in line with the participant‐assessed changes, 17 of 20 in the tetracycline group reported they had improved versus 9/17 in the ampicillin group (RR 1.61, 95% CI 0.99 to 2.61). </p> <p> <ul id="CD003262-list-0192"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>There were no significant changes in erythema.</p> <p> <ul id="CD003262-list-0193"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean change from baseline was ‐16.45 (SD 8.83) in the tetracycline group and ‐11.53 (SD 15.96) in the placebo group, but these had large SDs and skewed data (MD ‐4.86 (SD 16.4); P = 0.4249). </p> <p> <ul id="CD003262-list-0194"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0195"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0408"> <h5 class="title">(48) Oral oxytetracycline versus oral metronidazole</h5> <p>Only one study assessed as at unclear risk of bias provided data for this comparison (<a href="./references#CD003262-bbs2-0076" title="SaihanEM , BurtonJL . A double‐blind trial of metronidazole versus oxytetracycline therapy for rosacea. British Journal of Dermatology1980;102(4):443‐5. [PUBMED: 6446314] ">Saihan 1980</a>). </p> <section id="CD003262-sec-0409"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0410"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0411"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>These were combined with the physician assessments and reported as unified scores.</p> </section> <section id="CD003262-sec-0412"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>No adverse events were reported in either group.</p> </section> </section> <section id="CD003262-sec-0413"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0414"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The combined scores of the participants and physicians demonstrated that there was no statistically significant difference between the two groups in rosacea severity at the completion of the study. The mean severity scores (scale ‐1 to 3, with 3 = much improved) were 2.60 (SD 0.70) in the tetracycline group (n = 20) versus 2.30 (SD 1.00) in the metronidazole group (n = 18) with a MD of 0.30 (95% CI ‐0.25 to 0.85; P = 0.29). </p> <p> <ul id="CD003262-list-0196"> <li> <p>Assessment of erythema or telangiectasia or both at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0197"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0198"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0199"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0415"> <h5 class="title">(49) Clarithromycin and omeprazole versus placebo in <i>Helicobacter pylori</i> positive patients with rosacea </h5> <p>The data from the single study at unclear risk of bias evaluating these interventions were skewed, had large SDs and were considered to be unusable (<a href="./references#CD003262-bbs2-0003" title="BamfordJT , TildenRL , BlankushJL , GangenessDE . Effect of treatment of Helicobacter pylori infection on rosacea. Archives of Dermatology1999;135(6):659‐63. [UI: 99303186; PUBMED: 10376693] ">Bamford 1999</a>). There were 22 participants in the clarithromycin and omeprazole group and 22 in the placebo group. </p> <section id="CD003262-sec-0416"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0417"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0418"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0419"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>One participant in the treatment group reported headaches during treatment, but no adverse events were reported in the placebo group (RR 3.00, 95% CI 0.13 to 69.87). </p> </section> </section> <section id="CD003262-sec-0420"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0421"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The mean change in total rosacea severity score was ‐4.50 (SD 2.12) in the active treatment group compared to ‐3.20 (SD 2.95) in the placebo group, but these data were very skewed. It should be noted that 25% of the participants in the active treatment group were still positive for <i>Helicobacter pylori</i> despite having reported completing the antibiotic therapy. </p> <p> <ul id="CD003262-list-0200"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean reductions in erythema intensity were 2.00 (SD 1.55) in the active treatment group and 1.80 (SD 1.71) in the placebo group. </p> <p> <ul id="CD003262-list-0201"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean reduction in pustule count was 15.30 (SD 9.56) in the active treatment group and 9.30 (SD 12.03) in the placebo group, and the data were very skewed. </p> <p> <ul id="CD003262-list-0202"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0203"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0422"> <h4 class="title">Systemic interventions: studies with oral antibiotics combined with topical treatments</h4> <section id="CD003262-sec-0423"> <h5 class="title">(50) Anti‐inflammatory dose doxycycline 40 mg and metronidazole gel 1% versus doxycycline 100 mg and metronidazole gel 1% </h5> <p>Only one study assessed as at unclear risk of bias evaluated these interventions (<a href="./references#CD003262-bbs2-0024" title="DelRossoJQ , CaveneyS . Comparison of anti‐inflammatory dose doxycycline (30‐mg immediate‐release beads, 10 mg delayed‐release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery2012;31(1):A7‐8. [EMBASE: 70706922] DelRossoJQ , SchlessingerJ , WerschlerP . Comparison of anti‐inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology2008;7(6):573‐6. [PUBMED: 18561589] ">Del Rosso 2008</a>). SDs were missing, some of which we were able to calculate. See <a href="./full#CD003262-tbl-0012">summary of findings Table 12</a>. </p> <section id="CD003262-sec-0424"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0425"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0426"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0427"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Four times as many adverse events were reported in the higher dose group compared with the 40 mg dose group. Six of the 44 participants treated with the anti‐inflammatory dose of 40 mg had adverse events versus 26 of 47 participants in the 100 mg group (RR 0.25, 95% CI 0.11 to 0.54; P = 0.0005; NNTH = 3, 95% CI 2 to 5). The majority of these adverse events were gastrointestinal complaints. </p> </section> </section> <section id="CD003262-sec-0428"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0429"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The mean reduction in IGA was 1.6 (SD 0.27) in the 40 mg doxycycline group (n = 44) and also in the 100 mg doxycycline group (n = 47) (MD 0.00, 95% CI ‐0.11 to 0.11). </p> <p> <ul id="CD003262-list-0204"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Change in CEA from baseline (0 to 4, 0 = no redness present, 4 = severe redness) was ‐4.2 for the 40 mg group and ‐4.0 for the 100 mg group (investigators stated P = 0.50). </p> <p> <ul id="CD003262-list-0205"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The mean change from baseline in lesion count was ‐12.5 (SD 6.64) for the 40 mg group versus ‐12.2 (SD 6.64) for the 100 mg group (MD ‐0.30, 95% CI ‐3.03 to 2.43). </p> <p> <ul id="CD003262-list-0206"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Although this was not a pre‐specified outcome a clear improvement was seen from week four in both groups. </p> <p> <ul id="CD003262-list-0207"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0430"> <h5 class="title">(51) Anti‐inflammatory dose doxycycline 40 mg and azelaic acid 15% gel versus anti‐inflammatory dose doxycycline 40 mg and metronidazole gel 1% </h5> <p>These treatments were evaluated in one study at unclear risk of bias (<a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a>). See <a href="./full#CD003262-tbl-0013">summary of findings Table 13</a>. </p> <section id="CD003262-sec-0431"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0432"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0433"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Excellent improvement was reported by 52/106 of the participants in the doxycycline + azelaic acid group compared to 47/101 in the doxycycline + metronidazole group (RR 1.05, 95% CI 0.79 to 1.40). The improvement score (1 = excellent, 4 = worse) was 1.6 in the doxycycline + azelaic acid group and 1.7 in the comparator group. </p> </section> <section id="CD003262-sec-0434"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Very few participants reported adverse events: 2/106 in the doxycycline + azelaic acid group and 7/101 in the doxycycline + metronidazole group (RR 0.27, 95% CI 0.06 to 1.28). </p> </section> </section> <section id="CD003262-sec-0435"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0436"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Treatment responses based on an IGA score of 0, 1 or 2 (clear, minimal or mild) were seen in 83/106 in the doxycycline + azelaic acid group and in 73/101 in the doxycycline + metronidazole group (RR 1.08, 95% CI 0.93 to 1.27). Assessments of treatment success (IGA 0 or 1) were 66/106 versus 53/101 participants respectively (RR 1.19, 95% CI 0.94 to 1.50). Investigators' overall rating of improvement was 1.8 for both groups. </p> <p> <ul id="CD003262-list-0208"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0209"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Mean reductions in lesion counts were 10.5 (SD 9.14) for the doxycycline + azelaic acid group and 9.4 (SD 9.38) in the comparator group (MD ‐1.10, 95% CI ‐4.91 to 2.71). </p> <p> <ul id="CD003262-list-0210"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Although this was not a pre‐specified outcome, improvement could be seen for both treatment arms after four weeks. </p> <p> <ul id="CD003262-list-0211"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0437"> <h5 class="title">(52) Anti‐inflammatory dose doxycycline 40 mg combined with topical metronidazole 1% gel twice daily versus placebo capsules combined with topical metronidazole 1% gel twice daily </h5> <p>A single study assessed as at unclear risk of bias was included but provided very limited outcome data for this comparison, and SDs were missing (<a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a>). After week 12 metronidazole was discontinued, therefore we have reported data at 12 weeks. </p> <section id="CD003262-sec-0438"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0439"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0440"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0441"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Participants in the doxycycline with metronidazole group reported 39 adverse events compared with 23 in the placebo with metronidazole group, however the report was unclear on how many of the participants experienced these adverse events. </p> </section> </section> <section id="CD003262-sec-0442"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0443"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The IGA score reduced by 1.3 in the doxycycline + metronidazole group (n = 30) compared to 0.8 in the placebo + metronidazole group (n = 32) (investigators reported P = 0.01). </p> <p> <ul id="CD003262-list-0212"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>The mean reduction in erythema in the doxycycline + metronidazole group was 0.91 and in the comparator group 0.66 (investigators reported P = 0.01). </p> <p> <ul id="CD003262-list-0213"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>At 12 weeks the mean reduction in inflammatory lesion counts was 13.86 in the doxycycline + metronidazole group and 8.47 in the comparator group (investigators reported P = 0.002). </p> <p> <ul id="CD003262-list-0214"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Improvement in the lesion counts was seen within four weeks in the doxycycline + metronidazole group as compared to within eight weeks for the placebo + metronidazole group. </p> <p> <ul id="CD003262-list-0215"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0444"> <h5 class="title">(53) Combined effect of anti‐inflammatory dose doxycycline with metronidazole gel versus metronidazole gel alone </h5> <p>Only one study (<a href="./references#CD003262-bbs2-0078" title="SanchezJ , SomolinosAL , AlmodóvarPI , WebsterG , BradshawM , PowalaC . A randomized, double‐blind, placebo‐controlled trial of the combined effect of doxycycline hyclate 20‐mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. Journal of the American Academy of Dermatology2005;53(5):791‐7. [PUBMED: 16243127] SanchezJL , SomolinosA , WebsterG , BradshawM . Combined effect of doxycycline hyclate 20 mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. Journal of the American Academy of Dermatology2004;50(3):48. ">Sanchez 2005</a>) at unclear risk of bias provided data for this comparison. </p> <section id="CD003262-sec-0445"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0446"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0447"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0448"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Thirty‐three adverse events were reported: 14 in the doxycycline plus metronidazole group versus 19 in the metronidazole gel alone group, but it was unclear in how many participants these occurred. </p> </section> </section> <section id="CD003262-sec-0449"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0450"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Numeric data were not provided and both of these outcome measures had to be estimated from figures in the report, and SDs were calculated. The mean change from baseline in Global Severity score was ‐1.43 (SD 1.6) for the doxycycline combined with metronidazole group (n = 20) compared to ‐0.42 (SD 1.6) for the metronidazole gel only group (n = 20) (MD ‐1.01, 95% CI ‐2.00 to ‐0.02; P = 0.05). </p> <p> <ul id="CD003262-list-0216"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Mean changes from baseline also had to be estimated from figures, but the investigators reported that they "failed to demonstrate a change in Clinician's Global erythema scale due to disparity in location number of affected facial sites". </p> <p> <ul id="CD003262-list-0217"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Changes from baseline in lesion counts at week 12 were ‐15.6 (SD 9.5) for the doxycycline with metronidazole group and ‐7.9 (SD 9.5) for the metronidazole gel only group with a MD of ‐7.70 (95% CI ‐13.59 to ‐1.81; P = 0.01), which was a clinically important difference. </p> <p> <ul id="CD003262-list-0218"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Improvements were seen between four and eight weeks.</p> <p> <ul id="CD003262-list-0219"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0451"> <h5 class="title">(54) Minocycline 45 mg versus minocycline 45 mg and topical azelaic acid 15% gel</h5> <p>This comparison was evaluated in a single study assessed as at unclear risk of bias (<a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a>). There was no statistically significant difference for any outcome between the treatment arms. See <a href="./full#CD003262-tbl-0014">summary of findings Table 14</a>. </p> <section id="CD003262-sec-0452"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0453"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0454"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0455"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Although only two adverse events were related to the study medication (upset stomach and urticaria), 11/30 in the minocycline only group reported an adverse event compared to 16/30 in the combined treatment group (RR 0.69, 95% CI 0.39 to 1.22). </p> </section> </section> <section id="CD003262-sec-0456"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0457"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The mean change from baseline in the IGA was ‐2.00 (SD 0.63) for both groups (MD 0.00, 95% CI ‐0.32 to 0.32). </p> <p> <ul id="CD003262-list-0220"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Erythema was evaluated with the CEA scale and scored ‐3.00 (SD 2.68) in the minocycline only group compared to ‐4.00 (SD 1.90) in the minocycline with azelaic acid group (MD 1.00, 95% CI ‐0.18 to 2.18). </p> <p> <ul id="CD003262-list-0221"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>In both groups there was a clinically important reduction in lesion counts of 11.00 (SD 4.49) in the minocycline group and 12.00 (SD 3.00) in the comparator group (MD 1.00, 95% CI ‐0.93 to 2.93). </p> <p> <ul id="CD003262-list-0222"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Although this was not a pre‐specified outcome, improvement was seen in both arms at four weeks. </p> <p> <ul id="CD003262-list-0223"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0458"> <h5 class="title">(55) Oral metronidazole and topical hydrocortisone 1% cream versus oral placebo and topical hydrocortisone 1% cream </h5> <p>Only one study (<a href="./references#CD003262-bbs2-0072" title="PyeRJ , BurtonJL . Treatment of rosacea by metronidazole. Lancet1976;1(7971):1211‐2. [UI: 76195079; PUBMED: 58258] ">Pye 1976</a>) assessed as at unclear risk of bias provided outcome data for these interventions. </p> <section id="CD003262-sec-0459"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0460"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0461"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0462"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Adverse events were confined to two participants in the metronidazole plus hydrocortisone group and one participant in the placebo group (RR 1.87, 95% CI 0.19 to 18.38). </p> </section> </section> <section id="CD003262-sec-0463"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0464"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Although the study was inadequately reported, the data available for this outcome indicated that oral metronidazole appeared to be almost four times more effective than placebo. Ten of the 15 participants treated with oral metronidazole plus hydrocortisone showed an improvement in severity scores compared with only two of the 14 participants in the placebo plus hydrocortisone group (RR 4.64, 95% CI 1.23 to 17.68; P = 0.02; NNTB = 2, 95% CI 2 to 5). </p> <p> <ul id="CD003262-list-0224"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0225"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0226"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0227"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0465"> <h4 class="title">Systemic interventions: studies with oral antibiotics compared with topical antibiotics</h4> <section id="CD003262-sec-0466"> <h5 class="title">(56) Topical metronidazole versus oral (oxy)tetracycline</h5> <p>Four studies at unclear risk of bias were included in this comparison. <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> investigated the effects of metronidazole 1% cream versus oral oxytetracycline for the treatment of rosacea. The other two studies, <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> and <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>, utilised tetracycline instead of oxytetracycline. In <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a> metronidazole gel 0.75% was compared with oxytetracycline. </p> <p>Although the quality of reporting of these studies was generally poor, they indicated that there was no statistically significant difference in effectiveness between metronidazole cream and oxytetracycline. The <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> study was assessed as being at high risk of bias and provided only very limited data. See <a href="./full#CD003262-tbl-0015">summary of findings Table 15</a>. </p> <section id="CD003262-sec-0467"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0468"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0469"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Based on these assessments no statistically significant difference in efficacy could be demonstrated. In <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a> eight of the 16 participants in the topical metronidazole group considered themselves improved versus 12 of 17 in the oxytetracycline group (RR 0.71, 95% CI 0.40 to 1.26). Correspondingly, in <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> there was no statistically significant difference in the assessments between the interventions in that 22/25 participants in the metronidazole group considered themselves improved versus 21/23 in the oxytetracycline group (RR 0.96, 95% CI 0.80 to 1.17). In <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> no exact data were provided other than that "both groups considered their condition much improved". </p> </section> <section id="CD003262-sec-0470"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>No adverse events were reported in <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>. In both groups in <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a> two participants reported flaking of the skin and two participants experienced gastrointestinal problems (RR 1.06, 95% CI 0.32 to 3.55). It was unclear how many participants were randomised in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> to each group, but 12 participants reported an adverse event in the metronidazole group and nine in the tetracycline group. In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> 7/38 participants in the metronidazole group (skin irritation (4), skin dryness (1), stinging (2)) and 10/38 in the tetracycline group (skin irritation (4), skin dryness (4), stinging (2)) reported adverse events (RR 0.70, 95% CI 0.30 to 1.65). </p> </section> </section> <section id="CD003262-sec-0471"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0472"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>These were in agreement with the participants' assessments and showed no statistically significant difference between the two interventions. In <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a> 9 out of 16 in the metronidazole group were improved versus 12 of 17 in the oxytetracycline group (RR 0.80, 95% CI 0.47 to 1.35); and 24 of 25 versus 22 of 23 respectively in <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> (RR 1.00, 95% CI 0.89 to 1.13). No baseline data were provided in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>, making the data unusable. </p> <p> <ul id="CD003262-list-0228"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>In <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a> all participants (16) showed improvement in erythema in the metronidazole group compared to 9/17 in the oxytetracycline group. The mean erythema score reduced from 2.5 to 1.1 in the metronidazole group and from 2.4 to 1.1 in the oxytetracycline group. No exact data were provided in <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> but it was stated that "the reduction of erythema was the same in both groups, and the number and extent of telangiectases were unchanged". In <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> no differences in erythema nor telangiectasia were seen in either group. In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> the percentages of no improvement of erythema after 8 weeks were 11.1% in the metronidazole group versus 12.5% in the tetracycline group. </p> <p> <ul id="CD003262-list-0229"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>In <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a> at baseline the metronidazole group had a mean papule and pustule count of 25 (mean grade 3.7) versus a mean count of 20 (mean grade 2.9) in the oxytetracycline group. By week nine both treatment groups had shown a reduction of more than 50%, with 100% clearing in 75% versus 66% respectively; while the mean papule and pustule grade had fallen to 1.3 versus 1.1. In <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> the investigators stated that "the reduction of papules and pustules was the same in both groups". In <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> a decrease of 68% in papule count was seen in the metronidazole group and of 77% in the tetracycline group; for pustules the percentage decrease was 53% and 61% respectively. In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> only medians were provided, and at week eight the median for inflammatory lesions was 11.1 for metronidazole versus 0 in the tetracycline group. </p> <p> <ul id="CD003262-list-0230"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0231"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0473"> <h4 class="title">Studies with other systemic treatments</h4> <section id="CD003262-sec-0474"> <h5 class="title">(57) Zinc sulphate versus placebo</h5> <p>Two studies provided data for this comparison (<a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>; <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a>). No SDs or exact data were reported in follow‐up assessments in the study of <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> (study assessed as at high risk of bias). In <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a> (assessed as at unclear risk of bias) there were no statistically significant differences for any outcome between the groups, whilst in <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> the authors reported that zinc sulphate was effective for rosacea. </p> <section id="CD003262-sec-0475"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0476"> <p><b>Change in HRQOL at end of study</b></p> <p>This was assessed with the RosaQoL (rated 1 to 5) in <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>. The baseline value for the group treated with zinc sulphate (n = 22) was 3.10 (95% CI 2.88 to 3.50) and for the placebo group (n = 22) 3.29 (95% CI 3.06 to 3.53). At the end of three months the score reduced to 2.90 (95% CI 2.67 to 3.12) in the zinc sulphate group and to 2.99 (95% CI 2.73 to 3.26) in the placebo group. The adjusted MD between the groups was 0.07 (95% CI ‐0.14 to 0.27; P = 0.53). </p> </section> <section id="CD003262-sec-0477"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0478"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>The number of participants experiencing adverse events in <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a> was 17/27 in the group treated with zinc sulphate and 14/26 in the placebo group (RR 1.17, 95% CI 0.74 to 1.85). In <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> the number of participants who reported an adverse event in the zinc sulphate group was 3/13 compared to 0/12 for the placebo group (RR 6.50, 95% CI 0.37 to 114.12). Most of the adverse events reported in the zinc sulphate group were gastric upset, nausea, discomfort and diarrhoea. </p> </section> </section> <section id="CD003262-sec-0479"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0480"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>In <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a> this was assessed with the Standard Grading System for Rosacea, with a total severity score ranging from 0 to 12. At baseline the score in the zinc sulphate group was 6.32 (95% CI 5.76 to 6.87), and reduced to 5.09 (95% CI 4.18 to 6.00). For the placebo group the baseline score was 6.91 (95% CI 6.31 to 7.50), and at 3 months 4.06 (95% CI 4.07 to 5.65) with an adjusted MD between the groups of 0.57 (95% CI 0.47 to 1.62; P = 0.28). </p> <p>In <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> the Physician Global Evaluation score in the zinc sulphate group decreased from 8 (SD 2.0) at baseline to 1.6 (no SD provided) and in the placebo group an increase from 7 (SD 1.3) at baseline to 7.6 (no SD provided) was reported. Although no details were provided the investigators reported that for the nine participants with ocular rosacea "all eye involvement disappeared after 3 months' treatment with zinc sulphate". </p> <p> <ul id="CD003262-list-0232"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>This was not assessed in <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>. In <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> the authors reported an improvement in the zinc sulphate group but no exact data were provided. </p> <p> <ul id="CD003262-list-0233"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>This outcome was not assessed in <a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>. The numbers of papules and pustules were not reported in <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> and although the investigators reported improvements in the zinc sulphate group this was not supported by the data in the figures. </p> <p> <ul id="CD003262-list-0234"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0235"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0481"> <h5 class="title">(58) Isotretinoin versus doxycycline</h5> <p>One study at low risk of bias assessed this comparison (<a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a>), see <a href="./full#CD003262-tbl-0016">summary of findings Table 16</a>. This study consisted of two time periods, the first was a dose finding study for isotretinoin, and the second phase compared 0.3 mg isotretinoin with doxycycline 100 mg 14 days and then tapered to 50 mg per day. We have noted and reported that there was inconsistency in the denominators used by the investigators in the per‐protocol analyses for the different outcomes. See '<a href="./references#CD003262-sec-0596" title="">Characteristics of included studies</a>' and '<a href="#CD003262-tbl-0021">Table 3</a>'. </p> <section id="CD003262-sec-0482"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0483"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0484"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Data were presented, as reported, in a per‐protocol analysis. In the group treated with isotretinoin 0.3 mg/kg daily 102/129 participants considered themselves to have achieved a good to excellent improvement compared to 85/132 in the doxycycline group (RR 1.23, 95% CI 1.05 to 1.43; P = 0.009; NNTB 7, 95% CI 4 to 25), which was a statistically significant difference in favour of isotretinoin. </p> </section> <section id="CD003262-sec-0485"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>In the isotretinoin group 30/147 participants reported adverse events compared to 26/152 in the doxycycline group (RR 1.19, 95% CI 0.74 to 1.92). There were more gastrointestinal and respiratory complaints reported in the doxycycline group; and cheilitis, dry mouth and lips were more frequent occurrences in the isotretinoin group. </p> </section> </section> <section id="CD003262-sec-0486"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0487"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Data were presented based on a per‐protocol analysis. A complete remission or marked improvement was observed in 105/129 participants in the isotretinoin group compared to 91/132 in the doxycycline group (RR 1.18, 95% CI 1.03 to 1.36; P = 0.02; NNTB = 9, 95% CI 5 to 50), which was in concordance with the participant‐assessed changes. </p> <p> <ul id="CD003262-list-0236"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Erythema was improved or "healed" in 105/142 participants in the isotretinoin group compared to 112/143 in the doxycycline group (RR 0.94, 95% CI 0.83 to 1.08). </p> <p>Telangiectasia improved or were "healed" in 56/142 of the participants isotretinoin group versus 55/143 in the doxycycline group (RR 1.03, 95% CI 0.77 to 1.37). </p> <p> <ul id="CD003262-list-0237"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>There was an overall reduction of 16 lesions in the isotretinoin group compared to a reduction of 13 in the doxycycline group. </p> <p> <ul id="CD003262-list-0238"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0239"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0488"> <h5 class="title">(59) Oral ivermectin with oral metronidazole versus oral ivermectin</h5> <p>These treatments were assessed in <a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a> but the report only provided limited data and was assessed as at high risk of bias. </p> <section id="CD003262-sec-0489"> <h6 class="title">Primary outcomes</h6> <p>None of our primary outcomes were assessed.</p> </section> <section id="CD003262-sec-0490"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0491"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>A marked improvement or complete remission was seen in 47/60 participants in the oral ivermectin only group compared to 59/60 in the combined treatment group (RR 0.80, 95% CI 0.69 to 0.91; P = 0.001; NNTB = 5, 95% CI 4 to 12), an effect which was statistically significant in favour of the combined treatment. Although no details were provided regarding signs and symptoms of ocular rosacea, the investigators reported that "combined therapy was superior in decreasing the D. folliculorum count in all groups and in reducing the mite count to the normal level in rosacea and in anterior blepharitis". </p> <p> <ul id="CD003262-list-0240"> <li> <p>Assessment of erythema or telangiectasia or both at end of study</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0241"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0242"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0243"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0492"> <h5 class="title">(60) Rilmenidine versus placebo</h5> <p>Only one study assessed as at unclear risk of bias examined this comparison (<a href="./references#CD003262-bbs2-0042" title="GrosshansE , MichelC , ArcadeB , CribierB . Rilmenidine in rosacea: a double blind study versus placebo [Rilménidine dans la rosacée: étude en double insu contre placebo]. Annales de Dermatologie et Venereologie1997;124(10):687‐91. [UI: 98413298; PUBMED: 9740864] ">Grosshans 1997</a>). </p> <section id="CD003262-sec-0493"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0494"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0495"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Six out of 15 participants in the rilmenidine group considered their rosacea improved compared with 6/19 in the placebo group (RR 1.27, 95% CI 0.51 to 3.14). Based on these data rilmenidine appeared to be of limited effectiveness when compared to placebo. </p> </section> <section id="CD003262-sec-0496"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Although only mild adverse events were reported, there was no statistically significant difference in the number of participants experiencing adverse events, that is 8/15 (rilmenidine) versus 8/19 (placebo) (RR 1.27, 95% CI 0.62 to 2.57). </p> </section> </section> <section id="CD003262-sec-0497"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0498"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>The physicians' assessments indicated that 5/15 participants in the rilmenidine group versus 1/19 in the placebo group showed improvement (RR 6.33, 95% CI 0.83 to 48.59), which was in line with the participants' assessments that rilmenidine was not considered to be effective. There was a tendency towards fewer flushing episodes in the rilmenidine group. The mean decrease in number of flushes was 13 versus 5 (rilmenidine and placebo respectively). No SDs were reported in this study. </p> <p> <ul id="CD003262-list-0244"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>There was no apparent difference in facial redness between the groups but no exact data were reported. </p> <p> <ul id="CD003262-list-0245"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>The number of participants with at least a 50% reduction in lesion count was 10/15 in the rilmenidine group versus 11/19 with placebo (decrease in lesion count 1 versus 2 and no SDs were provided). </p> <p> <ul id="CD003262-list-0246"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0247"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0499"> <h5 class="title">(61) Dark sulphonated shale oil versus placebo</h5> <p>One study at unclear risk of bias evaluated the effectiveness of this intervention but it was only available as an abstract, which provided very limited usable data (<a href="./references#CD003262-bbs2-0053" title="KochR , WilbrandG . Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea [P‐011]. Journal of the European Academy of Dermatology and Venerology1999;12(32 Suppl):S143‐4. ">Koch 1999</a>). </p> <section id="CD003262-sec-0500"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0501"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0502"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0503"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>No side events were reported in any group.</p> </section> </section> <section id="CD003262-sec-0504"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0505"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>No data were provided but the authors reported that there was a statistically significant difference in favour of dark sulphonated oil. </p> <p> <ul id="CD003262-list-0248"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>It was reported by the investigators that there was a statistically significant difference in reduction of erythema in favour of the active treatment group. </p> <p> <ul id="CD003262-list-0249"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Lesion counts reduced from 15.9 to 4.3 in the treatment group and 16.1 to 14.1 in the placebo group (investigators reported P &lt; 0.0001). </p> <p> <ul id="CD003262-list-0250"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0251"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0506"> <h4 class="title">Other interventions: studies with laser or light‐based treatment</h4> <section id="CD003262-sec-0507"> <h5 class="title">(62) Dual wavelength laser system (595 + 1064 nm) versus 595 nm pulsed dye laser (PDL) or Nd:YAG laser </h5> <p>One study (<a href="./references#CD003262-bbs2-0048" title="KarsaiS , RoosS , RaulinC . Treatment of facial telangiectasia using a dual‐wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery2008;34(5):702‐8. [PUBMED: 18318728] ">Karsai 2008</a>) assessed as at unclear risk of bias evaluated the efficacy of these treatments for telangiectasia on the nose. Dual wavelength laser was allocated to one side of the nose, and PDL or Nd:YAG on the other side. As only limited data were available we have not reported the data for these three treatments based on the individual comparisons. </p> <section id="CD003262-sec-0508"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0509"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0510"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0511"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Adverse events included transient purpura and immediate post‐treatment erythema. The investigators stated "there was no significant between‐group difference in the incidence of treatment related adverse effects". </p> </section> </section> <section id="CD003262-sec-0512"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0513"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0252"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Dual wavelength laser resulted in an improvement in 18 of the 20 sides of the nose versus two of the 10 sides treated with PDL and two of the 10 sides treated with Nd:YAG, an RR of 4.5 in favour of the dual wavelength treatment over both single wavelength therapies. </p> <p> <ul id="CD003262-list-0253"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0254"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0255"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0514"> <h5 class="title">(63) Pulsed dye laser (PDL) versus Nd:YAG laser</h5> <p>In contrast with the previous comparison, in this study assessed at unclear risk of bias the cheek on one side of the face was treated with PDL and the other side with Nd:YAG (<a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a>). See <a href="./full#CD003262-tbl-0017">summary of findings Table 17</a>. </p> <section id="CD003262-sec-0515"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0516"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0517"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>According to the participants, redness improved by a mean of 52% on the PDL treated site and 34% on the Nd:YAG treated site with a MD of ‐16.33 (95% CI ‐34.6 to ‐1.94; P = 0.03). </p> </section> <section id="CD003262-sec-0518"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Two participants experienced post‐treatment swelling and dropped out of the trial. A VAS was used to assess pain, and a score of 3.87 was recorded on the PDL treated side and 3.07 on the Nd:YAG side, which according to the investigators was statistically significant in favour of Nd:YAG (P = 0.0028). </p> </section> </section> <section id="CD003262-sec-0519"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0520"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0256"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Erythema was assessed with a spectrophotometer and there was a reduction of 8.9% on the PDL treated side compared to a lower reduction of 2.5% on the Nd:YAG treated side, with a MD of ‐6.4 (95% CI ‐11.6 to ‐1.2; P = 0.02). </p> <p> <ul id="CD003262-list-0257"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0258"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0259"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0521"> <h5 class="title">(64) Pulsed dye laser (PDL) versus intense pulsed light therapy (IPL) versus no treatment</h5> <p>Very limited and largely unusable data were reported in this single within‐participant study which addressed these interventions (<a href="./references#CD003262-bbs2-0068" title="NeuhausIM , ZaneLT , TopeWD . Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery2009;35(6):920‐8. [PUBMED: 19397667] ">Neuhaus 2009</a>). The investigators concluded that both PDL and IPL were equally effective for erythematotelangiectatic rosacea. The study was assessed as at high risk of bias. </p> <section id="CD003262-sec-0522"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0523"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0524"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>The efficacy of treatment and improvement in symptoms was assessed on a VAS. The participants rated a reduction of 3.2 for erythema on the side treated with PDL, and a reduction of 3.6 on the IPL treated side. The investigators reported that this was statistically significant compared to no treatment (P &lt; 0.05), however no data were provided for the untreated group. They also concluded that there was no statistically significant difference between PDL and IPL. </p> </section> <section id="CD003262-sec-0525"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Not assessed.</p> </section> </section> <section id="CD003262-sec-0526"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0527"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0260"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>No statistically significant reduction in erythema, compared to no treatment, was seen in the spectrophotometer assessments for PDL and IPL, except for IPL on the cheek (investigators reported P = 0.04). </p> <p>The investigators also graded telangiectasia and erythema on a 4‐point Likert scale and, although they did not provide specific data, stated that compared to the untreated control there were statistically significant differences in favour of PDL and IPL of the overall telangiectasia score and erythema score (P &lt; 0.01), but not between PDL and IPL. </p> <p> <ul id="CD003262-list-0261"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0262"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0263"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0528"> <h5 class="title">(65) Pulsed dye laser (PDL) versus intense pulsed light (IPL) therapy</h5> <p>Whilst in the previous comparison the emphasis was on comparing PDL or IPL to no treatment, in this within‐participant study with 40 participants these treatments were compared against each other (<a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a>). See also <a href="./full#CD003262-tbl-0018">summary of findings Table 18</a>. The study was assessed as at high risk of bias. </p> <section id="CD003262-sec-0529"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0530"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0531"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Satisfaction with treatment was scored on a VAS with 0 being a poor and 10 an excellent result. The median score (with 10% and 90% percentiles) at end of treatment was 8 (2. 10) for PDL treatment and 7 (2, 10) for the IPL treated side (investigators reported P = 0.05). </p> </section> <section id="CD003262-sec-0532"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>Pain was also assessed on a VAS with 0 being no pain and 10 worst imaginable pain. The median scores and their 10% and 90% percentiles were 4 (2, 6) for PDL and 7 (2, 10), indicating that PDL was less painful (investigators reported P &lt; 0.001). </p> </section> </section> <section id="CD003262-sec-0533"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0534"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0264"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>For the PDL treated side 18 had an excellent response (75% to 100% vessel clearance) and 12 a good response (50% to 74% clearance), and for the IPL treated side 11 had an excellent response and 19 a good response. </p> <p> <ul id="CD003262-list-0265"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0266"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0267"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> <section id="CD003262-sec-0535"> <h4 class="title">Other treatments or treatment combinations</h4> <section id="CD003262-sec-0536"> <h5 class="title">(66) Pulsed dye laser (PDL) combined with tacrolimus ointment versus tacrolimus ointment</h5> <p>These treatment modalities were evaluated in one study (<a href="./references#CD003262-bbs2-0044" title="HuangYE , LiXL , LiTJ . Clinical research of topical tacrolimus ointment combined with 585 nm pulsed dye laser in the treatment of rosacea [Chinese]. Journal of Clinical Dermatology2012;41(5):308‐9. [EMBASE: 2012449799] ">Huang 2012</a>) assessed as at high risk of bias. </p> <section id="CD003262-sec-0537"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0538"> <p><b>Change in HRQOL at end of study</b></p> </section> <section id="CD003262-sec-0539"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Neither of the above outcomes were assessed.</p> </section> <section id="CD003262-sec-0540"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>The data for this outcome were inadequately reported. Four participants reported local reactions to tacrolimus, and in the combined treatment group erythema and purpura, which are well known side effects of PDL therapy. </p> </section> </section> <section id="CD003262-sec-0541"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0542"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Treatment was rated to be very effective (effective rate 60% to 89%) or cured (effective rate ≥ 90%) in 24/30 participants treated with PDL combined with tacrolimus and in 18/30 of the participants treated with tacrolimus only (RR 1.33, 95% CI 0.95 to 1.88). </p> <p> <ul id="CD003262-list-0268"> <li> <p>Assessment of erythema or telangiectasia or both at end of study</p> </li> </ul> </p> <p>Not assessed separately.</p> <p> <ul id="CD003262-list-0269"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed separately.</p> <p> <ul id="CD003262-list-0270"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0271"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> <section id="CD003262-sec-0543"> <h5 class="title">(67) Pulsed dye laser (PDL) combined with pretreatment of niacin cream versus PDL</h5> <p>A single within‐participant study assessed as at high risk of bias provided data for this comparison (<a href="./references#CD003262-bbs2-0050" title="KimTG , RohHJ , ChoSB , LeeJH , LeeSJ , OhSH . Enhancing effect of pretreatment with topical niacin in the treatment of rosacea‐associated erythema by 585‐nm pulsed dye laser in Koreans: A randomized, prospective, split‐face trial. British Journal of Dermatology2011; Vol. 38, issue 5:510‐3. [DOI: 10.1111/j.1365‐2133.2010.10174.x.; PUBMED: 21143465] ">Kim 2011</a>). </p> <section id="CD003262-sec-0544"> <h6 class="title">Primary outcomes</h6> <section id="CD003262-sec-0545"> <p><b>Change in HRQOL at end of study</b></p> <p>Not assessed.</p> </section> <section id="CD003262-sec-0546"> <p><b>Participant‐assessed changes in rosacea severity at end of study</b></p> <p>Satisfaction with treatment was scored on a VAS (10 highest satisfaction). At the end of treatment the VAS score was 5.06 (SD 2.73) for the combined treatment on the halves of 18 faces compared to 3.67 (SD 2.06) on the PDL only treated other halves of 18 faces. The data were aggregated and analysed as PDL with combined treatment versus PDL alone, but because no adjustments were made to account for the within‐participant variation we have only presented the summary statistics. </p> </section> <section id="CD003262-sec-0547"> <p><b>Proportion of participants who reported an adverse event throughout the study period</b></p> <p>All participants experienced transient erythema and oedema after exposure to laser, but without scarring, infections, crusting or hyperpigmentation in the treated areas. </p> </section> </section> <section id="CD003262-sec-0548"> <h6 class="title">Secondary outcomes</h6> <section id="CD003262-sec-0549"> <p><b>Physician‐assessed changes in rosacea severity at end of study</b></p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0272"> <li> <p>Assessment of erythema or telangiectasia, or both, at end of study</p> </li> </ul> </p> <p>Objective assessments of erythema were made using polarization colour imaging, rated on an erythema scale (100 to 1000), in addition to subjective improvement of erythema which was assessed on a 4‐point Likert scale. </p> <p>The reduction on the objective erythema scale was 29.2 for the PDL + niacin cream and 18.4 for the PDL only group, which were both clinically important; but according to the investigators the difference was not statistically significant. In the subjective assessments where improvement was scored on a Likert scale from 0 to 3 (with 3 being an excellent improvement) 76% to 100% showed a score of 1.65 (SD 1.01) for the combined treatment group versus 0.87 (SD 0.76) for the PDL only group. </p> <p>On the combined treatment side, 10 sides showed an improvement of more than 50% and three showed a &gt; 75% improvement whilst on the side treated with only PDL just three showed an improvement of more than 50% and none an improvement of more than 75%. </p> <p> <ul id="CD003262-list-0273"> <li> <p>Lesion counts</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0274"> <li> <p>Time needed until improvement of the skin lesions</p> </li> </ul> </p> <p>Not assessed.</p> <p> <ul id="CD003262-list-0275"> <li> <p>Duration of remission</p> </li> </ul> </p> <p>Not assessed.</p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003262-sec-0550" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003262-sec-0550"></div> <section id="CD003262-sec-0551"> <h3 class="title" id="CD003262-sec-0551">Summary of main results</h3> <p>One hundred and six studies were included in the updated version of this review. In this update there was a small increase in the number of studies which reported assessments of our first primary outcome 'change in quality of life', but there was little change in the number of studies (approximately half) which addressed participants' assessments of improvement in rosacea severity, which was one of the other primary outcomes in this review. Adverse events were reported in most of the studies, although the data were often very limited and frequently incomplete. </p> <p>The majority of studies focused on papule and pustule counts which, although they may provide a quantifiable, objective and more readily intelligible outcome, are generally considered to be clinician‐centred rather than patient‐preferred. Rosacea is a chronic skin disease and the importance of self‐assessments by the participants of the effectiveness of the interventions should not be underestimated. Slightly more than half of the studies evaluated erythema, using a variety of scales, principally Likert scales, but there was a lack of uniformity in their ratings making interpretations in any of the relevant comparisons more difficult. </p> <p>In day‐to‐day clinical practice, clinicians and patients need to know how rapidly lesions will respond to treatment and, once an optimal response has been achieved, how long this will last. Although these would appear to be key issues in clinical decision making, the time to response, which was one of our secondary outcomes, was not a pre‐specified outcome in any study. In a few instances it could be roughly estimated from some of the interim data that were reported. Duration of remission was only assessed and reported in four of the studies (<a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a>; <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>; <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>; <a href="./references#CD003262-bbs2-0093" title="ThiboutotDM , FleischerAB , DelRossoJQ , RichPH . A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. Journal of Drugs in Dermatology2009;8(7):639‐48. [PUBMED: 19588640] ">Thiboutot 2009</a>). </p> <p>Pooling of data was not feasible for most of the treatment options, and was only possible for several outcomes in the trials which evaluated topical metronidazole and azelaic acid (see <a href="./full#CD003262-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003262-tbl-0002">summary of findings Table 2</a>). Both these treatments were shown to be more effective than placebo, with the quality of evidence rated as moderate to high for several outcomes for metronidazole, and high for azelaic acid. Which of these two treatments is most effective still needs to be established because the results from three of the studies (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>; <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>; <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>) were contradictory (quality of the evidence moderate to low, see <a href="./full#CD003262-tbl-0005">summary of findings Table 5</a>). </p> <p>Although most comparisons were evaluated in single studies, we have provided 'Summary of findings' tables for the most current and more frequently prescribed therapies as we considered these would prove to be the most useful for clinical decision making. We did not provide 'Summary of findings' tables for treatments that are no longer favoured or had been evaluated in studies at high risk of bias, factors which we consider would make their data less usable. </p> <p>Topical ivermectin 1% is registered for papulopustular rosacea by the FDA and registration in Europe is expected in the near future. Two studies showed a statistically significant and clinically important improvement in favour of topical ivermectin when compared to placebo, with the quality of evidence rated as high (<a href="./full#CD003262-tbl-0003">summary of findings Table 3</a>). Furthermore, based on one recently published study (<a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>) topical ivermectin appeared to be slightly more effective than topical metronidazole for subtype 2 rosacea (<a href="./full#CD003262-tbl-0006">summary of findings Table 6</a>). Another new compound, brimonidine, which was recently approved by both the FDA and EMA for treatment of erythema in rosacea, was shown to be more effective than vehicle in reducing erythema at all time points over 12 hours, with the quality of evidence rated as high (see <a href="./full#CD003262-tbl-0004">summary of findings Table 4</a>). Topical clindamycin phosphate combined with tretinoin was not considered to be effective compared to placebo (moderate quality of the evidence) (see <a href="./full#CD003262-tbl-0008">summary of findings Table 8</a>). For ocular rosacea topical ciclosporin ophthalmic emulsion demonstrated effectiveness with the quality of the evidence rated as low (see <a href="./full#CD003262-tbl-0007">summary of findings Table 7</a>). </p> <p>Of the comparisons assessing oral treatments, there was moderate quality evidence that tetracycline is effective but this was based on two rather old studies which were of short duration (<a href="./full#CD003262-tbl-0009">summary of findings Table 9</a>). The newer tetracyclines such as doxycycline and minocycline were evaluated in several comparisons but mainly at the lower dose. The anti‐inflammatory dose of 40 mg doxycycline was shown to be effective for papulopustular rosacea (moderate to high quality evidence for the outcomes listed) (see <a href="./full#CD003262-tbl-0010">summary of findings Table 10</a>) and as effective as 100 mg doxycycline but with one quarter of the side effects (low quality evidence) (see <a href="./full#CD003262-tbl-0012">summary of findings Table 12</a>). There was no statistically significant difference in effectiveness or safety when low dose doxycycline was combined with either topical metronidazole or azelaic acid (<a href="./full#CD003262-tbl-0013">summary of findings Table 13</a>). There was very low quality evidence from one study assessed as at high risk of bias that doxycycline 100 mg was as effective as azithromycin (<a href="./full#CD003262-tbl-0011">summary of findings Table 11</a>). Unfortunately we were unable to include further studies evaluating the effectiveness of azithromycin, even though this is a frequently prescribed drug for rosacea. Low dose minocycline 45 mg either combined with topical azelaic acid gel or as stand‐alone therapy was effective for papulopustular rosacea (low quality evidence) (see <a href="./full#CD003262-tbl-0014">summary of findings Table 14</a>). </p> <p>Oral (oxy)tetracycline was compared with topical metronidazole in four studies (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>; <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>; <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>; <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a>) and showed no statistically significant difference between the two treatment modalities for any outcome, with the quality of evidence rated as low to moderate for the outcomes listed (see <a href="./full#CD003262-tbl-0015">summary of findings Table 15</a>). </p> <p>Isotretinoin is frequently prescribed 'off‐label' for rosacea, albeit in the absence of any evidence underpinned by RCTs, therefore it was reassuring to be able to include one study comparing the effectiveness of isotretinoin 0.3 mg/kg with doxycycline 100 mg. Low dose isotretinoin was considered by both the participants and the physicians to be slightly more effective than doxycycline 50 to 100 mg (high quality of the evidence) (see <a href="./full#CD003262-tbl-0016">summary of findings Table 16</a>). Although there was no statistically significant difference in the number of adverse events between the two treatment groups, isotretinoin has a well known safety profile and can only be prescribed in women of child bearing age following the Risk Management Programme of the FDA and American Medical Association (AMA). </p> <p>Pulsed dye laser (PDL) was more effective than Nd:YAG laser based on one study (quality of evidence rated low) (see <a href="./full#CD003262-tbl-0017">summary of findings Table 17</a>), and it appeared to be as effective as intense pulsed light therapy (quality of the evidence rated low to moderate) (see <a href="./full#CD003262-tbl-0018">summary of findings Table 18</a>). </p> <p>No studies could be included that addressed the variant granulomatous rosacea.</p> </section> <section id="CD003262-sec-0552"> <h3 class="title" id="CD003262-sec-0552">Overall completeness and applicability of evidence</h3> <p>Study duration was less than eight weeks in 32/106 studies, which is an inadequate period of time to demonstrate an optimal treatment effect for some of the interventions. Because rosacea is a chronic disease there is a pressing need for more studies that evaluate strategies focused on therapies that are capable of maintaining remission. Consequently, the evidence was noticeably incomplete for some of these interventions such as, for example, patient education and avoidance measures for trigger factors, that is certain foods and exposure to heat and sunlight, or the use of non‐irritating cosmetics. The review also failed to identify any eligible studies addressing dietary manipulation or sun protective measures for the treatment of rosacea. However, the majority of included studies provided enough evidence to draw conclusions on effectiveness of the various treatment options for the different subtypes, notwithstanding the fact that most people with rosacea suffer from more than one subtype and often a combination of treatments will be needed to reach a satisfactory result. Moreover, in clinical practice it is not always possible to definitively differentiate between subtype 1 and subtype 2 rosacea. Indeed, people may have more signs and symptoms of subtype 1 at a point in time and at another point in time more features of subtype 2. </p> <section id="CD003262-sec-0553"> <h4 class="title">Treatments for subtype 1, erythematotelangiectatic rosacea</h4> <p>Erythema or telangiectasia, or both, were inclusion criteria in 63 studies, however only 16 studies addressed subtype 1, erythematotelangiectatic rosacea. In 47 studies erythema and telangiectasia were part of the diagnosis of subtype 2, papulopustular rosacea. Whilst erythema or telangiectasia were not pre‐specified inclusion criteria for 18 studies, these were assessed as an outcome at baseline and follow‐up in a study only in participants with papulopustular rosacea. </p> <p>Around 40% (43) of the total number of included studies demonstrated a reduction in erythema but in general not of telangiectasia. In view of the potential impact of these reductions on the quality of life for people with rosacea, future updates of this review should place increased emphasis on the effects of interventions on both erythema and telangiectasia. The use of different scoring systems to assess improvements of erythema and telangiectasia, and the paucity and variability of evidence on the effects of interventions on this subtype of rosacea, did not in most cases permit firm conclusions to be made. The Clinician's Erythema Assessment (CEA) tool which rates erythema on a 5‐point Likert scale (from 0 = clear to 4 = severe erythema, fiery redness) was used in 16 of the 106 studies included in this review. The CEA has been validated and is reported to have a high inter‐rater and good intra‐rater reliability when used by experienced and trained raters (<a href="./references#CD003262-bbs2-0293" title="TanJ , LiuH , LeydenJJ , LeoniMJ . Reliability of Clinician Erythema Assessment grading scale. Journal of the American Academy of Dermatology2014; Vol. 71, issue 4:760‐3. [PUBMED: 24999270] ">Tan 2014</a>). Applying the same scale in future studies will enable more accurate and directly quantifiable comparisons of erythema between the different interventions. </p> <section id="CD003262-sec-0554"> <h5 class="title">Topical treatments</h5> <p>Robust evidence based on data gathered using the CEA scale came from several studies evaluating brimonidine (<a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>; <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>; <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>; <a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a>; <a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a>). There was high quality evidence that brimonidine was effective for erythema over a 12 hour period, with a peak effect occurring between three and six hours. As erythema also occurs in other subtypes of rosacea, its use is not restricted to subtype 1.<br/> None of the data showed that BFH772 1% (betamethasone and calcipotriol) was any better than vehicle ointment (<a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a>), and the same holds true for TDT 068 gel (ultra‐deformable Sequessome<sup>TM</sup> vesicles) (<a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a>). </p> </section> <section id="CD003262-sec-0555"> <h5 class="title">Laser and light therapies</h5> <p>Lasers and light therapies would appear to have a major clinical role to play in the treatment of erythematotelangiectatic rosacea, but these treatment modalities are still largely under researched in RCTs. There was some evidence that PDL, Nd:YAG laser and intense pulsed light therapy are capable of reducing erythema and telangiectasia on the face (<a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a>; <a href="./references#CD003262-bbs2-0048" title="KarsaiS , RoosS , RaulinC . Treatment of facial telangiectasia using a dual‐wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery2008;34(5):702‐8. [PUBMED: 18318728] ">Karsai 2008</a>; <a href="./references#CD003262-bbs2-0050" title="KimTG , RohHJ , ChoSB , LeeJH , LeeSJ , OhSH . Enhancing effect of pretreatment with topical niacin in the treatment of rosacea‐associated erythema by 585‐nm pulsed dye laser in Koreans: A randomized, prospective, split‐face trial. British Journal of Dermatology2011; Vol. 38, issue 5:510‐3. [DOI: 10.1111/j.1365‐2133.2010.10174.x.; PUBMED: 21143465] ">Kim 2011</a>; <a href="./references#CD003262-bbs2-0068" title="NeuhausIM , ZaneLT , TopeWD . Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery2009;35(6):920‐8. [PUBMED: 19397667] ">Neuhaus 2009</a>; <a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a>). Because clearance of the redness and telangiectasia occurring on the face is highly desirable, and can be a source of personal embarrassment and lead to low self esteem, further studies of laser and light‐based therapies should be considered a priority (<a href="./references#CD003262-bbs2-0272" title="MenezesN , MoreiraA , MotaG , BaptistaA . Quality of life and rosacea: Pulsed dye laser impact. Journal of Cosmetic &amp; Laser Therapy2009;11(3):139‐41. [DOI: 10.1080/14764170902741311; PUBMED: 19462330] ">Menezes 2009</a>). </p> </section> </section> <section id="CD003262-sec-0556"> <h4 class="title">Treatments for subtype 2, papulopustular rosacea</h4> <section id="CD003262-sec-0557"> <h5 class="title">Topical treatments for papules and pustules</h5> <p>Pooled data for topical metronidazole (<a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>; <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>) and azelaic acid (<a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>; <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>; <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a;</a><a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>) indicate that both are effective treatments for rosacea. However, based on the assessments in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>, azelaic acid would appear to be more effective than metronidazole albeit with more side effects. The more recent study of <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> failed to demonstrate improved effectiveness of one of these two treatments over the other and, therefore, further supporting evidence is still required. </p> <p>No statistically significant difference in effect was reported between the two concentrations of topical metronidazole or when different vehicles were compared in three studies (<a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>; <a href="./references#CD003262-bbs2-0021" title="DahlMV , JarrattMJ , KaplanD , TuleyMR , BakerMD . Once‐daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. Journal of the American Academy of Dermatology2001;45(5):723‐30. [PUBMED: 11606923] ">Dahl 2001</a>; <a href="./references#CD003262-bbs2-0031" title="DrenoB , DubertretL , NaeyaertJM , de laBrassineM , MarksR , PowellF , et al. Comparison of the clinical efficacy and safety of metronidazole 0.75% cream with metronidazole 0.75% gel in the treatment of rosacea. Journal of the European Academy of Dermatology &amp; Venereology1998;11(2 Suppl):S272‐3. ">Dreno 1998</a>). Topical metronidazole was also shown to be effective in maintaining remission (<a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>). </p> <p>A single daily dose of azelaic acid appears to be as effective as the twice daily dose, and is also likely to result in improved compliance (<a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>). This comparison warrants further investigation. </p> <p>The results in <a href="./references#CD003262-bbs2-0093" title="ThiboutotDM , FleischerAB , DelRossoJQ , RichPH . A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. Journal of Drugs in Dermatology2009;8(7):639‐48. [PUBMED: 19588640] ">Thiboutot 2009</a> illustrate that there is insufficient evidence to conclude that azelaic acid is either effective or ineffective for maintenance treatment. Rosacea is a chronic disease and therefore RCTs investigating the effectiveness of azelaic acid and metronidazole used in maintenance therapy are still required. </p> <p>Topical ivermectin was shown to be more effective than placebo (high quality evidence) (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>; <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>) and slightly more effective than metronidazole (moderate to high quality evidence) (<a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a>). </p> <p>The effectiveness or otherwise of benzoyl peroxide in the treatment of papulopustular rosacea remains unclear. The conflicting results in <a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a> and the inadequate study design coupled with a short study duration of four weeks did not enable any definitive conclusions to be drawn from <a href="./references#CD003262-bbs2-0062" title="MontesLF , CorderoAA , KrinerJ , LoderJ , FlanaganAD . Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis1983;32(2):185‐90. [PUBMED: 6225627] ">Montes 1983</a>. Benzoyl peroxide combined with clindamycin was investigated in <a href="./references#CD003262-bbs2-0015" title="BrenemanD , SavinR , VandePolC , VamvakiasG , LevyS , LeydenJ . Double‐blind, randomized, vehicle‐controlled clinical trial of once‐daily benzoyl peroxide/clindamycin topical gel in the treatment of moderate to severe rosacea. International Journal of Dermatology2004;43(5):381‐7. [PUBMED: 15117375] LeydenLL , ThiboutotD , ShalitaA . Photographic review of results from a clinical study comparing benzoyl peroxide 5%/Clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis2004;73(6 Suppl):11‐7. [PUBMED: 15228129] ">Breneman 2004</a> but the data were incomplete; no standard deviations were reported and the data were skewed, which did not permit firm conclusions to be made about the efficacy of this combined intervention. </p> <p>Sodium sulphacetamide 10% in combination with sulphur 5% would appear to be more effective than metronidazole but further research is warranted, especially because two of the studies for this intervention were assessed as being at high risk of bias (<a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a>; <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a>) and one study (<a href="./references#CD003262-bbs2-0079" title="SauderDN , MillerR , GrattonD , DanbyW , GriffithsC , PhilipsSB . The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double‐blind study. Journal of Dermatological Treatment1997;8(2):79‐85. [EMBASE: 1997242784] ">Sauder 1997</a>) at unclear risk of bias. </p> <p>The evidence for the effectiveness of permethrin for rosacea was inconclusive, and therefore further trials with a rigorous study design are still required (<a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>; <a href="./references#CD003262-bbs2-0063" title="MostafaFF , ElHarrasMA , GomaaSM , Al MokademS , NassarAA , Abdel GawadEH . Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(1):22‐8. [PUBMED: 18705632] ">Mostafa 2009</a>). </p> <p>There was no evidence to support the effectiveness of pimecrolimus, however this was based on very limited and largely unusable data presented in two studies (<a href="./references#CD003262-bbs2-0051" title="KocaR , AltinyazarHC , AnkaraliH , MuhtarS , TekinNS , CinarS . A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open‐label clinical trial. Clinical and Experimental Dermatology2010;35(3):251‐6. [PUBMED: 19594764] ">Koca 2010</a>; <a href="./references#CD003262-bbs2-0101" title="WeissenbacherS , MerklJ , HildebrandtB , WollenbergA , BraeutigamM , RingJ , et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle‐controlled double‐blind trial. British Journal of Dermatology2007;156(4):728‐32. [PUBMED: 17493072] ">Weissenbacher 2007</a>). </p> <p>Several studies which examined topical calcineurin antagonists could not be included as they were not RCTs or did not match the pre‐specified inclusion criteria for this review (<a href="./references#CD003262-bbs2-0119" title="ChuCY . The use of 1% pimecrolimus cream for the treatment of steroid‐induced rosacea. British Journal of Dermatology2005;152(2):396‐9. [PUBMED: 15727676] ">Chu 2005</a>; <a href="./references#CD003262-bbs2-0242" title="ChuCY . An open‐label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid‐induced rosacea‐like eruption. Journal of the European Academy of Dermatology and Venereology2007;21(4):484‐90. [PUBMED: 17373975] ">Chu 2007</a>; <a href="./references#CD003262-bbs2-0243" title="CrawfordKM , RussB , BostromP . Pimecrolimus for treatment of acne rosacea. Skinmed2005;4(3):147‐50. [PUBMED: 15891250] ">Crawford 2005</a>; <a href="./references#CD003262-bbs2-0131" title="GargG , ThamiGP . Clinical efficacy of tacrolimus in rosacea. Journal of the European Academy of Dermatology and Venereology2008;23(2):239‐40. [PUBMED: 18498336] ">Garg 2008</a>; <a href="./references#CD003262-bbs2-0141" title="LeeDH , LiK , SuhDH . Pimecrolimus 1% cream for the treatment of steroid‐induced rosacea: An 8‐week split‐face clinical trial. British Journal of Dermatology2008;158(5):1069‐76. [PUBMED: 18363758] ">Lee 2008</a>). Further well‐designed, double‐blind RCTs which examine the potential benefits of calcineurin antagonists as a treatment option for rosacea are required. </p> <p>No eligible studies were identified for dapsone or topical tretinoin, although these treatments are still in fairly common use in the treatment of rosacea (<a href="./references#CD003262-bbs2-0262" title="JansenT , PlewigG . Rosacea: Classification and treatment. Journal of the Royal Society of Medicine1997;90(3):144‐50. [PUBMED: 9135612] ">Jansen 1997</a>; <a href="./references#CD003262-bbs2-0295" title="ThiboutotDM . Acne and rosacea. New and emerging therapies. Dermatologic Clinics2000;18(1):63‐71. [PUBMED: 10626112] ">Thiboutot 2000</a>; <a href="./references#CD003262-bbs2-0304" title="WilkinJK . Rosacea. Pathophysiology and treatment. Archives of Dermatology1994;130(3):359‐62. [EMBASE: 1994109375] ">Wilkin 1994</a>). Clindamycin combined with topical tretinoin was not shown to be effective compared to placebo in treating papulopustular rosacea (<a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a>). </p> </section> <section id="CD003262-sec-0558"> <h5 class="title">Oral treatments for papules and pustules</h5> <p>Two studies (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>; <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a>) evaluated the effects of tetracycline. In both of these studies the physicians' assessments indicated an improvement in severity, but only <a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> provided data on the participants' assessments of treatment. In contrast, although the six week study duration may appear to have been too short, the assessments of the participants nevertheless failed to provide any evidence of a difference in effectiveness between tetracycline and placebo. The data from these two studies are further supported by <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>; <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>; <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> and <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a>, which compared (oxy)tetracycline with topical metronidazole. Tetracyclines are used extensively for the treatment of rosacea and, although their efficacy may be widely accepted by clinicians, this is currently not substantiated by high level evidence from robust and methodologically sound clinical trials. </p> <p>Whilst a number of studies included in this review (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>; <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>; <a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a>; <a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a>; <a href="./references#CD003262-bbs2-0078" title="SanchezJ , SomolinosAL , AlmodóvarPI , WebsterG , BradshawM , PowalaC . A randomized, double‐blind, placebo‐controlled trial of the combined effect of doxycycline hyclate 20‐mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. Journal of the American Academy of Dermatology2005;53(5):791‐7. [PUBMED: 16243127] SanchezJL , SomolinosA , WebsterG , BradshawM . Combined effect of doxycycline hyclate 20 mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. Journal of the American Academy of Dermatology2004;50(3):48. ">Sanchez 2005</a>) demonstrated the efficacy of an anti‐inflammatory dose of doxycycline as a reduction in physician‐assessed lesion counts, quite significantly the participants' views and satisfaction with the effects of this intervention were not assessed. Furthermore, while there was a measurable decrease in lesion counts as a result of the intervention, it was unclear if these counts were continuing to decrease or had stabilised by the time the studies were completed. </p> <p>Although a number of studies have shown that anti‐inflammatory doses of doxycycline do not have an antimicrobial effect on skin flora, nor do they lead to an increase in the number or severity of resistant organisms, studies with a longer duration and which are capable of providing conclusive evidence of the efficacy of an anti‐inflammatory dose of doxycycline are still required (<a href="./references#CD003262-bbs2-0239" title="BikowskiJ . Demystifying anti‐inflammatory dose antibiotics for management of rosacea. Practical Dermatology2007;April:22‐4. ">Bikowski 2007</a>; <a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a>; <a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0286" title="SloanB , ScheinfeldN . The use and safety of doxycycline hyclate and other second‐generation tetracyclines. Expert Opinion on Drug Safety2008;7(5):571‐7. [PUBMED: 18759709] ">Sloan 2008</a>). There is evidence from these trials that the 40 mg dose is at least as effective as the 100 mg dose and has a correspondingly lower risk of adverse effects (<a href="./references#CD003262-bbs2-0024" title="DelRossoJQ , CaveneyS . Comparison of anti‐inflammatory dose doxycycline (30‐mg immediate‐release beads, 10 mg delayed‐release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery2012;31(1):A7‐8. [EMBASE: 70706922] DelRossoJQ , SchlessingerJ , WerschlerP . Comparison of anti‐inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology2008;7(6):573‐6. [PUBMED: 18561589] ">Del Rosso 2008</a>); although these events may be mild to moderate, more were reported with the 100 mg of doxycycline than the 40 mg dose. Therefore, because anti‐inflammatory doses of antibiotics represent a novel approach in the management of rosacea, further trials evaluating the effects of such dosing regimens of other antibiotics should be encouraged (<a href="./references#CD003262-bbs2-0239" title="BikowskiJ . Demystifying anti‐inflammatory dose antibiotics for management of rosacea. Practical Dermatology2007;April:22‐4. ">Bikowski 2007</a>; <a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a>). Low dose minocycline is yet another tetracycline with demonstrable effectiveness in papulopustular rosacea. The data for the various outcomes of all investigated tetracyclines were assessed as low to high quality evidence. </p> <p>Although a number of studies which examined the effects of azithromycin were retrieved in our searches, they were excluded from this review because they were not RCTs (<a href="./references#CD003262-bbs2-0226" title="BakarO , DemirçayZ , GürbüzO . Therapeutic potential of azithromycin in rosacea. International Journal of Dermatology2004;43(2):151‐4. [MEDLINE: 15125511] ">Bakar 2004</a>; <a href="./references#CD003262-bbs2-0111" title="BakarB . Acne rosacea: an open comparative trial of azithromycin versus oxytetracycline therapy: study of 50 patients [P139]. Journal of the American Academy of Dermatology2006;54(3 Suppl 1):AB24. ">Bakar 2006</a>; <a href="./references#CD003262-bbs2-0227" title="BakarO , DemircayZ , TokerE , CakirS . Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. Journal of the European Academy of Dermatology and Venereology2009;23(5):544‐9. [PUBMED: 19250326] ">Bakar 2009</a>; <a href="./references#CD003262-bbs2-0123" title="DereliT , InanirI , KilinçI , GençoğlanG . Azithromycin in the treatment of papulopustular rosacea. The Journal of Dermatology2005;32(11):926‐8. [MEDLINE: 16361757] ">Dereli 2005</a>). Only one study which compared azithromycin with doxycycline (<a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a>), assessed as at high risk of bias, was included but the data were skewed and consequently more research is required on the effects of this intervention. </p> <p>Low dose isotretinoin 0.3 kg/kg was slightly more effective for papulopustular rosacea than doxycycline 50 to 100 mg (high quality evidence) (<a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a>). </p> <p>Several studies examined other interventions such as rilmenidine and ampicillin (<a href="./references#CD003262-bbs2-0042" title="GrosshansE , MichelC , ArcadeB , CribierB . Rilmenidine in rosacea: a double blind study versus placebo [Rilménidine dans la rosacée: étude en double insu contre placebo]. Annales de Dermatologie et Venereologie1997;124(10):687‐91. [UI: 98413298; PUBMED: 9740864] ">Grosshans 1997</a>; <a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) and, although the latter showed some evidence of effectiveness, neither are now considered as treatment options by clinicians. There were contradictory results for oral zinc (<a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a>; <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a>) and limited data on oral ivermectin (<a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a>). </p> </section> <section id="CD003262-sec-0559"> <h5 class="title">Topical treatments for erythema and telangiectasia in papulopustular rosacea</h5> <p>More than half of the included studies assessed the effects of interventions on erythema or telangiectasia, or both, in participants with papulopustular rosacea. These are important participant‐preferred outcomes and are also integral to the physician‐assessed changes in rosacea severity. These outcomes have been reported in the <a href="#CD003262-sec-0083">Effects of interventions</a> section of this review. As stated above under 'Topical treatments for erythema is subtype 1', brimonidine can also be used for treatment of erythema in other subtypes. </p> <p>Based on the data reported in <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>; <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>; <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>, <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>, <a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>, <a href="./references#CD003262-bbs2-0088" title="TanJKL , GirardC , KrolA , MurrayHE , PappKA , PoulinY , et al. Randomized placebo‐controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. Journal of Cutaneous Medicine and Surgery2002;6(6):529‐34. [PUBMED: 12001006] ">Tan 2002</a>, <a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a> and <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>, topical metronidazole appears to be effective in reducing erythema. Azelaic acid (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>; <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>; <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>) and sulphacetamide combined with sulphur (<a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a>; <a href="./references#CD003262-bbs2-0079" title="SauderDN , MillerR , GrattonD , DanbyW , GriffithsC , PhilipsSB . The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double‐blind study. Journal of Dermatological Treatment1997;8(2):79‐85. [EMBASE: 1997242784] ">Sauder 1997</a>; <a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a>) are equally effective in reducing erythema. Two studies provided some evidence for the effectiveness of permethrin on erythema (<a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>; <a href="./references#CD003262-bbs2-0063" title="MostafaFF , ElHarrasMA , GomaaSM , Al MokademS , NassarAA , Abdel GawadEH . Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(1):22‐8. [PUBMED: 18705632] ">Mostafa 2009</a>), however further research is required. The scales used in the assessments of these treatments varied widely, the reporting was mostly incomplete, and it remained unclear if these treatments merely had an effect on perilesional redness or additionally improved background or persistent redness. More evidence is needed on the effectiveness or otherwise of five other topical interventions, P‐3075 cream (<a href="./references#CD003262-bbs2-0007" title="BerardescaE , IorizzoM , AbrilE , GuglielminiG , CaseriniM , PalmieriR , et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology2012;11(1):37‐41. [PUBMED: 22360333] ">Berardesca 2012</a>); 4‐ethoxybenzaldehyde (<a href="./references#CD003262-bbs2-0026" title="DraelosZD , FullerBB . Efficacy of 1% 4‐ethoxybenzaldehyde in reducing facial erythema. Dermatologic Surgery2005;31(7 Pt 2):881‐5. [PUBMED: 16029682] ">Draelos 2005b</a>); praziquantel (<a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a>); a skin care product containing ambophenol, neurosensine and La Roche‐Posay thermal spring water (<a href="./references#CD003262-bbs2-0082" title="SeitéS , BenechF , BerdahS , BayerM , VeyratS , SegotE , et al. Management of rosacea‐prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche‐Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology2013;12(8):920‐4. [EMBASE: 2013521246] ">Seité 2013</a>); and SEI003 cream (serine protease inhibitor) (<a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a>). These interventions were addressed in small sample size studies. A rosacea treatment system consisting of gentle cleanser, metronidazole 0.75% gel, hydrating complexion corrector and skin balancing sunscreen SPF 30 was not more effective than metronidazole + the standard care regimen of the rosacea treatment system without metronidazole; data reporting was however incomplete and SDs were missing (<a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a>). Cream containing a 1% extract of a flavonoid‐rich plant <i>Chrysanthellum indicum</i> was also not more effective than placebo in reducing erythema (<a href="./references#CD003262-bbs2-0074" title="RigopoulosD , KalogeromitrosD , GregoriouS , PacouretJM , KochC , FisherN , et al. Randomized placebo‐controlled trial of a flavonoid‐rich plant extract‐based cream in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2005;19(5):564‐8. [PUBMED: 16164709] ">Rigopoulos 2005</a>). </p> </section> <section id="CD003262-sec-0560"> <h5 class="title">Oral treatment for erythema and telangiectasia in papulopustular rosacea</h5> <p>Oral doxycycline (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>; <a href="./references#CD003262-bbs2-0024" title="DelRossoJQ , CaveneyS . Comparison of anti‐inflammatory dose doxycycline (30‐mg immediate‐release beads, 10 mg delayed‐release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery2012;31(1):A7‐8. [EMBASE: 70706922] DelRossoJQ , SchlessingerJ , WerschlerP . Comparison of anti‐inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology2008;7(6):573‐6. [PUBMED: 18561589] ">Del Rosso 2008</a>; <a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a>; <a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a>), (oxy)tetracycline (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>; <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>; <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a>), minocycline (<a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a>) and isotretinoin (<a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a>) appeared to be effective for reducing erythema, but further research is needed to confirm these findings. These outcomes were reported incompletely, on different scales, and it was unclear if erythema only diminished around the lesions because of a satisfactory response to treatment or if this was attributable to fading of the background or persistent erythema. </p> </section> </section> <section id="CD003262-sec-0561"> <h4 class="title">Treatments for subtype 3, phymatous rosacea</h4> <p>Surgical therapies as well as ablative laser therapies have been used with reportedly good results for this subtype of rosacea, but no eligible RCTs were identified for this systematic review. </p> </section> <section id="CD003262-sec-0562"> <h4 class="title">Treatments for subtype 4, ocular rosacea</h4> <p>The symptoms of ocular rosacea are often mild but can also be severe and debilitating, and although ocular involvement occurs in 60% of people with rosacea, only five trials included in this review examined the treatment of ocular rosacea (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>; <a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a>; <a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a>; <a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a>; <a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a>). Only the studies of <a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a> and <a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a> provided usable data. </p> <section id="CD003262-sec-0563"> <h5 class="title">Topical treatments</h5> <p>Although there was insufficient evidence to support the efficacy of topical metronidazole for ocular rosacea (<a href="./references#CD003262-bbs2-0005" title="BarnhorstDA , FosterJA , ChernKC , MeislerDM . The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology1996;103(11):1880‐3. [UI:97098344; PUBMED: 8942885] ">Barnhorst 1996</a>), there was some evidence of a consistent improvement in all outcomes and that ciclosporin a 0.05% ophthalmic emulsion was more effective than artificial tears in the treatment of ocular rosacea (<a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a>). </p> </section> </section> <section id="CD003262-sec-0564"> <h4 class="title">Treatments for the variant granulomatous rosacea</h4> <p>No studies were identified that assessed the variant granulomatous rosacea.</p> </section> <section id="CD003262-sec-0565"> <h4 class="title">Adverse events</h4> <p>The adverse events reported were mostly mild and transient and were comprised of skin irritation, pruritus, tinging or burning or dry skin. In most of the studies the number and types of adverse events did not differ significantly between active treatment and the placebo group, however these were not always reported adequately or completely. </p> </section> </section> <section id="CD003262-sec-0566"> <h3 class="title" id="CD003262-sec-0566">Quality of the evidence</h3> <section id="CD003262-sec-0567"> <h4 class="title">Limitations in study design and implementation</h4> <p>Although the overall clinical design of the included studies appeared to be adequate, our assessments of risk of bias revealed some of the limitations in the quality of the studies covering many of the interventions. </p> <p> <ol id="CD003262-list-0276"> <li> <p>There was considerable variation in how well the studies were reported and in particular the methods used to generate the randomisation sequence, to conceal the allocation, and the measures taken to blind investigators and participants. These factors, compounded with unsuccessful attempts to contact many of the investigators for additional information, created difficulties in making accurate assessments of the risk of bias in some of the included studies. </p> </li> <li> <p>A significant proportion of the outcome data was not normally distributed (skewed). SDs were frequently missing from study reports, which meant that in many instances continuous outcome data could not be entered in a meta‐analysis. For most treatment comparators it was not possible to pool data relating to the various studies, and it was only possible to pool the data for a limited number of outcomes in the trials evaluating topical metronidazole and azelaic acid. </p> </li> </ol> </p> <p>However, whilst recognising these limitations the authors consider that the body of evidence summarised in this review is sufficient to allow certain conclusions to be drawn about the effectiveness of several of the interventions used in the treatment of rosacea. </p> </section> <section id="CD003262-sec-0568"> <h4 class="title">Indirectness of the evidence</h4> <p>The participants included in the studies were to a large extent representative of the population as pre‐specified in '<a href="#CD003262-sec-0038">Types of participants</a>'. Almost half of the studies (49) included in this review were placebo‐controlled trials, which may only provide limited evidence on the advantages or disadvantages of new relative to existing interventions. However, 46 active‐controlled studies were also included and these gave access to data not only on the risks and benefits of individual interventions but also the comparative efficacy of these interventions; thus these head‐to‐head trials are more likely to have provided evidence that is both relevant and direct. Eleven studies included a placebo in addition to an active treatment arm. </p> <p>Patient‐relevant primary outcomes are a pre‐requisite for informing evidence‐based clinical decision making but the importance of patient‐reported outcomes (PRO), and specifically those used in evaluating the impact of interventions on quality of life, appears to have been underestimated by the investigators in most of the included studies. Improvement in symptoms may not necessarily equate with or translate into measurably significant changes in quality of life for the individual; and therefore whilst a moderate change in some of the physical symptoms, that is erythema, may be interpreted by clinicians as evidence of effective treatment it does little to address the wider psychological distress or physical disfigurement that may occur in those with chronic rosacea. Thus, although the majority of reports appeared to recognise the importance of patient‐assessment of symptoms, in reality greater emphasis was placed on the reporting of lesion counts as primary outcomes whereas self‐assessments were almost always considered as secondary outcomes. </p> </section> <section id="CD003262-sec-0569"> <h4 class="title">Inconsistency of results</h4> <p>Although a diverse range of interventions were considered in this systematic review, the majority of participants in the included studies had subtype 1 and 2 rosacea. The results for specific outcomes were fairly consistent across the very limited number of studies and interventions where pooling of data was feasible. </p> </section> <section id="CD003262-sec-0570"> <h4 class="title">Imprecision of results</h4> <p>The rather limited number of studies that were included in this review examining similar interventions did not permit any substantive assessment of the degree of precision of effect. Small sample sizes were responsible for most of the imprecision. </p> </section> <section id="CD003262-sec-0571"> <h4 class="title">Publication bias</h4> <p>A large number of abstracts to conference proceedings were identified. Some were published in full but a number were not otherwise available. There is a possibility that a number of reports, in particular those which conclude negative outcomes, involve serious adverse effects or a lack of effect, may have been sponsored by parties with potentially vested interests, remain unpublished. </p> </section> </section> <section id="CD003262-sec-0572"> <h3 class="title" id="CD003262-sec-0572">Potential biases in the review process</h3> <p>Serious attempts were made to limit bias in the review process by ensuring a comprehensive search for potentially eligible studies. The authors' independent assessments of eligibility of studies for inclusion in this review and the extraction of data minimised the potential for additional bias beyond that detailed in the 'Risk of bias' tables. The incomplete reporting of trial details, results, or both in some of the included studies, and our inability to obtain satisfactory clarification from trial investigators, may have contributed to some biased assessment in the review process. Where these conditions applied this was explicitly stated in the text of our review. </p> </section> <section id="CD003262-sec-0573"> <h3 class="title" id="CD003262-sec-0573">Agreements and disagreements with other studies or reviews</h3> <p>A number of studies, reviews and guidelines have been published since we last updated this review, a fuller listing of these can be found in DynaMed (<a href="https://dynamed.ebscohost.com/" target="_blank">https://dynamed.ebscohost.com/</a>). Although we are in broad agreement that the conclusions reached in these other studies reflect the present findings, we express a level of disagreement with the methods used to reach these conclusions, more specifically in the assessments of the quality of the evidence and how these might correlate with the individual recommendations. All of the studies that were identified appear to have comprehensively and succinctly covered this clinical topic and, based on the references cited, providing a degree of reassurance that a competent literature search had been undertaken. These studies included an update of guidelines produced by the American Acne and Rosacea Society (AARS) (<a href="./references#CD003262-bbs2-0248" title="DelRossoJQ , ThiboutotD , GalloR , WebsterG , TanghettiE , EichenfieldL , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis2013;92(6):277‐84. [PUBMED: 24416742] ">Del Rosso 2013b</a>; <a href="./references#CD003262-bbs2-0250" title="DelRossoJQ , ThiboutotD , GalloR , WebsterG , TanghettiE , EichenfieldL , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, Part 3: A status report on systemic therapies. Cutis2014;93(1):18‐28. [PUBMED: 24505581] ">Del Rosso 2014a</a>; <a href="./references#CD003262-bbs2-0251" title="DelRossoJQ , ThiboutotD , GalloR , WebsterG , TanghettiE , EichenfieldLF , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis2014;93(3):134‐8. [PUBMED: 24738094] ">Del Rosso 2014b</a>; <a href="./references#CD003262-bbs2-0251" title="DelRossoJQ , ThiboutotD , GalloR , WebsterG , TanghettiE , EichenfieldLF , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis2014;93(3):134‐8. [PUBMED: 24738094] ">Del Rosso 2014b</a>; <a href="./references#CD003262-bbs2-0294" title="TanghettiE , DelRossoJQ , ThiboutotD , GalloR , WebsterG , EichenfieldLF , et al. Consensus recommendations from the American Acne &amp; Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis2014;93(2):71‐6. [PUBMED: 24605343] ">Tanghetti 2014</a>), the S1 Guideline developed by the German Society of Dermatology (<a href="./references#CD003262-bbs2-0280" title="ReinholzM , TietzeJK , KilianK , SchallerM , SchöferH , LehmannP , et al. Rosacea ‐ S1 guideline. Journal der Deutschen Dermatologischen Gesellschaft2013;11(8):768‐90. [PUBMED: 23647643] ">Reinholz 2013</a>), a consensus document proposing an evidence‐based treatment approach by the Rosacea International Expert Group (ROSIE) (<a href="./references#CD003262-bbs2-0255" title="ElewskiBE , DraelosZ , DrénoB , JansenT , LaytonA , PicardoM . Rosacea ‐ global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology2011;25(2):188‐200. [PUBMED: 20586834] ">Elewski 2011</a>) and two literature reviews (<a href="./references#CD003262-bbs2-0265" title="KortingHC , SchöllmannC . Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(8):876‐82. [PUBMED: 19508315] ">Korting 2009</a>; <a href="./references#CD003262-bbs2-0274" title="MoustafaFA , SandovalLF , FeldmanSR . Rosacea: new and emerging treatments. Drugs2014;74(13):1457‐65. [PUBMED: 25154627] ">Moustafa 2014b</a>). </p> <p>No details were reported on how studies were selected for inclusion, however the S1 Guideline developers stated that the consensus recommendations of the AARS were based on a "thorough literature review and observations from clinical experience", and also indicated that the process involved an "informal expert panel for consensus". The literature cited in both of these guidelines was complete but there was no indication of how the primary research had been critically appraised by the expert panels, and it appeared that the recommendations, although consensus based, were underpinned by study level assessments of evidence from relevant clinical trials. Similarly, neither of the two other reviews or the consensus document referred to any aspects of the methodological quality of the studies supporting the specific interventions, which was distinct from the more detailed exploration of the quality of the evidence undertaken in this review. We have emphasized, where appropriate in this review, the limitations in study design of the included studies and the potential impact of these limitations on the quality of the evidence. Although we have identified these limitations in our review, they may be of less relevance to well‐established therapies, but may provide cautionary information for those interventions where benefits may marginally exceed potential harms or, indeed, may be critical for the further assessment of newer therapies. </p> <p>Effect measures can enable clinically meaningful comparisons of efficacy to be made between trials. These were reported, mostly in general terms, in only one of the guidelines (<a href="./references#CD003262-bbs2-0280" title="ReinholzM , TietzeJK , KilianK , SchallerM , SchöferH , LehmannP , et al. Rosacea ‐ S1 guideline. Journal der Deutschen Dermatologischen Gesellschaft2013;11(8):768‐90. [PUBMED: 23647643] ">Reinholz 2013</a>), and only for the emerging therapies in <a href="./references#CD003262-bbs2-0274" title="MoustafaFA , SandovalLF , FeldmanSR . Rosacea: new and emerging treatments. Drugs2014;74(13):1457‐65. [PUBMED: 25154627] ">Moustafa 2014b</a>; whereas we have reported these magnitudes of effect in more detail, as either RR or MD, for many of the outcomes in single studies as well as in the meta‐analyses across several studies. </p> <p>Many of the studies evaluating the effects of interventions on rosacea emphasize the significant impact of this condition on the psychosocial well‐being and quality of life of the individual, thus it was somewhat surprising to see that neither of the guidelines involved patients or patient advocacy groups but appeared to be more reliant on the contribution of expert panels. In contrast, and in terms of recognising the significant impact of this condition on patients, we have tried to ensure that we received timely, patient‐relevant input at all stages of conducting and reporting in this review and have also included a consumer as a co‐author. </p> <p>Guidelines provide balanced information on the benefits and limitations of the therapeutic interventions being evaluated. Their process of development should be transparent, robust and reproducible, and should clearly demonstrate that the supporting evidence was systematically reviewed. The strength of clinical recommendations in the two guidelines did not correspond to the widely‐recognised GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach to developing and presenting recommendations for the appropriate health care for specific clinical conditions or circumstances (<a href="./references#CD003262-bbs2-0260" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>). In contrast, we used the GRADE method in this review to examine and categorise the quality level of a body of evidence and to explain our confidence in the effect estimates for several of the interventions, which we have presented in the 'Summary of findings' tables. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003262-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003262-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003262-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003262-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical metronidazole versus placebo, Outcome 1 Adverse events." data-id="CD003262-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topical metronidazole versus placebo, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical metronidazole versus placebo, Outcome 2 Physician's global evaluation of improvement." data-id="CD003262-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topical metronidazole versus placebo, Outcome 2 Physician's global evaluation of improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0006"> <p> <div class="table" id="CD003262-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barnhorst 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 participants were treated with lid hygiene plus warm compresses plus metronidazole 0.75% gel in one eye BID, versus lid hygiene plus warm compresses in the other eye. </p> <p>Within‐patient comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events reported. Eye and eyelid grading pre‐post mean (SD) ‐1.5 (1.7) versus ‐1.0 (1.7). </p> <p>Authors report significant improvement in treatment group but not in control group, P = 0.022 versus P = 0.10 [inappropriate analysis]. No direct comparison reported. </p> <p>Eye pre‐post mean (SD) ‐0.4 (1.0) versus ‐0.3 (0.9). Eyelid pre‐post mean (SD) ‐1.1 (0.9) versus ‐0.7 (0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small group (13 participants),<br/> within‐patient comparison. </p> <p>Not much data. Participant not blinded.<br/> Data skewed. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beutner 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557 were treated with metronidazole gel 1% QD versus 553 with metronidazole 1% cream QD versus 189 with metronidazole gel vehicle. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events 186/557 versus 176/553 versus 51/189.<br/> Subjects rated as success according to physicians 38.4% versus 35.4% versus 27.5%. </p> <p>Reduction in lesion count 66.7% versus 58.3% vs. 46.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large vehicle effect.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QD = once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bitar 1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 were treated with metronidazole cream 1% BID versus 50 with placebo cream BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythema and telangiectasia, no statistical difference.<br/> Number of papules after a month 4.5 (4.24) versus 6.5 (4.96). Number of pustules 1.5 (1.41) versus 3.4 (4.94). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data on papules and pustules are skewed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bjerke 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 were treated with metronidazole cream 1% BID versus 47 with placebo cream BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erythema: 3 score reduction 2% versus 5%, 2 score reduction 26% versus 5% and 1 score reduction 46% versus 45%, unchanged 26% versus 41%, worse 0% versus 5%.<br/> Lesion count reduction 78% versus 48%, reduction of papules 75% versus 43%, reduction of pustules 100% versus 81%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>N = number</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleicher 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 were treated with metronidazole 0.75% BID versus 40 with placebo BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events, one complained of tearing when gel came to close to the eyes.<br/> Reduction in erythema, 0.8 versus 0.3 (erythema rating 0 to 3, higher is worse).<br/> Increase in telangiectasia of 0.3 at both sides (rating 0‐3) </p> <p>Decrease in lesion counts, 65.1% versus 14.9%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported. Within‐patient comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breneman 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104 were treated with metronidazole 1% QD versus 52 with placebo QD.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in erythema score of 0.9 in metronidazole group versus 0.5 in placebo group. </p> <p>Decrease in lesion count 8 versus 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD = standard deviation</p> <p>QD = once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dahl 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 were treated with metronidazole 0.75% BID versus 44 with placebo BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At baseline 35/44 had no or mild erythema versus 32/44. At end of study this was 32/43 versus 24/44. Telangiectasia (no significant difference or effect)<br/> Lesion count 3.3 versus 5.8, relapse rate 23% versus 42%, free of lesions 53% versus 32%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs reported.<br/> N of adverse events unclear. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Koçak 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 patients were treated with metronidazole 0.75% gel BID versus 20 with placebo BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No local adverse events in any group</p> <p>Mean change from baseline in papules ‐5.10 (23.36) versus 0.25 (11.25) with a MD of ‐5.35 (95% CI ‐16.71 to 6.01). Mean change from baseline in pustules ‐2.50 (13.65) versus ‐0.20 (9.20) with a MD of ‐2.30 (95% CI ‐9.51 to 4.91). </p> <p>No effects on rhinophyma and telangiectasia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most data are skewed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen 1983a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 were treated with metronidazole 1% QD versus 40 with placebo QD.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduction on erythema from 3.8 to 2.5 for metronidazole group and from 3.7 to 3.1 in placebo group. Authors state P &lt; 0.05. </p> <p>There were no effects on telangiectasia.</p> <p>Papules count 8.6 versus 16.6, and pustules count 0.3 versus 0.8.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD = standard deviation</p> <p>QD = once daily</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topical metronidazole versus placebo, Outcome 3 Incomplete data on which further analysis is not possible. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-fig-0006">Navigate to figure in review</a></div> </div> <div class="figure" id="CD003262-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical azelaic acid versus placebo, Outcome 1 Participant‐assessed improvement of rosacea." data-id="CD003262-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Topical azelaic acid versus placebo, Outcome 1 Participant‐assessed improvement of rosacea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/urn:x-wiley:14651858:media:CD003262:CD003262-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_t/tCD003262-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical azelaic acid versus placebo, Outcome 2 Physician's global evaluation of improvement." data-id="CD003262-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Topical azelaic acid versus placebo, Outcome 2 Physician's global evaluation of improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/media/CDSR/CD003262/image_n/nCD003262-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003262-fig-0009"> <p> <div class="table" id="CD003262-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bjerke 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 were treated with azelaic cream 20% BID versus 38 with placebo BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in erythema 47.9% versus 37.9%, in telangiectasia 22.3% versus 23.5%.</p> <p>Decrease in lesions 73.4% versus 50.6%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carmichael 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azelaic cream 20% BID versus placebo BID.</p> <p>Within‐patient comparison in 33 patients.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS scale of improvement 6.9 (1.15) to 2.6 (1.72) for azelaic acid treated side versus 7.0 (1.15) to 4.5 (2.30) for placebo treated side<br/> Erythema index decreased from 539.6 (76.98) to 500.6 (84.45) at the azelaic acid treated side and from 533.5 (82.15) to 518.3 (95.36) at the placebo treated side<br/> Telangiectasia (VAS scores) decreased from 4.3 (2.30) to 4.2 (1.71) at the azelaic acid treated side and from 4.4 (2.30) to 4.5 (2.30) at the placebo side </p> <p>Papule count 2.5 (2.87) versus 6.3 (4.6), pustule count 0.0 (0.17) versus 0.4 (0.57).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data are skewed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Draelos 2013a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198 were treated with azelaic acid 15% foam BID versus 203 vehicle foam BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were no statistically significant differences between the 2 groups in end‐of‐treatment or end‐of‐study erythema and telangiectasia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thiboutot 2003a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 were treated with azelaic acid 15% BID versus 165 with vehicle BID.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked improvement or complete remission according to investigator: 51% versus 27% (investigators reported P &lt; 0.001).<br/> Overall improvement in erythema : 44% versus 29% (investigators reported P = 0.0017).<br/> Overall improvement in telangiectasia: Unchanged in 77% versus 80% (investigators reported 'not statistically significant').<br/> Change in number of inflammatory lesions from 17.5 to 6.8 versus 17.6 to 10.5. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported, can only be estimated from figures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thiboutot 2003b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169 were treated with azelaic acid 15% BID versus 166 with vehicle BID</p> <p>Same reference describes 2 studies.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked improvement or complete remission according to investigator: 46% versus 31% (investigators reported P &lt; 0.0048). </p> <p>Overall improvement in erythema : 46% versus 28% (investigators reported P = 0.0005).<br/> Overall improvement in telangiectasia: Unchanged in 73% versus 78% (investigators reported 'not statistically significant'). </p> <p>Change in number of inflammatory lesions from 17.8 to 8.9 versus 18.5 to 12.1.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SDs were reported, can only be estimated from figures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BID = twice a day</p> <p>SD = standard deviation</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Topical azelaic acid versus placebo, Outcome 3 Incomplete data on which further analysis is not possible. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-fig-0009">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metronidazole compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metronidazole compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Metronidazole<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Metronidazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> RR 1.68, 95% CI 1.25 to 2.28; P = 0.0007, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> RR 3.05, 95% CI 1.57 to 5.94; P = 0.001, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a> (within‐participant study) RR 7. These are clinically important improvements </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> <br/> (151 to 243) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.94 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1773<br/> (6 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most instances of these adverse events were mild and consisted of pruritus, skin irritation and dry skin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>570 per 1000</b> <br/> (371 to 869) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.98</b> <br/> (1.29 to 3.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/> (3 studies<sup>4</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results are both statistically significant and clinically important</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602<br/> (7 studies<sup>6</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the separate studies (but not in <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>) there was a greater reduction of erythema in the groups treated with metronidazole, but data were inadequately reported. Except in <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a> data were adequately reported with a MD of ‐1.40 (95% CI ‐2.47 to ‐0.33; P = 0.01) in favour of metronidazole </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1964<br/> (8 studies<sup>8</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SDs reported, data were skewed but appeared to support data of physician‐assessed improvement </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514<br/> (5 studies<sup>9</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on interim data improvement started around four weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>205 per 1000</b> <br/> (102 to 405) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> <br/> (0.25 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study<sup>10</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/44 in metronidazole group relapsed, versus 18/44 in vehicle group during six months follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence intervals)<br/> <sup>3</sup><a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>, <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>4</sup><a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>5</sup> Although for two studies the sequence generation and allocation concealment was unclear (<a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> and <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>), the blinding was ensured for both <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a> and <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a>, and stated as double‐blind for <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a> and therefore we considered it unlikely that this would have an impact on this outcome assessment and decided only to downgrade for imprecision<br/> <sup>6</sup> Bitar 1990, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002,</a><a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>7</sup> Downgraded one level due to serious imprecision (small sample sizes in the individual studies, pooling not possible due to missing SDs)<br/> <sup>8</sup><a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a>, <a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a>, <a href="./references#CD003262-bbs2-0052" title="KoçakM , YagliS , VahapogluG , EksiogluM . Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. Dermatology2002;205(3):265‐70. [PUBMED: 12399675] ">Koçak 2002</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>9</sup><a href="./references#CD003262-bbs2-0009" title="BitarA , BourgouinJ , DoréN , DubucR , GirouxJM , Madeleine‐LandryEA . A double‐blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Investigation1990;2(4):242‐8. [EMBASE: 1991066113] ">Bitar 1990</a>, <a href="./references#CD003262-bbs2-0010" title="BjerkeJR , NyforsA , AustadJ , RajkaG , GjertsenBT , HaavelsrudO , et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clinical Trials Journal1989;26(3):187‐94. [EMBASE: 1989151247] ">Bjerke 1989</a>, <a href="./references#CD003262-bbs2-0012" title="BleicherPA , CharlesJH , SoberAJ . Topical metronidazole therapy for rosacea. Archives of Dermatology1987;123(5):609‐14. [UI: 8721097; PUBMED: 2953312] ">Bleicher 1987</a>, <a href="./references#CD003262-bbs2-0014" title="BrenemanDL , StewartD , HeviaO , HinoPD , DrakeLA . A double‐blind, multicenter clinical trial comparing efficacy of once‐daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis1998;61(1):44‐7. [UI:98127231; PUBMED: 9466083] ">Breneman 1998</a>, <a href="./references#CD003262-bbs2-0069" title="NielsenPG . Treatment of rosacea with 1% metronidazole cream. A double‐blind study. British Journal of Dermatology1983;108(3):327‐32. [PUBMED: 6219689] ">Nielsen 1983a</a> <br/> <sup>10</sup><a href="./references#CD003262-bbs2-0020" title="DahlMV , KatzHI , KruegerGG , MillikanLE , OdomRB , ParkerF , et al. Topical metronidazole maintains remissions of rosacea. Archives of Dermatology1998;134(6):679‐83. [UI: 98307542; PUBMED: 9645635] ">Dahl 1998</a> </p> <p><sup>11</sup> Although we judged the domains for sequence generation, allocation concealment as unclear and the method of blinding of participants and physicians was not reported, there was no attrition bias nor selective reporting and therefore we concluded there was no serious risk of bias for this outcome assessment </p> <p>12 Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metronidazole compared to placebo for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azelaic acid compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Azelaic acid<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Azelaic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Marked improvement to complete remission on Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>636 per 1000</b> <br/> (552 to 733) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/> (1.30 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1179<br/> (4 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a clinically important improvement in favour of azelaic acid</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/> (5 studies<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a> RR 1.00, 95% CI 0.62 to 1.62; P = 0.02, <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a> (within‐participant) 24/33 on the azelaic acid side and 19/33 on placebo side, <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> RR 2.39, 95% CI 1.12 to 5.09; P = 0.02, <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a> and <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> 18% and 8% respectively for azelaic acid treated groups and limited to no data for the placebo groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>497 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>655 per 1000</b> <br/> (586 to 730) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> <br/> (1.18 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1179<br/> (4 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for these assessments from four studies illustrated that azelaic acid was more effective than placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/> (5 studies<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decrease in erythema in groups treated with azelaic acid ranged from 44% to 47.9% and for placebo from 28% to 37.9%, telangiectasia minimal changes. SDs missing </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was <b>‐9.5 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was <b>3.90 lower</b> (5.87 to 1.93 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>401<br/> (1 study<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SDs were reported in (<a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>; <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>; <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>) and data were skewed in <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>. All four studies showed a greater reduction in lesions in azelaic acid treated groups (see <a href="./references#CD003262-fig-0009" title="">Analysis 2.3</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/> (5 studies<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome, but all studies showed clear improvement after three to six weeks </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>, <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>, <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>, <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> <br/> <sup>2</sup><a href="./references#CD003262-bbs2-0011" title="BjerkeR , FyrandO , GraupeK . Double‐blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo‐pustular rosacea. Acta Dermato‐Venerologica1999;79(6):456‐9. [UI: 20065819; PUBMED: 10598760] ">Bjerke 1999</a>, <a href="./references#CD003262-bbs2-0018" title="CarmichaelA , MarksR , GraupeKA , ZaumseilRP . Topical azelaic acid in the treatment of rosacea. Journal of Dermatological Treatment1993;4(1 Suppl):S19‐22. [EMBASE: 1993216511] ">Carmichael 1993</a>, <a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a>, <a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>, <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a> <br/> <sup>3</sup><a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> <br/> <sup>4</sup> Downgraded one level due to serious imprecision (wide confidence interval) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azelaic acid compared to placebo for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Topical ivermectin compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical ivermectin compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical ivermectin<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical ivermectin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> DLQI and RosaQoL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although data were statistically significant in favour of ivermectin, the clinical importance is unclear as MID in reduction of DLQI score was not reached and the MID is not yet established for RosaQoL<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Likert scale, good to excellent improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78, 95% CI 1.50 to 2.11 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), RR 1.92, 95% CI 1.59 to 2.32 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>). Both studies showed a statistically significant and clinically important improvement in favour of topical ivermectin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54, 95% CI 0.29 to 1.01 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), RR 1.00, 95% CI 0.55 to 1.82 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Investigator's Global Assessment of clear or almost clear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.30, 95% CI 2.27 to 4.79 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), RR 2.10, 95% CI 1.57 to 2.81 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>). The results of both studies are in concordance with the assessments of the participants </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐8.40, 95% CI ‐9.93 to ‐6.87 (<a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>), MD ‐8.90, 95% CI ‐10.45 to ‐7.35 (<a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a>). Both of these differences are statistically significant and clinically important </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1371<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in both studies was seen after four weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a>, <a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> <br/> <sup>2</sup> MID = minimal important difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Topical ivermectin compared to placebo for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topical brimonidine compared to vehicle for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical brimonidine compared to vehicle for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical brimonidine<br/> <b>Comparison:</b> Vehicle </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical brimonidine </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Patient Satisfaction Assessment ‐ grade 2 improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 3 hours RR 2.21, 95% CI 1.52 to 3.22 (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>) and RR 2.00, 95% CI 1.33 to 3.01 (<a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>). At each time point in both studies brimonidine was shown to be more effective than vehicle in an improvement which was statistically significant </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17, 95% CI 0.79 to 1.74 (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>), RR 1.40, 95% CI 0.97 to 2.02 (<a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>). Adverse events were mild and transient </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reporting of data other than "No aggravations in the severity of IGA were observed"</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Clinician Erythema Assessment ‐ grade 2 improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 3 hours RR 2.82, 95% CI 1.85 to 4.30 (<a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>), RR 1.78, 95% CI 1.25 to 2.55 (<a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reporting of data other than "No aggravations in the severity of lesion counts were observed" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement was seen within 30 min</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no rebound or worsening of erythema after treatment cessation in comparison to baseline assessments </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>, <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topical brimonidine compared to vehicle for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Topical azelaic acid compared to topical metronidazole for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical azelaic acid compared to topical metronidazole for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical azelaic acid<br/> <b>Comparison:</b> Topical metronidazole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical metronidazole</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical azelaic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.23, CI 95% 1.04 to 1.44; P = 0.01 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 1.00, 95% CI 0.83 to 1.21 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> (within‐participant) authors report P = 0.02 in favour of azelaic acid </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.64, 95% CI 1.81 to 7.31; P = 0.0003 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 0.74, 95% CI 0.52 to 1.07 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>). In <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> 1 participant reported stinging on azelaic acid treated site </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.26, 95% CI 1.03 to 1.53; P = 0.02 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 1.05, 95% CI 0.79 to 1.39 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> score 2.7 (SD 1.0) versus 3.1 (SD 1.0) (higher is worse) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.35, 95% CI 1.05 to 1.75; P = 0.02 (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>), RR 0.99, 95% CI 0.69 to 1.42 (<a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>), in <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> the participants and physicians had contradictory judgements </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion counts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SDs were reported, all three studies demonstrated a clinically important reduction in lesion count in both treatment arms </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>491<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement for both arms was seen after four to six weeks in all three studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a>, <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>, <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> <br/> <sup>2</sup> Downgraded one level due to serious risk of bias (all three studies stated to be double‐blind, but method of blinding was not described)<br/> <sup>3</sup> Downgraded one level due to serious inconsistency (<a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> no statistically significant difference (severe heterogeneity unexplained (I<sup>2</sup> &gt;60%), and the 95% CIs do overlap but lead to different interpretation of the effect estimate, but in <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> azelaic was more effective)<br/> <sup>4</sup> Downgraded one level due to serious inconsistency (statistically significant difference in participants reporting adverse events in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> (in favour of metronidazole), not confirmed in Wolf 2006 (severe heterogeneity unexplained (I<sup>2</sup>&gt;60% and the 95% CIs did not overlap))<br/> <sup>5</sup> Downgraded one level due to serious inconsistency (no statistically significant difference in <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>, but in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> azelaic acid is more effective, severe heterogeneity unexplained and the 95% CI do overlap but lead to different interpretation of the effect estimate)<br/> <sup>6</sup> Downgraded one level due to inconsistency (no statistically significant difference in <a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a>, but in <a href="./references#CD003262-bbs2-0032" title="ElewskiBE , FleisherAB , PariserDM . A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Archives of Dermatology2003;139(11):1444‐50. [PUBMED: 14623704] ">Elewski 2003</a> and <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a> azelaic acid is more effective according to physicians (but metronidazole is more effective according to participants in <a href="./references#CD003262-bbs2-0059" title="MaddinS . A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. Journal of the American Academy of Dermatology1999;40(6 Pt 1):961‐5. [UI: 99292050; PUBMED: 10365928] ">Maddin 1999</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Topical azelaic acid compared to topical metronidazole for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Topical ivermectin compared to topical metronidazole for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical ivermectin compared to topical metronidazole for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical ivermectin<br/> <b>Comparison:</b> Topical metronidazole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical metronidazole</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical ivermectin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> DLQI, proportion of participants that reported at end of study that rosacea had no impact on QoL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>640 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>711 per 1000</b> <br/> (647 to 775) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/> (1.01 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in DLQI was 5.18 in ivermectin group and 3.92 in metronidazole group (both meeting minimal important difference) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Likert scale ‐ good to excellent improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>748 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>853 per 1000</b> <br/> (800 to 912) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/> (1.07 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a statistically significant difference and in concordance with the results on number of participants that experienced no deleterious effect on their quality of life </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (6 to 61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.28</b> <br/> (0.71 to 7.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>754 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>852 per 1000</b> <br/> (799 to 905) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (1.06 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These assessments are consistent with the assessments of the participants</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control groups was<br/> <b>‐23.60 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention groups was<br/> <b>4.10 lower</b> <br/> (5.18 to 3.02 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both treatments showed clinically important reductions in lesion counts</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a predefined outcome, but clear improvement could be seen for both treatment arms around six weeks </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low occurrence of events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Topical ivermectin compared to topical metronidazole for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Ciclosporin ophthalmic emulsion 0.05% compared to artificial tears for ocular rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclosporin ophthalmic emulsion 0.05% compared to artificial tears for ocular rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with ocular rosacea<br/> <b>Intervention:</b> Ciclosporin ophthalmic emulsion 0.05%<br/> <b>Comparison:</b> Artificial tears </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Artificial tears</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclosporinophthalmic emulsion 0.05%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> Ocular Surface Disease Index (scale 0 to 100, 100 worst) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OSDI in the control group was<br/> <b>16.9</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean OSDI in the intervention group was<br/> <b>8.6 lower</b> <br/> (15.42 to 1.78 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The difference between change scores at end of study equates to a moderate improvement in quality of life in favour of ciclosporin ophthalmic emulsion </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b> <br/> (0.10 to 53.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Schirmer score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the control group was<br/> <b>‐1.4</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the intervention group was<br/> <b>4.1 higher</b> <br/> (1.66 to 6.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0081" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. [PUBMED: 19551353] ">Schechter 2009</a> <br/> <sup>2</sup> Downgraded two levels due to very serious imprecision (very wide confidence interval due to low sample size, optimal information size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Ciclosporin ophthalmic emulsion 0.05% compared to artificial tears for ocular rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Clindamycin phosphate 1.2% + tretinoin 0.025% gel compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clindamycin phosphate 1.2% + tretinoin 0.025% gel compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Clindamycin phosphate 1.2% + tretinoin 0.025% gel<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clindamycin phosphate 1.2% + tretinoin 0.025% gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> <br/> RosaQoL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No mean scores were provided, only percentages of participants that had improved per item on the 21 survey items, no statistically significant difference for any item </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>674 per 1000</b> <br/> (390 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.45</b> <br/> (1.42 to 4.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsening of rosacea, facial scaling, as well as dry skin were reported most often in the active treatment group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> PGA as defined by <a href="./references#CD003262-bbs2-0306" title="WilkinJ , DahlM , DetmarM , DrakeL , LiangMH , OdomR , et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology2004;50(6):907‐12. [PUBMED: 15153893] ">Wilkin 2004</a> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the primary features of the PGA showed statistically significant differences between the treatment groups except for oedema in favour of placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> <br/> (105 to 627) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/> (0.70 to 4.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.71 (95% CI 0.70 to 4.18) refers to erythema. Telangiectasia RR 2.42, 95% CI 0.95 to 6.17 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐3.13 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>3.96 higher</b> <br/> (1.28 lower to 9.20 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no improvement</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Clindamycin phosphate 1.2% + tretinoin 0.025% gel compared to placebo for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Tetracycline compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tetracycline compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Tetracycline<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tetracycline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>701 per 1000</b> <br/> (403 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.48</b> <br/> (0.85 to 2.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (3 to 744) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/> (0.06 to 14.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only one adverse event was reported in each group, diarrhoea in the tetracycline group, maculopapular rash in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (2 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.04, 95% CI 1.66 to 9.83; P = 0.002 (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) and RR 1.72, 95% CI 1.18 to 2.50; P = 0.005 (<a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant changes in erythema (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>1.41 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>14.64 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crude MD ‐14.64 but skewed data (<a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>3</sup><a href="./references#CD003262-bbs2-0060" title="MarksR , EllisJ . Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet1971;2(7733):1049‐52. [UI: 72022755; PUBMED: 4106909] ">Marks 1971</a> and <a href="./references#CD003262-bbs2-0084" title="SneddonIB . A clinical trial of tetracycline in rosacea. British Journal of Dermatology1966;78(12):649‐52. [PUBMED: 4224811] ">Sneddon 1966</a> <br/> <sup>4</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met)<br/> <sup>5</sup> Downgraded one level due to serious imprecision (skewed data and low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Tetracycline compared to placebo for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Doxycycline 40 mg compared to placebo for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxycycline 40 mg compared to placebo for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Doxycycline 40 mg<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14, 95% CI 0.85 to 1.53 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and RR 1.27, 95% CI 1.04 to 1.55 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Investigator's Global Assessment, two point improvement </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.77, 95% CI 1.24 to 2.52; P = 0.002 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and RR 1.41, 95% CI 0.87 to 2.29 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) and IGA score of 0 or 1 RR 1.59, 95% CI 1.02 to 2.47; P = 0.04 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and RR 2.37, 95% CI 1.12 to 4.99; P = 0.02 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Clinician's Erythema Assessments scale 0 to 4 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in CEA ‐2.7 (doxycycline group) versus ‐1.8 (placebo group), investigators report P = 0.017 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>); and ‐1.4 and ‐1.2 respectively (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion counts</b> <br/> Scale from: ‐4.3 to ‐11.8 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5.90, 95% CI ‐9.37 to ‐2.43; P = 0.0009 (<a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a>) and MD ‐5.20, 95% CI ‐8.27 to ‐2.13; P = 0.0009 (<a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (2 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The steepest changes in graph plots occurred within three weeks in the doxycycline group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0022" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007a</a> and <a href="./references#CD003262-bbs2-0023" title="DelRossoJQ , WebsterGF , JacksonM , RendonM , RichP , TorokH , et al. Two randomized phase III clinical trials evaluating anti‐inflammatory dose doxycycline (40‐mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology2007;56(5):791‐802. [PUBMED: 17367893] ">Del Rosso 2007b</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Doxycycline 40 mg compared to placebo for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Azithromycin compared to doxycycline 100 mg for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azithromycin compared to doxycycline 100 mg for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Azithromycin<br/> <b>Comparison:</b> Doxycycline 100 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 100 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Azithromycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> <br/> (616 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.77 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no statistically significant difference between the groups, but in both treatment arms the majority of participants considered themselves improved </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> <br/> (21 to 551) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.62</b> <br/> (0.32 to 8.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion counts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesions count in the control group was<br/> <b>2.34 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesions count in the intervention group was<br/> <b>0 higher</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesion count decreased in azithromycin group from 19.24 (SD 9.67) to 1.90 (SD 3.28) at 3 months and for doxycycline from 18.86 (SD 8.95) to 2.34 (SD 3.47). Skewed data </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data on duration of remission, but both groups showed no statistically significant change between the third month of treatment and the second month post‐treatment in the mean inflammatory lesion counts </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a> <br/> <sup>2</sup> Downgraded two levels due to very serious risk of bias (allocation concealment was at high risk of bias, no blinding)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met, optimal sample size is not met)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>5</sup> Downgraded one level due to serious imprecision (large SDs and skewed data, low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Azithromycin compared to doxycycline 100 mg for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Doxycycline 40 mg + metronidazole 1% gel compared to doxycycline 100 mg + metronidazole 1% gel for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxycycline 40 mg + metronidazole 1% gel compared to doxycycline 100 mg + metronidazole 1% gel for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Doxycycline 40 mg + metronidazole 1% gel<br/> <b>Comparison:</b> Doxycycline 100 mg + metronidazole 1% gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 100 mg + metronidazole 1% gel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg + metronidazole 1% gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>553 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (61 to 299) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.25</b> <br/> (0.11 to 0.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The majority of these adverse events were gastrointestinal complaints</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Reduction in Investigator's Global Assessment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the control group was<br/> <b>‐1.6</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the intervention group was<br/> <b>0.00 higher</b> <br/> (0.11 lower to 0.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Clinician's Erythema Assessment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the control group was<br/> <b>‐4.0</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the intervention group was<br/> <b>0 higher</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in CEA 4.2 in doxycycline 40 mg and 4.0 in doxycycline 100 mg group, investigator's state P = 0.50 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐12.2 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>0.30 lower</b> <br/> (3.03 lower to 2.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement of the skin lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clear improvement was seen from week four for both groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0024" title="DelRossoJQ , CaveneyS . Comparison of anti‐inflammatory dose doxycycline (30‐mg immediate‐release beads, 10 mg delayed‐release beads)vs antibiotic dose doxycycline (100mg) in the treatment of rosacea. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States, 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine and Surgery2012;31(1):A7‐8. [EMBASE: 70706922] DelRossoJQ , SchlessingerJ , WerschlerP . Comparison of anti‐inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. Journal of Drugs in Dermatology2008;7(6):573‐6. [PUBMED: 18561589] ">Del Rosso 2008</a> <br/> <sup>2</sup> Downgraded one level due to serious risk of selection bias and attrition bias (sequence generation and allocation concealment at unclear risk of bias, high drop‐out rate and although ITT analysis judged at unclear risk of bias)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Doxycycline 40 mg + metronidazole 1% gel compared to doxycycline 100 mg + metronidazole 1% gel for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Doxycycline 40 mg + azelaic acid gel compared to doxycycline 40 mg + metronidazole gel for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Doxycycline 40 mg + azelaic acid gel compared to doxycycline 40 mg + metronidazole gel for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Doxycycline 40 mg + azelaic acid gel<br/> <b>Comparison:</b> Doxycycline 40 mg + metronidazole gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg + metronidazole gel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 40 mg + azelaic acid gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> <br/> Excellent improvement on a 4‐point Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>489 per 1000</b> <br/> (368 to 651) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> <br/> (0.79 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excellent improvement was reported in approximately half of each intervention group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (4 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.27</b> <br/> (0.06 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Investigator's Global Assessment of 0, 1 or 2 (clear to mild) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>723 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>781 per 1000</b> <br/> (672 to 918) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.93 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician's Erythema Assessment</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐9.4 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>1.10 lower</b> <br/> (4.91 lower to 2.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From four weeks on improvement could be seen for both treatment arms</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> <br/> <sup>2</sup> Downgraded one level due to serious imprecision (wide confidence interval) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Doxycycline 40 mg + azelaic acid gel compared to doxycycline 40 mg + metronidazole gel for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0014"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Minocycline 45 mg compared to minocycline 45 mg + azelaic acid gel for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Minocycline 45 mg compared to minocycline 45 mg + azelaic acid gel for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Minocycline 45 mg<br/> <b>Comparison:</b> Minocycline 45 mg + azelaic acid gel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Minocycline 45 mg + azelaic acid gel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Minocycline 45 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>533 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> <br/> (208 to 651) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> <br/> (0.39 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> <br/> Mean change in Investigator's Global Assessment (Likert scale 0 to 5). Scale from: 0 to 4. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the control groups was<br/> <b>‐2.0 on IGA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physician‐assessed improvement in rosacea severity in the intervention groups was<br/> <b>0.00 higher</b> <br/> (0.32 lower to 0.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Mean change in CEA scale (Likert scale 0 to 4). Scale from: 0 to 4. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the control group was<br/> <b>‐4 on CEA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the intervention group was<br/> <b>1.00 higher</b> <br/> (0.18 lower to 2.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐12 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>1.00 higher</b> <br/> (0.93 lower to 2.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In both groups there was a clinically important reduction in lesion counts of 11.00 (SD 4.49) in the minocycline group and 12.00 (SD 3.00) in the comparator group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement was seen in both arms at four weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a> <br/> <sup>2</sup> Downgraded one level due to serious risk of performance and detection bias (blinding was assessed as at unclear risk of bias)<br/> <sup>3</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Minocycline 45 mg compared to minocycline 45 mg + azelaic acid gel for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0015"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Topical metronidazole compared to oral (oxy)tetracycline for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical metronidazole compared to oral (oxy)tetracycline for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Topical metronidazole<br/> <b>Comparison:</b> Oral (oxy)tetracycline </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral (oxy) tetracycline</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical metronidazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182<br/> (3 studies<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71, 95% CI 0.40 to 1.26 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), RR 0.96, 95% CI 0.80 to 1.17 (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>) and in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> no exact data were provided other than that "both groups considered their condition much improved" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (4 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse event (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>), RR 1.06, 95% CI 0.32 to 3.55 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), 12 adverse events reported in metronidazole group and 9 in tetracycline group (<a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>), RR 0.70, 95% CI 0.30 to 1.65 (<a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (2 studies<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80, 95% CI 0.47 to 1.35 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), RR 1.00, 95% 0.89 to 1.13 (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (4 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema score ‐1.4 versus ‐1.3 (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), "the reduction of erythema was the same in both groups, and the number and extent of telangiectases were unchanged" (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>), in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> no differences in erythema nor telangiectasia were seen in either group. In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> the percentage of no improvement was 11.1 in the metronidazole group versus 12.5 in the tetracycline group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (4 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete clearance in 75% versus 66% of participants (<a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>), "the reduction of papules and pustules was the same in both groups" (<a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>), decrease of 68% versus 77% in papule count and of 53% and 61% in pustule count (<a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>). In <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> only medians were provided with 11.1 lesions in the metronidazole group and 0 in the tetracycline group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>, <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> (number of participants randomised in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> was unclear)<br/> <sup>2</sup> Downgraded one level due to serious imprecision (low sample sizes)<br/> <sup>3</sup><a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a>, <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a>, <a href="./references#CD003262-bbs2-0099" title="VeienNK , ChristiansenJV , HjorthN , SchmidtH . Topical metronidazole in the treatment of rosacea. Cutis1986;38:209‐10. [PUBMED: 2945705] ">Veien 1986</a> (number of participants randomised in <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> was unclear)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (wide confidence intervals due to low sample sizes)<br/> <sup>5</sup><a href="./references#CD003262-bbs2-0061" title="MonkBE , LoganRA , CookJ , WhiteJE , MasonRBS . Topical metronidazole in the treatment of rosacea. Journal of Dermatological Treatment1991;2(3):91‐3. [EMBASE: 1991353230] ">Monk 1991</a>, <a href="./references#CD003262-bbs2-0070" title="NielsenPG . A double‐blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. British Journal of Dermatology1983;109(1):63‐5. [UI: 83231308; PUBMED: 6222756] ">Nielsen 1983b</a> <br/> <sup>6</sup> Downgraded one level due to serious heterogeneity (in contrast to the other three studies, <a href="./references#CD003262-bbs2-0080" title="SchachterD , SchachterRK , LongB , ShiffmanN , LesterR , MillerS , et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Investigation1991;3(4):220‐4. [EMBASE: 1991314872] ">Schachter 1991</a> did not show any improvement in erythema and telangiectasia </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Topical metronidazole compared to oral (oxy)tetracycline for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0016"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Low dose isotretinoin 0.3 mg/kg compared to doxycycline 50‐100 mg for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Low dose isotretinoin 0.3 mg/kg compared to doxycycline 100 mg for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Low dose isotretinoin 0.3 mg/kg<br/> <b>Comparison:</b> Doxycycline 100 mg after 14 days tapered to 50 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Doxycycline 100 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Low dose isotretinoin 0.3 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b><sup>1</sup> <br/> Good to excellent improvement on 5‐point Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>644 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>792 per 1000</b> <br/> (676 to 921) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/> (1.05 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low dose isotretinoin is considered by the participants to be slightly more effective than doxycycline 100 mg </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (127 to 328) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.74 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b><sup>1</sup> <br/> Complete remission or marked improvement on a 6‐point Likert scale) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>689 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>813 per 1000</b> <br/> (710 to 938) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (1.03 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In agreement with the participant‐assessed changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> Improved or healed </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>783 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>736 per 1000</b> <br/> (650 to 846) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/> (0.83 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia were improved or "healed" RR 1.03, 95% CI 0.77 to 1.37</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the control group was<br/> <b>‐13 inflammatory lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean lesion count in the intervention group was<br/> <b>3 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time needed until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Per‐protocol analysis<br/> <sup>2</sup><a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Low dose isotretinoin 0.3 mg/kg compared to doxycycline 50‐100 mg for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0017"> <div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Pulsed dye laser compared to Nd:YAG laser for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pulsed dye laser compared to Nd:YAG laser for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Pulsed dye laser<br/> <b>Comparison:</b> Nd:YAG laser </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Nd: YAG laser</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pulsed dye laser</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the control group was<br/> <b>34 percent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the intervention group was<br/> <b>16.33 higher</b> <br/> (1.94 to 34.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b><sup>1</sup> <br/> Pain as assessed by VAS (0 to 10; higher score is worse) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain was assessed on the PDL treated side 3.87 and 3.07 on the Nd:YAG side, the investigators state P = 0.0028 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b><sup>1</sup> <br/> Spectrophotometer to assess facial redness </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the control group was<br/> <b>‐2.5 percent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean assessment of erythema or telangiectasia in the intervention group was<br/> <b>6.4 lower</b> <br/> (11.6 to 1.2 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Within‐participant<br/> <sup>2</sup><a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a> <br/> <sup>3</sup> Downgraded two levels due to very serious imprecision (very wide confidence interval due to low sample size, optimal sample size is not met)<br/> <sup>4</sup> Downgraded two levels due to very serious imprecision (very low sample size, optimal sample size is not met) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Pulsed dye laser compared to Nd:YAG laser for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003262-tbl-0018"> <div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Pulsed dye laser compared to intense pulsed light therapy for rosacea</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pulsed dye laser compared to intense pulsed light therapy for rosacea</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Participants with rosacea<br/> <b>Intervention:</b> Pulsed dye laser (PDL)<br/> <b>Comparison:</b> Intense pulsed light therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intense Pulsed Light Therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pulsed Dye Laser</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQOL</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed improvement in rosacea severity</b><sup>1</sup> <br/> VAS. Scale from: 0 to 10 (0 being a poor and 10 an excellent result) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the control group was<br/> <b>7</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean participant‐assessed improvement in rosacea severity in the intervention group was<br/> <b>1 higher</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median was 8 (range 2 to 10) for PDL group and 7 (range 2 to 10) for IPL group (10% and 90% percentiles) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with adverse event</b> <br/> Pain as assessed with a VAS scale. Scale from: 0 to 10 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Pain assessed on a VAS scale in the control group was<br/> <b>7</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Pain assessed on a VAS scale in the intervention group was<br/> <b>3 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median was 4 (range 2 to 6) for PDL group and 7 (range 2 to 10) for IPL group (10% and 90% percentiles) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐assessed improvement in rosacea severity</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment of erythema or telangiectasia</b> <br/> 5‐point Likert scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study<sup>2</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>On the PDL treated side 18 had an excellent (75% to 100% vessel clearance) response and 12 a good response (50% to 74% clearance) and on the IPL treated sides 11 had an excellent response and 19 a good response </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lesion count</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time until improvement</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of remission</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Within‐participant design<br/> <sup>2</sup><a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a> <br/> <sup>3</sup> Downgraded one level due to serious performance and detection bias (investigators and participants were not blinded)<br/> <sup>4</sup> Downgraded one level due to serious imprecision (low sample size, optimal sample size is not met)<br/> <sup>5</sup> "Clinical efficacy was evaluated by one blinded trained physician" </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Pulsed dye laser compared to intense pulsed light therapy for rosacea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003262-tbl-0019"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Term</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A skin condition characterised by the inflammation or infection of sebaceous glands (usually attached to hair follicles) resulting in comedones (whiteheads and blackheads) and inflammatory lesions such as papules (pimples), pustules, and nodules) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Bacillus oleronius</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A bacteria found in Demodex mites</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance of a micro‐organism to an antimicrobial drug that was originally effective for treatment of infections caused by this micro‐organism </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body dysmorphic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An anxiety disorder surrounding perceived flaws in one's own appearance</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cytokines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small protein released by cells, and having a specific effect on the behavior of other cells, or on the interactions or communications between cells </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Demodex folliculorum</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A species of face mite found in human hair follicles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Down‐regulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Process of reducing or suppressing a response to a stimulus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epidermal barrier</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The skin's front line of defence in the upper layer of the skin (the epidermis) against environmental factors such as UV light, chemicals, bacteria and other organisms and limits water loss from the body </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Innate immune response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The first line generic defence of the immune system against infection and other organisms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Keratinocytes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A predominant cell type in the outermost layer of skin (epidermis), and when found in the basal layer, are referred to as 'basal cells' or 'basal keratinocytes'. Their main function is the formation of a barrier against environmental damage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Matrix‐Metalloproteinases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc dependent enzymes that promote break down of proteins like collagen. They regulate various inflammatory and repair processes </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurovascular dysregulation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A failure of the vascular response, vasodilation, and neurosensory symptoms to regulate properly </p> <p>Dysfunction of both nerves and vascular elements, controlling the calibre of blood vessels </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nodule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Solid, raised area in or under the skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nodularities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An increased density of tissues</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pathophysiology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The functional changes that accompany a particular syndrome or disease (combined terms of ‘patho’ (path, related to disease) and ‘physiology’ (a branch of biology that specialises in the study of the functions of living organisms and their parts) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phototype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A classification of skin type based on a person's sensitivity to sunlight</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pustule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small bump on the skin containing purulent material (pus) in the top layer (epidermis) or beneath it (dermis) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reactive oxygen species (ROS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemically reactive molecules containing oxygen, or oxygen‐derived radicals, having important roles in cell signalling (communication and interaction) and homeostasis (the maintenance of a steady state) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemical compounds related chemically to Vitamin A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stratum corneum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outermost layer of the epidermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A bacterial infection of a gland at the base of any eyelash, causing painful swelling on the inner or outer eyelid </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Toll‐like receptors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A class of proteins that play a key role in the innate immune system, activating immune cell responses </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003262-tbl-0020"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Pharmaceutical companies contacted</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Additional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bayer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Added information on <a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> Christopher Billis &lt;<a class="__cf_email__" data-cfemail="1e7d766c776d6a716e767b6c307c777272776d5e7c7f677b6c307d7173" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt; and that ongoing studies were not yet published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roche</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASTA Medica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Merck</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dumex‐Alpharma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galderma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="63330217110a000a024d35020d2f0a170b2304020f0706110e024d000c0e" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a href="http://mailto:michael.graeber%40galderma.com?subject=NCT00989014, RD.06.SPR.18144, Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="7c11151f141d1910521b0e1d191e190e3c1b1d1018190e111d521f1311">[email protected]</span></a> </p> <p>August 2014 several times contact with Galderma NL, France and US, provided lots of extra information regarding brimonidine and ivermectin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHP Pharma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yamanouchi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dermik Laboratories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CollaGenex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taken over by Galderma</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Pharmaceutical companies contacted</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003262-tbl-0021"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Investigators contacted</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Additional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0001" title="AkhyaniM , EhsaniAH , GhiasiM , JafariAK . Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. International Journal of Dermatology2008;47(3):284‐8. [PUBMED: 18289334] ">Akhyani 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="fa979d92939b8993ba8993949bd48e8f9789d49b99d49388" href="/cdn-cgi/l/email-protection">[email protected]</a>. (sequence generation and allocation concealment) "In efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomised open clinical trial" Patients were allocated to the trial using a randomised numbers table. Unfortunately this trial was not blinded" "The randomised number table generated by computer. The list was only in access of physician, and patients could not see that </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0109" title="AltinyazarHC , KocaR , TekinNS , EştürkE . Adalapene vs. metronidazole gel for the treatment of rosacea. International Journal of Dermatology2005;44(3):252‐5. [MEDLINE: 15807740] ">Altinyazar 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After email contact with the primary investigator and following on from discussion between the review authors, this was judged to be quasi‐randomised, i.e. a CCT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0006" title="BenkaliK , LeoniM , RonyF , BouerR , FernandoA , GraeberM , et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate‐to‐severe facial erythema associated with rosacea. British Journal of Dermatology2014;171(1):162‐9. [PUBMED: 24506775] ">Benkali 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="92fcf3e6faf3fefbf7bce5f3f5fcf7e0d2f5f3fef6f7e0fff3bcf1fdff" href="/cdn-cgi/l/email-protection">[email protected]</a>, 1‐8‐2014 (sequence generation and allocation concealment)<br/> 1) Regarding the allocation sequence generated for the 4 subsequent groups consisting of different doses or regimen for topical applications, the randomisation list was created before the study started, with a 1:1:1:1 ratio and block size of 4. This randomisation list was generated by a designated biostatistician and was distributed to the clinical supply team in a sealed envelope (see the attached pdf file for the randomisation memo) </p> <p>2) As explained above, only the 4 arms treated with topical products were to be randomised. The block size of 4 was not known by the sites, so foreseeing the next allocation was possible but unlikely. Since the study had 2 treatment groups for QD regimen and 2 treatment groups for BID regimen, subjects and the personnel who distributed the medication necessarily knew this information </p> <p>Of note, the primary objective of this study was PK assessment (and not efficacy), an objective measure, and the primary comparison was topical versus eye drop which was in no way planned to be randomised or blinded </p> <p>3) This study was not posted on CT.gov since it was classified as a phase 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0114" title="BerardescaE , CameliN , CavallottiC , LevyJL , PiérardGE , dePaoli AmbrosiG . Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. Journal of Cosmetic Dermatology2008;7(1):8‐14. [MEDLINE: 18254805] ">Berardesca 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="8fcdeafdeefdebeafceceecfedeafdeefdebeafceceea1e6fb" href="/cdn-cgi/l/email-protection">[email protected]</a>. After email communication with the investigators to clarify aspects of trial conduct, the criterion for sequence generation was changed from UNCLEAR to High risk, i.e. the study was not a RCT and participants appear to have been allocated to the intervention by alternation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0007" title="BerardescaE , IorizzoM , AbrilE , GuglielminiG , CaseriniM , PalmieriR , et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology2012;11(1):37‐41. [PUBMED: 22360333] ">Berardesca 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐8‐2014 <a class="__cf_email__" data-cfemail="8ae7ebfff8e3f0e3e5a4e9ebf9eff8e3e4e3cafae5e6e3e9e2efe7a4e9e5e7" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation and allocation concealment and blinding) </p> <p>29‐9‐2013 replies </p> <p>1. This was a randomised, double‐blind, parallel‐group, placebo‐controlled study</p> <p>Patients, having signed their informed consent and who satisfied all inclusion and exclusion criteria at inclusion visit were randomly assigned to one of two treatment groups (P‐3075 cream, placebo), according to a computer‐generated randomisation list </p> <p>Patients were sequentially assigned to the next available randomisation number, starting from the lowest number provided to each investigational site </p> <p>Furthermore, for ethical reason, in order to minimise the exposure to placebo, randomisation was unbalanced between the P‐3075 and placebo groups with a 2:1 ratio using blocks of 3 treatments </p> <p>2/3. The double blind study design was guaranteed by the use of placebo cream units, which were identical to the active product in terms of size, shape, volume, colour. The tubes (P‐3075 and placebo) were identically labelled for clinical use as it is in a double‐blind procedure </p> <p>4. Thank you for this observation (you are the first). We confirm that the correct value is ‐167.00 and not 167.00, as reported in our database. It was a typing error that was not detected when the manuscript was transformed in draft paper by the editor </p> <p>5. As described in the paper, a 4‐point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) was used by the investigators at each visit for the clinical evaluation of erythema </p> <p>The results at Day 28 (end of treatment) showed that, in the P‐3075 group, erythema was absent in 27 patients (96.4%) and mild in 1 (3.6%), while in the placebo group, erythema was absent in 9 patients (64.3%) and mild in 5 (35.7%). There were no cases of moderate or severe intensity at Day 28 in both groups. The statistically significance values were reported in the paper as you underlined. For completeness the baseline clinical assessment for erythema was as follows: for P‐3075 absent in 7 patients, mild in 14, moderate in 6 and severe in 1 and for placebo absent in 3 patients, mild in 6 and moderate in 5 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0008" title="BeutnerK , CalvareseB . A multi‐center, investigator‐blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl):P10. ">Beutner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="a0cbc2c5d5d4cec5d2e0c1cec1c3cfd28ec3cfcd" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="2b49484a475d4a594e584e6b4f445c5b434a594658484205484446" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="fdb1bc90999c9591bd99928a8d959c8f908e9e94d39e9290" href="/cdn-cgi/l/email-protection">[email protected]</a>. Useful additional information provided by primary investigator, on randomisation, allocation concealment and characteristics of patients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'<a class="__cf_email__" data-cfemail="1d6f7479757c337f6f747f787e755d7a707c7471337e7270" href="/cdn-cgi/l/email-protection">[email protected]</a>' 30‐8‐2014<br/> Dear professor Bribeche (allocation concealment and blinding)<br/> reply 7‐9‐2014: 1‐ During enrolment we used an allocation randomiser programme: http://www.randomizer.org/<br/> 2‐ Only the participants were blinded to treatment, praziquantel ointment and the placebo had the same colour (white), and ointment were given to participants in identical boxes for both groups (white box with a blue cover)<br/> Next mail 7‐9‐2014: The reply to our first question is more on sequence generation, and not concealment of the allocation. Who was responsible for using that programme and who had access to the generated list? </p> <p>Reply 10‐9‐2014: Me and professor Fedotov VP, were responsible for using this programme, both of us had access to the generated list and a doctor from our department (Dr Makurina); who was fully unaware of the aims of the study and overseen the enrolment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] ">Buendia‐Bordera 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Can't find mail address, sent invite on LinkedIn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chosidow 2014</p> <p><a href="./references#CD003262-bbs2-0173" title="NCT00882531 . Evaluation of the efficacy of isotretinoin versus placebo in terms of response rate among patients presenting papular‐pustular rosacea resistant to standard therapy. clinicaltrials.gov/ct2/show/NCT00882531 (accessed 18 July 2014). ">NCT00882531</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="37585b5e415e524519545f58445e535840775f5a591956475f47195145" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="3f5a525653565a114c5d565b565e517f575251115e4f574f11594d" href="/cdn-cgi/l/email-protection">[email protected]</a>,18‐7‐2014<br/> Is the NCT00882531 published and if so give us a pdf of the publication? </p> <p>Reply 18‐7‐2014 "Hi Esther, we are still in processing the manuscript and hope submitting the paper before the end of 2014" and "We could send your our submitted manuscript?" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0121" title="CunliffeWJ , DodmanB , BinnerJG . Clonidine and facial flushing in rosacea. British Medical Journal1977;1(6053):105. [EMBASE: 0978017820] ">Cunliffe 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0021" title="DahlMV , JarrattMJ , KaplanD , TuleyMR , BakerMD . Once‐daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. Journal of the American Academy of Dermatology2001;45(5):723‐30. [PUBMED: 11606923] ">Dahl 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="115570797d3f5c70637a47517c70687e3f747564" href="/cdn-cgi/l/email-protection">[email protected]</a>."Subjects will be randomised to 1 of the 2 treatment groups at a ratio of 1:1. The randomisation process will be done in blocks of 4, stratified by investigators. The randomisation will be carried out using SAS PROC PLAN" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="d1bba0b5b4bda3bea2a2be91a8b0b9bebeffb2bebc" href="/cdn-cgi/l/email-protection">[email protected]</a>, 1‐8‐2014 ‎(sequence generation, allocation concealment)</p> <p>Chris Billis ‎[<a class="__cf_email__" data-cfemail="8ecde6fce7fdfae1fee6ebfca0ece7e2e2e7fdceeceff7ebfca0ede1e3" href="/cdn-cgi/l/email-protection">[email protected]</a>]‎‎; Keith Flanders ‎[<a class="__cf_email__" data-cfemail="2c4749455844024a404d4248495e5f6c4e4d55495e024f4341" href="/cdn-cgi/l/email-protection">[email protected]</a>]‎<br/> 15‐8‐2014 Randomisation was done centrally by the generation of a randomisation list using the randomisation program RANCODE (version 3.6). Randomisation used blocks. Whole randomisation blocks were allocated to each site. In each study site, each newly enrolled patient was allocated to study medication with the lowest randomisation number available in that particular site at the subjects baseline visit. The patient randomisation number was entered into the CRF immediately after allocation. Each patient retained the randomisation number originally allocated at Baseline for the duration of the study<br/> <br/> Six drug tubes (tubes with a blinded label to cover the trademarks) and 3 bottles were packaged by a CMO in individual numbered kit boxes. Each patient was issued an individual numbered kit box containing 6 tubes and 3 bottles of study materials. The study drug was not to be dispensed by the investigator, but was dispensed by and returned to qualified study personnel (e.g., practice or clinic nurses) not involved with the selection and the assessment of the patients. At the control visits after Weeks 4, 8 and 12, patients returned empty, partially used, and unused containers to qualified study personnel before being examined by the investigator. Study drug compliance was assessed by the qualified study personnel. The patient was advised not to discuss the treatment schedule with the investigator<br/> 19‐8‐2014 sent additional mail regarding SD of lesions<br/> 3‐9‐2014, resent, received 4‐9‐2014 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0031" title="DrenoB , DubertretL , NaeyaertJM , de laBrassineM , MarksR , PowellF , et al. Comparison of the clinical efficacy and safety of metronidazole 0.75% cream with metronidazole 0.75% gel in the treatment of rosacea. Journal of the European Academy of Dermatology &amp; Venereology1998;11(2 Suppl):S272‐3. ">Dreno 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Old study, no further data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0026" title="DraelosZD , FullerBB . Efficacy of 1% 4‐ethoxybenzaldehyde in reducing facial erythema. Dermatologic Surgery2005;31(7 Pt 2):881‐5. [PUBMED: 16029682] ">Draelos 2005b</a>; <a href="./references#CD003262-bbs2-0027" title="DraelosZD , GreenBA , EdisonBL . An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. Journal of Cosmetic Dermatology2006;5(1):23‐9. [PUBMED: 17173568] ">Draelos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f48e90869591989b87b49a9b86809c8780958091da9a9180" href="/cdn-cgi/l/email-protection">[email protected]</a>. On 2006. Sequence generation? "Subjects were randomised based on the order in which they presented to the office". Allocation concealment? "The research coordinator maintained the blind which was not shared with anyone, including the investigator."<br/> 5 dropouts but in which group? The dropouts were for personal reasons, not related to product. They were random between the groups<br/> On 2005 Sequence generation? "Subjects were randomised based on severity of disease and the order in which they presented to the office". Allocation concealment? 'The research coordinator maintained the double blind." Dropouts? "The drop outs were one in each group." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0028" title="DraelosZ , ErthelK , SchnickerM , BaconR , VickeryS . Facial foundation with niacinamide and N‐acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB82. [EMBASE: 70142048] ">Draelos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="047e60766561686b77446a6b76706c77706570612a6a6170" href="/cdn-cgi/l/email-protection">[email protected]</a>, 2‐8‐2014 (sequence generation and allocation concealment and blinding, how many randomised to each group, separate data for participants with rosacea? losses to follow‐up?) </p> <p>9‐8‐2014 sent again. No reaction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="80fae4f2e1e5eceff3c0eeeff2f4e8f3f4e1f4e5aeeee5f4" href="/cdn-cgi/l/email-protection">[email protected]</a>, 2‐8‐2014 (blinding and details on RosaQoL data)</p> <p>Reply 2‐8‐2014 This was the pivotal trial for FDA approval. The blind was maintained by dispensing the vehicle and the vehicle plus the active in identical containers. I do not have more detail on the QOL scores </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0030" title="DraelosZ , HornbyS , WaltersRM , AppaY . Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers. Journal of Cosmetic Dermatology2013;12(4):314‐21. [PUBMED: 24305430] HornbyS , FowlerJ , WaltersRM , AppaY , DraelosZ . Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB66. [EMBASE: 70997350] ">Draelos 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="http://mailto:zdraelos@northstate.net" target="_blank"><span class="__cf_email__" data-cfemail="116b756370747d7e62517f7e63657962657065743f7f7465">[email protected]</span></a> (sequence generation, stratification and allocation concealment and blinding) </p> <p>Reply 2‐8‐2014 <br/> I will answer your questions below:<br/> 1. the method used to generate the allocation sequence as “were divided equally into two groups” does not seem at random. Subjects were randomised in two balanced populations based on a computer generated randomisation sequence<br/> 2. How was stratification done during the sequence generation? That is, can you describe the method used to generate the allocation sequence in sufficient detail to allow us an assessment of whether it should produce comparable groups stratified for demographics and presence and severity of acne, eczema, rosacea and atopic dermatitis?<br/> The data for each person was entered into a database and then the computer randomisation balanced the two groups for all of the characteristics you have mentioned<br/> 3. the method used to conceal the allocation sequence to ensure that intervention allocations could not have been foreseen in advance of, or during, enrolment i.e. participants and investigators enrolling participants could not foresee the upcoming assignment (this is not the same as blinding!!).<br/> I realize that randomisation and blinding are not the same. The products were identically packaged<br/> 4. How were the investigators and participants blinded to the treatment the participants received?<br/> Yes, both the investigator and the participant did not know the product identity which was concealed through identically appearing products packaged identically<br/> 5. Are there separate data for women on rosacea? No, the data was not analysed in this fashion. </p> <p>follow‐up mail that allocation concealment is not yet satisfactorily answered<br/> 9‐8: sent again, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0033" title="ErtlGA , LevineN , KligmanAM . A comparison of the efficacy of topical tretinoin and low‐dose oral isotretinoin in rosacea. Archives of Dermatology1994;130(3):319‐24. [UI: 94175557; PUBMED: 8129410] ">Ertl 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dr Levine, study 17 years old, no further data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] ">Fabi 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="http://mailto:sfabi@gbkderm.com" target="_blank"><span class="__cf_email__" data-cfemail="c8bbaea9aaa188afaaa3acadbaa5e6aba7a5">[email protected]</span></a> 2‐8‐2014 (sequence generation and allocation concealment and dropouts?) </p> <p>Follow‐up mail 11‐8‐2014 and 17‐8‐2014, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0036" title="FowlerJFJr . Combined effect of anti‐inflammatory dose doxycycline (40‐mg doxycycline, usp monohydrate controlled‐release capsules) and metronidazole topical gel 1% in the treatment of rosacea. Journal of Drugs in Dermatology2007;6(6):641‐5. [PUBMED: 17668530] ">Fowler 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="2b4d445c474e5941444e6b46584505484446" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="a8cbc0dac1dbdcc1c9c686c4c7cddbcbc0cde8cfc9c4cccddac5c986cbc7c5" href="/cdn-cgi/l/email-protection">[email protected]</a>. "Randomisation was done by using a computer generated table provided by the sponsor. Neither subjects nor investigators and study staff had any control over this" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a>; <a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a>; <a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a>; <a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="167079617a73647c7973567b65783875797b" href="/cdn-cgi/l/email-protection">[email protected]</a> and Jean Jacovella (<a class="__cf_email__" data-cfemail="1e547b7f7030545f5d51485b52525f5e797f727a7b6c737f307d7173" href="/cdn-cgi/l/email-protection">[email protected]</a>) 22‐8‐2014, 27‐8</p> <p>Asked for separate exact data of PSA and CEA at different time points, wash‐out period and details on AE </p> <p>Received replies 25‐9‐2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20‐7‐2014 asked Galderma if it is published (Patricia van Lith) is this Fowler 2013? 28‐7‐2014 confirmed (NCT01355471 and NCT01789775 are the same studies) </p> <p>Received replies 25‐9‐2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0128" title="FreemanSA , MoonSD , SpencerJM . Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo‐controlled, double‐blind trial. Journal of Drugs in Dermatology2012;11(12):1410‐4. [PUBMED: 23377509] ">Freeman 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'<a class="__cf_email__" data-cfemail="3241475f5f57401c5f5d5d5c725f57561c5e57515d5f1c575647" href="/cdn-cgi/l/email-protection">[email protected]</a>' 3‐8‐2014 (sequence generation and allocation concealment and blinding)<br/> Follow‐up mail 11‐8‐2014 <br/> reply 12‐8‐2014 1) Random selection by study coordinator<br/> 2) Medication and placebo allocation was the responsibility of the study coordinator who randomly selected which product to provide each subject (2:1 ratio). The investigators were unaware of the selection process and the study coordinator was not privy, prior to selection of product, of the type or severity of disease of any subject </p> <p>3) Investigators were not privy to the medication/placebo selection process. No medication tubes were shown to the investigators. No questions were asked about the topical product (i.e. Odor, color or feel). There was no communication between the study coordinator and the investigators regarding the medication/placebo selection </p> <p>follow‐up mail 12‐8‐2014 <br/> Regarding 1) this answer still does not inform us the method, so what method did the study coordinator used?<br/> Regarding 2) You describe that the investigators were unaware of selection process, but if the study coordinator was aware who received what, then the allocation was NOT concealed, even if he was not privy<br/> Regarding 3) if the patients knew what they received they could tell the investigators, as slip of the tongue. So it might be that study coordinator did not say anything, the patients could say something to the investigator. So was there any possibility that patients knew what they received? And if not why not? Why did they not know what they received (as stated as double‐blinded)<br/> Response: 12‐8‐2014: Randomisation: every third patient was given placebo to create a 2:1 ratio<br/> Follow‐up mail: then it is not truly randomised but quasi‐randomised as you know every third patient gets placebo it is no longer at random and we have to exclude the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0130" title="Frucht‐PeryJ , SagiE , HemoI , Ever‐HadaniP . Efficacy of doxycycline and tetracycline in ocular rosacea. American Journal of Ophthalmology1993;116(1):88‐92. [UI: 93318953; PUBMED: 8328549] ">Frucht‐Pery 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐8‐2014 <a class="__cf_email__" data-cfemail="a4ccc5d6c5c8c08ac3cbc8c8cacdc7cfe4c9c1c08acbd2c3d18ac0c1" href="/cdn-cgi/l/email-protection">[email protected]</a> <a class="__cf_email__" data-cfemail="f4979c869d87809b849cda839d9898918687b49598999d86959898da979b99" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation and allocation concealment clarification of N)<br/> 5‐9‐2014 follow‐up, and received replies with clear information </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0044" title="HuangYE , LiXL , LiTJ . Clinical research of topical tacrolimus ointment combined with 585 nm pulsed dye laser in the treatment of rosacea [Chinese]. Journal of Clinical Dermatology2012;41(5):308‐9. [EMBASE: 2012449799] ">Huang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 <a class="__cf_email__" data-cfemail="caa6ada6b0b9a08afbfcf9e4a9a5a7" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation and allocation concealment)</p> <p>9‐8‐2014 follow‐up mail and 17‐8‐2014, no reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0137" title="JacksonM . Combined effect of anti‐inflammatory dose doxycycline and azelaic acid gel 15% in the treatment of rosacea. Journal of the American Academy of Dermatology2007;56(2 Suppl 2):AB19. ">Jackson 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="a7cdc6c4ccd4c8c9cdcac6d5cce7c0cac6cecb89c4c8ca" href="/cdn-cgi/l/email-protection">[email protected]</a> 9‐8‐2014<br/> 1. The dropouts are noted below: 5 total<br/> Two adverse events were classified as possibly related to the study medication – an upset stomach and generalized urticaria in separate patients both receiving ER minocycline + azelaic acid 15%. Four adverse events in three patients (all receiving ER minocycline + azelaic acid 15%) were severe but not suspected to be related to the study medication (bilateral oophorectomy with dermoid cyst removal, gastric erosion after lap band surgery, a severe respiratory infection, and cholecystitis)<br/> <br/> 2. The CEA was a scale of 0 to 4 so there was a typo on 295. The IGA went from 0 to 5. As for the total CEA it was a combined number of the CEA for each location of the face as per the table below<br/> APPENDIX B<br/> Clinician’s Erythema Assessment Scale<br/> ERYTHEMA Definition<br/> 0 None No redness present 1 Mild Slight pinkness 2 Moderate Definite redness 3 Significant Marked erythema 4 Severe Fiery redness<br/> ERYTHEMA Score<br/> • Check one box for each area of the face based upon the definitions given above • Enter the Erythema Score for each area of the face • Sum all of the individual Erythema Scores to obtain the Total Erythema Score<br/> Erythema Score Forehead Chin Nose Right Cheek Left Cheek none (0) none (0) none (0) none (0) none (0) mild (1) mild (1) mild (1) mild (1) mild (1) moderate (2) moderate (2) moderate (2) moderate (2) moderate (2) significant (3) significant (3) significant (3) significant (3) significant (3) severe (4) severe (4) severe (4) severe (4) severe (4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0262" title="JansenT , PlewigG . Rosacea: Classification and treatment. Journal of the Royal Society of Medicine1997;90(3):144‐50. [PUBMED: 9135612] ">Jansen 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0047" title="JorizzoJL , LebwohlM , TobeyRE . The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double blind clinical trial. Journal of the American Academy of Dermatology1998;39(3):502‐4. [UI: 98409174; PUBMED: 9738794] ">Jorizzo 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0138" title="KarabulutAA , Izol SerelB , EksiogluHM . A randomized, single‐blind, placebo‐controlled, split‐face study with pimecrolimus cream 1% for papulopustular rosacea. Journal of the European Academy of Dermatology and Venereology2008;22(6):729‐34. [PUBMED: 18328059] ">Karabulut 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="8ce8fea2ededa2e7edfeedeef9e0f9f8ccebe1ede5e0a2efe3e1" href="/cdn-cgi/l/email-protection">[email protected]</a>. After email contact with the primary investigator this study was excluded </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0048" title="KarsaiS , RoosS , RaulinC . Treatment of facial telangiectasia using a dual‐wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatologic Surgery2008;34(5):702‐8. [PUBMED: 18318728] ">Karsai 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="http://mailto:james.kendall@galderma.com" target="_blank"><span class="__cf_email__" data-cfemail="9ef4fff3fbedb0f5fbf0fafff2f2def9fff2fafbecf3ffb0fdf1f3">[email protected]</span></a> 6‐8‐2014 (sequence generation and allocation concealment and blinding and dropouts) </p> <p>9‐9‐2014 reply: </p> <p>I did not receive your previous e‐mails as my address is <a class="__cf_email__" data-cfemail="c5afaca8ebaea0aba1a4a9a985a2a4a9a1a0b7a8a4eba6aaa8" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>70 patients were enrolled in the study. Two subjects withdrew from the study and they were both in the brimonidine tartrate gel 0.5% treatment group in phase 1 and did not enter phase 2. One for an adverse event and one for a protocol deviation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0053" title="KochR , WilbrandG . Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea [P‐011]. Journal of the European Academy of Dermatology and Venerology1999;12(32 Suppl):S143‐4. ">Koch 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appeared to be wrong R Koch</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0139" title="Koçak‐AltintasAG , Koçak‐MidilliogluI , GulU , BilezickciB , IsiksacanO , DumanS . Effects of topical metranidazole in ocular rosacea. Annals of Ophthalmology2005;37(2):77‐84. [EMBASE: 2005358977] ">Koçak‐Altintas 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After extensive email contact, clarified as a CCT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0140" title="LaquiezeS , CzernielewskiJ , BaltasE . Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. Journal of Dermatological Treatment2007;18(3):158‐62. [PUBMED: 17538804] ">Laquieze 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0054" title="LebwohlMG , MedanskyRS , RussoCL , PlottRT . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet‐R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea. Journal of Geriatric Dermatology1995;3(5):183‐5. ">Lebwohl 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Old study, no further data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="177d7d7b726e737279577a7e79736467657e79703974787a" href="/cdn-cgi/l/email-protection">[email protected]</a> 7‐8‐2014 (sequence generation and allocation concealment)<br/> Reply 12‐8‐2014: I am now Emeritus and mostly out of the loop and my clinical research nurse has retired. Nobody in the clinical trials unit was there when that study was done and I can't get the details you are asking for Sorry! Jim Leyden </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, <a href="http://mailto:info@sol-gel.com" target="_blank">info@sol‐gel.com</a> Ofer.Toledano@sol‐gel.com </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT00940992 “A Study of DER 45‐EV Gel to Treat Rosacea (SGTDER45EV)”. Can you tell us if the NCT00940992 is published and if so give us a pdf of the publication? </p> <p>Reply 19‐7‐2014 Ofer.Toledano@sol‐gel.com, Gaby.Peleg@sol‐gel.com . The study results were published by James Leyden in the JDD (journal of drugs in dermatology) in June 2014, volume 13, issue 6, p.685 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mderma@uni‐muenster.de (allocation concealment and blinding)</p> <p>Reply 18‐8‐2014 <br/> The generation of the random code list was performed in a validated environment by an independent CRO not involved in study conduct and monitoring using the software RANCODE Version 3.6. Central randomisation was performed by this CRO. For eligible subjects, investigators called the randomisation centre and provided the patient’s identification number and gender. Patients were subsequently randomised and the study centre was notified of the treatment number of the patient via telefax by the randomisation centre. Treatment allocation provided by the central randomisation service was documented in the CRF and monitored.<br/> ad 2) The investigational product and its matching vehicle had a similar appearance and all subject kits were packaged in the same way. The randomisation list was kept strictly confidential. It was accessible only to authorized persons who were not involved in the conduct, monitoring and analysis of the study, until time of unblinding. Based on the randomisation list, sets of sealed individual code envelopes were prepared for emergency procedures. No emergency unblinding occurred during the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0058" title="LupinM . Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB43. [EMBASE: 71390263] ">Lupin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulthera, Inc. Mark Lupin, M.D 23‐7‐2014 info @cosmedica.ca <a class="__cf_email__" data-cfemail="d7b8b1b1beb4b297b4b8a4bab2b3beb4b6f9b4b8ba" href="/cdn-cgi/l/email-protection">[email protected]</a>, sent several mails no reply (sequence generation and allocation concealment, dropouts) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0063" title="MostafaFF , ElHarrasMA , GomaaSM , Al MokademS , NassarAA , Abdel GawadEH . Comparative study of some treatment modalities of rosacea. Journal of the European Academy of Dermatology and Venereology2009;23(1):22‐8. [PUBMED: 18705632] ">Mostafa 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S Mokadem no response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Rosacea Society</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0068" title="NeuhausIM , ZaneLT , TopeWD . Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surgery2009;35(6):920‐8. [PUBMED: 19397667] ">Neuhaus 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G Plewig</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0279" title="PowellFC . Clinical practice. Rosacea. New England Journal of Medicine2005;352(8):793‐803. [PUBMED: 15728812] ">Powell 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A Rebora</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0074" title="RigopoulosD , KalogeromitrosD , GregoriouS , PacouretJM , KochC , FisherN , et al. Randomized placebo‐controlled trial of a flavonoid‐rich plant extract‐based cream in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology2005;19(5):564‐8. [PUBMED: 16164709] ">Rigopoulos 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0154" title="SainthillierJ‐M , Mac‐MaryS , CreidiP , MsikaP , ChadoutaudB , HumbertP . Comparative evaluation by colorimetry and videocapillaroscopy of the efficacy of a cream composed of peptide of lupin and soya isoflavones on erythrocouperose [Évaluation comparative par colorimétrie et vidéocapillaroscopie de l'efficacité d'une crème composée de peptide de lupin et d'isoflavones de soja sur l'érythrocouperose]. Nouvelles Dermatologiques2005;24(2):99‐104. [EMBASE: 2005110281] ">Sainthillier 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="d4b0a68bb0bbb5b5a7b5b8b1b994adb5bcbbbbfab7bbb9" href="/cdn-cgi/l/email-protection">[email protected]</a> 10‐08‐2014 Resent 17‐8‐2014 and 3‐9‐2014 (sequence generation and allocation concealment and blinding), no replies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0082" title="SeitéS , BenechF , BerdahS , BayerM , VeyratS , SegotE , et al. Management of rosacea‐prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche‐Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology2013;12(8):920‐4. [EMBASE: 2013521246] ">Seité 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="691a061901000c471a0c001d0c2905061b0c0805470a0604" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014 (sequence generation and allocation concealment and blinding, dropouts)<br/> Reply 12‐8‐2014: </p> <p>1. The allocation sequence was generated by a statistician using a specific software</p> <p>2. As soon as they have been recruited (because they answered to the inclusion criteria) by the investigating dermatologist (only one = Dr Zelenkova) a number given chronologically, as indicated in the allocation sequence purchase to the investigator, was attributed to the patient (the first was the N°1, the 2<sup>nd</sup> the N° 2…) </p> <p>3. After enrolment and at the end of the 1<sup>st</sup> visit, a nurse (in the absence of the investigating dermatologist) give the products allocated to the patient’s number. Both products was in the same packaging (blind white packaging) without any indication about formula reference (only reference of study and number of patient) and some information about use (topical use only…) </p> <p>4. None dropped out between the stop of metronidazole treatment (Week 8) and the end of the study (week 16). 67 patients were included before metronidazole treatment, 1 dropped out due to irritative dermatitis at day 53 (before the end of the 8‐week Metronidazole treatment); So 66 patients remained after 8 weeks, 32 received the test formula and 34 the vehicle </p> <p>5. More detail about the 66 patients included in this study are available (see below (printscreens))<br/> 25‐8‐2014, received additional info on Investigator's assessments </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0083" title="SharquieKE , NajimRA , Al‐SalmanHN . Oral zinc sulfate in the treatment of rosacea: a double‐blind, placebo‐controlled study. International Journal of Dermatology2006;45(7):857‐61. [PUBMED: 16863527] ">Sharquie 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 asked Galderma if NCT01493687 it is published and looks the same as NCT01494467 (Patricia van Lith), confirmed 28‐7 are the same and are Stein Gold<br/> <a class="__cf_email__" data-cfemail="83cecfd0d7c6cacdb2c3ebe5ebf0adecf1e4" href="/cdn-cgi/l/email-protection">[email protected]</a> and <a class="__cf_email__" data-cfemail="dc96b9bdb2f2969d9f938a9990909d9cbbbdb0b8b9aeb1bdf2bfb3b1" href="/cdn-cgi/l/email-protection">[email protected]</a> on details DLQI and SDs </p> <p>3‐9‐2014, received data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 asked Galderma if NCT01493947 is published (Patricia van Lith), confirmation 28‐7‐2014, EADV abstract 2014 </p> <p>alain.taieb@chu‐bordeaux.fr (sequence generation and allocation concealment and blinding, dropouts)<br/> Response 19‐8‐2014 </p> <p>The study was a parallel group study of 960 subjects; however 1800 kit numbers are randomised in blocks of 6. The RANUNI routine of the SAS system was used to randomly assign, in balanced blocks, kit to a treatment (Ivermectin 1% cream, Metronidazole 0.75% cream). Prior to the start of the study, a randomisation list was generated by the statistician and was secured with restricted access. Treatment assignment was balanced into consecutive blocks in a 1:1 ratio and kit numbers were assigned sequentially in chronological order. The study design was investigator‐blinded. The integrity of the blinding was ensured by packaging the products in identical tubes, not allowing the investigator and subject to discuss study treatments, and requiring a third party other than the investigator to dispense the medication. </p> <p>Study population and causes for withdrawal are summarised in the figure below</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0089" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003a</a>; <a href="./references#CD003262-bbs2-0090" title="ThiboutotD , Thieroff‐EkerdtR , GraupeK . Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from 2 vehicle‐controlled, randomized phase III studies. Journal of the American Academy of Dermatology2003;48(6):836‐45. [PUBMED: 12789172] ">Thiboutot 2003b</a>; <a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>; <a href="./references#CD003262-bbs2-0093" title="ThiboutotDM , FleischerAB , DelRossoJQ , RichPH . A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. Journal of Drugs in Dermatology2009;8(7):639‐48. [PUBMED: 19588640] ">Thiboutot 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="31575856545f4558435f505a42584b71565c50585d1f525e5c" href="/cdn-cgi/l/email-protection">[email protected]</a> 17‐8‐2014 ((sequence generation and allocation concealment)<br/> resent 3‐9‐2014 no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0095" title="TorokHM , WebsterG , DunlapFE , EganN , JarrattM , StewartD . Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis2005;75(6):357‐63. [PUBMED: 16047874] ">Torok 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="0e666b626b60637a617c61654e6f6162206d6163" href="/cdn-cgi/l/email-protection">[email protected]</a>. "The patients were not cognizant nor were they aware of the different formulations Nor their unique characteristics so they were easily utilized and dispensed in unmarked tubes". "Central randomisation that was computer generated" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f88a9f99949497b88d9b8b9cd69d9c8d" href="/cdn-cgi/l/email-protection">[email protected]</a> 17‐8‐2014 (sequence generation and allocation concealment and blinding)<br/> resent 3‐9‐2014, received reply 4‐9‐2014 </p> <p>1. The allocation sequence was generated by an unblinded member of the study team who worked off‐site in a separate laboratory to group in a 2‐to‐1 fashion, so that 8 of those numbers were assigned to the treatment group, and 4 to the control group. As subjects were enrolled in the study, they were sequentially assigned a unique study identification number from 1‐12 by the blinded study coordinator, with the first subject to enrol in the study being assigned the study identification number of 1. The list matching study identification numbers to their corresponding treatment group was only accessible by this unblinded member of the study team </p> <p>2. The allocation sequence was created prior to enrolling any subjects in the study, therefore ensuring that intervention allocations could not be foreseen in advance of, or during, enrolment </p> <p>3. This study was conducted in a double‐blind fashion so that both participants and investigators were blinded as to which intervention group participants were assigned. As stated previously, randomisation was completed by an unblinded member of the study team who worked off‐site and had no contact with enrolled subjects. The list of treatment group assignments was stored on a password‐protected computer accessible only to this unblinded study team member. This same unblinded member of the study team was also responsible for preparing all study medication. Once prepared, the study medication was placed into a bottle labelled with the participant’s unique study identification number that was assigned to the participant at the time of enrolment in the trial. The unblinded study team member dispensed the bottles of prepared medication to the study’s clinical coordinator, who was also blinded, for distribution to subjects. Both the treatment and the control creams were identical in appearance and viscosity so that the two drugs could not be distinguished by look or feel<br/> Resent regarding exact data IGE and CEA 12‐9‐2013<br/> Received 12‐9‐2013 exact data + SD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0102" title="WilkinJK . Effect of nadolol on flushing reactions in rosacea. Journal of the American Academy of Dermatology1989;20(2 Pt 1):202‐5. [PUBMED: 2521641] ">Wilkin 1989</a>; <a href="./references#CD003262-bbs2-0103" title="DeWittS , WilkinJK . Double blind, parallel study of efficacy and safety of clindamycin lotion in the treatment of rosacea. Clinical Pharmacology and Therapeutics1987;41(2):176. WilkinJK , DeWittS . Treatment of rosacea: topical clindamycin versus oral tetracycline. International Journal of Dermatology1993;32(1):65‐7. [UI: 93146772; PUBMED: 8425809] ">Wilkin 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Additional information could not be used</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0105" title="WolfJEJr , KerroucheN , ArsonnaudS . Efficacy and safety of once‐daily metronidazole 1% gel compared with twice‐daily azelaic acid 15% gel in the treatment of rosacea. Cutis2006;77(4 Suppl):3‐11. [PUBMED: 16706244] ">Wolf 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. ">Yoo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="16737a7a7378387b77647b6364567b79637862657f78777f38796471" href="/cdn-cgi/l/email-protection">[email protected]</a> 18‐8‐2014 (sequence generation and allocation concealment and blinding) </p> <p>Resent 3‐9 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0169" title="ACTRN12614000004662 . A single‐blind randomised controlled trial of topical Kanuka honey for the treatment of rosacea. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365179 (accessed 21 July 2014). ">ACTRN12614000004662</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medical Research Institute of New Zealand, Anna Hunt <a class="__cf_email__" data-cfemail="ef8e81818ec1879a819baf829d868195c18e8cc18195" href="/cdn-cgi/l/email-protection">[email protected]</a>. sent 23‐7‐2014</p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> ACTRN12614000004662 “A single‐blind randomised controlled trial of topical Kanuka honey for the treatment of rosacea”. Can you tell us if ACTRN12614000004662 is published and if so give us a pdf of the publication? </p> <p>email reply 29‐7‐2014 </p> <p>Dear Dr van Zuuren,</p> <p>Thank you for your email and interest in our study. We are currently analysing this 138 participant Phase 3 study. It is not yet published, but we would be happy to send you the publication when that time comes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0181" title="EUCTR2006‐001999‐20‐HU . Assessment of the efficacy and safety of three concentration:1%, 0.3%, 0.1% of CD5024 cream once daily and CD5024 1% cream twice daily, versus its vehicle and versus metronidazole cream (Rozex®) in patients with papulopustular rosacea over 12 weeks. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2006‐001999‐20‐HU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0182" title="EUCTR2006‐003707‐40‐DE . Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato‐telangiectatic rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2006‐003707‐40‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0185" title="EUCTR2009‐013111‐35‐DE . Effect of CD08514 versus placebo, in patients presenting with type 1 rosacea, over an 8‐week treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2009‐013111‐35‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0186" title="EUCTR2010‐018319‐13‐DE . A double‐blind, vehicle controlled, parallel group study assessing the activity of CD5024 1% cream in subjects with papulopustular rosacea over 12 weeks treatment. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2010‐018319‐13‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0187" title="EUCTR2010‐021150‐19‐NL . Doxycycline versus minocycline in the treatment of rosacea: a randomised controlled trial. ‐ DoMino‐study. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2010‐021150‐19‐NL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study of Mireille, is still ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0188" title="EUCTR2010‐023566‐43‐DE . No English title [Multizentrische, randomisierte, doppelblinde, kontrollierte Phase III‐Studie zur Behandlung der papulopustulären Rosazea mit Permethrin Creme 5 % (InfectoScab®) versus Permethrin Creme 2,5 % versus Metronidazol Creme 0,75 % (Rozex®) ‐ Papulopustuläre Rosazea‐Behandlung mit Permethrin Creme versus Metronidazol Creme]. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2010‐023566‐43‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014 Dr. Bertil Wachall, <a class="__cf_email__" data-cfemail="43303736272a262d032a2d252620372c332b22312e6d202c2e" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>2‐10‐2014 Thank you for your request concerning our permethrin rosacea trial (permethrin 5% and 2.5% vs metronidazole cream). Unfortunately, the data are not published or submitted up to now. We hope this will be done in the next months, but the principal investigator who is responsible for the publication seems to be very busy. </p> <p>In addition, please be informed that we are currently conducting another permethrin trial (permethrin 5% vs placebo cream) in PPR‐patients. We expect the results of this trial in spring 2015 (we discussed with PI, study does NOT appear in EUCTR (EUDRACT‐Nr. 2013‐000979‐32) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0189" title="EUCTR2011‐002057‐65‐DE . Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2011‐002057‐65‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0190" title="EUCTR2011‐002058‐30‐DE . Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6‐week treatment period. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2011‐002058‐30‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0191" title="EUCTR2011‐004791‐11‐CZ . Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36‐week extension period. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2011‐004791‐11‐CZ</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0192" title="EUCTR2012‐001044‐22‐SE . A multicenter, randomized, double‐blind, vehicle‐controlled, parallel group study to demonstrate the efficacy and assess the safety of CD07805/47 gel 0.5%applied topically once daily in subjects with moderate to severe facial erythema of rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2012‐001044‐22‐SE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0193" title="EUCTR2013‐005083‐26‐DE . Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea ‐ Effect of CD07805/47 gel in rosacea flushing. apps.who.int/trialsearch/ (accessed 23 September 2014). ">EUCTR2013‐005083‐26‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014, sent e‐mail to Galderma NL and several more to Galderma International, no reply </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0194" title="IRCT2014010516079N1 . Comparison of dapsone 5% topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">IRCT2014010516079N1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014 <a class="__cf_email__" data-cfemail="01465e67606669686968416c64652f6c74682f60622f6873" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="ff8fa09497908c8d9e899e9196bf8d9a8c969b9a918bd1928a96d19e9cd1968d" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already completed or submitted for publication.<br/> IRCT2014010516079N1 “Comparison of dapsone 5% Topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea”. Can you tell us if IRCT2014010516079N1 is already completed? Or submitted for publication? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0194" title="IRCT2014010516079N1 . Comparison of dapsone 5% topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline in papulopustular rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">IRCT2014010516079N1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23‐9‐2014 <a class="__cf_email__" data-cfemail="e08b8f938192818f8f8689a09981888f8fce838f8d" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="3d56524e5c4f5c52525b547d5a505c5451135e5250" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="563b333e323f243c1637393a78353978233d" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already submitted for publication.<br/> IRCT2014030416837N1 “Effects of permethrin 5% topical gel in comparison with placebo on Demodex density in rosacea patients: a double‐blind, randomised clinical trial”. Can you tell us if IRCT2014030416837N1 is already submitted for publication? </p> <p>Reply: 23‐9‐2014</p> <p>Dear Dr Zuuren</p> <p>Many thanks for your query,</p> <p>We are in the process of completing and submitting the article.</p> <p>Regards,</p> <p>Mehdi</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0195" title="JPRN‐UMIN000008315 . Clinical trial for development of topical rapamycin treatment for rosacea. apps.who.int/trialsearch/ (accessed 23 September 2014). ">JPRN‐UMIN000008315</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mari Wataya‐Kaneda <a class="__cf_email__" data-cfemail="a1cccac0cfc4c5c0e1c5c4d3ccc08fccc4c58fced2c0cac0" href="/cdn-cgi/l/email-protection">[email protected]</a>‐u.ac.jp not sent mail as they are still recruiting </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0196" title="NCT00041977 . A multicenter, randomized, double‐blind, placebo‐controlled, clinical trial to determine the effects of doxycycline hyclate 20 mg tablets [Periostat(R)] administered twice daily for the treatment of acne rosacea. clinicaltrials.gov/ct2/show/NCT00041977 (accessed 21 July 2014). ">NCT00041977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="3f765159507f4f5e4d564c5a4d5b5a4d52115c5052" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014<br/> My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion (NCT00041977 “A Multicentre, randomised, Double‐Blind, Placebo‐Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea”)<br/> <br/> Has this study ever been published as I could not find it? If not, do you have a contact at CollaGenex Pharmaceuticals, as on the web site of clinicaltrials.gov this is not provided, but we found your name on it, also asked Galderma (Patricia van Lith) </p> <p>Follow up mail to Dr Pariser 11‐8‐2014 <br/> Reply 13‐8: They sent me a study, but is not correct one, but on acne, so sent again request </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0064" title="NCT00249782 . A phase II, randomized, partial‐blind, parallel‐group, active‐ and vehicle‐controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). ">NCT00249782</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan, results published on the Internet, as word doc and pdf we made several, but unsuccessful, attempts to contact Allergan </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00348335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="7f150d08160b0b0f1a11113f1e1013511c1012" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="59332e302d2d293c373719363a353077373c2d" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014</p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion (NCT00348335 “Efficacy of topical cyclosporin 0.05% for the treatment of ocular rosacea”)<br/> Has this study ever been published as I could not find it? (I do have the 2005 one) </p> <p>Follow‐up mail 11‐8‐2014 <br/> Reply: 12‐8‐2014 The study was discontinued when early results showed that we did not have a reproducible method of quantifying injection. It was far too variable and did not appear to correspond at all to patients reporting symptomatic improvement. </p> <p>John Wittpenn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00417937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 Alan Fleischer &lt;<a class="__cf_email__" data-cfemail="a9c8cfc5ccc0dacac1e9dec8c2ccc1ccc8c5ddc187cccddc" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;My colleagues and I are updating our Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already included in our review?<br/> NCT00417937 “A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily”. Is this the same study as published in Thiboutot DM, Fleisher AB, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology 2008;7(6):541‐6.? Or is it another one? </p> <p>Reply 19‐7‐2014: I do believe that this is the exact same study. Sorry that my name appears in lots of clinical trials settings (<a href="./references#CD003262-bbs2-0092" title="ThiboutotDM , FleisherAB , DelRossoJQ , GraupeK . Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. Journal of Drugs in Dermatology2008;7(6):541‐6. [PUBMED: 18561584 ] ">Thiboutot 2008</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0197" title="NCT00436527 . MetroGel 1% hydration study: a kinetic regression study. clinicaltrials.gov/show/NCT00436527 (accessed 19 July 2014). ">NCT00436527</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, asked Galderma if it is published (Patricia van Lith), several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="4b2124382e65393e2e2f2a0b2c2a272f2e39262a65282426" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00483145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="0c61646d6968697e7f686d604c686d6860626978226867" href="/cdn-cgi/l/email-protection">[email protected]</a> 16‐7‐2014<br/> My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion (NCT00483145 Laser‐mediated photodynamic therapy of acne vulgaris and rosacea). It has been completed in 2007.<br/> Has this study ever been published as I could not find it? </p> <p>Reply 16‐7‐2014: We were unsuccessful in recruiting rosacea patients and as thus, published a case report, which is attached. Results from treating acne patients were published as a RCT, we have removed this one from ongoing studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0198" title="NCT00495313 . Determine the effects of COL‐101 administered once daily with metronidazole topical gel, 1% versus doxycycline hyclate 100 mg administered once daily with metronidazole topical gel, 1% in patients with moderate to severe rosacea. clinicaltrials.gov/ct2/show/NCT00495313 (accessed 16 July 2014). ">NCT00495313</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sent 16‐7‐2014 message via LinkedIn, and Galderma (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="f49e9b8791da8681919095b49395989091869995da979b99" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0171" title="NCT00560703 . Efficacy and safety of COL‐101 for the treatment of blepharitis in patients with facial rosacea. clinicaltrials.gov/ct2/show/NCT00560703 (accessed 16 July 2014). ">NCT00560703</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16‐7‐2014, asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="7d17120e18530f0818191c3d1a1c1119180f101c531e1210" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0172" title="NCT00617903 . A 12‐week exploratory, multicenter, double‐blind, vehicle‐controlled study to investigate the efficacy and safety of topical azelaic acid 15% foam twice daily in patients with papulopustular rosacea. clinicaltrials.gov/ct2/show/NCT00617903 (accessed 18 July 2014). ">NCT00617903</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 clinical‐trials‐<a class="__cf_email__" data-cfemail="b5d6dadbc1d4d6c1f5d7d4ccd0c7ddd0d4d9c1ddd6d4c7d09bd6dad8" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT00617903 “Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea”. I found a study of Draelos published in 2013 in CUTIS, but that one included far more participants than the 84 mentioned in the NCT00617903 study.<br/> Can you tell us if the NCT00617903 is published and if so give us a pdf of the publication?<br/> 11‐8‐2014 follow‐up mail<br/> 15‐8‐2014: Christopher Billis &lt;<a class="__cf_email__" data-cfemail="94f7fce6fde7e0fbe4fcf1e6baf6fdf8f8fde7d4f6f5edf1e6baf7fbf9" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;, resent<br/> 15‐8‐2014, not published and no additional info </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0199" title="NCT00621218 . A pilot study to compare tretinoin gel, 0.05% to tretinoin gel vehicle when dosed once or twice daily in female subjects with classical rosacea. clinicaltrials.gov/ct2/show/NCT00621218 (accessed 18 July 2014). ">NCT00621218</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 via website Valeant Pharmaceuticals who took over Coria Laboratories, asked if it is published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0200" title="NCT00667173 . A phase 2, multi‐center, evaluator‐blind, randomized, vehicle‐controlled clinical study to assess the safety and efficacy of IDP‐115 in the treatment of rosacea. clinicaltrials.gov/ct2/show/NCT00667173 (accessed 18 July 2014). ">NCT00667173</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 via website Valeant Pharmaceuticals who took over Dow Pharmaceutical Sciences, Inc, asked if it is published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0201" title="NCT00697541 . A phase II, single‐center, two‐way crossover relative systemic bioavailability study of Col‐118 administered topically as a 0.18 % facial gel and brimonidine ophthalmic solution 0.2% administered to the eye in subjects with moderate to severe erythematous rosacea. clinicaltrials.gov/ct2/show/NCT00697541 (accessed 18 July 2014). ">NCT00697541</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="eb8184988ec5999e8e8f8aab8c8a878f8e99868ac5888486" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0202" title="NCT01016782 . Multi‐center, double‐blind, randomized, vehicle‐controlled, parallel group study of 0444 gel. clinicaltrials.gov/ct2/show/NCT01016782 (accessed 19 July 2014). ">NCT01016782</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, mail though website Sandoz. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT01016782 “Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea)”. Can you tell us if the NCT01016782 is published and if so give us a pdf of the publication? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0174" title="NCT01125930 . Investigation of the topical retinoid, Atralin gel 0.05% for the treatment of erythematotelangiectatic rosacea. clinicaltrials.gov/ct2/show/NCT01125930 (accessed 19 July 2014). ">NCT01125930</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014, <a href="http://mailto:maierl%40med.umich.edu?subject=NCT01125930, Derm 616, Atralin Gel for the Treatment of Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="b2dfd3dbd7c0def2dfd7d69cc7dfdbd1da9cd7d6c7">[email protected]</span></a>. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT01125930 “Atralin Gel for the Treatment of Rosacea”. Can you tell us if NCT01125930 is published and if so give us a pdf of the publication?<br/> Reply 29‐7‐2014: </p> <p>Dear Dr. van Zuuren, The study has not yet been published yet. When it has been accepted for publication, I can notify you. Thank you, Lisa Maier </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0203" title="NCT01134991 . Pilot, randomized, double blind, placebo controlled, parallel group, dose range finding study, to evaluate the tolerability and safety of FXFM244 antibiotic foam and to monitor its clinical effect in moderate to severe rosacea patients. clinicaltrials.gov/ct2/show/NCT01134991 (accessed 19 July 2014). ">NCT01134991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 <a class="__cf_email__" data-cfemail="23474c5563454c424e4a5b0d404c0d4a4f" href="/cdn-cgi/l/email-protection">[email protected]</a>. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? NCT01134991 “Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients”. Can you tell us if NCT01134991 is published and if so give us a pdf of the publication? </p> <p>Reply 21‐7 Dov Tamarkin, Ph.D. <a class="__cf_email__" data-cfemail="fb9f948dd58f9a969a89909295bb9d949a9692838b939a89969ad5989496" href="/cdn-cgi/l/email-protection">[email protected]</a>, study is still ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0204" title="NCT01186068 . A randomized, double‐blind, vehicle‐controlled, parallel‐group study of the dose‐response profile of V‐101 cream in subjects with erythematous rosacea. clinicaltrials.gov/ct2/show/NCT01186068 (accessed 19 July 2014). ">NCT01186068</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 <a class="__cf_email__" data-cfemail="54323b233831263e3b311439273a7a373b39" href="/cdn-cgi/l/email-protection">[email protected]</a> My colleagues and I are updating our Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT01186068 “A randomised, double‐blind, vehicle‐controlled, parallel‐group study of the dose‐response profile of V‐101 cream in subjects with erythematous rosacea”<br/> Can you tell us if the NCT01186068 is published and if so give us a pdf of the publication? (By the way we will include your dose‐finding studies and phase III studies on brimonidine, and might need to contact you later about these. </p> <p>Follow‐up 11‐8‐2014 <a class="__cf_email__" data-cfemail="b7d5d2ced2c5f7c4d6dad5c5d8c0d999d4d8da" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> Reply 12‐8‐2014 Dr Fowler: not published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0205" title="NCT01257919 . Investigator‐blinded, randomized, cross‐over, multiple dose phase I study on safety and pharmacokinetics of topically applied azelaic acid foam, 15% compared to azelaic acid gel, 15% in subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01257919 (accessed 19 July 2014). ">NCT01257919</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014. Bayer sent though website, Novum, <a class="__cf_email__" data-cfemail="c3aaada5ac83adacb5b6aeb3b1b0eda0acae" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? </p> <p>The study was supported by Bayer and Novum are listed as "locations" on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> </p> <p>NCT01257919 “ Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea </p> <p>Can you tell us if the study has been published if so could I request a pdf of the publication? </p> <p>If not could we please access the data?<br/> 15‐8‐2014: Christopher Billis &lt;<a class="__cf_email__" data-cfemail="6d0e051f041e19021d05081f430f040101041e2d0f0c14081f430e0200" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;, resent<br/> 15‐8‐2014, not published and no additional info </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0206" title="NCT01308619 . A multicenter, randomized, double‐blind, placebo‐controlled evaluation of rosacea‐related inflammatory biochemical markers in the skin of adults with papulopustular rosacea treated with daily doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) capsules. clinicaltrials.gov/show/NCT01308619 (accessed 19 July 2014). ">NCT01308619</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="204a4f53450e52554544416047414c4445524d410e434f4d" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT01398280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014 Tissa Hata, MD, University of California, San Diego, <a class="__cf_email__" data-cfemail="b7c3dfd6c3d6f7c2d4c4d399d2d3c2" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? </p> <p>NCT01398280 Effects of Aminocaproic Acid (ACA) on Rosacea‐specific Inflammation</p> <p>If this has been published could I kindly ask for the citation and/or if you have a pdf available? </p> <p>If it has not been published are the data available?<br/> Follow‐up 11‐8‐2014 and 17‐8‐2014 </p> <p>17‐8‐2014: EvZ: This is <b>Two 2014</b>!!! </p> <p>Reply: 18‐8‐2014: Thank you for your interest in our research. Attached is the paper which was published in the JID. Thanks! Tissa </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="fa9095899fd4888f9f9e9bba9d9b969e9f88979bd4999597" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 August with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> <p>5‐9‐2014: <a class="__cf_email__" data-cfemail="0d5a6c7f7f6863235a4443464841404c434d6a6c6169687f606c236e6260" href="/cdn-cgi/l/email-protection">[email protected]</a>. ‎ 22‐9‐2014, received all we needed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Novartis Pharmaceuticals, no contact details, sent mail through Dutch website<br/> 12‐8‐2014 reply <a href="http://mailto:pieter.ekkel@novartis.com_" target="_blank"><span class="__cf_email__" data-cfemail="cdbda4a8b9a8bfe3a8a6a6a8a18da3a2bbacbfb9a4bee3aea2a0">[email protected]</span></a> </p> <p>U vraagt om informatie over de studie NCT01449591 (CBFH772A2203) met als compound BFH772. </p> <p>De enige informatie die we nu kunnen delen over deze studie zijn gepubliceerd op ‘Novartis clinical trial database’, onder ‘Novartis Institute for Biomedical Research’, Dermatology/Skin, CBFH772 <a href="http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public" target="_blank">http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public</a> <br/> 22‐8‐2014: What was the rationale behind study, are they going to proceed with further studies? will it be published? </p> <p>Reply 9‐9‐2014: BFH772 is currently under investigation and has not been approved for use other than for use as part of a clinical trial.<br/> Therefore, at this present time, no further information can be provided other than what is publicly available at the previously indicated location (http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public )<br/> Whether or not results of trial NCT01449591 "Safety, Tolerability and Efficacy of BFH77s in Rosacea Patients" will be published in medical journals in the future cannot be anticipated at this stage.<br/> Please do not hesitate to reach out to us again in six months' time to inquire about potential updates, if of interest.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0175" title="NCT01451619 . A randomized, double‐blind, placebo‐controlled, multi‐center, parallel group study to assess the pharmacodynamics of MK‐0524 in subjects with moderate to severe erythematotelangiectatic rosacea. (protocol No. 155). clinicaltrials.gov/show/NCT01451619 (accessed 19 July 2014). ">NCT01451619</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014. Merck Sharp &amp; Dohme Corp, <a class="__cf_email__" data-cfemail="bdcec9d8cbd8d393decfdcdad1d8fdd0d8cfded693ded2d0" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="adc5c8ccd9c5c8df83ded9ccc0ccd9cccec2deedc0c8dfcec683cec2c0" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="91faf4fdfdf4e8bff5fee4f6f9f4e3e5e8d1fcf4e3f2fabff2fefc" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> Reply 23‐7‐2014<a href="http://mailto:pamela_eisele@merck.com" target="_blank"><span class="__cf_email__" data-cfemail="ccbcada1a9a0ad93a9a5bfa9a0a98ca1a9beafa7e2afa3a1">[email protected]</span></a> I checked with our researchers and have been told that the study results have been submitted for publication and are currently under review for consideration by the <i>Journal of Clinical Pharmacology</i>. It is unclear at this point when the data may be available, as they are being considered by the publication </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0207" title="NCT01513863 . A randomized, double‐blind, placebo controlled, parallel design, multi‐site clinical study to compare the bioequivalence of two metronidazole 1% topical gel formulations in patients with moderate to severe rosacea. clinicaltrials.gov/show/NCT01513863 (accessed 19 July 2014). ">NCT01513863</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19‐7‐2014 <a class="__cf_email__" data-cfemail="743330331b1a131507341a1b0201190406075a171b19" href="/cdn-cgi/l/email-protection">[email protected]</a>. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published? NCT01513863 “A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea (MTZG)”. Can you tell us if NCT01513863 is published and if so give us a pdf of the publication? </p> <p>21‐7‐2014 reply Aimee Brown, <a class="__cf_email__" data-cfemail="450407372a322b052b2a3330283537366b262a28" href="/cdn-cgi/l/email-protection">[email protected]</a>. "Thank you Dr. Zuuren for your inquiry, however this study has not yet been published." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0208" title="NCT01555463 . A randomized, double‐blind, vehicle‐controlled, multicenter, parallel‐group clinical trial to assess the safety and efficacy of azelaic acid foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01555463 (accessed 20 Juy 2014). ">NCT01555463</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bayer, mailed via website 22‐7‐2014<br/> 15‐8‐2014: Christopher Billis &lt;<a class="__cf_email__" data-cfemail="a6c5ced4cfd5d2c9d6cec3d488c4cfcacacfd5e6c4c7dfc3d488c5c9cb" href="/cdn-cgi/l/email-protection">[email protected]</a>&gt;, resent<br/> 15‐8‐2014, not published and no additional info </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0176" title="NCT01579084 . Safety and tolerability of AGN‐199201 in patients with erythema associated with rosacea. clinicaltrials.gov/show/NCT01579084 (accessed 21 July 2014). ">NCT01579084</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan, sent mail 22‐07‐2014 through website no response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0177" title="NCT01614743 . A double‐blinded, randomized placebo controlled pilot study comparing the efficacy and safety of Incobotulinumtoxin A versus saline injections to the cheek region in patients with rosacea. clinicaltrials.gov/show/NCT01614743 (accessed 19 July 2014). ">NCT01614743</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22‐7‐2014 Steven H. Dayan, Medical Director, DeNova Research, <a href="http://mailto:MyClinicalTeam@drdayan.com" target="_blank"><span class="__cf_email__" data-cfemail="d09da993bcb9beb9b3b1bc84b5b1bd90b4a2b4b1a9b1befeb3bfbd">[email protected]</span></a> </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, could you kindly confirm the status? </p> <p>It is reported on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> as <b>This study is ongoing, but not recruiting participants</b> </p> <p>When do you expect to complete it or if it is completed ... publish the data?</p> <p>Reply 22‐7‐2014. We appreciate your inquiry, and look forward to speaking with you. We are currently forwarding your message to Annie, our patient coordinator, and she will respond soon. </p> <p>emailed again 29‐7 2014. reply 29‐7‐2014 of <a href="http://mailto:Selika@denovaresearch.com" target="_blank"><span class="__cf_email__" data-cfemail="0152646d686a604165646f6e776073647264607362692f626e6c">[email protected]</span></a> I appreciate you reaching out to us. This study is in the process of being written up, unfortunately due to a signed confidentiality agreement, we cannot provide you with any of the data at this time </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0178" title="NCT01631656 . Combination Finacea gel and vascular Nd:Yag laser therapy for mild to moderate rosacea. clinicaltrials.gov/show/NCT01631656 (accessed 20 July 2014). ">NCT01631656</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amy McMichael, Wake Forest School of Medicine</p> <p>23‐7‐2014</p> <p><a class="__cf_email__" data-cfemail="99f8f4faf4f0faf1f8d9eef8f2fcf1fcf8f5edf1b7fcfdec" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="16777b757b7f757e7756617063747b7538737263" href="/cdn-cgi/l/email-protection">[email protected]</a> (sequence generation, allocation concealment), several e‐mail exchanges, no replies to this </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0209" title="NCT01659853 . A multicenter, randomized, controlled, double‐masked, crossover design study to compare efficacy and assess safety of CD07805/47 gel 0.5% applied once daily vs azelaic acid gel 15% applied twice daily in subjects with erythema of rosacea. clinicaltrials.gov/show/NCT01659853 (accessed 20 July 2014). ">NCT01659853</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20‐7‐2014 asked Galderma if it is published (Patricia van Lith), 28‐7‐2014, not yet published, but I thought already submitted so sent another mail. several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="83e9ecf0e6adf1f6e6e7e2c3e4e2efe7e6f1eee2ade0ecee" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 August with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0179" title="NCT01735201 . AGN‐199201 for the treatment of erythema with rosacea. clinicaltrials.gov/show/NCT01735201 (accessed 21 July 2014). ">NCT01735201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan, results posted on clinicaltrials.gov <a href="http://mailto:clinicaltrials%40allergan.com?subject=NCT01735201, 199201-002, AGN-199201 for the Treatment of Erythema With Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="95f6f9fcfbfcf6f4f9e1e7fcf4f9e6d5f4f9f9f0e7f2f4fbbbf6faf8">[email protected]</span></a>, 23‐7‐2014 </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published, we saw results published on clinicaltrials.gov? NCT01735201 “AGN‐199201 for the Treatment of Erythema With Rosacea”. Can you tell us if NCT01735201 is published and if so give us a pdf of the publication? </p> <p>Follow‐up 11‐8‐2014 and 17‐8‐2014 no replies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0180" title="NCT01740934 . An eight‐week, multi‐site, double‐blind, randomized, vehicle‐controlled, parallel‐group trial to evaluate the safety, tolerability, and effects of Anatabloc® crème in subjects with rosacea followed by an open‐label extension. clinicaltrials.gov/show/NCT01740934 (accessed 20 July 2014). ">NCT01740934</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rock Creek Pharmaceuticals, Inc. M Varga, 23‐7‐2014 <a class="__cf_email__" data-cfemail="1a727f7b766e725a6875797179687f7f716a727b68777b34797577" href="/cdn-cgi/l/email-protection">[email protected]</a><br/> response 1‐8‐2014: Thanks very much for your interest in our just concluded clinical trial, we are in the process of writing the clinical study report. We will make it available to you. If you have additional question, please do not hesitate to contact me.Dr Ernest Okorie,MD <a href="http://mailto:gddssconsultant@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="9bfcffffe8e8f8f4f5e8eef7effaf5efdbfcf6faf2f7b5f8f4f6">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0210" title="NCT01784133 . A phase 2, randomized, vehicle‐controlled, double‐blind, multicenter study to evaluate the safety and efficacy of three once‐daily CLS001 topical gels versus vehicle administered for 12 weeks to subjects with papulopustular rosacea. clinicaltrials.gov/show/NCT01784133 (accessed 20 July 2014). ">NCT01784133</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutanea Life Sciences, Inc</p> <p>23‐7‐2014, <a class="__cf_email__" data-cfemail="137a7d757c53706667727d76727f7a75763d707c7e" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>This study has been completed. My colleagues and I are conducting a Cochrane review (Interventions for rosacea) this study has been identified as potentially eligible for inclusion. Can you please indicate if the study has been published and if so could I request a pdf or the citation? If not are the data available? </p> <p>10‐8‐2014 Resent e‐mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0211" title="NCT01828177 . A multicenter randomized evaluator‐blinded vehicle‐controlled parallel group evaluation of twice daily PDI‐320 in comparison to its monads in adults with rosacea. clinicaltrials.gov/show/NCT01828177 (accessed 20 July 2014). ">NCT01828177</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PreCision Dermatology, Inc.Syd Dromgoole, as study is still ongoing not sent mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21‐7‐2014 asked Galderma if it is published (Patricia van Lith) several follow‐up mails also to Maria‐Jose Rueda marie‐<a class="__cf_email__" data-cfemail="b3d9dcc0d69dc1c6d6d7d2f3d4d2dfd7d6c1ded29dd0dcde" href="/cdn-cgi/l/email-protection">[email protected]</a> last 11‐8‐2014<br/> Follow‐up mails 14 august with several people of Galderma including Maria‐Jose Rueda and Jean Jacovella </p> <p>19‐8‐2014 received poster abstracts Layton 2014 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0212" title="NCT01917539 . Efficacy of Pulsed Light Therapy for Meibomian gland dysfunction and dry eye syndrome. clinicaltrials.gov/show/NCT01917539 (accessed 21 July 2014). ">NCT01917539</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angela Chang, University of Miami <a href="http://mailto:AChang2%40med.miami.edu?subject=NCT01917539, 20120140, Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome" target="_blank"><span class="__cf_email__" data-cfemail="90d1d3f8f1fef7a2d0fdf5f4befdf9f1fdf9bef5f4e5">[email protected]</span></a> or Bradford Lee <a href="http://mailto:blee%40post.harvard.edu?subject=NCT01917539, 20120140, Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome" target="_blank"><span class="__cf_email__" data-cfemail="ea88868f8faa9a85999ec4828b989c8b988ec48f8e9f">[email protected]</span></a> </p> <p>Still recruiting patients at the moment, not sent mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0213" title="NCT01933464 . An analysis of the effect of topical cromolyn sodium on rosacea‐associated erythema. clinicaltrials.gov/show/NCT01933464 (accessed 20 July 2014). ">NCT01933464</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anna Di Nardo, MD, PhD, University of California, San Diego. As study is still recruiting not sent mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0214" title="NCT01993446 . A randomized, double‐blind, vehicle controlled study of the safety and efficacy of topical DRM02 in subjects with rosacea. clinicaltrials.gov/show/NCT01993446 (accessed 20 July 2014). ">NCT01993446</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dermira, Inc. Beth Zib, <a href="http://mailto:info@dermira.com" target="_blank"><span class="__cf_email__" data-cfemail="f29b9c949db29697809f9b8093dc919d9f">[email protected]</span></a> 23‐7‐2014 </p> <p>Follow‐up 11‐8‐2014 no replies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0215" title="NCT02036229 . A randomised, double blind, placebo controlled, half‐face study to evaluate the effect of topical ivermectin cream 0.5% on demodicidosis. clinicaltrials.gov/ct2/show/NCT02036229 (accessed 20 July 2014). ">NCT02036229</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rina Segal, Rabin Medical Center, <a href="http://mailto:rinas3%40clalit.org.il?subject=NCT02036229, topical ivermectin, demodex, Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis" target="_blank"><span class="__cf_email__" data-cfemail="b3c1daddd2c080f3d0dfd2dfdac79ddcc1d49ddadf">[email protected]</span></a> not sent mail as not yet open to recruitment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0216" title="NCT02052999 . An open label pilot study to evaluate the efficacy of PAC‐14028 in the treatment of erythematotelangiectatic rosacea and papulopustular rosacea. clinicaltrials.gov/show/NCT02052999 (accessed 20 July 2014). ">NCT02052999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amorepacific Corporation BeomJoon Kim, Professor Department of Dermatology, Chungang University Hospital, sent mail through website 23‐7‐2014 </p> <p>My colleagues and I are conducting a Cochrane review (Interventions for rosacea) and one of your studies have been identified as potentially eligible for inclusion, but not sure if it is already published?<br/> NCT02052999 “Study to evaluate the efficacy and safety of PAC‐14028 cream in rosacea patients”. Can you tell us if NCT02052999 is published and if so give us a pdf of the publication? Study is performed by BeomJoon Kim </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0217" title="NCT02075671 . Photodynamic therapy for papulopustular rosacea. clinicaltrials.gov/show/NCT02075671 (accessed 20 July 2014). ">NCT02075671</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>George Washington University, Jack Short, <a href="http://mailto:jshort%40mfa.gwu.edu?subject=NCT02075671, 031416, Photodynamic Therapy for Papulopustular Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="442e372c2b3630042922256a2333316a212031">[email protected]</span></a> as they are still recruiting, not sent mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0218" title="NCT02120924 . A multicenter, double‐blind, randomized, parallel‐group, vehicle‐controlled study to evaluate the safety and clinical equivalence of a generic azelaic acid gel, 15% and the reference listed Finacea® (azelaic acid) gel, 15% in patients with moderate facial rosacea. clinicaltrials.gov/show/NCT02120924 (accessed 20 July 2014). ">NCT02120924</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Actavis Inc. John Capicchioni Akesis, LLC As they are still recruiting, not sent mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0219" title="NCT02132117 . Safety and efficacy of AGN‐199201 in patients with persistent erythema associated with rosacea. clinicaltrials.gov/show/NCT02132117 (website accessed 20 July 2014). ">NCT02132117</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergan <a href="http://mailto:clinicaltrials%40allergan.com?subject=NCT02132117, 199201-005, Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="a4c7c8cdcacdc7c5c8d0d6cdc5c8d7e4c5c8c8c1d6c3c5ca8ac7cbc9">[email protected]</span></a> seems the same as NCT02131636 which I did NOT add? </p> <p><b>NCT02131636</b> Efficacy and Safety of AGN‐199201 in Patients With Persistent Erythema Associated With Rosacea </p> <p><b>NCT02132117</b> Safety and Efficacy of AGN‐199201 in Patients With Persistent Erythema Associated With Rosacea </p> <p>Also <b>NCT02095158</b> Longterm and efficacy and safety<br/> <a href="http://mailto:clinicaltrials%40allergan.com?subject=NCT02132117, 199201-005, Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea" target="_blank"><span class="__cf_email__" data-cfemail="b0d3dcd9ded9d3d1dcc4c2d9d1dcc3f0d1dcdcd5c2d7d1de9ed3dfdd">[email protected]</span></a> sent several mails, to ask if these are same studies, no replies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0220" title="NCT02144181 . Evaluation of the safety and efficacy of the Ulthera® System for the treatment of signs and symptoms of erythematotelangiectatic rosacea. clinicaltrials.gov/show/NCT02144181 (accessed 20 July 2014). ">NCT02144181</a> </p> <p>Evaluation of the Safety and Efficacy of the Ulthera® System for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulthera, Inc. Mark Lupin, MD is LUPIN 2014 part of this? As they are still recruiting, not sent mail </p> <p>e‐mail sent 29‐7‐2014 to confirm, <a class="__cf_email__" data-cfemail="bcd3dadad5dfd9fcdfd3cfd1d9d8d5dfdd92dfd3d1" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>Dear Colleagues</p> <p>I have received no further response could you please confirm with Dr Lupin?There appears to be a poster in JAAD 2014 vol17 Iss 5 referring to this trial? <b>NCT01756027</b> </p> <p>Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea Mark Lupin, MD, The Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada<br/> I also have this trial <a href="http://nct02144181/" target="_blank">NCT02144181</a> which appears to be still recruiting and the contact person is Dr Mark Lupin<br/> Resent 22‐8‐2014 no replies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0221" title="NCT02147691 . Finacea 15% and brimonidine 0.33% gel in the treatment of rosacea ‐ a pilot study. clinicaltrials.gov/show/NCT02147691 (accessed 20 July 2014). ">NCT02147691</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leon Kircik, M.D., Derm Research, PLLC <a href="http://mailto:wedoderm%40yahoo.com?subject=NCT02147691, FIN1302, Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study" target="_blank"><span class="__cf_email__" data-cfemail="daadbfbeb5bebfa8b79aa3bbb2b5b5f4b9b5b7">[email protected]</span></a> As they are still recruiting, not sent mail </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0222" title="NCT02204254 . Prospective, open label, randomized study comparing bipolar radiofrequency potentiated by infrared light to doxycycline in patient with papulopustular rosacea. clinicaltrials.gov/show/NCT02204254 (accessed 23 September 2014). ">NCT02204254</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Florence Le Duff, leduff.f2@chu‐nice.fr, not sent e‐mail as they are still recruiting</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>RCT = randomised controlled trial<br/> CCT = controlled clinical trial (quasi‐randomised) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Investigators contacted</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003262-tbl-0022"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Newly included studies for this update</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Newly included studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0002" title="AlamM , VoravutinonN , WarychaM , WhitingD , NodzenskiM , YooS , et al. Comparative effectiveness of nonpurpuragenic 595‐nm pulsed dye laser and microsecond 1064‐nm neodymium:yttrium‐aluminum‐garnet laser for treatment of diffuse facial erythema: A double‐blind randomized controlled trial. Journal of the American Academy of Dermatology2013;69(3):438‐43. [PUBMED: 23688651] ">Alam 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0004" title="BamfordJT , GessertCE , HallerIV , KrugerK . Rosacea unresponsive to oral zinc sulfate, a randomized controlled clinical trial. Journal of Investigative Dermatology2009;129 Suppl 1:S41. [EMBASE: 70385883] BamfordJT , GessertCE , HallerIV , KrugerK , JohnsonBP . Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. International Journal of Dermatology2012;51(4):459‐62. [PUBMED: 22435439] ">Bamford 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0006" title="BenkaliK , LeoniM , RonyF , BouerR , FernandoA , GraeberM , et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate‐to‐severe facial erythema associated with rosacea. British Journal of Dermatology2014;171(1):162‐9. [PUBMED: 24506775] ">Benkali 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0007" title="BerardescaE , IorizzoM , AbrilE , GuglielminiG , CaseriniM , PalmieriR , et al. Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea. Journal of Cosmetic Dermatology2012;11(1):37‐41. [PUBMED: 22360333] ">Berardesca 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0016" title="BribecheMR , FedotovVP , GladichevVV , PukhalskayaDM , KolitchevaNL . Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. International Journal of Dermatology2015; Vol. 54, issue 4:481‐7. [DOI: 10.1111/ijd.12552; PUBMED: 25040098] ">Bribeche 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] ">Buendia‐Bordera 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0019" title="ChangAL , Alora‐PalliM , LimaXT , ChangTC , ChengC , ChungCM , et al. A randomized, double‐blind, placebo‐controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. Journal of Drugs in Dermatology2012;11(3):333‐9. [PUBMED: 22395584] ">Chang 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0025" title="DelRossoJQ , BruceS , JarrattM , MenterA , StaedtlerG . Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild‐to‐moderate papulopustular rosacea. Journal of Drugs in Dermatology2010;9(6):607‐13. [PUBMED: 20645521] ">Del Rosso 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0028" title="DraelosZ , ErthelK , SchnickerM , BaconR , VickeryS . Facial foundation with niacinamide and N‐acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB82. [EMBASE: 70142048] ">Draelos 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0029" title="DraelosZD , ElewskiB , StaedtlerG , HavlickovaB . Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double‐blind, vehicle‐controlled study. Cutis; Cutaneous Medicine for the Practitioner2013;92(6):306‐17. [PUBMED: 24416747] ">Draelos 2013a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0030" title="DraelosZ , HornbyS , WaltersRM , AppaY . Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers. Journal of Cosmetic Dermatology2013;12(4):314‐21. [PUBMED: 24305430] HornbyS , FowlerJ , WaltersRM , AppaY , DraelosZ . Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB66. [EMBASE: 70997350] ">Draelos 2013b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] ">Fabi 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0037" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] MeadowsK , JarrattM , JonesT , PollackA , StoughD , LeoniM . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48. [EMBASE: 71067783] MeadowsK , PollackA , JarrattM , JonesT . A single application of brimonidine tartrate gel significantly reduces moderate to severe facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB41. [EMBASE: 70704014] ">Fowler 2012a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0038" title="FowlerJ , JarrattM , MooreA , MeadowsK , PollackA , SteinhoffM , et al. Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. British Journal of Dermatology2012;166(3):633‐41. [PUBMED: 22050040] FowlerJ , MooreA , MeadowsK , GrandeK . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema associated with rosacea. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB17. [EMBASE: 70703920] FowlerJ , MooreA , MeadowsK , GrandeK , SteinhoffM , LeoniM . Once‐daily topical brimonidine tartrate gel 0.5% is safe and efficacious in the treatment of moderate to severe persistent facial erythema of rosacea. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:48‐9. [EMBASE: 71067784] ">Fowler 2012b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0039" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] FowlerJ , JacksonM , SteinhoffM , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea – Two randomized, double‐blind and vehicle controlled Phase III studies. 46th Annual Scientific Meeting of the Australasian College of Dermatologists Sydney, NSW Australia. Conference Start: 20130519 Conference End: 20130522. Australasian Journal of Dermatology2013;54 Suppl 2:49. [EMBASE: 71067785] FowlerJF , MooreA , MeadowsK , JacksonM , LeoniM , JarrattMT , atal . Efficacy and safety of once‐daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double‐blind,and vehicle‐controlled phase III studies. 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States. Conference Start: 20130301 Conference End: 20130305. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB15. [EMBASE: 70997145] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0040" title="FowlerJJr , JacksonM , MooreA , JarrattM , JonesT , MeadowsK , et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2013;12(6):650‐6. [PUBMED: 23839181] JacksonJM , FowlerJ , MooreA , JarrattM , JonesT , MeadowsK , et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of Drugs in Dermatology2014;13(6):699‐704. [PUBMED: 24918560] ">Fowler 2013b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0041" title="GollnickH , Blume‐PeytaviU , SzabóEL , MeyerKG , HauptmannP , PoppG , et al. Systemic isotretinoin in the treatment of rosacea ‐ doxycycline ‐ and placebo‐controlled, randomized clinical study. Journal der Deutschen Dermatologischen Gesellschaft2010;8(7):505‐15. [DOI: 10.1111/j.1610‐0387.2010.07345.x; PUBMED: 20337772] GollnickH , MatthiesC , Von DerWerthR . Double‐blind, double‐dummy, randomized, placebo‐controlled, five armed,multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III. 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB41. [EMBASE: 70142682] ">Gollnick 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0044" title="HuangYE , LiXL , LiTJ . Clinical research of topical tacrolimus ointment combined with 585 nm pulsed dye laser in the treatment of rosacea [Chinese]. Journal of Clinical Dermatology2012;41(5):308‐9. [EMBASE: 2012449799] ">Huang 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0045" title="HuangE , DiNardoA , GalloR , CaveneyS , GottschalkRW . Surface cathelicidin expression is a predictor of treatment success in papulopustular rosacea. 2013 International Investigative Dermatology Meeting Edinburgh United Kingdom. Conference Start: 20130508 Conference End: 20130511. Journal of Investigative Dermatology2013;133 Suppl 1:S181. [EMBASE: 71083535] HuangEY , DiNardoA , PresonNJ , GalloRL , GottschalkRW . Multicenter, randomized, double‐blind, placebo‐controlled evaluation of rosacea related inflammatory biomarkers in papulopustular rosacea adults treated with doxycycline 40 mg modified release. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [EMBASE: 71390129] ">Huang 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0046" title="JacksonJM , KircikLH , LorenzDJ . Efficacy of extended‐release 45 mg oral minocycline and extended‐release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. Journal of Drugs in Dermatology2013;12(3):292‐8. [PUBMED: 23545911] ">Jackson 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0049" title="KendallJ , WinkelmanW . A comparison of 3 assessments in the treatment of rosacea in the context of a comparative effectiveness study. ISPOR 19th Annual International Meeting Montreal, QC Canada. Conference Start: 20140531 Conference End: 20140604. Value in Health2014;17(3):A181‐2. [EMBASE: 71488504] ">Kendall 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0050" title="KimTG , RohHJ , ChoSB , LeeJH , LeeSJ , OhSH . Enhancing effect of pretreatment with topical niacin in the treatment of rosacea‐associated erythema by 585‐nm pulsed dye laser in Koreans: A randomized, prospective, split‐face trial. British Journal of Dermatology2011; Vol. 38, issue 5:510‐3. [DOI: 10.1111/j.1365‐2133.2010.10174.x.; PUBMED: 21143465] ">Kim 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0055" title="LeydenJJ . Efficacy of a novel rosacea treatment system: an investigator‐blind, randomized, parallel‐group study. Journal of Drugs in Dermatology2011;10(10):1179‐85. [PUBMED: 21968669] ">Leyden 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0056" title="LeydenJJ . Randomized, phase 2, dose‐ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. Journal of Drugs in Dermatology2014;13(6):685‐8. [PUBMED: 24918558] ">Leyden 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0057" title="LugerT , PeukertN , RotherM . A multicentre, randomized, placebo‐controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug‐free ultra‐deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. Journal of the European Academy of Dermatology and Venereology2015; Vol. 29, issue 2:283‐90. [DOI: 10.1111/jdv.12520; PUBMED: 24754379] ">Luger 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0058" title="LupinM . Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB43. [EMBASE: 71390263] ">Lupin 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0064" title="NCT00249782 . A phase II, randomized, partial‐blind, parallel‐group, active‐ and vehicle‐controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). ">NCT00249782</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0065" title="NCT01426269 . Evaluation of relapse, efficacy and safety of long‐term treatment with Oracea® capsules compared to placebo after an initial 12 week treatment regimen with Oracea® and MetroGel® 1% in adults with rosacea. clinicaltrials.gov/show/NCT01426269 (accessed 21 July 2014). ">NCT01426269</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0066" title="NCT01449591 . A proof of concept (PoC) study to evaluate the safety, tolerability, and efficacy of 12 week administration of BFH772 ointment in rosacea patients. clinicaltrials.gov/show/NCT01449591 (accessed 19 July 2014). ">NCT01449591</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0067" title="NCT01885000 . Patient‐Reported Outcome of facial erythema (PROOF). clinicaltrials.gov/show/NCT01885000 (accessed 21 July 2014). ">NCT01885000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0071" title="NymannP , HedelundL , HaedersdalM . Long‐pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2010;24(2):143‐6. [PUBMED: 20205349] ">Nymann 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0075" title="Rodríguez AcarM , Medina HernándezE . A comparative, double‐blind study about efficacy and safety of crotamiton vs benzyl benzoate in the treatment of rosacea with demodecidosis [Estudio doble ciego, comparativo, sobre la eficacia y seguridad del crotamitón versus benzoato de bencilo en el tratamiento de la rosácea con demodecidosis]. Dermatología Revista Mexicana2003;47(3):126‐30. [EMBASE: 2007502703] ">Rodríguez 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0077" title="SalemDA , El‐ShazlyA , NabihN , El‐BayoumyY , SalehS . Evaluation of the efficacy of oral ivermectin in comparison with ivermectin‐metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. International Journal of Infectious Diseases2013;17(5):343‐7. [PUBMED: 23294870] ">Salem 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0082" title="SeitéS , BenechF , BerdahS , BayerM , VeyratS , SegotE , et al. Management of rosacea‐prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche‐Posay Thermal spring water as monotherapy or adjunctive therapy. Journal of Drugs in Dermatology2013;12(8):920‐4. [EMBASE: 2013521246] ">Seité 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0085" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0086" title="SteinL , KircikL , FowlerJ , TanJ , DraelosZ , FleischerA , et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double‐blind, vehicle‐controlled pivotal studies. Journal of Drugs in Dermatology2014;13(3):316‐23. [PUBMED: 24595578] ">Stein 2014b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0087" title="TaiebA , OrtonneJP , RuzickaT , RoszkiewiczJ , Berth‐JonesJ , PeironeMH , et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator‐blinded trial. British Journal of Dermatology2015; Vol. 172, issue 4:1103‐10. [PUBMED: 25228137] ">Taieb 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0094" title="TirnaksizF , KayişA , ÇelebiN , AdişenE , ErelA . Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chemical &amp; Pharmaceutical Bulletin2012;60(5):583‐92. [PUBMED: 22689395] ">Tirnaksiz 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0096" title="TwoAM , HataTR , NakatsujiT , CodaAB , KotolPF , WuW , et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. Journal of Investigative Dermatology2014;134(4):1143‐5. [PUBMED: 24213369] ">Two 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. ">Yoo 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Formerly excluded studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0013" title="BlomI , HornmarkAM . Topical treatment with sulfur 10 per cent for rosacea. Acta Dermato‐Venereologica1984;64(4):358‐9. [EMBASE: 1984179892] ">Blom 1984</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0033" title="ErtlGA , LevineN , KligmanAM . A comparison of the efficacy of topical tretinoin and low‐dose oral isotretinoin in rosacea. Archives of Dermatology1994;130(3):319‐24. [UI: 94175557; PUBMED: 8129410] ">Ertl 1994</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0034" title="EspagneE , GuillaumeJC , ArchimbaudA , BaspeyrasM , BoitierF , BussièreM , et al. Double‐blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea [Étude en double insu contre excipient du métronidazole gel a 0,75 p.100 dans le traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1993;120(2):129‐33. [UI: 93370955; PUBMED: 8240534] ">Espagne 1993</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0073" title="RehmusW , KimJ . A double‐blind, placebo‐controlled study of a natural anti‐inflammatory for treatment of rosacea. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB64. ">Rehmus 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0091" title="ThiboutotD . Efficacy and safety of subantimicrobial‐dose doxycycline for the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl 1):17. ">Thiboutot 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0097" title="UtaşS , ÜnverÜ . Treatment of rosacea with ketoconazole. Journal of the European Academy of Dermatology and Venereology1997;8(1):69‐70. [EMBASE: 1997013740] ">Utaş 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0098" title="VanLanduytH , Joubert‐LequainI , HumbertP , LucasA , DrobacheffC , MercierM , et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results) [Traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1997;124(10):729. [PUBMED: 9740876] ">Van Landuyt 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. ">Wittpenn 2005</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Newly included studies for this update</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003262-tbl-0023"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Checklist for describing and assessing patient‐reported outcomes (PROs) in clinical trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. What were PROs measuring?<br/> a. What concepts were the PROs used in the study measuring?<br/> b. What rationale (if any) for selection of concepts or constructs did the authors provide?<br/> c. Were patients involved in the selection of outcomes measured by the PROs? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Omissions<br/> a. Were there any important aspects of health (e.g. symptoms, function, perceptions) or quality of life (e.g. overall evaluation, satisfaction with life) that were omitted in this study from the perspectives of the patient, clinician, significant others, payers, or other administrators and decision‐makers? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. If randomised trials and other studies measured PROs, what were the instruments' measurement strategies?<br/> a. Did investigators use instruments that yield a single indicator or index number, a profile, or a battery of instruments?<br/> b. If investigators measure PROs, did they use specific or generic measures, or both? </p> <p>c. Who exactly completed the instruments?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Did the instruments work in the way they were supposed to work ‐ validity?<br/> a. Had the instruments used been validated previously (provide reference)? Was evidence of prior validation for use in this population presented?<br/> b. Were the instruments re‐validated in this study? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Did the instruments work in the way they were supposed to work ‐ ability to measure change?<br/> a. Are the PROs able to detect change in patient status, even if those changes are small? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Can you make the magnitude of effect (if any) understandable to readers?<br/> a. Can you provide an estimate of the difference in patients achieving a threshold of function or improvement, and the associated number needed to treat (NNT)? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Table 17.6.a </p> <p>Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient‐reported outcomes. In: Higgins JPT, Green S (editors), <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Checklist for describing and assessing patient‐reported outcomes (PROs) in clinical trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003262-tbl-0024"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Included studies with no usable or irretrievable data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions and comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0006" title="BenkaliK , LeoniM , RonyF , BouerR , FernandoA , GraeberM , et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate‐to‐severe facial erythema associated with rosacea. British Journal of Dermatology2014;171(1):162‐9. [PUBMED: 24506775] "><b>Benkali 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four different concentrations brimonidine tartrate gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of our outcomes were addressed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0013" title="BlomI , HornmarkAM . Topical treatment with sulfur 10 per cent for rosacea. Acta Dermato‐Venereologica1984;64(4):358‐9. [EMBASE: 1984179892] "><b>Blom 1984</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulphur 10% cream versus lymecycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many were randomised to each group, minimal reporting of outcomes. Participants who failed to respond or got worse were switched to the alternative treatment, unclear who and how many </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0017" title="Buendia‐BorderaG , CiscarE . Skin barrier function assessment by in vivo confocal microscopy and other non‐invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post‐laser serum. Lasers in Surgery and Medicine2013;45 Suppl 25:43. [EMBASE: 71034059] "><b>Buendia‐Bordera 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL + post‐laser serum versus PDL + placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, very limited data reported, not able to contact PI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0027" title="DraelosZD , GreenBA , EdisonBL . An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. Journal of Cosmetic Dermatology2006;5(1):23‐9. [PUBMED: 17173568] "><b>Draelos 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azelaic acid 15% gel + habitual self‐selected skin cleanser and moisturizer versus</p> <p>azelaic acid 15% gel + standardised PHA (polyhydroxy acid) containing cleanser, and anti‐aging moisturizer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of our primary outcomes were addressed combined with that it was unclear how many participants were randomised to each intervention. Because very limited outcomes data were reported no reliable conclusions could be drawn </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0028" title="DraelosZ , ErthelK , SchnickerM , BaconR , VickeryS . Facial foundation with niacinamide and N‐acetylglucosamine improves skin condition in women with sensitive skin. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB82. [EMBASE: 70142048] "><b>Draelos 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Facial foundation with niacinamide and N‐acetylglucosamine, cleanser and moisturizer versus marketed foundation + cleanser and moisturizer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, lot of data missing, PI did not reply to e‐mail. Also included patients with sensitive skin, no separate data reported for participants with rosacea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0030" title="DraelosZ , HornbyS , WaltersRM , AppaY . Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers. Journal of Cosmetic Dermatology2013;12(4):314‐21. [PUBMED: 24305430] HornbyS , FowlerJ , WaltersRM , AppaY , DraelosZ . Tolerance of facial cleansers on adults with clinically sensitive skin. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB66. [EMBASE: 70997350] "><b>Draelos 2013b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gentle foaming cleanser containing hydrophobically modified polymers versus commercial gentle liquid non‐foaming facial cleanser </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants with other skin diseases (atopic dermatitis, eczema, acne) were included and no separate data reported for participants with rosacea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0033" title="ErtlGA , LevineN , KligmanAM . A comparison of the efficacy of topical tretinoin and low‐dose oral isotretinoin in rosacea. Archives of Dermatology1994;130(3):319‐24. [UI: 94175557; PUBMED: 8129410] "><b>Ertl 1994</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isotretinoin + topical tretinoin versus topical tretinoin versus isotretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data unreliable, its re‐analysis using the individual participant data confirmed its flawed analysis by the investigators </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0034" title="EspagneE , GuillaumeJC , ArchimbaudA , BaspeyrasM , BoitierF , BussièreM , et al. Double‐blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea [Étude en double insu contre excipient du métronidazole gel a 0,75 p.100 dans le traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1993;120(2):129‐33. [UI: 93370955; PUBMED: 8240534] "><b>Espagne 1993</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole gel versus placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to intervention was based on up to four participants in each of 18 clinics but not all clinics enrolled four participants. The report did not provide any reassurance that the allocation sequence was adequately generated and no evidence that any form of central randomisation had been employed for the 18 clinics involved in this study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0035" title="FabiS , PetersonJ , GoldmanM . Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:968‐9. [EMBASE: 70640329] "><b>Fabi 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IPL + azelaic acid versus IPL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, very limited data reported, PI failed to respond to several e‐mails</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0043" title="GuilletB , RostainE , PowellF , Gimenez CamarasaC , DahanE , Piérard , et al. Metronidazole 0.75% gel and lotion are both effective in the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology1999;12(2 Suppl):S145. "><b>Guillet 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole 75% gel versus metronidazole 0.75% lotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, very limited data reported, old study, not able to contact PI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0045" title="HuangE , DiNardoA , GalloR , CaveneyS , GottschalkRW . Surface cathelicidin expression is a predictor of treatment success in papulopustular rosacea. 2013 International Investigative Dermatology Meeting Edinburgh United Kingdom. Conference Start: 20130508 Conference End: 20130511. Journal of Investigative Dermatology2013;133 Suppl 1:S181. [EMBASE: 71083535] HuangEY , DiNardoA , PresonNJ , GalloRL , GottschalkRW . Multicenter, randomized, double‐blind, placebo‐controlled evaluation of rosacea related inflammatory biomarkers in papulopustular rosacea adults treated with doxycycline 40 mg modified release. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [EMBASE: 71390129] "><b>Huang 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxycycline 40 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster abstract, limited data, unclear how many were randomised to each group, PI failed to respond to several e‐mails </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0047" title="JorizzoJL , LebwohlM , TobeyRE . The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double blind clinical trial. Journal of the American Academy of Dermatology1998;39(3):502‐4. [UI: 98409174; PUBMED: 9738794] "><b>Jorizzo 1998</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many participants were initially recruited. Unclear how many participants started in each group, no SDs, dropout rate unclear. Data seem very skewed </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0058" title="LupinM . Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU‐V) for the treatment of erythematotelangiectatic rosacea. 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States. Conference Start: 20140321 Conference End: 20140325. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB43. [EMBASE: 71390263] "><b>Lupin 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MFU‐V one treatment versus MFU‐V two treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster abstract, limited data, unclear how many were randomised to each group, PI failed to respond to several e‐mails </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0064" title="NCT00249782 . A phase II, randomized, partial‐blind, parallel‐group, active‐ and vehicle‐controlled, multicenter study of the safety and efficacy of ACZONE™ (dapsone) gel, 5% in subjects with papulopustular rosacea. http://clinicaltrials.gov/ct/show/NCT00249782 (accessed 19 July 2014). "><b>NCT00249782</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dapsone 5% gel QD vs dapsone 5% BID, versus metronidazole gel versus dapsone + metronidazole gel versus vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many were randomised to each group, Allergan failed to respond to several e‐mails requesting further data </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0073" title="RehmusW , KimJ . A double‐blind, placebo‐controlled study of a natural anti‐inflammatory for treatment of rosacea. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB64. "><b>Rehmus 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antiinflammatory cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, no results provided, very limited data reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0091" title="ThiboutotD . Efficacy and safety of subantimicrobial‐dose doxycycline for the treatment of rosacea. Journal of the American Academy of Dermatology2005;52(3 Suppl 1):17. "><b>Thiboutot 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxycycline versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, lot of data are missing, PI did not reply to e‐mail</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0097" title="UtaşS , ÜnverÜ . Treatment of rosacea with ketoconazole. Journal of the European Academy of Dermatology and Venereology1997;8(1):69‐70. [EMBASE: 1997013740] "><b>Utaş 1997</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketoconazole oral versus ketoconazole cream versus ketoconazole oral + cream versus placebo cream versus placebo pills </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Letter, limited and no exact data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0098" title="VanLanduytH , Joubert‐LequainI , HumbertP , LucasA , DrobacheffC , MercierM , et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results) [Traitement de la rosacée]. Annales de Dermatologie et de Vénéréologie1997;124(10):729. [PUBMED: 9740876] "><b>Van Landuyt 1997</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clonidine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim report only on first 30 participants, incomplete and very limited data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0102" title="WilkinJK . Effect of nadolol on flushing reactions in rosacea. Journal of the American Academy of Dermatology1989;20(2 Pt 1):202‐5. [PUBMED: 2521641] "><b>Wilkin 1989</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nadolol versus placebo, four arms, crossover, 3 periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small groups, unclear what dropout rate was. No separate data for period A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0103" title="DeWittS , WilkinJK . Double blind, parallel study of efficacy and safety of clindamycin lotion in the treatment of rosacea. Clinical Pharmacology and Therapeutics1987;41(2):176. WilkinJK , DeWittS . Treatment of rosacea: topical clindamycin versus oral tetracycline. International Journal of Dermatology1993;32(1):65‐7. [UI: 93146772; PUBMED: 8425809] "><b>Wilkin 1993</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical clindamycin versus tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many participants were assigned to each group, dropouts not mentioned, no exact data provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0104" title="WittpennJR , SchechterB . Efficacy of cyclosporine a for the treatment of ocular rosacea. Investigative Ophthalmology &amp; Visual Science2005;46:E‐Abstract 2846. "><b>Wittpenn 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical ciclosporin A versus artificial tears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how many randomised to each group, poster with very limited data see also <a href="#CD003262-tbl-0021">Table 3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003262-bbs2-0106" title="YooJ , MarmurE , FrankelAL , ChaaraniJ , TurnerR , SingerG . Combination therapy for the treatment of erythematotelangiectatic rosacea. Lasers in Surgery &amp; Medicine2011;43 Suppl 23:918. "><b>Yoo 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PDL + calcium dobesilate versus PDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poster, with incomplete and missing data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Included studies with no usable or irretrievable data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/full#CD003262-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003262-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical metronidazole versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.94, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physician's global evaluation of improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.29, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incomplete data on which further analysis is not possible <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical metronidazole versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003262-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical azelaic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐assessed improvement of rosacea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.30, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physician's global evaluation of improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.18, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incomplete data on which further analysis is not possible <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical azelaic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003262.pub5/references#CD003262-tbl-0026">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003262.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003262-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003262-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003262-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD003262-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003262-note-0026">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003262\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003262\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003262\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003262\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003262\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003262.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003262.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003262.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003262.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003262.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725979370"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003262.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725979374"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003262.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8869082e9371',t:'MTc0MDcyNTk3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 